0000950170-24-12539910-Q Perspective Therapeutics, Inc. 20241112202411121611581611581611581 58 0 0000950170-24-125399 10-Q 78 20240930 20241112 20241112 Perspective Therapeutics, Inc. 0000728387 3841 411458152 DE 1231 10-Q 34 001-33407 241448253 2401 ELLIOTT AVENUE SUITE 320 SEATTLE WA 98121 206-676-0900 2401 ELLIOTT AVENUE SUITE 320 SEATTLE WA 98121 Isoray, Inc. 20181231 IsoRay, Inc. 20050805 CENTURY PARK PICTURES CORP 19920703 10-Q 1 catx-20240930.htm 10-Q 10-Q Q3--12-31false00007283870.10.10.10.10.10000728387catx:LeaseWithBoardOfRegentsMember2024-04-010000728387catx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-240000728387us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000728387872024-03-310000728387catx:ViewpointMolecularTargetingIncMember2024-07-012024-09-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember2024-03-310000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:CommonStockMember2024-01-012024-03-310000728387catx:LantheusInvestmentAgreementMemberus-gaap:CommonStockMember2024-01-012024-03-310000728387us-gaap:AdditionalPaidInCapitalMember2023-09-300000728387catx:PublicOfferingMember2024-01-172024-01-170000728387catx:LantheusInvestmentAgreementMember2024-01-012024-03-310000728387catx:ViewpointMolecularTargetingIncMember2023-02-032023-02-030000728387us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000728387catx:StockholderPlaintiffSettlementsMember2024-09-300000728387us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310000728387us-gaap:CommonStockMembercatx:TwoThousandTwentyFourAtMarketOfferingMember2024-08-130000728387srt:ScenarioForecastMember2024-01-012024-12-310000728387catx:PromissoryNoteMember2023-12-310000728387us-gaap:RetainedEarningsMembercatx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-310000728387catx:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:GTMedicalTechnologiesIncMember2024-04-122024-04-120000728387872023-07-012023-09-3000007283872024-06-300000728387catx:RegisteredOfferingMember2024-04-012024-06-300000728387us-gaap:RetainedEarningsMembercatx:PublicOfferingMember2024-01-012024-03-3100007283872023-04-012023-06-300000728387us-gaap:RetainedEarningsMember2023-03-310000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-03-060000728387us-gaap:RetainedEarningsMember2023-04-012023-06-300000728387us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000728387us-gaap:AdditionalPaidInCapitalMember2024-09-300000728387srt:MinimumMembercatx:ViewpointMolecularTargetingIncMember2023-02-032023-02-030000728387us-gaap:FairValueMeasurementsRecurringMember2023-12-310000728387us-gaap:CommonStockMember2023-01-012023-03-310000728387catx:ViewpointMolecularTargetingIncMember2024-01-012024-09-300000728387us-gaap:CommonStockMember2024-07-012024-09-300000728387us-gaap:AdditionalPaidInCapitalMember2024-06-300000728387catx:OtherMember2023-12-310000728387us-gaap:USTreasuryBillSecuritiesMember2024-09-300000728387us-gaap:BuildingMember2023-12-310000728387us-gaap:RetainedEarningsMember2024-03-310000728387us-gaap:USTreasuryBillSecuritiesMember2023-12-310000728387us-gaap:AdditionalPaidInCapitalMember2024-03-310000728387catx:OfficeSpaceWithUnicoPropertiesMember2023-07-010000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:CommonStockMember2024-04-012024-06-300000728387us-gaap:CommonStockMember2024-01-012024-03-310000728387us-gaap:AdditionalPaidInCapitalMember2023-12-310000728387catx:SeriesBConvertiblePreferredStockMember2024-09-300000728387catx:LantheusInvestmentAgreementMemberus-gaap:RetainedEarningsMember2024-01-012024-03-310000728387us-gaap:EquipmentMember2023-12-310000728387catx:RegisteredOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-01-012023-09-300000728387us-gaap:AdditionalPaidInCapitalMembercatx:ATMAgreementMember2024-04-012024-06-300000728387catx:ChinoCaliforniaMemberus-gaap:SubsequentEventMember2024-10-132024-10-130000728387us-gaap:LeaseholdImprovementsMember2024-09-3000007283872023-01-012023-03-310000728387catx:ProgenicsMember2024-08-080000728387us-gaap:LeaseholdImprovementsMember2023-12-310000728387catx:PublicOfferingMember2024-01-012024-03-310000728387us-gaap:RetainedEarningsMember2024-01-012024-03-310000728387us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000728387us-gaap:RetainedEarningsMember2023-09-300000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-172024-01-170000728387catx:RegisteredOfferingMemberus-gaap:RetainedEarningsMember2024-04-012024-06-300000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-01-080000728387us-gaap:CommonStockMember2024-06-300000728387us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387us-gaap:CommonStockMembercatx:ATMAgreementMember2024-04-012024-06-300000728387us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000728387catx:OtherMember2024-01-012024-09-300000728387catx:LantheusAlphaTherapyLlcMember2024-08-082024-08-080000728387us-gaap:RetainedEarningsMember2024-09-300000728387us-gaap:EquipmentMember2024-09-300000728387us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000728387us-gaap:RetainedEarningsMember2022-12-310000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-07-012024-09-300000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-1700007283872023-01-012023-09-300000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:RetainedEarningsMember2024-04-012024-06-300000728387us-gaap:CommonStockMember2023-09-300000728387us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:PublicOfferingMember2024-01-170000728387catx:March2024PrivatePlacementMember2024-03-040000728387us-gaap:AdditionalPaidInCapitalMember2022-12-310000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-12-310000728387us-gaap:BuildingMember2024-09-300000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000007283872024-01-012024-09-300000728387catx:LantheusInvestmentAgreementMembercatx:OptionAgreementMember2024-01-082024-01-080000728387us-gaap:RetainedEarningsMember2024-04-012024-06-300000728387catx:ViewpointMolecularTargetingIncMember2023-02-030000728387catx:MayTwoThousandTwentyFourPreFundedWarrantsMember2024-04-012024-06-300000728387us-gaap:CommonStockMember2024-03-310000728387catx:HoustonTexasMember2024-07-152024-07-150000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-03-042024-03-040000728387us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000728387catx:OtherMember2023-01-012023-12-310000728387catx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-242024-05-240000728387us-gaap:CommonStockMember2022-12-310000728387us-gaap:RetainedEarningsMembercatx:ATMAgreementMember2024-04-012024-06-300000728387us-gaap:RetainedEarningsMember2023-12-310000728387catx:ProgenicsMember2024-03-010000728387us-gaap:OverAllotmentOptionMember2024-01-172024-01-170000728387catx:NetSalesGreaterThan15MillionMembercatx:GTMedicalTechnologiesIncMember2024-04-120000728387us-gaap:RetainedEarningsMember2023-07-012023-09-300000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-09-300000728387us-gaap:CommonStockMember2023-03-310000728387catx:StockholderPlaintiffSettlementsMember2023-12-310000728387catx:ViewpointMolecularTargetingIncMember2023-07-012023-09-300000728387catx:ATMAgreementMember2024-04-012024-06-300000728387us-gaap:WarrantMember2023-01-012023-09-300000728387us-gaap:RetainedEarningsMember2023-06-300000728387us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000728387us-gaap:CommonStockMembercatx:RegisteredOfferingMember2024-04-012024-06-300000728387us-gaap:LandMember2023-12-310000728387us-gaap:AdditionalPaidInCapitalMember2023-03-3100007283872023-03-3100007283872024-01-012024-03-310000728387us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000728387catx:RegisteredOfferingMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-242024-05-240000728387catx:LantheusInvestmentAgreementMembercatx:LantheusAlphaTherapyLlcMember2024-01-082024-01-080000728387catx:OppenheimerCoMember2024-04-110000728387catx:May2024PreFundedWarrantsMembercatx:TheUnderwritingAgreementMembercatx:BofASecuritiesIncMember2024-05-240000728387catx:SeriesBConvertiblePreferredStockMember2023-12-310000728387catx:GTMedicalTechnologiesIncMember2024-04-120000728387us-gaap:CommonStockMembercatx:PublicOfferingMember2024-01-012024-03-310000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-09-300000728387us-gaap:RetainedEarningsMember2023-01-012023-03-310000728387us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000728387catx:OppenheimerCoMember2024-04-112024-04-1100007283872024-09-300000728387us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000728387us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000728387us-gaap:CommonStockMember2024-09-300000728387catx:NetSalesOf10MillionOrLessMembercatx:GTMedicalTechnologiesIncMember2024-04-120000728387us-gaap:WarrantMember2024-01-012024-09-3000007283872024-04-012024-06-300000728387us-gaap:InProcessResearchAndDevelopmentMember2024-09-3000007283872023-09-300000728387us-gaap:RetainedEarningsMember2024-07-012024-09-300000728387catx:ProgenicsApaMember2024-01-082024-01-080000728387catx:PromissoryNoteMember2024-09-300000728387us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMemberus-gaap:RetainedEarningsMember2024-01-012024-03-310000728387us-gaap:CommonStockMember2023-12-3100007283872023-12-140000728387catx:AmendedTwoThousandTwentyIncentivePlanMember2024-08-142024-08-140000728387us-gaap:CommonStockMembercatx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-310000728387catx:TwoThousandTwentyFourAtMarketOfferingMember2024-08-130000728387us-gaap:CommonStockMember2024-04-012024-06-3000007283872024-06-142024-06-140000728387catx:GTMedicalTechnologiesIncMembercatx:GTMedicalStockMember2024-04-120000728387catx:March2024PrivatePlacementMember2024-03-042024-03-040000728387catx:PromissoryNoteMembercatx:ViewpointMolecularTargetingIncMember2019-07-190000728387us-gaap:AdditionalPaidInCapitalMember2023-06-300000728387catx:MarchTwoThousandTwentyFourInvestmentAgreementMember2024-01-012024-03-310000728387us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000728387us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300000728387catx:Cesium131BusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-07-012023-09-300000728387us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000728387catx:PromissoryNoteMembercatx:ViewpointMolecularTargetingIncMember2019-07-192019-07-190000728387us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000728387catx:LantheusInvestmentAgreementMember2024-01-0800007283872024-11-070000728387catx:ViewpointMolecularTargetingIncMembersrt:MaximumMember2023-02-032023-02-0300007283872023-06-3000007283872023-12-3100007283872024-07-012024-09-300000728387catx:IsorayNoteMembercatx:ViewpointMolecularTargetingIncMember2022-11-220000728387catx:ChicagoIllinoisMember2024-08-022024-08-020000728387catx:OppenheimerCoMember2023-12-310000728387catx:OppenheimerCoMember2023-12-012023-12-310000728387catx:AmendedTwoThousandTwentyIncentivePlanMember2024-05-3100007283872024-08-080000728387us-gaap:RetainedEarningsMember2024-06-300000728387catx:OppenheimerCoMember2023-11-170000728387us-gaap:LandMember2024-09-3000007283872022-12-310000728387catx:PromissoryNoteForPurchasingLandAndBuildingMembercatx:ViewpointMolecularTargetingIncMember2022-12-290000728387catx:LantheusInvestmentAgreementMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000728387catx:OtherMember2024-09-300000728387us-gaap:CommonStockMember2023-06-300000728387srt:MaximumMembercatx:LantheusAlphaTherapyLlcMember2024-08-080000728387catx:LantheusInvestmentAgreementMember2024-01-082024-01-0800007283872024-09-182024-09-180000728387catx:AmendedTwoThousandTwentyIncentivePlanMember2024-05-312024-05-3100007283872024-09-300000728387catx:ViewpointMolecularTargetingIncMember2023-01-012023-09-300000728387catx:GTMedicalTechnologiesIncMembercatx:NetSalesBetween10And15MillionMember2024-04-120000728387us-gaap:CommonStockMember2023-07-012023-09-300000728387us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000728387catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember2024-01-012024-03-310000728387us-gaap:CommonStockMember2023-04-012023-06-30iso4217:EURiso4217:USDxbrli:sharesxbrli:purecatx:MonthlyPaymentsxbrli:sharescatx:Plaintiffiso4217:USDcatx:RenewalOption Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q â˜' QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR â˜ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _____ to _____ Â Commission File Number: 001-33407 Â PERSPECTIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Â Delaware 41-1458152 (State or other jurisdiction of incorporation ororganization) (I.R.S. EmployerIdentification No.) Â Â 2401 Elliott Avenue, Suite 320Seattle, Washington 98121 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (206) 676-0900 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CATX NYSE American LLC Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜' No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜' No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜' Smaller reporting company â˜' Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜' Â Number of shares outstanding of each of the issuerâ€™s classes of common stock as of the latest practicable date: Â Class Outstanding as of November 7, 2024 Common stock, $0.001 par value 67,587,540 Â Â Â Â Table of Contents Â Â Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â In addition to historical information, this Quarterly Report on Form 10-Q (Form 10-Q), contains certain â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing Perspective Therapeutics, Inc. of the protections of the safe harbor provisions of the PSLRA. Â This Form 10-Q, including Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements contained in this Form 10-Q other than statements of historical fact, including, without limitation, statements regarding our future financial condition, results of operations, business strategy and plans and objectives of management for future operations, industry trends and other future events are forward-looking statements. In some cases, you can identify forward-looking statements by terminology, such as â€œbelieve,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œestimate,â€ â€œforecast,â€ â€œproject,â€ â€œmay,â€ â€œcould,â€ â€œmight,â€ â€œplan,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or the negative of these terms and other similar expressions, although not all forward-looking statements contain these identifying terms. Forward-looking statements in this Form 10-Q include, among other things: Â â€¢the timing, progress and results of our preclinical studies and clinical trials of our current and future program candidates, including statements regarding the timing of our planned regulatory communications, submissions and approvals, initiation and completion of studies or trials and related preparatory work and the period during which the results of the trials will become available, and our research and

development programs; â€¢our ability to obtain and maintain regulatory approvals for our future program candidates; â€¢our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes; â€¢our ability to identify patients with the diseases treated by our program candidates and to enroll these patients in our clinical trials; â€¢our expectations regarding the potential functionality, capabilities and benefits of our program candidates, if approved, for commercial use; â€¢the potential size of the commercial market for our program candidates; â€¢our expectations regarding the scope of any approved indication for any program candidate; â€¢our ability to successfully commercialize our program candidates; â€¢our ability to leverage technology to identify and develop future program candidates; â€¢our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional funding before we can expect to generate any revenue from product sales; â€¢our belief regarding the sufficiency of our cash resources to fund our current planned operating expenses and capital expenditure requirements into mid-2026; â€¢our competitive position and expectations regarding developments and projections relating to our competitors or our industry; and â€¢expectations, beliefs, intentions and strategies regarding the future. Â These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of our views as of the date the statement was made (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we undertake no obligation to do so, whether as a result of new information, future events or otherwise, except as required by applicable law. Our U.S. Securities and Exchange Commission (SEC) filings are available publicly on the SECâ€™s website at www.sec.gov. Â Â i Table of Contents Â AVAILABLE INFORMATION As soon as reasonably practicable after they are filed electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, other SEC filings and amendments to those reports are available without charge on our website, www.perspectivetherapeutics.com, which we also use to announce material information to the public. We are providing the address to our website solely for the information of investors. We do not intend the address to be an active link or to otherwise incorporate the contents of the website into this Form 10-Q. ii Table of Contents Â PERSPECTIVE THERAPEUTICS, INC. Table of Contents Â PART I FINANCIAL INFORMATION Â Â Item 1 Financial Statements 1 Â Â Â Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 1 Â Â Â Â Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) 2 Â Â Â Â Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 3 Â Â Â Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 4 Â Â Â Notes to the Unaudited Condensed Consolidated Financial Statements 5 Â Â Item 2 Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 18 Â Â Item 3 Quantitative and Qualitative Disclosures About Market Risk 29 Â Â Item 4 Controls and Procedures 29 Â Â PART II OTHER INFORMATION Â Â Item 1 Legal Proceedings 30 Â Â Item 1A Risk Factors 30 Â Â Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 30 Â Â Item 3 Defaults Upon Senior Securities 30 Â Â Item 4 Mine Safety Disclosures 30 Â Â Item 5 Other Information 31 Â Â Item 6 Exhibits 32 Â Â Signatures Â 33 Â iii Table of Contents Â PART I - FINANCIAL INFORMATION ITEM 1 - FINANCIAL STATEMENTS Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except shares and par value data) Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â (unaudited) Â Â Â Â ASSETS Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 226,443 Â Â $ 9,238 Â Short-term investments Â Â 41,404 Â Â Â - Â Accounts receivable, net of allowance for doubtful accounts: 2024 - $592; 2023 - $650 Â Â 217 Â Â Â 1,165 Â Prepaid expenses and other current assets Â Â 2,108 Â Â Â 1,133 Â Current assets held for sale, discontinued operations Â Â - Â Â Â 5,301 Â Total current assets Â Â 270,172 Â Â Â 16,837 Â Noncurrent assets: Â Â Â Â Â Â Property and equipment, net Â Â 43,792 Â Â Â 5,576 Â Right-of-use asset, net Â Â 2,433 Â Â Â 747 Â Restricted cash Â Â - Â Â Â 182 Â Intangible assets, in-process research and development Â Â 50,000 Â Â Â 50,000 Â Goodwill Â Â 24,062 Â Â Â 24,062 Â Other assets, net Â Â 694 Â Â Â 487 Â Total assets Â $ 391,153 Â Â $ 97,891 Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITY Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable and accrued expenses Â $ 21,813 Â Â $ 6,909 Â Lease liability Â Â 903 Â Â Â 46 Â Accrued personnel expenses Â Â 3,976 Â Â Â 3,588 Â Note payable Â Â 51 Â Â Â 49 Â Deferred Income (Note 3) Â Â 1,400 Â Â Â - Â Current liabilities of discontinued operations Â Â - Â Â Â 5,072 Â Total current liabilities Â Â 28,143 Â Â Â 15,664 Â Noncurrent liabilities: Â Â Â Â Â Â Lease liability, net of current portion Â Â 1,676 Â Â Â 780 Â Note payable, net of current portion Â Â 1,638 Â Â Â 1,676 Â Deferred Income, net of current portion (Note 3) Â Â 26,600 Â Â Â - Â Deferred tax liability Â Â 4,592 Â Â Â 4,592 Â Other noncurrent liabilities Â Â 33 Â Â Â - Â Total liabilities Â Â 62,682 Â Â Â 22,712 Â Â Â Â Â Â Â Commitments and contingenciesÂ (Note 10) Â Â Â Â Â Â Â Â Â Â Â Stockholders' equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value; 7,000,000Â shares authorized; 5,000,000Â designated Series B convertible preferred stock; noÂ shares issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â - Â Â Â - Â Common stock, $0.001Â par value; 750,000,000Â shares authorized; 67,562,781Â and 28,180,985Â shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively1 Â Â 67 Â Â Â 28 Â Additional paid-in capital1 Â Â 519,954 Â Â Â 227,591 Â Accumulated deficit Â Â (191,550) Â Â (152,440) Total stockholders' equity Â Â 328,471 Â Â Â 75,179 Â Â Â Â Â Â Total liabilities and stockholders' equity Â $ 391,153 Â Â $ 97,891 Â Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents Â Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (unaudited) (Dollars and shares in thousands, except for per-share amounts) Â Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Grant revenue Â $ 369 Â Â $ 276 Â Â $ 1,220 Â Â $ 1,097 Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Research and development Â Â 12,028 Â Â Â 5,552 Â Â Â 28,755 Â Â Â 14,231 Â General and administrative Â Â 6,975 Â Â Â 4,474 Â Â Â 18,367 Â Â Â 16,124 Â Change in estimate of asset retirement obligation (Note 4) Â Â - Â Â Â - Â Â Â - Â Â Â (15) Loss on disposal of property and equipment Â Â - Â Â Â - Â Â Â - Â Â Â 22 Â Total operating expenses Â Â 19,003 Â Â Â 10,026 Â Â Â 47,122 Â Â Â 30,362 Â Â Â Â Â Â Â Â Â Â Operating loss Â Â (18,634) Â Â (9,750) Â Â (45,902) Â Â (29,265) Â Â Â Â Â Â Â Â Â Â Non-operating income (expense): Â Â Â Â Â Â Â Â Â Â Interest income Â Â 3,581 Â Â Â 204 Â Â Â 7,868 Â Â Â 872 Â Interest and other expense Â Â (69) Â Â (14) Â Â (121) Â Â (58) Equity in loss of affiliate Â Â - Â Â Â (12) Â Â (6) Â Â (12) Total non-operating income (expense), net Â Â 3,512 Â Â Â 178 Â Â Â 7,741 Â Â Â 802 Â Â Â Â Â Â Â Â Â Â Net loss from continuing operations Â Â (15,122) Â Â (9,572) Â Â (38,161) Â Â (28,463) Net loss from discontinued operations Â Â - Â Â Â (784) Â Â (890) Â Â (3,870) Loss recognized on classification as held for sale Â Â - Â Â Â - Â Â Â (59) Â Â - Â Net loss before deferred income tax benefit Â Â (15,122) Â Â (10,356) Â Â (39,110) Â Â (32,333) Deferred income tax benefit Â Â - Â Â Â - Â Â Â - Â Â Â 10,500 Â Net loss Â $ (15,122) Â $ (10,356) Â $ (39,110) Â $ (21,833) Â Â Â Â Â Â Â Â Â Â Basic and diluted loss per share: Â Â Â Â Â Â Â Â Â Â Loss from continuing operations1 Â $ (0.21) Â $ (0.34) Â $ (0.61) Â $ (0.68) Loss from discontinued operations1 Â Â - Â Â Â (0.03) Â Â (0.01) Â Â (0.15) Basic and diluted loss per share1 Â $ (0.21) Â $ (0.37) Â $ (0.62) Â $ (0.83) Â Â Â Â Â Â Â Â Â Â Weighted average shares used in computing net loss per share: Â Â Â Â Â Â Â Â Â Â Basic and diluted1 Â Â 70,629 Â Â Â 28,055 Â Â Â 62,293 Â Â Â 26,323 Â Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. Â The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents Â Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (unaudited) (In thousands) Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Net loss Â $ (39,110) Â $ (21,833) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Â Â Â Â Â Â Â Foreign currency adjustments Â Â 39 Â Â Â - Â Lease expense Â Â 100 Â Â Â 35 Â Depreciation expense Â Â 1,585 Â Â Â 684 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Loss on disposal of property and equipment Â Â - Â Â Â 22 Â Amortization of other assets Â Â 12 Â Â Â 30 Â Accretion of asset retirement obligation Â Â - Â Â Â 26 Â Equity in loss of affiliate Â Â 6 Â Â Â 12 Â Accrued interest on short-term investments Â Â (899) Â Â - Â Change in allowance for doubtful accounts Â Â (58) Â Â - Â Change in estimate of asset retirement obligation Â Â - Â Â Â (15) Loss on divestiture Â Â 59 Â Â Â - Â Share-based compensation Â Â 3,327 Â Â Â 3,018 Â Deferred income tax benefit Â Â - Â Â Â (10,500) Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 890 Â Â Â (368) Inventory related to discontinued operations (Note 4) Â Â 11 Â Â Â 257 Â Prepaid expenses and other current assets Â Â (975) Â Â 12 Â Accounts payable and accrued expenses Â Â 14,937 Â Â Â (683) Deferred Income1 Â Â 28,000 Â Â Â - Â Accrued personnel expenses Â Â 388 Â Â Â 1,100 Â Net cash provided by (used in) operating activities Â Â 8,312 Â Â Â (27,905) Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Additions to property and equipment Â Â (39,800) Â Â (983) Additions to other assets Â Â (24) Â Â (18) Proceeds from maturity of short-term investments Â Â 38,225 Â Â Â 22,764 Â Purchases of short-term investments Â Â (78,730) Â Â - Â Net cash acquired in acquisition of Viewpoint Â Â - Â Â Â 2,699 Â Net cash (used in) provided by investing activities Â Â (80,329) Â Â 24,462 Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Repayment of notes payable Â Â (36) Â Â (56) Proceeds from sales of common stock, pursuant to exercise of warrants, net Â Â 125 Â Â Â - Â Proceeds from sales of common stock, pursuant to exercise of options Â Â 896 Â Â Â 554 Â Proceeds from the issuance of common stock and Pre-funded Warrants, net1 Â Â 288,055 Â Â Â - Â Issuance costs related to common stock issued in exchange for Viewpoint common stock Â Â - Â Â Â (65) Net cash provided by financing activities Â Â 289,040 Â Â Â 433 Â Â Â Â Â Â Net increase (decrease) in cash, cash equivalents and restricted cash Â Â 217,023 Â Â Â (3,010) Cash, cash equivalents and restricted cash beginning of period Â Â 9,420 Â Â Â 21,175 Â CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD Â $ 226,443 Â Â $ 18,165 Â Â Â Â Â Â Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Â Â Â Â Â Â Cash and cash equivalents Â $ 226,443 Â Â $ 17,983 Â Restricted cash Â Â - Â Â Â 182 Â Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows Â $ 226,443 Â Â $ 18,165 Â Â Â Â Â Â Supplemental schedule of noncash investing and financing activities: Â Â Â Â Â Â Recognition of operating lease liability and right-of-use asset Â $ 2,115 Â Â $ 811 Â Additions to property and equipment Â Â 16,518 Â Â Â - Â Fair value of Viewpoint assets acquired including goodwill Â Â - Â Â Â 85,885 Â 13,654,5072Â shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock Â Â - Â Â Â (54,618) Assumption of Viewpoint stock options and warrants at fair value Â Â - Â Â Â (7,836) Note receivable and accrued interest from Viewpoint forgiven Â Â - Â Â Â (6,171) 1. See Note 3, Investments and Agreements, for additional information. 2. Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Table of Contents Â Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity (unaudited) (In thousands, except shares) Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares1 Â Â Amount1 Â Â Additional Paid-in Capital1 Â Â Accumulated Deficit Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balances at December 31, 2022 Â Â 14,211,276 Â Â $ 14 Â Â $ 160,560 Â Â $ (105,932) Â $ 54,642 Â Issuance of common stock in exchange forÂ Â Â Viewpoint common stock, net Â Â 13,654,507 Â Â 14 Â Â Â 54,539 Â Â Â - Â Â Â 54,553 Â Assumption of Viewpoint stock options andÂ Â Â warrants at fair value Â Â - Â Â Â - Â Â Â 7,836 Â Â Â - Â Â Â 7,836 Â Share-based compensation Â Â - Â Â Â - Â Â Â 1,368 Â Â Â - Â Â Â 1,368 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (371) Â Â (371) Balances at March 31, 2023 Â Â 27,865,783 Â Â $ 28 Â Â $ 224,303 Â Â $ (106,303) Â $ 118,028 Â Issuance of common stock pursuant to exerciseÂ Â Â of options Â Â 182,158 Â Â Â - Â Â Â 532 Â Â Â - Â Â Â 532 Â Share-based compensation Â Â - Â Â Â - Â Â Â 1,199 Â Â Â - Â Â Â 1,199 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (11,106) Â Â (11,106) Balances at June 30, 2023 Â Â 28,047,941 Â Â $ 28 Â Â $ 226,034 Â Â $ (117,409) Â $ 108,653 Â Issuance of common stock pursuant to exerciseÂ Â Â of options Â Â 9,160 Â Â Â - Â Â Â 22 Â Â Â - Â Â Â 22 Â Share-based compensation Â Â - Â Â Â - Â Â Â 451 Â Â Â - Â Â Â 451 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (10,356) Â Â (10,356) Balances at September 30, 2023 Â Â 28,057,101 Â Â $ 28 Â Â $ 226,507 Â Â $ (127,765) Â $ 98,770 Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares1 Â Â Amount1 Â Â Additional Paid-in Capital1 Â Â Accumulated Deficit Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balances at December 31, 2023 Â Â 28,180,985 Â Â $ 28 Â Â $ 227,591 Â Â $ (152,440) Â $ 75,179 Â Â Issuance of common stock pursuant to theÂ Â Â Public Offering, net2 Â Â 15,639,954 Â Â Â 16 Â Â Â 53,125 Â Â Â - Â Â Â 53,141 Â Issuance of Jan. 2024 Pre-funded Warrants, net2 Â Â - Â Â Â - Â Â Â 10,208 Â Â Â - Â Â Â 10,208 Â Issuance of common stock pursuant to theÂ Â Â Lantheus Investment Agreement, net2 Â Â 5,634,235 Â Â Â 6 Â Â Â 20,840 Â Â Â - Â Â Â 20,846 Â Issuance of common stock pursuant to theÂ Â Â March 2024 Investment Agreement, net2 Â Â 9,200,998 Â Â Â 9 Â Â Â 82,010 Â Â Â - Â Â Â 82,019 Â Issuance of common stock pursuant to exerciseÂ Â Â of options Â Â 35,424 Â Â Â - Â Â Â 126 Â Â Â - Â Â Â 126 Â Share-based compensation Â Â - Â Â Â - Â Â Â 656 Â Â Â - Â Â Â 656 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (12,284) Â Â (12,284) Balances at March 31, 2024 Â Â 58,691,596 Â Â $ 59 Â Â $ 394,556 Â Â $ (164,724) Â $ 229,891 Â Issuance of common stock pursuant to exerciseÂ Â Â of options Â Â 24,450 Â Â Â - Â Â Â 128 Â Â Â - Â Â Â 128 Â Issuance of stock pursuant to exerciseÂ Â Â common stock warrants Â Â 22,401 Â Â Â - Â Â Â 123 Â Â Â - Â Â Â 123 Â Issuance of common stock pursuant to theÂ Â Â ATM, net2 Â Â 3,535,246 Â Â Â 3 Â Â Â 47,930 Â Â Â - Â Â Â 47,933 Â Issuance of common stock pursuant to theÂ Â Â Registered Offering, net2 Â Â 5,151,588 Â Â Â 5 Â Â Â 71,863 Â Â Â - Â Â Â 71,868 Â Issuance of May 2024 Pre-funded Warrants, net2 Â Â - Â Â Â - Â Â Â 2,040 Â Â Â - Â Â Â 2,040 Â Share-based compensation Â Â - Â Â Â - Â Â Â 719 Â Â Â - Â Â Â 719 Â Cancellation of fractional shares due to theÂ Â 1-for-10 reverse stock split Â Â (114) Â Â - Â Â Â (1) Â Â - Â Â Â (1) Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (11,704) Â Â (11,704) Balances at June 30, 2024 Â Â 67,425,167 Â Â $ 67 Â Â $ 517,358 Â Â $ (176,428) Â $ 340,997 Â Issuance of common stock pursuant to exerciseÂ Â Â of options Â Â 137,229 Â Â Â - Â Â Â 642 Â Â Â - Â Â Â 642 Â Issuance of stock pursuant to exercise ofÂ Â Â common stock warrants Â Â 385 Â Â Â - Â Â Â 2 Â Â Â - Â Â Â 2 Â Share-based compensation Â Â - Â Â Â - Â Â Â 1,952 Â Â Â - Â Â Â 1,952 Â Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (15,122) Â Â (15,122) Balances at September 30, 2024 Â Â 67,562,781 Â Â $ 67 Â Â $ 519,954 Â Â $ (191,550) Â $ 328,471 Â 1. Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. 2. See Note 3, Investments and Agreements, for additional information. Â The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Table of Contents Â Perspective Therapeutics, Inc. Notes to the Unaudited Condensed Consolidated Financial Statements Â 1.Basis of Presentation and Summary of Significant Accounting PoliciesPerspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as â€œPerspective Therapeuticsâ€ or the â€œCompany.â€ All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes as set forth in the Companyâ€™s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K).The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in managementâ€™s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Companyâ€™s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.MergerOn February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company

in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.Discontinued OperationsOn April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.Reverse Stock SplitOn June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Companyâ€™s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Companyâ€™s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholderâ€™s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Companyâ€™s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.LiquidityThe Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At September 30, 5 Table of Contents Â 2024, the Company had cash, cash equivalents and short-term investments of $267.8 million and total accumulated deficit of $191.6 million. The Company has historically financed its operations primarily through selling equity.The Company believes that its $267.8 million of cash, cash equivalents and short-term investments as of September 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors.ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.Significant Accounting PoliciesThe Companyâ€™s significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Companyâ€™s significant accounting policies, and the Company has not adopted any significant accounting policies during the nine months ended September 30, 2024. 2.Loss per ShareBasic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form 10-Q). As the pre-funded warrantsâ€™ exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of September 30, 2024. At each of September 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Companyâ€™s net loss position.Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â September 30, 2024 Â Â September 30, 2023 Â Common stock warrants Â Â 416 Â Â Â 576 Â Common stock options Â Â 7,252 Â Â Â 4,468 Â Total potential dilutive securities Â Â 7,668 Â Â Â 5,044 Â Â Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30 to $3.00 per share. Â 3.Investments and Agreements2024 At-the-Market (ATM) AgreementOn August 13, 2024, the Company entered into a Controlled Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM Agent, and together, the ATM Agents) pursuant to which the Company 6 Table of Contents Â from time to time may offer and sell shares (2024 ATM Shares) of its Common Stock, through or to the ATM Agents having an aggregate sales price of up to $250.0 million.Subject to the terms and conditions of the 2024 ATM Agreement, each ATM Agent is required to use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Companyâ€™s instructions. The Company has provided the ATM Agents with customary indemnification rights, and the ATM Agents will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the ATM Shares effectuated through or to the applicable ATM Agent selling the ATM Shares.Â Sales of the 2024 ATM Shares, if any, under the 2024 ATM Agreement may be made in transactions that are deemed to be â€œat the market offeringsâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the 2024 ATM Shares and may at any time suspend offers under the 2024 ATM Agreement or terminate the 2024 ATM Agreement.Â The Common Stock to be sold under the 2024 ATM Agreement, if any, will be issued and sold pursuant to the Companyâ€™s automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024. On August 13, 2024, the Company filed a prospectus supplement to the May 2024 Registration Statement with the SEC in connection with the offer and sale of the 2024 ATM Shares pursuant to the 2024 ATM Agreement.Â As of September 30, 2024, the Company has not completed any transactions pursuant to the 2024 ATM Agreement.May 2024 Registered OfferingOn May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering.The gross proceeds to the Company from the Registered Offering were approximately $80.0 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering.The Registered Offering was made pursuant to the May 2024 Registration Statement, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024.The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Companyâ€™s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â March 2024 Private Placement with Institutional InvestorsOn March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024.The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses.The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee 7 Table of Contents Â equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment AgreementOn January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $50.0 million of gross proceeds (excluding Lantheusâ€™ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024.The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362).The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions.The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions.Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase AgreementOn January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenicsâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option AgreementOn January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-Î±-NET, the Companyâ€™s clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-Î±-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA.Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024.The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with Accounting Standards Codification (ASC) 730-20, Research and Development Arrangements, as Lantheus held approximately 8 Table of Contents Â 19.9% of the Companyâ€™s outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way.Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, â€œDeferred Income.â€ The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public OfferingOn January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024.The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering.The Public Offering was made pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024.The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-

funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â 2023 ATM AgreementThe Company entered into an ATM Issuance Sales Agreement, dated November 17, 2023, by and among the Company, Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (2023 ATM Agreement). Pursuant to the 2023 ATM Agreement, the Company established an ATM equity program under which it may offer and sell shares of its Common Stock, from time to time.On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200.0 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50.0 million of shares of its Common Stock pursuant to the 2023 ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the 2023 ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million.On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the 2023 ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million.On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement.On August 7, 2024, the Company delivered written notice to Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC that it was terminating the 2023 ATM Sales Agreement, which termination became effective August 12, 2024. 9 Table of Contents Â For additional information related to certain of the agreements discussed above, see Note 20, Subsequent Events, in the Companyâ€™s 2023 Form 10-K. Â 4.Discontinued OperationsThe GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray.Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below:â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10.0 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10.0 million and less than $15.0 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15.0 million or more, 5.0% of such net sales; andâ€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period.In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â September 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â Â 10 Table of Contents Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sales, net Â $ - Â Â $ 1,909 Â Â $ 2,178 Â Â $ 5,239 Â Cost of sales Â Â - Â Â Â 1,447 Â Â Â 1,564 Â Â Â 4,863 Â Gross profit Â Â - Â Â Â 462 Â Â Â 614 Â Â Â 376 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â - Â Â Â 169 Â Â Â 69 Â Â Â 1,000 Â Sales and marketing Â Â - Â Â Â 855 Â Â Â 941 Â Â Â 2,578 Â General and administrative Â Â - Â Â Â 222 Â Â Â 494 Â Â Â 668 Â Total operating expenses Â Â - Â Â Â 1,246 Â Â Â 1,504 Â Â Â 4,246 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total loss from discontinued operations Â $ - Â Â $ (784) Â $ (890) Â $ (3,870) The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales.Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Depreciation Â $ - Â Â $ 171 Â Amortization Â Â - Â Â Â 27 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Share-based compensation Â Â 166 Â Â Â 568 Â Additions to property and equipment Â Â - Â Â Â 287 Â The Company previously had a restricted cash account to provide collateral for the decommissioning of its leased facility for Cesium-131 production. This facility lease was assumed by GT Medical as part of the GT Medical APA which included the commitment to decommission the facility. The Company has subsequently moved the full balance of the restricted cash account to its general operating cash accounts.For the three and nine months ended September 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. Â 5.Property and EquipmentOn July 15, 2024, August 2, 2024 and October 31, 2024, the Company purchased a building located in the Houston, Texas, metropolitan area for $4.7 million, a building in the Chicago, Illinois, metropolitan area for $5.0 million, and a building in the Los Angeles, California, metropolitan area for $11.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment.On September 18, 2024, the Company entered into a Master Equipment and Services Agreement (MESA) and statements of work (SOWs) thereunder with Comecer SpA (Comecer), pursuant to which the Company agreed to purchase from Comecer manufacturing equipment for the production of the Companyâ€™s radiopharmaceutical products including, but not limited to, isotope processing hot cells and production suites and related equipment (collectively, the Deliverables) and services for installation and validation of the Deliverables at several of the Companyâ€™s production facilities in the United States. The aggregate consideration for such equipment and services pursuant to the MESA and SOWs is approximately â‚¬49.0 million payable in cash, excluding certain incidental costs such as taxes, customs and duties, local transport, insurance and rigging. The Company may also elect to purchase certain additional equipment 11 Table of Contents Â and services pursuant to the SOWs. The MESA provides for the payment of certain amounts in installments over the course of the production, installation and validation of the Deliverables.The Companyâ€™s property and equipment consisted of the following as of:Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Building Â $ 1,770 Â Â $ 1,770 Â Land Â Â 1,283 Â Â Â 1,283 Â Equipment Â Â 10,601 Â Â Â 2,683 Â Leasehold improvements Â Â 3,497 Â Â Â 179 Â Other1 Â Â 28,895 Â Â Â 330 Â Property and equipment Â Â 46,046 Â Â Â 6,245 Â Less accumulated depreciation Â Â (2,254) Â Â (669) Property and equipment, net Â $ 43,792 Â Â $ 5,576 Â 1.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. Â 6.Goodwill and Other Intangible AssetsGoodwillThe carrying amount of goodwill as of both September 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Companyâ€™s Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and nine months ended September 30, 2024.The following table summarizes the components of the Companyâ€™s other intangible assets (in thousands): Â September 30, 2024 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Â Â December 31, 2023 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â The Companyâ€™s IPR&D assets represent the estimated fair value of Viewpointâ€™s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpointâ€™s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. Â 7.Held-to-Maturity InvestmentsThe following table summarizes the carrying values and fair values of the Companyâ€™s financial instruments (in thousands): Â September 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury Bills Â $ 41,404 Â Â $ 11 Â Â $ - Â Â $ 41,415 Â Â 12 Table of Contents Â The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Companyâ€™s condensed consolidated statement of operations. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. Â 8.Fair Value MeasurementsFair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:Level 1 - Observable inputs such as quoted prices in active markets;Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; andLevel 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.Included in the Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â Â September 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 224,502 Â There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at September 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023.For information related to short-term investments, see Note 7, Held-to-Maturity Investments. Â 9.Share-Based CompensationOn May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Companyâ€™s stockholders approved the Companyâ€™s Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Companyâ€™s Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. On August 14, 2024, the Company filed a Form S-8 to register 4,870,092 additional shares of Common Stock authorized for issuance under the Amended and Restated Plan as approved by stockholders at the Annual Meeting.The following table presents the share-based compensation expense recognized for all share-based compensation arrangements, excluding share-based compensation expense reported in Note 4, Discontinued Operations (in thousands):Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Research and development $ 814 Â Â $ 179 Â Â $ 1,336 Â Â $ 763 Â General and administrative Â 1,138 Â Â Â 239 Â Â Â 1,825 Â Â Â 1,687 Â Total share-based compensation $ 1,952 Â Â $ 418 Â Â $ 3,161 Â Â $ 2,450 Â Â 13 Table of Contents Â 10.Commitments and ContingenciesThe Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Companyâ€™s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of September 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. Â 11.Related PartiesÂ In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024.Â On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA.Â On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024.Â For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements.Â On August 8, 2024, the Company entered into an access and license agreement with Lantheus. For additional information, see Note 12, Leases. Â 12.LeasesThe Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.On August 8, 2024, the Company assumed a lease from Progenics for office space in Somerset, New Jersey (Office). The lease terminates on November 30, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.6 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.Upon assuming the lease, the Company entered into a license and access agreement with Lantheus, which provides access to both dedicated and shared space of the Office (Access Agreement). There is no renewal option, and the termination options are available only for material breaches. In consideration of the Access Agreement, Lantheus agreed to pay base rent and associated costs through December 2024 directly to the landlord. The base rent through December 2024 is less than $0.1 million (Prepaid Rent). Pursuant to ASC 842, Leases, the Access Agreement is a sublease in which the Company is a sublessor and Lantheus is a

sublessee. The Company will amortize the Prepaid Rent over the entire lease term of 52 months.On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate 14 Table of Contents Â of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The weighted average remaining term and discount rate for the Companyâ€™s operating leases as of September 30, 2024 was 3.2 years and 8%, respectively.The Companyâ€™s operating lease expense was $0.3 million and $0.5 million for the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.4 million for the three and nine months ended September 30, 2023.The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of September 30, 2024 (in thousands):Â Year Ending December 31, Â Â Â 2024 (remaining three months) Â $ 245 Â 2025 Â Â 1,112 Â 2026 Â Â 647 Â 2027 Â Â 493 Â 2028 Â Â 443 Â Total Â Â 2,940 Â Less: imputed interest Â Â (361) Total lease liability Â Â 2,579 Â Less: current portion Â Â (903) Noncurrent lease liability Â $ 1,676 Â Â Asset Retirement ObligationThe Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Companyâ€™s condensed consolidated financial statements as of September 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of September 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets. Â 13.Notes PayableThe Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered into a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA.Â On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.The following table presents the current and long-term portions of the note payable (in thousands):Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Note payable Â $ 1,689 Â Â $ 1,725 Â Less: current portion Â Â (51) Â Â (49) Note payable, long-term portion Â $ 1,638 Â Â $ 1,676 Â Â 15 Table of Contents Â The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of September 30, 2024 (in thousands):Â Years ending December 31: Â Â Â 2024 (remaining three months) Â $ 13 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,689 Â Â 14.MergerOn February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpointâ€™s outstanding stock options and warrants as of the Merger date. The Merger was completed to provide the Company with a new isotope in a larger market.Â The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Â Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right-of-use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Â Liabilities assumed Â Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Goodwill Â $ 24,062 Â Â Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint. 16 Table of Contents Â Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Companyâ€™s condensed consolidated financial statements.Since the closing date, Viewpointâ€™s results of operations have been reported in the Companyâ€™s condensed consolidated financial statements and include grant revenue of approximately $0.4 million and $0.3 million, respectively, and operating loss of $18.6 million and $9.8 million, respectively, for the three months ended September 30, 2024 and 2023, and grant revenue of approximately $1.2 million and $1.1 million, respectively, and operating loss of $45.9 million and $29.3 million, respectively, for the nine months ended September 30, 2024 and 2023. 17 Table of Contents Â ITEM 2 â€“ MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together (i) with the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (Form 10-Q), (ii) with our audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on March 28, 2024 (2023 Form 10-K) and (iii) with other filings we have made with the SEC. As discussed under the heading â€œCautionary Note Regarding Forward-Looking Statements,â€ this discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involves numerous risks and uncertainties, including but not limited to those described under the heading â€œRisk Factorsâ€ in our 2023 Form 10-K that may cause actual results to differ materially from those described in or implied by any forward-looking statements. Unless the context otherwise requires, references in these notes to â€œthe Company,â€ â€œPerspective,â€ â€œwe,â€ â€œusâ€ and â€œourâ€ except where the context requires otherwise, refer to Perspective Therapeutics, Inc. and its subsidiaries. References to â€œViewpointâ€ refer to Viewpoint Molecular Targeting, Inc., a wholly owned subsidiary, and references to â€œIsorayâ€ refer to Isoray Medical, Inc., a wholly owned subsidiary. Overview We are developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. By leveraging our proprietary TAT platform, we aim to develop alpha-emitting radiopharmaceuticals that can be attached to targeting peptides to deliver the radioactive payload directly to difficult-to-treat tumors. The foundation of our TAT platform is our Pb-specific chelator (PSC) and peptide linker technology, which is designed to enable us to connect our alpha-emitting isotope of choice, Lead-212 (212Pb or Pb-212), to a desired targeting peptide to deliver radiation directly to cancer cells. Unlike commercially available chelators and linkers, our proprietary PSC and peptide linker have shown, in preclinical studies, the differentiated ability to promote enhanced clearance of the non-tumor localized 212Pb payload without sacrificing the uptake of the alpha particle into the tumor. Rapid clearance of the alpha-emitting isotope from normal tissues is important to enhance tolerability and widen the therapeutic window of our program candidates. We are also developing complementary diagnostics that utilize the same targeting peptide and imaging isotopes such as Lead-203 (203Pb or Pb-203), Gallium-68 (68Ga or Ga-68) or Copper-64 (64Cu or Cu-64) to provide the opportunity to understand which patients may respond to targeted therapy. Our platform generates TATs that are comprised of three components: (i) a targeting peptide that is designed to selectively target ligands that are unique to, or preferentially expressed on, cancer cells throughout the body; (ii) the alpha-emitting medical isotope 212Pb designed to kill cancer cells; and (iii) our proprietary linker that attaches the targeting molecule to the radioactive payload. We utilized our TAT platform to discover, design and develop our initial programs, VMT-Î±-NET and VMT01, which are currently in ongoing Phase 1/2a clinical trials, and we plan to continue to leverage our platform to assess the potential of and develop multiple additional pipeline programs. Using our proprietary platform technology, VMT-Î±-NET and VMT01 are engineered to target cancer-specific receptors on tumor cells. VMT-Î±-NET [212Pb]VMT-Î±-NET is a TAT in development for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing tumors who have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera. We have initiated dosing in Cohorts 1 and 2 of our Phase 1/2a study of [212Pb]VMT-Î±-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs). In April 2024, we announced that this program was selected by the U.S. Food and Drug Administration (FDA) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. The FDAâ€™s CDRP Program was initiated in 2022 to facilitate alignment of CMC development of novel products under investigational new drug (IND) applications with expedited clinical development timeframes based upon the anticipated clinical benefits of earlier patient access. The observation period was completed for dose limiting toxicity (DLT) in seven patients enrolled in Cohort 2 during the second quarter of 2024. Subsequently, the safety monitoring committee (SMC) determined that the safety data observations during the DLT period supported proceeding with dose escalation to Cohort 3. A protocol amendment to expand the number of patients dosed at 5 mCi (up to 40 patients) has been submitted to sites and patient enrollment is open. During the third quarter, data informing the SMCâ€™s recommendations were submitted to and accepted for presentation at the 2024 North American Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. We plan to host a conference call at the start of the conference and will provide details prior to the call. Based on FDA interactions prior to the initiation of patient dosing in this study, the decision to open a Cohort 3 will follow after consultation and alignment with the agency. Â On June 10, 2024, we announced multiple updates featuring our alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting. The data presentations highlighted favorable safety profiles and potential benefits of our lead clinical candidates. Specifically, we reported on a Phase 0 imaging trial that is evaluating the optimal imaging timepoint(s) for diagnostic/dosimetric performance of [203Pb]VMT-Î±-NET in neuroendocrine tumors. Investigators analyzed 48 lesions across nine patients, and the results showed that tumor uptake of [203Pb]VMT-Î±-NET peaked at approximately four hours post-injection, 18 Table of Contents Â with 98% of maximum uptake observed at one hour. The results suggest that imaging with [203Pb]VMT-Î±-NET at four hours post-injection has the best overall diagnostic performance, followed closely by imaging at one hour. Â Also at SNMMI, an investigator reported on [212Pb]VMT-Î±-NET planning based on [203Pb]VMT-Î±-NET predictive dosimetry in an investigator-sponsored trial. The investigators applied patient-specific dosimetry in a Phase 0 imaging trial (NCT05111509) of [203Pb]VMT-a-NET and in the first cohort of a Phase 1 absorbed-dose escalation study (NCT06148636) of [212Pb]VMT-Î±-NET. Ten patients with Î²-peptide receptor radionuclide therapy (PRRT)-relapsed or refractory gastroenteropancreatic (GEP)-NETs received [203Pb]VMT-Î±-NET (5 mCi) followed by sequential blood sampling, planar imaging and qSPECT/CT imaging at 1 hour, 4 hours, 24 hours and 48 hours post-administration. Three of ten patients received amino acid infusions while seven patients did not receive amino acids. Â The dosimetry showed that the average renal doses for patients who received amino acids was 0.46Â±0.20 Gy/mCi, as compared to 0.56Â±0.16 Gy/mCi for patients who did not receive amino acids; the difference was not statistically significant. For the three patients who received [212Pb]VMT-Î±-NET treatment, based upon their individual dosimetry results, they were prescribed 5.3, 7.3, and 13.3 mCi cumulative activity (delivered over two cycles), respectively, to reach the cohort target renal dose of 3.5 Gy. Higher levels of targeted renal-absorbed doses are in the protocol for subsequent cohorts. Â Additionally at SNMMI, the lead investigator reported on an exploratory first-in-human use of [212Pb]VMT-Î±-NET in adult patients with histologically confirmed metastatic NETs and medullary thyroid carcinomas in an investigator-led research study in India. The investigator reported updated safety and anti-tumor activity of [212Pb]VMT-Î±-NET administered at 67 ÂµCi/kg (2.5 MBq/kg) every eight weeks in 13 patients as of the data cut-off date of May 31, 2024. All patients received prior treatments, eight of whom received prior PRRT treatment. Six patients remained eligible for further treatments as of the data cut-off date. The investigator concluded that the toxicity profile suggests the potential for dose escalation to achieve optimal treatment responses. Confirmed tumor response per RECIST 1.1 was reported to be observed in eight of the 13 patients, while unconfirmed responses were observed in two additional patients who eventually had progressive disease and died. Median progression free survival was reported to be 16.4 months (95% confidence interval: 3.5 to NA). The investigator also reported higher absorbed doses in the tumors compared to select other tissues. Subsequently, in October 2024, at the 37th Annual Congress of the European Association of Nuclear Medicine in Hamburg, Germany, the investigator presented an update on a subset of the previously reported investigator-led research study in India. The cut-off date was September 15, 2024, and the study focused on 10 patients with well-differentiated GEP-NETs. These patients were treated with [212Pb]VMT-Î±-NET at a dosage of 67 ÂµCi/kg (2.5 MBq/kg), with an interval of eight weeks for up to six cycles. Treatment was well tolerated with a modest and manageable adverse effect profile. Confirmed tumor response per RECIST 1.1 was observed in six of the 10 GEP-NETs patients. The investigator again concluded that the toxicity profile suggests the potential for dose escalation to achieve optimal treatment responses. Long-term survival data will mature with continued follow up. Additionally, dosimetry estimates were collected from five of the 10 GEP-NETs patients discussed above. The results demonstrated that SPECT/CT imaging with [212Pb]VMT-Î±-NET showed prompt tumor accumulation, high tumor retention and rapid renal excretion in all patients. Overall, the findings suggest that post-treatment imaging of [212Pb]VMT-Î±-NET is feasible and can potentially serve as a valuable tool to evaluate and monitor patients through a full course of treatment. VMT01 [212Pb]VMT01 is a TAT in development for second-line or later treatment of patients with progressive MC1R-positive metastatic melanoma. MC1R, or melanocortin 1 receptor, is a protein that can be overexpressed in metastatic melanoma. VMT01 can be radiolabeled with either 203Pb for patient selection and dosimetry assessments, or 212Pb for alpha-particle therapy. In preclinical experiments [212Pb]VMT01 demonstrated efficacy via two distinct mechanisms of action: direct cell killing at high radiation doses and through immunostimulatory low-dose induction of immune-mediated cell death. Efficacy was augmented by immune checkpoint inhibitors. In September 2024, we announced that on the basis of these results, the FDA granted Fast Track Designation for the clinical development of [212Pb]VMT01. This study is a multi-center, open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05655312) in patients with histologically confirmed melanoma and MC1R-positive imaging scans. Patients were required to have already received standard of care. Eligible patients may receive up to three treatments with [212Pb]VMT01, eight weeks apart. In March 2024, we entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with Bristol Myers Squibbâ€™s checkpoint inhibitor nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. A protocol amendment was submitted in July 2024 to explore the combination of nivolumab with [212Pb]VMT01 in patients with histologically confirmed melanoma and positive MC1R imaging scans in our ongoing Phase 1/2a clinical study of [212Pb]VMT01. 19 Table of Contents Â In October 2024, we announced initial results from the first two dosing cohorts in our Phase 1/2a clinical study of [212Pb]VMT01. Three patients were enrolled in Cohort 1 (who received 3 mCi of [212Pb]VMT01), while seven patients were enrolled in Cohort 2 (who received 5 mCi of [212Pb]VMT01). Patients in each cohort received a median of five prior lines of systematic therapy, including a median of three prior lines of immunotherapy. â€¢Safety findings: No dose-limiting toxicities were observed among any patients, and no adverse events led to treatment discontinuation. Treatment emergent adverse events (TEAEs) were mostly Grades 1 and 2. None of the four cases of grade 3 TEAEs were deemed to be treatment related. There were no grade 4 or 5 TEAEs. No renal toxicities had been reported as of October 11, 2024 (there were no clinically significant changes in blood urea nitrogen or serum creatinine) in spite of dosimetry estimated renal radiation that approached the higher end of conventional dosing. â€¢Efficacy findings: All patients in Cohort 1 completed three treatments, with one patient experiencing an unconfirmed RECIST version 1.1 objective response after completion of treatment, and two patients experiencing stable disease at nine and 11 months from the start of treatment, respectively. In Cohort 2, patients progressed after either the first cycle (three patients) or the second cycle (four patients). These findings are consistent with published and ongoing preclinical studies showing immunostimulatory effects at lower radiation doses. The SMC reviewed these findings and recommended exploring a lower dose level of 1.5 mCi per dose, both as a single agent and in combination with nivolumab. The SMC recommendation would allow for the monotherapy and combination cohorts to proceed concurrently. An amendment to further explore lower dose levels for monotherapy is planned. The combination cohort at 1.5 mCi per dose with nivolumab is active and now open for enrollment. PSV359 In March 2024, we disclosed a novel pre-IND stage asset (PSV359) that targets fibroblast activation protein-Î±, which is associated with a variety of solid tumors. We are currently

working on an IND for PSV359 which we expect to file in late 2024. If the study may proceed, we expect that the U.S. Phase 1 study would commence in 2025. On June 10, 2024, at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting, researchers presented a novel fibroblast activation protein (FAP), which is a protein abundantly expressed in certain cancer cells as well as cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression. The peptide was conjugated to a Pb-specific chelator via a molecular linker to form a novel construct, PSV359. The purpose of this study was to evaluate the in vitro and in vivo performance of [203/212Pb]PSV359 in preclinical xenograft models. Overall, strong anti-tumor clinical activity of [212Pb]PSV359 was found in both FAP on cancer cells and FAP in stromal tissues xenograft models. During an update at the World Molecular Imaging Congress on September 10, 2024, we announced that data substantiated favorable safety and strong efficacy profiles in preclinical studies of our novel human FAP-targeting candidate, PSV359. During preclinical evaluation of [203/212Pb]PSV359 for imaging and alpha-particle therapy of cancers expressing FAP, the researcher found that in vitro, [203/212Pb]PSV359 demonstrated superior FAP-binding affinity and specificity, and that [203Pb]PSV359 showed strong tumor uptake and clearance from the blood via the renal system. In the study, [212Pb]PSV359 also showed strong anti-tumor effects in xenograft models in which FAP was either on cancer cells or in stromal tissues. Other Data presented at the World Molecular Imaging Congress in September 2024 also demonstrated the need for customized chelators to maximize stability and targeted delivery of potent alpha-particles. With the support of computational modeling, investigators used multiple chelators that are commonly used in radionuclide therapy, along with alpha emitters, beta emitters and imaging tracers, to determine compatibility between chelators and radionuclides. The study confirmed that modified chelators demonstrated superior performance when compared to conventional chelators. Â Pre-targeting technology is designed to enable the use of antibodies to direct radiolabeled ligands to tumor sites. Antibodies can bind with high specificity to a wider variety of cancer-specific proteins preferentially expressed on the surface of tumor cells. However, the amount of time required for an adequate amount of antibodies to bind to the cancer-specific proteins may not align with the properties of the desired isotope. By attaching an additional chemical entity to an antibody that would bind to a radioligand, the resultant modified antibodies may be administered separately from and in advance of the radioligand as appropriate. Preclinical optimization of this platform is underway, and initial targeting antibodies have been identified for further investigation. In January 2024, we announced that we have a license agreement with Mayo Clinic for the rights to Mayo's prostate-specific membrane antigen (PSMA) Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. This radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived Cu-64 for imaging and alpha-particle targeted therapies using 212Pb. Preclinical studies are ongoing to assess whether this new molecular entity meets the hurdle for progressing into the clinic with potential to achieve best-in-class profile. 20 Table of Contents Â Also in January 2024, we entered into an exclusive in-licensing of Stony Brook Universityâ€™s Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform which covers the global intellectual property rights to such platform. Pre-targeting using the CB7-Adma platform involves two steps. First, an antibody that binds with high specificity to a cancer-specific protein is administered via intravenous injection. This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site. Then, a radionuclide held tightly by our proprietary chelator attached to an Adma group is administered. The Adma group binds to the CB7 group that was previously attached to the cancerous cells with remarkable specificity, delivering radiation dose selectively to the tumor sites. Central to this innovation is CB7-Adma (host-guest) complex formation, driving the interaction between the antibody and radioligand. The chosen host-guest pair, CB7-Adma, demonstrates promising in vivo stability, modularity and low immunogenicity. The platformâ€™s potential was validated through in vivo profiling of ligands, employing a CB7-modified CEA targeting antibody. The agreement with Stony Brook University will expire on the later of the expiration date of the last to expire licensed patents or 20 years from the date of the first sale of a product utilizing the intellectual property. Â Intellectual Property (IP) Â Two patents have recently been granted on key assets for which we have exclusive licenses from the University of Iowa. US 12,128,115, granted by the United States Patent and Trademark Office on October 29, 2024, is directed to the use of compounds comprising PSC for performing chelating reaction with divalent metals, including Pb2+, and the use of such compounds for diagnosing and treating diseases. AU 2017281940, granted by IP Australia on October 31, 2024, is directed to melanoma-targeting radiopharmaceutical compounds and the use of such compounds for treating melanoma. Both patents further strengthen our IP portfolio. Funding Requirements We have had recurring losses since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our program candidates. Our costs will also increase as we: â€¢continue the development of our clinical-stage metastatic melanoma tumor and neuroendocrine tumor assets, including VMT01 and VMT-Î±-NET; â€¢continue the development of our other program candidates; â€¢continue to initiate and progress other supporting studies required for regulatory approval of our program candidates; â€¢initiate preclinical studies and clinical trials for any additional indications for our current program candidates and any future program candidates that we may pursue; â€¢continue to build our portfolio of program candidates through the acquisition or in-license of additional program candidates or technologies; â€¢continue to develop, maintain, expand and protect our intellectual property portfolio; â€¢pursue regulatory approvals for our current and future program candidates that successfully complete clinical trials; â€¢continue to build our manufacturing capabilities; â€¢support our marketing and distribution infrastructure to commercialize any future program candidates for which we may obtain marketing approval; and â€¢hire additional clinical, medical, development and other personnel. As of September 30, 2024, we had cash, cash equivalents and short-term investments of $267.8 million. We believe our cash, cash equivalents and short-term investments will be sufficient to fund our current planned operations for at least the next 12 months from the date the consolidated financial statements in this report were issued and into mid-2026. Monthly operating expenses are budgeted to increase for research and development and general and administrative expenses as management works to implement its strategy to advance our clinical assets in their clinical trials and to progress our preclinical assets towards clinical trials. Management anticipates a significant increase in expenses, particularly in research and development, as we undertake these activities. Manufacturing Equipment On September 18, 2024, we entered into a Master Equipment and Services Agreement (MESA) and statements of work (SOWs) thereunder with Comecer SpA (Comecer), pursuant to which we agreed to purchase from Comecer manufacturing equipment for the production of our radiopharmaceutical products including, but not limited to, isotope processing hot cells and production suites and related equipment (collectively, the Deliverables) and services for installation and validation of the Deliverables at several of our production facilities in the United States. The aggregate consideration for such equipment and services pursuant to the MESA and SOWs is approximately â‚¬49.0 million payable in cash, excluding certain incidental costs such as taxes, customs and duties, local transport, insurance and rigging. We may also elect to purchase certain additional equipment and services pursuant to the SOWs. The MESA provides for the payment of certain amounts in installments over the course of the production, installation and validation of the Deliverables. 21 Table of Contents Â Facility Acquisitions On July 15, 2024, August 2, 2024 and October 31, 2024, we purchased a building located in the Houston, Texas, metropolitan area for $4.7 million, a building in the Chicago, Illinois, metropolitan area for $5.0 million, and a building in the Los Angeles, California, metropolitan area for $11.0 million, respectively, which we intend to use for the manufacture of our program candidates upon completion of modifications and installation of equipment. In March 2024, we acquired the assets and associated lease of Lantheusâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey. We believe we will be able to convert the facility, which has three production suites, to manufacture finished radiopharmaceutical product. As a Current Good Manufacturing Practice (CGMP) compliant facility, we intend to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with TAT. As of October 2024, this facility is operational to supply investigational products to support VMT-Î±-NET clinical studies, in addition to the Coralville, Iowa facility which has been producing our investigational products since 2023. Moreover, with three CGMP suites at the facility, we expect to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S. We intend to continue to expand our manufacturing and supply network in the future as we anticipate increasing our clinical trial activities. We continue to evaluate the suitability of additional facilities as we look to expand our research and development capabilities. 2024 At-the-Market (ATM) Agreement On August 13, 2024, we entered into a Controlled Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM Agent, and together, the ATM Agents) pursuant to which we, from time to time, may offer and sell shares (2024 ATM Shares) of our Common Stock, through or to the ATM Agents having an aggregate sales price of up to $250.0 million. Subject to the terms and conditions of the 2024 ATM Agreement, each ATM Agent is required to use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon our instructions. We have provided the ATM Agents with customary indemnification rights, and the ATM Agents will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the ATM Shares effectuated through or to the applicable ATM Agent selling the ATM Shares. Â Sales of the 2024 ATM Shares, if any, under the 2024 ATM Agreement may be made in transactions that are deemed to be â€œat the market offeringsâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. We have no obligation to sell any of the 2024 ATM Shares and may at any time suspend offers under the 2024 ATM Agreement or terminate the 2024 ATM Agreement. Â The Common Stock to be sold under the 2024 ATM Agreement, if any, will be issued and sold pursuant to our automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024. On August 13, 2024, we filed a prospectus supplement to the May 2024 Registration Statement with the SEC in connection with the offer and sale of the 2024 ATM Shares pursuant to the 2024 ATM Agreement. Â As of September 30, 2024, we have not completed any transactions pursuant to the 2024 ATM Agreement. Amended and Restated Equity Incentive Plan On May 31, 2024, we held our 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, our stockholders approved our Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that our Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. On August 14, 2024, we filed a Form S-8 to register 4,870,092 additional shares of Common Stock authorized for issuance under the Amended and Restated Plan as approved by stockholders at the Annual Meeting. Brachytherapy Divestiture On April 12, 2024 (GT Medical Closing Date), we completed the sale of substantially all of the assets (GT Medical Closing) of Isoray to GT Medical Technologies, Inc. (GT Medical). As previously disclosed, on December 7, 2023, we entered into an Asset Purchase Agreement (the GT Medical APA) with Isoray and GT Medical. Pursuant to the GT Medical APA, Isoray sold to GT Medical, and GT Medical purchased from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s 22 Table of Contents Â commercial Cesium-131 business including equipment, certain contracts and leases, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray. Â Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis (excluding Series C-1 warrants which, if exercised, will reduce Isorayâ€™s ownership to 0.44% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis) as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below: â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10.0 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10.0 million and less than $15.0 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15.0 million or more, 5.0% of such net sales; and â€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period. Â As a result of the transaction, we have effectively exited the brachytherapy segment and are focused exclusively on our radiopharmaceutical development segment, our only operating segment and reporting segment. The sale of the brachytherapy segment represents a strategic shift that had a major effect on our operations. We accounted for the transaction as discontinued operations on the date the divestiture was announced. Accordingly, we are reporting the results of the brachytherapy segment operations and cash flows, and balance sheet classifications for the current and comparative periods as discontinued operations. Prior to the consummation of the sale, we were neither actively marketing the brachytherapy business for sale nor had intentions to abandon it. Â For additional information regarding our brachytherapy divestiture, see our Forms 8-K filed with the SEC on December 12, 2023, April 3, 2024 and April 16, 2024. Â Viewpoint Merger On February 3, 2023, we completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of ours, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, we issued 13,654,507 shares of Common Stock, representing approximately 49% of our fully diluted outstanding capital stock as of the closing of the Merger. Viewpoint is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. Â For additional information regarding the Merger, see our Forms 8-K filed with the SEC on September 28, 2022 and on February 6, 2023, and our Form 8-K/A filed with the SEC on April 21, 2023. Critical Accounting Policies and Estimates The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. Actual results may differ from these estimates under different assumptions or conditions and could, therefore, differ materially from those estimates if actual conditions differ from our assumptions. The accounting policies and related risks described in Part II, Item 7 and Note 2, Accounting Policies, to the consolidated financial statements included in Part II, Item 8 of our 2023 Form 10-K are those that depend most heavily on these judgments and estimates. As of September 30, 2024, there have been no material changes to any of the critical accounting policies and estimates contained therein. Results of Operations We previously presented our results in two segments: Drug Operations and Brachytherapy. Due to the sale of our brachytherapy segment to GT Medical in the second quarter of 2024 and the classification of the assets and operations of the brachytherapy segment as discontinued operations in our condensed consolidated financial statements, we have now determined that we operate in only one segment. The following does not include a discussion of the results of our discontinued operations. For additional information regarding our discontinued operations, see Note 4, Discontinued Operations, to the condensed consolidated financial statements in this Form 10-Q. 23 Table of Contents Â The following table sets forth our results of operations for the periods presented (in thousands): Â Â Three Months Ended September 30, Â Â Â Â Â Nine Months Ended September 30, Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Â Â Â Â Â

ended September 30, 2024, compared to $4.5 million for the three months ended September 30, 2023, an increase of $2.5 million. The increase in general and administrative expenses during the three months ended September 30, 2024 was primarily due to increased personnel costs as well as increased fees for professional services, taxes and insurance. Â General and administrative expenses were $18.4 million for the nine months ended September 30, 2024, compared to $16.1 million for the nine months ended September 30, 2023, an increase of $2.3 million. The increase in general and administrative expenses for the nine months ended September 30, 2024 was primarily due to increased personnel costs as well as increased fees for professional services, taxes and insurance. Â Liquidity and Capital Resources We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. We have historically financed our operations primarily through selling equity to investors. During the nine months ended September 30, 2024, we entered into various agreements and raised approximately $306.7 million in gross proceeds. The following table summarizes our cash flows for the periods presented (in thousands): Â 24 Table of Contents Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Net cash provided by (used in) operating activities Â $ 8,312 Â Â $ (27,905) Net cash (used in) provided by investing activities Â Â (80,329) Â Â 24,462 Â Net cash provided by financing activities Â Â 289,040 Â Â Â 433 Â Net increase (decrease) in cash and cash equivalents Â $ 217,023 Â Â $ (3,010) Â Cash flows from operating activities Net cash provided by operating activities of $8.3 million in the nine months ended September 30, 2024, was primarily due to amounts received pursuant to that certain option agreement, dated January 8, 2024, of $28.0 million, between us and Lantheus Alpha Therapy, LLC, an increase of $14.9 million in accounts payable and accrued expenses, and an increase of $4.2 million in non-cash charges such as share-based compensation and depreciation expense, partially offset by a net loss of approximately $39.1 million. Net cash used in operating activities of $27.9 million in the nine months ended September 30, 2023, was primarily due to a net loss of approximately $21.8 million and approximately $6.4 million in adjustments for non-cash activities, such as share-based compensation, depreciation and amortization expense, loss on property and equipment disposals, and changes in deferred taxes, partially offset by an increase of approximately $0.3 million in changes in operating assets and liabilities, primarily from accrued personnel expenses. Cash flows from investing activities Net cash used in investing activities of $80.3 million in the nine months ended September 30, 2024, was primarily due to acquisitions of property and equipment and purchases of U.S. Treasury Bills, partially offset by proceeds from the maturity of these previously held short-term investments. Net cash provided by investing activities of $24.5 million in the nine months ended September 30, 2023, was primarily due to transactions related to the purchase of fixed assets and proceeds from the maturity of previously held short-term investments in U.S. Treasury Bills and cash acquired as part of the merger with Viewpoint. Cash flows from financing activities Net cash provided by financing activities of $289.0 million in the nine months ended September 30, 2024, was primarily related to the various capital markets transactions and other agreements we entered into, partially offset by repayment of a note payable. For additional information regarding the cash we raised, see Sources of Liquidity below. Net cash provided by financing activities of $0.4 million in the nine months ended September 30, 2023, was primarily related to cash provided by the exercise of stock options of approximately $0.6 million, partially offset by the costs related to Common Stock issued in exchange for Viewpoint common stock and the repayment of notes payable. Sources of Liquidity 2024 At-the-Market (ATM) Agreement On August 13, 2024, we entered into a Controlled Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM Agent, and together, the ATM Agents) pursuant to which we, from time to time, may offer and sell shares (2024 ATM Shares) of our Common Stock, through or to the ATM Agents having an aggregate sales price of up to $250.0 million. Subject to the terms and conditions of the 2024 ATM Agreement, each ATM Agent is required to use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon our instructions. We have provided the ATM Agents with customary indemnification rights, and the ATM Agents will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the ATM Shares effectuated through or to the applicable ATM Agent selling the ATM Shares. Â Sales of the 2024 ATM Shares, if any, under the 2024 ATM Agreement may be made in transactions that are deemed to be â€œat the market offeringsâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. We have no obligation to sell any of the 2024 ATM Shares and may at any time suspend offers under the 2024 ATM Agreement or terminate the 2024 ATM Agreement. Â The Common Stock to be sold under the 2024 ATM Agreement, if any, will be issued and sold pursuant to our automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024. On August 13, 2024, we filed a prospectus supplement to the May 2024 Registration Statement with the SEC in connection with the offer and sale of the 2024 ATM Shares pursuant to the 2024 ATM Agreement. Â As of September 30, 2024, we have not completed any transactions pursuant to the 2024 ATM Agreement. 25 Table of Contents Â May 2024 Registered Offering On May 24, 2024, we entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of our Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering. Our gross proceeds from the Registered Offering were approximately $80.0 million, before underwriting discounts and commissions and estimated expenses of the Offering. We intend to use the net proceeds from the Registered Offering for: (i) the continued clinical development of VMT-Î±-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as a broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although we have no present commitments or agreements to do so. The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to our stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to us. Â On April 11, 2024, we sold shares of our Common Stock pursuant to that certain At Market Issuance Sales Agreement (ATM Agreement), dated as of November 17, 2023, by and among us, Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC. The sales resulted in gross proceeds to us of approximately $49.5 million. For additional information regarding the ATM Agreement, see our Form S-3 filed on November 17, 2023 and Form S-3/A filed on December 7, 2023. Â March 2024 Private Placement with Institutional Investors Â On March 4, 2024, we entered into an investment agreement with certain accredited institutional investors pursuant to which we agreed to issue and sell, in a private placement (March 2024 Private Placement), 9,200,998 shares of our Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024. The gross proceeds to us from the March 2024 Private Placement were approximately $87.4 million, before deducting fees and other estimated transaction expenses. Â Investment Agreement Â On January 8, 2024, we entered into an investment agreement (Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which we agreed to sell and issue to Lantheus in a private placement transaction certain shares (Lantheus Shares) of our Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by us (Lantheus Closing) was subject to us raising at least $50.0 million of gross proceeds (excluding Lantheusâ€™ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, we agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating us to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. We filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362). The Lantheus Investment Agreement also contains agreements between us and Lantheus whereby Lantheus is provided certain board observer and information rights of us, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions. Â 26 Table of Contents Â January 2024 Public Offering Â On January 17, 2024, we entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (Underwriters), in connection with our underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of our Common Stock and in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, we granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which such option was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024. Â The gross proceeds to us from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering. The Public Offering was made pursuant to our shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024. Â The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to our stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to us. Funding Requirements We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our program candidates. Our costs will also increase as we: â€¢continue the development of our clinical-stage metastatic melanoma tumor and neuroendocrine tumor assets, including VMT01 and VMT-Î±-NET; â€¢continue the development of our other program candidates; â€¢continue to initiate and progress other supporting studies required for regulatory approval of our program candidates; â€¢initiate preclinical studies and clinical trials for any additional indications for our current program candidates and any future program candidates that we may pursue; â€¢continue to build our portfolio of program candidates through the acquisition or in-license of additional program candidates or technologies; â€¢continue to develop, maintain, expand and protect our intellectual property portfolio; â€¢pursue regulatory approvals for our current and future program candidates that successfully complete clinical trials; â€¢continue to build our manufacturing capabilities; â€¢support our marketing and distribution infrastructure to commercialize any future product candidates for which we may obtain marketing approval; and â€¢hire additional clinical, medical, development and other personnel. At September 30, 2024, we had cash, cash equivalents and short-term investments of $267.8 million. We believe our cash, cash equivalents and short-term investments will be sufficient to fund our current planned operations and capital investments into mid-2026. Monthly operating expenses are budgeted to increase for research and development and general and administrative expenses as management works to implement our strategy to advance our clinical assets in our clinical trials and to progress our preclinical assets towards clinical trials. Management anticipates a significant increase of expenses, particularly in research and development, as we undertake these activities. 27 Table of Contents Â We expect we will need to raise additional capital until we are profitable, which may never occur. If no additional capital is raised through either additional public or private equity financings, debt financings, strategic relationships, alliances and licensing agreements, or a combination thereof, we may delay, limit or reduce discretionary spending in areas related to research and development activities and other general and administrative expenses in order to fund our operating costs and working capital needs. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect that we will require additional capital to pursue in-licenses or acquisitions of other program candidates. If we receive regulatory approvals for our program candidates, we expect to incur commercialization expenses related to program manufacturing, sales, marketing and distribution, depending on where we choose to commercialize or whether we commercialize jointly or on our own. Because of the numerous risks and uncertainties associated with research, development and commercialization of our program candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including: â€¢the scope, progress, results and costs of researching and developing our program candidates, and conducting preclinical studies and clinical trials; â€¢the costs, timing and outcome of regulatory review of our program candidates; â€¢the costs and timing of hiring new employees to support our continued growth; â€¢the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; â€¢the extent to which we acquire or in-license other program candidates and technologies; and â€¢our ability to generate cash, and successfully obtain additional working capital, to fund our operating, investing and financing activities. Until such time, if ever, that we can generate program revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, strategic alliances, licensing arrangements, outright sales of program candidates or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, reduce or terminate our program development or future commercialization efforts or grant rights to develop and market programs or program candidates that we would otherwise prefer to develop and market ourselves. Capital expenditures Management is reviewing all aspects of research and development and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems and personnel are available to support and drive clinical trials and preclinical activities. Financing activities When we do require capital in the future, we expect to finance our cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing stockholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to stockholders. Other Commitments and Contingencies We presented our other commitments and contingencies in our 2023 Form 10-K for the period ended December 31, 2023. There have been no material changes outside of the ordinary course of business in those obligations during the nine months ended September 30, 2024, other than those disclosed in Note 10, Commitments and Contingencies, to the condensed consolidated financial statements in this Form 10-Q. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements. 28 Table of Contents Â ITEM 3 â€“ QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the Exchange Act), and are not required to provide the information required under this item. ITEM 4 â€“ CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Under the

supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2024. Based on that evaluation, our principal executive officer and our principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met. Changes in Internal Control over Financial Reporting There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 29 Table of Contents Â PART II - OTHER INFORMATION ITEM 1 â€“ LEGAL PROCEEDINGS We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition. ITEM 1A â€“ RISK FACTORS This section augments and updates certain risk factors disclosed under the heading â€œRisk Factorsâ€ contained in Part I, Item 1A of our 2023 Form 10-K. The following risk factors should be read together with the other risk factors disclosed in the Annual Report. In addition to the other information in this Quarterly Report on Form 10-Q, all the risk factors should be carefully considered in evaluating us and our common stock. Any of these risks, many of which are beyond our control, could materially and adversely affect our financial condition, results of operations or cash flows, or cause our actual results to differ materially from those projected in any forward-looking statements. We may also face other risks and uncertainties that are not presently known, are not currently believed to be material, or are not identified below because they are common to all businesses. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. There have been no material changes in our risk factors since such 2023 Form 10-K filing. We may not be successful in managing the build-out of our manufacturing facilities and associated costs or satisfying manufacturing-related regulatory requirements. We have been investing in our manufacturing capabilities and recently acquired several manufacturing facilities. In March 2024, we acquired the assets and associated lease of Lantheus Holdings, Inc.â€™s radiopharmaceutical manufacturing facility in Somerset, New Jersey. This site has three production suites that Perspective intends to utilize to supply drug product for the northeastern half of the United States. On July 15, 2024, August 2, 2024, and October 31, 2024, we purchased a building located in the Houston, Texas, metropolitan area for $4.7 million, a building in the Chicago, Illinois, metropolitan area for $5.0 million, and a building in the Los Angeles, California, metropolitan area for $11.0 million, respectively, which we intend to use for the manufacture of our program candidates upon completion of modifications and installation of equipment. The build-out of these facilities and related equipment purchases are complex and specialized and will involve substantial capital expenditures, and it could take longer, and cost more, than currently expected. Significant delays and/or cost overruns would result in higher expenditures and could be disruptive to operations, any of which could have a negative impact on our financial conditions or results of operations. We also may not successfully realize the anticipated benefits from the capital expenditure at such facilities based on factors such as delays and uncertainties regarding development, regulatory approval and commercialization of our product candidates, as well as the potential to lose access to any leased facilities. Moreover, any production shortfall that impairs the supply of our product or other product candidates could negatively impact our ability to complete clinical trials, obtain regulatory approvals and commercialize our other product candidates. A product shortfall could have a material adverse effect on our business, financial condition and results of operations. In addition, our planned operations, including our development, testing and future manufacturing activities, are subject to numerous environmental, health, and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, carcinogenic compounds, mutagenic compounds and compounds that may have a toxic effect on reproduction and laboratory procedures. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. Failure to successfully complete our build-outs and successfully operate our planned manufacturing facilities and satisfy manufacturing-related regulatory requirements could adversely affect the commercial viability of our product candidates and our business. ITEM 2 â€“ UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3 â€“ DEFAULTS UPON SENIOR SECURITIES None. ITEM 4 - MINE SAFETY DISCLOSURES Not applicable. 30 Table of Contents Â ITEM 5 â€“ OTHER INFORMATIONRule 10b5-1 Trading ArrangementsDuring the three months ended September 30, 2024, none of our directors or executive officers adopted, modified or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K. Â 31 Table of Contents Â ITEM 6 â€“ EXHIBITS (Except as otherwise indicated (a) all exhibits were previously filed, (b) all omitted exhibits are intentionally omitted, and (c) all documents referenced below were filed under SEC file number 001-33407.) Â Exhibits: 2.1 Agreement and Plan of Merger, dated September 27, 2022, by and between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on September 28, 2022. 2.2 First Amendment to Agreement and Plan of Merger, dated October 21, 2022, between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on October 24, 2022. Â Â Â 3.1 Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on February 16, 2023. 3.2 Â Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc., effective June 14, 2024, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on June 14, 2024. Â Â Â 3.3 Amended and Restated Bylaws of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.2 of the Form 8-K filed on February 16, 2023. Â Â Â 4.1 Â Form of Pre-funded Warrant to Purchase Common Stock, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on May 29, 2024. Â Â Â 10.1*! Â Separation Agreement between Perspective Therapeutics, Inc. and Mark Austin, dated August 26, 2024. Â Â Â 10.2+# Â Master Equipment and Services Agreement, dated as of September 18, 2024, by and between Perspective Therapeutics, Inc. and Comecer SpA, incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Company on September 20, 2024. Â Â Â 10.3+# Â Form of Statement of Work Pursuant to Master Equipment and Services Agreement, dated as of September 18, 2024, by and between Perspective Therapeutics, Inc. and Comecer SpA, incorporated by reference to Exhibit 10.2 to the Form 8-K filed by the Company on September 20, 2024. Â Â Â 10.4 Â Controlled Equity OfferingSM Sales Agreement, dated as of August 13, 2024, by and among Perspective Therapeutics, Inc., Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, incorporated by reference to Exhibit 1.1 of the form 8-K filed on August 13, 2024. Â Â Â 31.1* Â Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 31.2* Â Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 32** Â Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS* Â Inline XBRL Instance Document Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents Â Â Â 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â Â Â * Â Filed herewith ** Â Furnished herewith + Â Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished. # Â Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. ! Â Denotes Management Contract or Compensatory Plan or Arrangement Â 32 Table of Contents Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Dated: November 12, 2024 Â Â Â Â PERSPECTIVE THERAPEUTICS, INC., a Delaware corporation Â Â Â Â /s/ Johan (Thijs) Spoor Â Â Johan (Thijs) Spoor Â Â Chief Executive Officer(Principal Executive Officer) Â Â Â Â /s/ Jonathan Hunt Â Â Jonathan Hunt Â Â Chief Financial Officer and Chief Accounting Officer(Principal Financial Officer and Principal Accounting Officer) Â 33 EX-10.1 2 catx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1Â CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY â€œ[***]â€ HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Â Phone: (206) 676-0900 2401 Elliott Ave., Suite 320 Toll Free: (877) 447-6729 Seattle, WA 98121 https://perspectivetherapeutics.com Â Â August 19, 2024 Mark Austin [***] Â Re: Terms of Separation Dear Mark: This letter confirms the agreement (â€œAgreementâ€) between you and Perspective Therapeutics, Inc. (the â€œCompanyâ€) concerning the terms of your separation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1.Cessation of Employment: Your employment as the Companyâ€™s Vice President of Finance, Corporate Controller and Corporate Secretary and as the Companyâ€™s co-principal financial officer and principal accounting officer ceased effective August 16, 2024, (the â€œOfficer Separation Dateâ€). As of the Officer Separation Date, you are deemed to no longer serve as an officer or director (as applicable) of the Company and any of its subsidiaries and affiliates. Following the Officer Separation Date, you will remain a full-time employee of the Company in the role of Strategic Advisor, providing transition services from the Officer Separation Date through August 30, 2024 (such period, the â€œTransition Periodâ€). During the Transition Period, you will provide, on a best efforts basis, transition assistance and advice as set forth on Exhibit A and as reasonably requested from time to time by the Companyâ€™s Chief Executive Officer, Chief Financial Officer or Board of Directors. Your employment with the Company will cease effective as of 11:59pm PDT on the final day of the Transition Period (the â€œSeparation Dateâ€). 2.Salary and Expense Reimbursements: No later than the Companyâ€™s first regular payroll date following the Separation Date, we will provide you with one or more final paychecks for all wages, accrued but unused vacation and any similar payments due you from the Company as of the Separation Date. By signing below, you acknowledge that the Company does not owe you any other amounts (other than as provided for in Section 3 herein). Please promptly submit for reimbursement all final outstanding expenses, if any. 3.Separation Compensation: Subject to, and wholly contingent upon, you (i) executing and delivering this Agreement and thereby agreeing to the general release and waiver of claims and covenant not to sue set forth below and your other promises herein, on both the Officer Separation Date and the Separation Date, and such general release and waiver of claims becoming irrevocable, Â Â and (ii) complying with the terms of this Agreement, the Company agrees to provide you with the following (collectively, the â€œSeparation Compensationâ€): a.Severance: The Company agrees to pay you by the next payroll processing date following the Effective Date (as defined below) of this Agreement, a lump sum payment in the gross amount of $138,360.75, less applicable state and federal payroll deductions, which equals approximately six (6) months of your base salary. b.COBRA: A lump sum payment in the amount of $7,686.54, minus required withholdings, which is intended to help you pay for health insurance premiums for a period of six (6) months. This will be reported to the IRS as wages on your Form W-2. By signing below, you acknowledge that you are receiving the Separation Compensation outlined in this section in consideration for waiving your rights to claims referred to in this Agreement and that you would not otherwise be entitled to the Separation Compensation. 4.Post-Employment Obligations: You hereby acknowledge and agree that: (a) you will continue to be bound by the Companyâ€™s form of Confidentiality and Non-Disclosure Agreement, which is attached hereto as Exhibit B (the â€œConfidentiality Agreementâ€) and which is hereby incorporated by reference into this Agreement; (b) as a result of your employment with the Company, you have had access to the Companyâ€™s proprietary and/or confidential information, observations and data which may constitute trade secrets, and you agree not to disclose to any person or entity or use for your own (or any other personâ€™s or entityâ€™s) purposes any confidential information or any confidential or proprietary information of other persons or entities in the possession of the Company and its affiliates (â€œThird Party Informationâ€), without the prior written consent of the Company unless and to the extent that such confidential information or Third Party Information becomes generally known to and available for use by the public other than as a result of your direct or indirect acts or omissions; and (c) you must, and by your signature below confirm that you shall, deliver to the Company or its designated representative, no later than the Separation Date, all documents and data of any nature containing or pertaining to such information, and not take with you, or otherwise retain in any respect, any such documents or data or any reproduction thereof. For the avoidance of doubt, such proprietary and/or confidential information includes, but is not limited to, all information and materials concerning the business and affairs of the Company and its subsidiaries and predecessors, and information belonging to the Company or its clients, staff, or service providers, including office keys and Company equipment, credit cards, documents, policy or practice manuals, files, written materials, memoranda, electronic information, computer software or hardware, computer and other passwords, computer disks, records of the Company or its past, present or prospective clients, vendors and other third parties, and copies of such records, correspondence, memoranda, notes, plans, reports and other books or manuals issued by the Company. To the extent an electronic copy exists of such materials, you must permanently delete such electronic copy/copies on or before the Separation Date (following transmittal to the Company of such documents as set forth above). You hereby acknowledge that if you do not return any hard-copy paper documents and/or electronic media within the time set forth above, you are affirming and representing to the best of your knowledge that you have no such materials in your possession. 5.Inventions and Intellectual Property Rights: You acknowledge that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications and copyrightable work (whether or not including any Confidential Information) and all registrations or applications related thereto, all other proprietary Â Â Â information and all similar or related information (whether or not patentable) that relate to the Companyâ€™s or any of its subsidiariesâ€™ actual or anticipated business, research and development or existing or future products or services and that you have conceived, developed or made (whether alone or jointly with others) while employed by the Company or any of its subsidiaries or predecessors, whether before or after the date of this Agreement (â€œWork Productâ€), belong to the Company. You agree to disclose such Work Product to the Company and, at the Companyâ€™s expense, perform all actions reasonably requested by the Company (whether during or after your employment) to establish and confirm such ownership (including assignments, consents, powers of attorney and other instruments). You acknowledge that all Work Product shall be deemed to constitute â€œworks made for hireâ€ under the U.S. Copyright Act of 1976, as amended. 6.Stock Options: Pursuant to your Stock Option Agreement(s) with the Company and the Company's equity incentive plans (together, the â€œStock Option Agreementsâ€), you were granted options to purchase shares of the Company's common stock (the â€œOptionâ€). Your rights concerning the Options are summarized in the equity report which is attached hereto as Exhibit C. 7.General Release and Waiver of Claims: a.In consideration of and subject to the performance by the Company of its obligations under this Agreement, you acknowledge and agree that the payments and promises set forth in this Agreement are in full satisfaction of all accrued salary, vacation, bonus and commission pay, profitâ€‘sharing, stock, stock options or other ownership interest in the Company, termination benefits or other compensation to which you may be entitled by virtue of your employment with the Company or your separation from the Company. To the fullest extent permitted by law, you hereby release and waive any other claims you may have against the Company, all of its affiliates (including, but not limited, to, Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc.) and all of the Companyâ€™s present and former owners, representatives, agents, officers, shareholders, partners, members, employees, directors, attorneys, subscribers, subsidiaries, successors and assigns, and their respective affiliates (collectively, the â€œReleaseesâ€), whether known or not known, including, without limitation, claims under any employment laws, including, but not limited to, claims of unlawful discharge, breach of contract, breach of the covenant of good faith and fair dealing, fraud, violation of public policy, defamation, physical injury, emotional distress, claims for additional compensation or benefits arising out of your employment or your separation of employment, claims under Title VII of the 1964 Civil Rights Act, as amended, the Washington Law Against Discrimination and any other laws and/or regulations relating to employment or employment discrimination, including, without limitation, claims based on age or under the Age Discrimination in Employment Act or Older Workers Benefit Protection Act, and/or claims based on disability or under the Americans with Disabilities Act. b.You hereby acknowledge that you are aware of the principle that a general release does not extend to claims that the releasor does not know or suspect to exist in his or her favor at the time of executing the release, which, if known by him or her, must have materially affected his or her settlement with the releasee. With knowledge of this principle, you hereby agree to expressly waive any rights you may have to that effect. c.You and the Company do not intend to release claims that you may not release as a matter of law, including but not limited to claims for indemnity, and any claims for enforcement of this Agreement. To the fullest extent permitted by law, any dispute regarding the Â Â Â scope of this general release shall be determined by an arbitrator under the procedures set forth in the arbitration clause below. 8.Covenant Not to Sue: To the fullest extent permitted by law, at no time subsequent to the execution of this Agreement will you pursue, or cause or knowingly permit the prosecution, in any state, federal or foreign court, or before any local, state, federal or foreign administrative agency, or any other tribunal, of any charge, claim or action of any kind, nature and character whatsoever, known or unknown, which you may now have, have ever

had, or may in the future have against Releasees, which is based in whole or in part on any matter released by this Agreement. Nothing in this section shall prohibit or impair you or the Company from complying with all applicable laws, nor shall this Agreement be construed to obligate either party to commit (or aid or abet in the commission of) any unlawful act. 9.Cooperation: You agree to reasonably cooperate with the Company in any internal investigation, any administrative, regulatory, or judicial proceeding or any dispute with a third party. You understand and agree that you cooperation may include, but not be limited to, making yourself available to the Company for interviews and factual investigations; appearing at the Companyâ€™s request to give testimony without requiring service of a subpoena or other legal process; volunteering to the Company pertinent information; and turning over to the Company all relevant documents which are or may come into your possession. 10.Protected Rights: a.You understand that nothing in this Agreement, including the General Release and Waiver of Claims, Covenant Not to Sue, Non-Disparagement and Confidentiality sections contained herein, limits, impedes or restricts: (a) your ability to file a charge or complaint with the Equal Employment Opportunity Commission (the â€œEEOCâ€), the National Labor Relations Board (the â€œNLRBâ€), the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local government agency or commission (â€œGovernment Agenciesâ€); or (b) if you are a non-supervisory (as defined under the National Labor Relations Act (the â€œNLRAâ€)) Company employee, you from exercising your protected rights under Section 7 of the NLRA, including your right to file an unfair labor practice charge with the NLRB and/or assist other current or former Company employees in doing so. You further understand that this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate and/or assist in any investigation or proceeding that may be conducted by any Government Agency, including providing documents (including this Agreement) or other information, without notice to the Company. This Agreement does not limit your right to receive an award for information provided to any Government Agencies or prohibit you from providing truthful information in response to a subpoena or other legal process. b.Further, nothing in the Non-Disparagement and Confidentiality sections, or otherwise in this Agreement, shall prohibit you from discussing or disclosing workplace or work-related conduct (including conduct at the workplace, at work-related events coordinated by or through the Company, between employees, or between the Company and an employee, whether on or off the employment premises) that you reasonably believed, under Washington state, federal, or common law, to be illegal discrimination, illegal harassment, illegal retaliation, a wage and hour violation, sexual assault, or that is recognized as against a clear mandate of public policy. Â Â Â 11.Non-Disparagement: Subject to the Protected Rights section above, and otherwise to the fullest extent permitted by applicable law, you agree that you will not, directly or indirectly, make any disparaging oral or written statements that are disloyal or maliciously untrue (and specifically, made with knowledge of their falsity or with reckless disregard for the truth or falsity of the statements) regarding the Company and/or its products, services, directors, officers, employees and affiliated entities, including, but not limited to, any statement posted on social media (including online company review sites) or otherwise on the Internet, whether or not made anonymously or with attribution. Additionally, you acknowledge that all requests for employment references will be directed to the Companyâ€™s Human Resources department. The Company will provide a neutral reference confirming only the dates of employment and positions held unless otherwise required by law. 12.Arbitration: Except for any claim for injunctive relief arising out of a breach of a partyâ€™s obligations to protect the otherâ€™s proprietary information, the parties agree to arbitrate, in Seattle, Washington through JAMS, any and all disputes or claims arising out of or related to the validity, enforceability, interpretation, performance or breach of this Agreement, whether sounding in tort, contract, statutory violation or otherwise, or involving the construction or application or any of the terms, provisions, or conditions of this Agreement. Any arbitration may be initiated by a written demand to the other party. The arbitratorâ€™s decision shall be final, binding, and conclusive. The parties further agree that this Agreement is intended to be strictly construed to provide for arbitration as the sole and exclusive means for resolution of all disputes hereunder to the fullest extent permitted by law. The parties expressly waive any entitlement to have such controversies decided by a court or a jury. 13.Consequences of Breach: In the event you breach or threaten to breach the terms and provisions of this Agreement, the Company shall be entitled, if it so elects, to institute and prosecute any action or proceedings either in law or equity, for such relief as it deems appropriate, including without limiting the generality of the foregoing, proceedings to enforce the specific performance thereof by you or to enjoin you from engaging in conduct prohibited by this Agreement. You hereby waive the requirement that the Company post a bond or undertaking to obtain an injunction pursuant to this provision. 14.Attorneysâ€™ Fees: If any action is brought to enforce the terms of this Agreement, the prevailing party will be entitled to recover its reasonable attorneysâ€™ fees, costs and expenses from the other party, in addition to any other relief to which the prevailing party may be entitled. 15.Confidentiality: Subject to the Protected Rights section above, and otherwise to the fullest extent permitted by applicable law, the contents, terms and conditions of this Agreement must be kept confidential by you and may not be disclosed except to your immediate family, accountant or attorneys or pursuant to subpoena or court order. 16.No Admission of Liability: This Agreement is not and shall not be construed or contended by you to be an admission or evidence of any wrongdoing or liability on the part of Releasees, their representatives, heirs, executors, attorneys, agents, partners, officers, shareholders, directors, employees, subsidiaries, affiliates, divisions, successors or assigns. This Agreement shall be afforded the maximum protection allowable under Washington Rules of Evidence 408 and/or any other state or federal provisions of similar effect. Â Â Â 17.Complete and Voluntary Agreement: This Agreement, together with Exhibit A, Exhibit B and Exhibit C hereto and the Stock Option Agreements (if any), constitute the entire agreement between you and Releasees with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, relating to such subject matter. You acknowledge that neither Releasees nor their agents or attorneys have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this Agreement for the purpose of inducing you to execute the Agreement, and you acknowledge that you have executed this Agreement in reliance only upon such promises, representations and warranties as are contained herein, and that you are executing this Agreement voluntarily, free of duress or coercion. 18.Severability: The provisions of this Agreement are severable, and if any part of it is found to be invalid or unenforceable, including, without limitation, any part of the General Release, Covenant Not to Sue, Non-Disparagement and/or Confidentiality sections above, the other parts shall remain fully valid and enforceable. Specifically, should a court, arbitrator, or government agency conclude that a particular claim may not be released as a matter of law, it is the intention of the parties that the general release, the waiver of unknown claims and the covenant not to sue above shall otherwise remain effective to release any and all other claims. 19.Modification; Counterparts; Electronic/PDF Signatures: It is expressly agreed that this Agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement that specifically refers to this Agreement, executed by authorized representatives of each of the parties to this Agreement. This Agreement may be executed in any number of counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Execution of an electronic or PDF copy shall have the same force and effect as execution of an original, and a copy of a signature will be admissible in any legal proceedings as if an original. 20.Review of Separation Agreement; Expiration of Offer: You understand that you may take up to five (5) days to consider this Agreement (the â€œConsideration Periodâ€). The offer set forth in this Agreement, if not accepted by you before the end of the Consideration Period, will automatically expire. By signing below, you affirm that you were advised to consult with an attorney prior to signing this Agreement and that any modifications to this Agreement, whether or not material, will not restart the Consideration Period. 21.Effective Date: You will have seven (7) days after execution of this Agreement (the â€œRevocation Periodâ€) to revoke the release contained herein, and such release shall not become effective or enforceable until such Revocation Period has expired. The Companyâ€™s promises under this Agreement, including but not limited to its obligation to provide Separation Compensation, will arise only after this time. 22.Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the State of Washington. YOU MUST EXECUTE THIS RELEASE BY 11:59pm PDT ON AUGUST 26, 2024, and again within five (5) days after the separation Date IN ORDER TO BE ELIGIBLE TO RECEIVE THE SEPARATION COMPENSATION. Â Â Â Â If you agree to abide by the terms outlined in this Agreement, please sign and return it to Sarah Wille (HR) at [***]. I wish you the best in your future endeavors. Â Â Â Â Sincerely, Â Perspective Therapeutics, Inc. By: /s/ Thijs Spoor Â Thijs Spoor, Chief Executive Officer Â Â Â READ, UNDERSTOOD AND AGREED Â Â /s/ Mark Austin Â Date: 08/26/2024 Mark Austin Â Â Â Â Â Â Â RE-AFFIRMED Â Â /s/ Mark Austin Â Date: 09/03/2024 Mark Austin Â Â Â Â Â Â Â Â Â Â Â EXHIBIT A TRANSITION SERVICES Â [Omitted.] Â Â Â Â EXHIBIT B CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT Â This Confidentiality and Non-Disclosure Agreement (the â€œAgreementâ€), entered into and effective as of [ ], 2024 (the â€œEffective Dateâ€), by and between PERSPECTIVE THERAPEUTICS, INC., a Delaware corporation (together with its Affiliates and subsidiaries (the â€œDisclosing Partyâ€), and Mark Austin (the â€œReceiving Partyâ€). The Disclosing Party and the Receiving Party may each hereinafter be referred to individually as a â€œPartyâ€ and collectively as the â€œParties.â€ Â RECITALS Â WHEREAS, in conjunction with Receiving Partyâ€™s employment with the Disclosing Party (the â€œPurposeâ€), the Disclosing Party may wish to disclose certain Confidential Information (as defined hereunder) to the Receiving Party. NOW THEREFORE, as a material inducement for the disclosure of Confidential Information and in consideration of the covenants and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: Â ARTICLE I. DEFINITIONS Â For purposes of this Agreement, the following terms will have the meanings ascribed to them below, unless otherwise clearly required by the context in which such term is used: Â 1.1â€œAffiliateâ€ means, with respect to either Party, any other corporation or business entity that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party for as long as such control exists. For purposes of this definition, the term â€œcontrolâ€ means (i) the direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such entity, or (ii) the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. Â 1.2â€œDisclosing Partyâ€ has the meaning set forth in the introductory paragraph of this Agreement. Â 1.3â€œPurposeâ€ has the meaning set forth in the Recitals section of this Agreement. Â 1.4â€œReceiving Partyâ€ has the meaning set forth in the introductory paragraph of this Agreement. Â Â 9 Â ARTICLE II. CONFIDENTIAL INFORMATION Â 2.1 Confidential Information. As used in this Agreement, the term â€œConfidential Informationâ€ means any and all data, information, documents, records and/or materials including, but not limited to, that which relates to business plans, strategic plans or business methods that derive economic value from not being generally known to other persons or easily ascertainable by other persons, business policies, research, product plans, product pricing or product strategy, services, service pricing or service strategy, actual or proposed alliance partners, actual or proposed vendors, vendor offerings and pricing, actual or proposed customers, customer usage and customer purchasing potential, employee and consulting relationship information, actual or proposed markets, sales and marketing materials, plans and methods, specifications, shop-practices, software, developments, inventions (whether or not patented), product names or marks, trade secrets, technologies, discoveries, and any other intellectual property (whether or not registered), processes, designs, drawings, engineering, hardware configuration information or finance, accounting or financial plans and forecasts, compilations, formulas, devices, methods, prototypes, techniques, procedures, protocols, programs, records, and databases, that are disclosed or delivered by or on behalf of the Disclosing Party to the Receiving Party in connection with the Purpose, regardless of whether disclosed in writing, orally, visually, or in tangible, electronic, or any other form or manner. Each Partyâ€™s Confidential Information shall, if disclosed in writing, be marked â€œCONFIDENTIALâ€ and, if disclosed orally shall, within thirty (30) days of disclosure, be reduced to writing, marked â€œCONFIDENTIALâ€ and delivered to the Receiving Party; provided, however, any information which by its nature is confidential and would be judged so under a reasonable standard, or is disclosed, or provided, under circumstances reasonably indicating it is confidential, shall be considered Confidential Information regardless of whether it is marked as â€œCONFIDENTIALâ€ or reduced to writing and marked as â€œCONFIDENTIAL.â€ Â 2.2 Exclusions. The term â€œConfidential Informationâ€ excludes information that: Â 2.2.1 is or becomes publicly available through actions of persons or entities other than the Receiving Party or its Representatives (as hereinafter defined); Â 2.2.2 is obtained by the Receiving Party from a third party who is under no obligation of confidentiality with respect thereto and who is authorized to disclose such information on a non-confidential basis to the Receiving Party; Â 2.2.3 was in the possession of the Receiving Party prior to disclosure by the Disclosing Party, and was not acquired, directly or indirectly, from the Disclosing Party, as evidenced by the records of the Receiving Party; or Â 2.2.4 is independently developed by the Receiving Party without any use of the Disclosing Partyâ€™s Confidential Information, as evidenced by the records of the Receiving Party. Â Â 10 Â ARTICLE III. OBLIGATIONS OF THE RECEIVING PARTY Â 3.1 Maintenance of Confidentiality. The Receiving Party shall keep the Disclosing Partyâ€™s Confidential Information confidential, and in furtherance thereof: Â 3.1.1 The Receiving Party shall ensure that neither the Receiving Party nor its Affiliates, and their officers, directors, partners, employees, agents, or other representatives (collectively â€œRepresentativesâ€) disclose the Disclosing Partyâ€™s Confidential Information, in any manner whatsoever, in whole or in part, except to the extent expressly permitted by this Agreement, without the prior written consent of the Disclosing Party. Â 3.1.2 In handling the Confidential Information of the Disclosing Party, the Receiving Party must use the same care and discretion as it employs with its own confidential information (but in no event less than reasonable care and discretion) to prevent disclosure, publication, use, or dissemination of the Confidential Information of the Disclosing Party, except to the extent expressly permitted under this Agreement. Â 3.1.3 Without the prior written consent of the Disclosing Party, which consent shall not be unreasonably withheld, conditioned or delayed, the Receiving Party shall not, and shall direct its Representatives not to disclose any Confidential Information to any potential investors, co-bidders, consultants, financial advisors or other advisors, or banks or other debt or equity financing sources (collectively, the â€œFinancing Sourcesâ€), or otherwise discuss Confidential Information to any such Financing Sources; provided that if Disclosing Party should determine to provide such written consent in its sole and absolute discretion, Receiving Party agrees to promptly disclose to the Disclosing Party in writing all Financing Sources with whom Receiving Party proposes to share such Confidential Information. Receiving Party represents and covenants that it does not have (and will not enter into) any agreement or arrangement with any potential Financing Sources which may reasonably be expected to limit such financing source from acting as a Financing Source with the Disclosing Party. Â 3.1.4 In the event that the Receiving Party is required to disclose the Disclosing Partyâ€™s Confidential Information under operation of applicable law, regulation, or order of a court or governmental administrative body having competent jurisdiction, the Receiving Party shall, to the extent practicable, provide the Disclosing Party reasonable notice of such potential disclosure so that that the Disclosing Party may seek a protective order or other appropriate protection or legal relief to prevent or limit such disclosure. If, in the absence of, or pursuant to the terms of, such protection or legal relief, the Receiving Party is nonetheless required by applicable law, regulation, or order of a court or governmental administrative body having competent jurisdiction to disclose any portion of the Disclosing Partyâ€™s Confidential Information, the disclosure shall be limited to only that portion of the Disclosing Partyâ€™s Confidential Information that is required to be disclosed. Â 3.1.5 The Receiving Party and its Representatives may use the Disclosing Partyâ€™s Confidential Information only in connection with the Purpose and shall not use the Disclosing Partyâ€™s Confidential Information for any other purpose. Â Â 11 Â 3.1.6 The Disclosing Partyâ€™s Confidential Information shall remain the property of the Disclosing Party, and nothing in this Agreement grants the Receiving Party or its Representatives any license, assignment, right, title, or interest to any invention, work of authorship, product, material, patent, patent application or other intellectual property, or other subject matter pertaining to the Disclosing Partyâ€™s Confidential Information. The disclosure of Confidential Information shall not result in any obligation by the Disclosing Party to grant the Receiving Party any rights in and to such Confidential Information. Nothing herein grants or provides the Receiving Party the right to file patent applications on or arising from the Disclosing Partyâ€™s Confidential Information. Â 3.1.7 The Receiving Party shall promptly notify the other upon discovery of any loss or unauthorized disclosure of the Confidential Information of the Disclosing Party. Â 3.2 The Receiving Party hereby acknowledges that it understands that: (i) the Confidential Information provided by the Disclosing Party may contain or constitute material non-public information concerning the Disclosing Party or its Affiliates; and (ii) trading in the Disclosing Partyâ€™s securities while in possession of material nonpublic information or communicating that information to any other person who trades in such securities could subject the Receiving Party (or its Representatives) to liability under U.S. federal and state securities laws, and the rules and regulations promulgated thereunder, including Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. Â 3.2Receiving Partyâ€™s Representatives. The Receiving Party may disclose the Disclosing Partyâ€™s Confidential Information only to another Party or those Representatives of the Receiving Party who have been informed of this Agreement, who need to know such Confidential Information to assist the Receiving Party in evaluating the Purpose, and who are subject to obligations of confidentiality and non-use at least as strict as the Receiving Partyâ€™s obligations under this Agreement. The Receiving Party shall not disclose the Disclosing Partyâ€™s Confidential Information to any other person or entity. The Receiving Party shall ensure that its Representatives comply with the non-use and confidentiality obligations and restrictions set forth in this Agreement, and the Receiving Party shall be fully liable for any breach of such obligations and restrictions by its Representatives. Â 3.3Return and Destruction of Confidential Information. Within ten (10) business days after the Disclosing Partyâ€™s request: Â 3.3.1The Receiving Party shall deliver to the Disclosing Party all originals of the Disclosing Partyâ€™s Confidential Information provided to the Receiving Party or its

Representatives. Â 3.3.2The Receiving Party shall destroy or delete any duplicates, copies, abstracts, notes, memoranda, summaries, evaluations, studies, projections, analysis, extrapolations, or the like (in any form) generated by the Receiving Party or its Representatives that contain, incorporate or are based on any Confidential Information of the Disclosing Party. If requested by the Disclosing Party, the Receiving Party will provide the Disclosing Party a written confirmation, signed by an officer or other authorized Representative of the Receiving Party, that all such materials have been destroyed or deleted, as provided in this Agreement. Â 12 Â Â 3.3.3Notwithstanding the foregoing, the Receiving Party is not required to destroy any computer files containing the Disclosing Partyâ€™s Confidential Information that are created during automatic computer system backup, provided that such files are stored securely by the Receiving Party. Further, the Receiving Partyâ€™s records management or legal department may retain one copy of the Disclosing Partyâ€™s Confidential Information for archival purposes only to verify compliance with this Agreement, and for no other purpose. Â ARTICLE IV. ACCURACY OF INFORMATION Â 4.1 Representations and Warranties. Neither the Disclosing Party nor any of its Representatives has made or makes any representation or warranty, express or implied, as to the accuracy or completeness of the Disclosing Partyâ€™s Confidential Information. Neither the Disclosing Party nor its Representatives will have any liability to the Receiving Party or to any of its Representatives resulting from the provision or use of the Disclosing Partyâ€™s Confidential Information. Â ARTICLE V. INJUNCTIVE RELIEF Â 5.1 Breach by the Receiving Party. In the event of any breach of this Agreement, the Disclosing Party may be irreparably and immediately harmed and may not be made whole by monetary damages. Accordingly, in addition to any other remedy to which it may be entitled at law or in equity, the Disclosing Party will be entitled to seek immediate injunctive relief (without the posting of any bond and without proof of actual damages) as well as any other remedies available at law or in equity to prevent breaches or threatened breaches of this Agreement and/or to compel specific performance of this Agreement. Â ARTICLE VI. MISCELLANEOUS 6.1 Waiver of Breach. No failure or delay by the Disclosing Party in exercising any right, power, or privilege under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any such right, power, or privilege preclude any other or further exercise thereof. Â 6.2 Amendment. This Agreement may be modified or amended only by a separate writing signed by the Parties, expressly so modifying or amending such Agreement. Â 6.3 Severability. If one or more provisions of this Agreement will be held unenforceable, invalid, or illegal in any respect, such unenforceability, invalidity, or illegality will not affect any other provision of this Agreement, which will be construed as if such unenforceable, invalid or illegal provision had never been a part hereof. Â 6.4 Governing Law; Jurisdiction; Venue. This Agreement (including any claim or controversy arising out of or relating to this Agreement) shall be governed by the laws of the State of Delaware without regard to conflict of law principles that would result in the application of any law other than the laws of the State of Delaware. The exclusive venue and jurisdiction for any Â 13 Â disputes shall be the State of Delaware and the Parties each hereby waive any claims of inconvenient forum with respect thereto. Â 6.5 Nondisclosure. Except as required by law or regulation, neither a Party nor its Representatives will disclose to any person that discussions or negotiations are taking place concerning the Purpose, including the status thereof, without the prior written consent of the other Party. Notwithstanding the foregoing, a Party may disclose the existence of this Agreement to prospective investors or partners, provided that any such party to whom disclosure is permitted has agreed to keep such information confidential. Â 6.6 Non-Binding Negotiations. Unless and until a separate, definitive written agreement between the Parties with respect to the Purpose has been fully executed by, and delivered to, all parties thereto, no Party will be under any legal obligation of any kind whatsoever with respect to the Purpose by virtue of this or any other written or oral expression by it or by any of its Representatives except, in the case of this Agreement, for the matters specifically agreed to in this Agreement. This Agreement shall not place any Party under any obligation to enter into any further agreement with the other Parties. 6.7 Entire Agreement. This Agreement represents the full and complete agreement of the Parties hereto with respect to the disclosure of the Confidential Information relating to the Purpose and supersedes and cancels all prior communications, understandings, and agreements between the Parties with respect to the disclosure of information pertaining to the Purpose, whether oral, express, or implied. Â 6.8 Term. This Agreement is effective as of the Effective Date and will continue for a period of one (1) year after the Effective Date, unless terminated early on thirty (30) daysâ€™ written notice by any Party. A Partyâ€™s obligations of confidentiality and restrictions on use of the Confidential Information disclosed by another Party will survive the expiration or termination of this Agreement for a period of five (5) years from the date of such expiration or termination. Â 6.9 Authority to Enter Agreement. This Agreement has been duly authorized, and upon execution by all Parties, is a legal, valid and binding obligation of each Party, enforceable in accordance with its terms. Â 6.10 Use of a Partyâ€™s Name. No Party shall use the name of another Party or its employees without the express written consent of an authorized representative of the other Party. Â 6.11 Notice. All notices, requests, consents, claims, demands, waivers and other communications under this Agreement (each, a â€œNoticeâ€) must be in writing and addressed to the other Party at its address set forth below (or to such other address that the receiving Party may designate from time to time in accordance with this section). Notices shall be deemed properly given if delivered to the below-referenced locations or such other location as a Party may specify pursuant to a notice under this Section 6.11 by (a) certified mail, return receipt requested, (b) nationally-recognized courier services, or (c) email (at the email address set forth below or at such other email address as a Party may specify pursuant to a notice under this Section 6.11) followed by a confirmation of receipt. Except for formal notices (i.e., notices of termination, notice of Â 14 Â material breach, or similar notices), which must be provided under (a) or (b), day-to-day communications can be conducted via email under (c). Â To Disclosing Party, if by mail or courier: Perspective Therapeutics, Inc. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 [***] Â To Receiving Party, if by mail or courier: Mark Austin [***] Â Â or other addresses as may be given from time to time under the terms of this notice provision. Â 6.12 Electronic Copies of Signatures and Original Agreement. Facsimiles and scanned images of original signatures shall be considered as valid and binding as original signatures, and as such, a facsimile or scanned image of an original signature delivered by the executing Party to the other Parties shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or scanned signature was an original signature. In addition, images of an original of the fully executed Agreement (which original Agreement may have original signatures, facsimile or scanned images of original signatures, or combinations thereof as provided herein) may be stored electronically. The Parties intend that electronic copies or images of an original Agreement, which are reproduced from the electronically stored image of the original Agreement and which accurately reflect the original Agreement, shall be valid as an original. Â 6.13 Assignment. This Agreement may not be assigned or otherwise transferred by a Party without the consent of the other Parties; provided however, that any Party may, without such consent, assign its rights and obligations under this Agreement to any Affiliate or, in connection with a merger, consolidation or sale of substantially all of the business of the Party to which this Agreement relates. Â 6.14 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. [Signature Page Follows] Â 15 Â IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. DISCLOSING PARTY: Â PERSPECTIVE THERAPEUTICS, INC. Â Â Â Â Â By: Name: Title: Â Â RECEIVING PARTY: Â Mark Austin Â Â Â Â By: Name: Title: Â Â Â Â Â EXHIBIT C Â [Omitted.] Â Â EX-31.1 3 catx-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Johan (Thijs) Spoor, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Perspective Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: November 12, 2024 Â Â /s/ Johan (Thijs) Spoor Â Johan (Thijs) Spoor Â Chief Executive Officer Â (Principal Executive Officer) Â EX-31.2 4 catx-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jonathan Hunt, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Perspective Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: November 12, 2024 Â Â /s/ Jonathan Hunt Â Jonathan Hunt Â Chief Financial Officer Â (Principal Financial Officer and Principal Accounting Officer) Â EX-32 5 catx-ex32.htm EX-32 EX-32 Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Perspective Therapeutics, Inc. (the â€œCompanyâ€) for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), we, Johan (Thijs) Spoor, Chief Executive Officer of the Company, and Jonathan Hunt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge: Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 12, 2024 Â /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer(Principal Executive Officer) /s/ Jonathan Hunt Jonathan Hunt Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) Â GRAPHIC 6 img49486978_0.jpg GRAPHIC begin 644 img49486978_0.jpg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

=DH8EL$]/PKZ?KQ?XXZENN]+TM6X16G<>Y^5?Y-1&3;$T>4 M6MM+>7<-K NZ69UC0>K$X%=M_P *@\6_\^]M_P"! JI\+M-_M+Q[8;ES';;I MW_X"/E_\>(KZ3)P,GBG*33!*YP-
QX<2U\,Z5IT=U;K=6,(22-I5&2<%OUJSX M7T)HY9[B>6%OW1CV(X?[W!^(M1_M?Q'J.H9R)YV93_LY^7],5[^%], M^R^$[B^9<-> 3G!]53@?KNK7VTXT^0Y/J5)XA5^IY7=P&UO9[=OO12,A_XKV
M/X>>'5TW3QJ<%\TL=] K&,I@(WY]N17FGC6T^Q^,=3C X:4R#_@7S?UK>TCQ MNVD> 7L87_T\2M%"/[JD9W?J:[ZZG4I1Y>I]SC(U<1AH>SZV,'QA!';^)+I% MOWOIMV9Y2N!N]!SVZ5UWPTT!
(()O$EZN(XD;R,]@ =S?T_.N*\.:)/XCUV&S M0MM8[YG_ +J=S_GUKUSQ['OAS?16X$:F$6L2C :.^7^6:SQ53D@J2>IS9G MB70HK#Q>K6OH?.VI7CZCJMW?.L?#_ ,,S^%?#"V-V8S=/*TDIC.1D\#GZ
5X3X:N]7U?Q-IMA_:=Z5FN$ M5Q]H;[N?F[^F:^H ,#%1)LN-A:***@H**** "BBB@ HI*J:K.;;2+R<<&.!W M'X*:$KNPF?,'B;4CJ_B;4;XMD33L5/\ LCA?T K*HHK[6$5&*2/&;N[CD1I' M5$!+,<
#N:^H?".@Q>'/#=KIZ*!(%WS,/XI#]X_T_"OGWP-9K?\ C?2+=AE3 M.'(_W06_]EKZ>KQ,WJN\:?S.W"1TWD5A:27,[81!D^_M7FFKZ]=ZM,V] MRD&?EB4\?CZUO>.
[MLVUFI^4YD;^0_K7&5C@Z*Y>=[GAYQC9NHZ,7HM_,*D@ MN)K:420R-&XZ%3BHZ*[FDU9GAJ33NF>B^&O$7L])JFN2!=(,Y'1QZ_6NCKR#
M3[I[+4(+A"04<$X[CN*]>4[E!'>O'Q=)4YW6S/L,IQX?&NS63P_87F/GAN=F?9E/]5%>'U]!E]5U M*";Z!7CRU&D%?0OPEU(WW@B*%VR]I*T/X=1^A_2OGJO9/@=.3:ZS;Y^5'B<#
MZAA_[+6>:0OA[]B*[5+'KE%%%?,GI'/^-M2_LGP9JMV&PX@9$.?XF^4?SKY M: R<#KFOI7XB^']5\3>'X]-TLP@M.'E,K[1M .!T](+#2XL+'9V^=J\!2W_U ME%<9X6UBTT'7()0O=/6^CC1@6(
R1C)R#[UZ%XL^&?B;Q!XIO\ 4T:S\]:3 M]V&F.0H "]OO5B_*:\4_P!ZQ_[_ ! ^)JTU8AWN:W_"V-!_Z$RV_./_ .(K MH_!WCS3-9O+XVWAZ'3EM+5IY9T*_=&/EX4?Y%<-_PIKQ3_>L?^_Q_P#B:ZO0
M/AWK>C>#]?L\VO\ :6HJL*$2':L??G'N:3Y1JYXS>W3WM]<7807M_+^ZA;:&W9^G;O6G_PIGQ1GEK^_O\ ' "O:GT& M"7PG_8+@>3]D%MTZ87 /]:'+L"B?*]L\4=U"\\7FPJX+QYQN7/(S7T?JNOZ)
MX)\&1WFGP0I#*@-G!$,>:S#(_#N37EI^#7BG/WK'_O\ ' "O2]$\&/<^!X= M\4P0S-;LRPO$^2J_PD''!&@?%/7M(OYYKM_M]O/(7DAE.-I/] MP_P_3I5SQ?XN\(>)-)EDAT.:WUAL;)@%4
YYW$'YN,]15W6?@IJEO(SZ1>0W M/T-/W=Q:G%(C2_J(I9V.% ZDU MUGQ"N7;7[?3W;<=-LX;4_P"\$!;}3^E>E>"OA/%H=Y%J6L3I*]4U>\OG:RW7$S2!-5ETN#RY!;L#*QR\CGY5R?J>E?.-?2
MWQ#T'5/$GAQ=-TLPAGG5Y3*^T;0#QT]<5Y7_.*:\4_WK'_O\(?\ XFJBUU%) M$^C_ !(T/2]&M+%_"D,[P1*CRN4R[=SRM7O^%KZ#_P!"9;?G'_\ $5E_*9\ M4_WK'_O\?
_B:LZ=\'/$":G:O>-9_9EE5I=LI)VYY[4>Z&IT/Q=TZ:_\ !^E: MK';>5]G8>;$O/EJZC^1 'XUXQ:74UC>07=N^R:&19(V]&!R*^N+JT@OK26UN
M8ED@E4H\;#A@:\7\1?!>_BN7FT">.>W8Y6"9MKK[;NA_2B,ELPDATOQPO6TW MRXM(B2]VX\XS$H#Z[<9_#-5O!7Q6O;&]-IK\LEW:SR%A/C+Q,3^J^W;M6-#\
M)_&$DNUM.CB7^^]Q'C]"37HO@SX46N@W,>H:M*EY>I\T<:K^[C/KS]XT/E2! M7/2000".AKYG^).I?VGX]U*16S'"P@3_ ("_'] X=8&5#_M-\H_4U7\!>')O" A:'3[G8;DR-)*4.023QS] *K_ !$T M#5?
$OAY--TLPAFG5Y3*^T;0#[>N*'K(>R/FFOJSPGIO]D>%-,L<8:*W7>/\ M:/+?]37D&F?!W7XM6LY+UK/[*LR-+ME).T-S@8]*]W P,#I3FTQ11XK\5K7R M?%,4X'$]N#GW!(_PKA:]M^('A*]\2_87L#$)(-
X?S&(R#C'\JP/#/PSO;36X M;K5C UO#\X1&+;F[Y'3O7IT<3"-%7>J/<)F%*GA5S/5+8Z;X?>&?["T43S MIB]N@'DR.5'9?PKE/CCJ6RQTO3%;F1VG<>RC_\ 0C^5>MUY1\0? /B+Q5XE M-Y:-
:"UCB6.,22D'U/&/4UYKFYSYI'S=>K*M-SENSR#1KVWT[6;2]NK;[3!# M('>'.-^.U>E?\+8T'_H3+;\X_P#XBLK_(4SXI_O6\ W^/_,31_P *9\4_MWK'_+_'_P")IMQ9AJCL/"7C_2]>\26NGV?A:"UF?7_#
M?X>:EX7UNXU#&$;DF#RHO?=R2,]O:O4*SE:^A:"BBBD,**** "BBB@ K.UR M,RZ!]$8ZM;2 ?]\FM"FNH>-E89##!%.+L[B>J/D*BK6I6;Z?]EU9/PT$K1G\ M#BJM?:Q=XIH\9Z,ZCX\AXD@E6 M1?
J#FOJS3+^#5-,MKZW8-%/&)%/UKPN9M;2>]N%@MXR\C=A7J&M:3'K%E]G=MC*P97QG!I^F:3:Z5;^5;IR?O M.>K'WKFIXM0I*/4\S$93*OBG-NT6GTUD612KJ&4C!!K*&,J*5WJ=-7)\/*'+!6?
<\=AC::> M.)1EG<*![DU["@VQJ/08K"@*V=OK"WT651>1%C@-ZBN@IXJNJK7*&5X&>%4 MN?=GF_QGF5/"5M$?O27:X'T5J\(KTSXRZTMYKMKI43;ELT+28/\ &W\ !^=
M>9U[N6TW##J_4K$2O485[#\#4.-;D['R5'_C]>/5[Q\&;$V_A.>[88-UP\,KU$>D4445\P>F%%4K[2[34BAND=]F=NV5DZ_P"Z16!I M6@:==W6I2M',8%N/)A7[3)@!% 8_>_O;ORH
ZRBL#4K6*QT^VTVRWQ?:[I(Q M^\8D#.Y^2<_=5JWZ "BLB>1Y_$]G;H["WMY)Y0#P2Q"IG_Q_P#*JK6,&M:_M?&Z$CP6BQPHJRL@#D%F/RD=F2@##H:*Q_^$7TC_GA+_X$R?\ Q50ZK;1R2:5H
MT9=87D+R*LC F*->F MX^QSB-)GY9E**P#'N1NQGZ4 ;%%9NKWTMM%';V@5KZY;RX W1?5V_P!E1S^0 M[U5\.QM:1WVGO-),;6Y($DK;F8,JODGZL: -RBL?Q"S/816B,RO>7$<&5.#M M+9?
G_=#4A\+Z5CY8IU/JMU*"/ ']_-FBL729YK>74;&ZN&G2R=2D\GWO+9=V M&/0_0M3=.D>ZUG5;C>QBB=+9%SQ\[F/YOC_(#0!KT45A:3$NJ: M51LA!^+!:='H9OE$VMNUS, /V=7(AB_P!D*/O?
5L_A0!NT5B#1 M3IUU#-H[>3'O GMG=C&Z=R!SM8=>.O0U'/%_;.O7-C<32+9VD4;&&-RGFL^[MEB.=HQC'KF@#?HK$;PY;6Y$NER26$ZG.8V)1O9D)P1^1]ZVZ "BBB@ HHHH M**** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@#Y^^+>B'3?%IOD7$%^ M@D! XWCAA_(_C7 5]*^/O#(\3^&9;>, WD'[ZW/JP'W?Q"'Y5\ZV>F7VH:@M MA:6TDMTS;?*"\@]\^E?39?B8SHVD]8GFXBFU/3J5
,G%>_\ PHL=?F&.C5 M7LX*Z[_Y&^'H./O,6BBBO).L**** "H+KSOLLOV;9Y^P^7YGW=V.,^V:GHH M^5?$=AJUAKERNM12)>2.TCLW1\GJI[BLFOJG7_#FF^)+!K348 Z_P..'0^JG
MM7@/C#P'J7A2Q^2Y5>GLP[&OI<%CX54H2T9YM:A*+NMCEX8I+B:.& M)2TDC!$4=R> *^J/#FE+HGAZQTU<9@B"L1W;JQ_/->.?"3PLVIZR=:N8_P#1 M;(_NLC[\O;\NOY5[O7#FM?
FFJ<>AOA:=ES,6BBBO(.LANKA+6TFN9#A(D9V^ M@&:I>'X'M]"M!*,32)YTO^^YW-^K&EUNUFO=*DLX%SY[+')SC$98;S_WSFM$ M 8 H
Y_4XKJ_\2VL%I=+;FS@:=F:+S!N<[5XR.RO5G[#KG_0;A_\$?_ M !52Z?:S)J.I7=PNUII56+G/I[5/_'BY_&M%B0I*C) X'K0!@>'DG-WJU[= MW"SL9Q LHCV K&.>,G^(O5;1K/5KBR>^@U.."^F>Y6-
K4.0K'Y>=P_AVU;2 MQO[7P9+:PQ[]1>"0E0P'[U\EN>GWF-.MK[4;6UAMX_#MV$B144?:(>@&/[], M1FS233DJ"TUQ<2GE MV[L?\H*9K-G-,+:[LT#7EI*'09QO4\.F?=?U HO;.?
4=1@BE3;IT{$K@G_7 M29^52/[J_>]SCTI@8VE:_I,LTNJWM_"ES.-L<;'F&+LOU/4^_':K>EZG97?B MF^6SN8YEFM8Y#L/1E9E/Z%:Z+]!6;=6LIUS3[R)051)8IN<85@*"#_WTH_.@ M-
2AJUQ95DWVMRC;#HR0L?X[BZ7:/P7 M)-3V-I-'JNI7DR[?.=$BYS^[5>/_ !YGK21#.8U&QEL/#=[*;CS;_4I!$\VW M&9)"$X'8*O0?[-74T[6HT5%UJ$*HP +$<#_OJDUQ+QKO3)+:Q>[B@F:614=%
M.0A5?O$=VS^%/_M74_\ H7KO_O\ P_\ Q=,17@>F, MFJ?AEVD7RV\UNZ;@G*LK$]U:\@GO[?{):6[>9';%PSR2=F?' [#GGGM6T M>E &/IO^D:]JUWU5#':H?]T;F_5\?A2^)F+:)+;(7';W"PR3#$<<
!\@8_O$?,WZ>U5DOM8LU M\][TN2*\"XM'3#^Y5F!4^W/UH =97U];ZBFFZH(W>5&>"ZA&U9-N,AE_A;G M/4@\ULUBVL%[?ZK']%] +6.W1D@MRX=\MC+L1P.!@ 9ZFMJ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2L^ST?3K"]NKRULXHK MBZ;=-(J\L:T**$VM@LA:*** "BBB@ HHHH **** "HI[>*Z@>"*))8G&UD=<
M@CT(J6B@"GIVFVFDV4=E8P)!;QYVQIT&3DU;HI:&VW=AL%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1

Discontinued Operation, Operating Expense Net Sales Between $10.0 and 15.0 Million [Member] Net Sales Between 10 And 15 Million [Member] Relating to net sales between $10 and 15 million. HTM, Amortized Cost HTM, amortized cost HTM, amortized cost, Total Gain (Loss) on Sale of Assets and Asset Impairment Charges Loss recognized on classification as held for sale Income Statement [Abstract] Entity Address, State or Province Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] The value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Fair value of Viewpoint assets acquired including goodwill Net loss from continuing operations Net loss from continuing operations us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Note payable, net of current portion Note payable, long-term portion Note payable, long-term portion Portion at Fair Value Measurement [Member] [Default] Portion at Fair Value Measurement [Member] Loss Contingencies [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Chino California [Member] Chino California [Member] Chino california. Progenics APA [Member] Progenics APA. Number of affiliated predecessor companies acquired Number of Businesses Acquired Cover [Abstract] GT Medical Stock [Member] G T Medical Stock [Member] Relating to GT Medical stock. GT Medical Technologies, Inc. [Member] Refers to information regarding the entity GT Medical Technologies, Inc. GT Medical Technologies, Inc. [Member] Basic loss per share Basic and diluted loss per share (in dollars per share) Basic loss per share Repayment provisions Repayment Provisions Repayment provisions. Note 8 - Share-based Compensation Operating expenses: Issuance of common stock in exchange for Viewpoint common stock, net(in shares) Stock Issued During Period, Shares, Acquisitions us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Other assets Investments, Debt and Equity Securities [Abstract] Series B Convertible Preferred Stock [Member] Series B convertible preferred stock. us-gaap_AllocatedShareBasedCompensationExpense Share-based compensation Summary of Estimated Purchase Consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] us-gaap_LongTermDebt Total Aggregate maximum estimate settlement amount Aggregate maximum estimate settlement amount. Accumulated deficit Accumulated deficit Total accumulated deficit Accumulated deficit Lease expense Represents the noncash expense incurred for leases. Noncash lease expense Plan Name [Axis] U.S. Treasury Bills [Member] US Treasury Bill Securities [Member] Current assets: Current assets: Net cash provided by (used in) operating activities us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap_StockIssued1 13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock Lease term Lessee, Operating Lease, Term of Contract Debt Instrument [Line Items] Property and equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment General and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Property and equipment, net Property and equipment, net Property and equipment, net 2028 CASH FLOWS FROM OPERATING ACTIVITIES: Fair Value, Recurring [Member] 2024 At-the-Market (ATM) Agreement [Member] Two Thousand Twenty Four At Market Offering [Member] Two Thousand Twenty Four At Market Offering Member. Common stock, par value Common Stock, Par or Stated Value Per Share (in dollars per share) Common stock, par value (in dollars per share) Represents promissory note. Promissory Note [Member] Common Stock Options [Member] ROFO Option [Member] ROFO Option. us-gaap_RepaymentsOfNotesPayable Repayment of notes payable Intangible assets, in-process research and development us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Disposal Groups, Including Discontinued Operations [Table] Statement of Cash Flows [Abstract] Counterparty Name [Axis] Antidilutive Securities, Name [Domain] Warrants to purchase shares of common stock us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Entity [Domain] Equity Components [Axis] Entity Address, Address Line One Schedule of Change in Asset Retirement Obligation [Table Text Block] Progenics [Member] Progenics. Assumption fair value of stock options and warrants in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. Assumption of Viewpoint stock options and warrants at fair value Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued personnel expenses Related Party Transaction [Table] Property, Plant and Equipment [Line Items] Subsequent Event Type [Axis] Note 3 - Loss Per Share - Antidilutive Securities (Details) Total non-operating income (expense), net us-gaap_NonoperatingIncomeExpense Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] us-gaap_PaymentsToAcquireHeldToMaturitySecurities Purchases of short-term investments Public Offering [Member] Public Offering [Member] Public offering. Held-to-Maturity Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Note 10 - Leases Amendment Flag Percentage of issued and outstanding capital stock Percentage Of Issued And Outstanding Capital Stock Percentage of issued and outstanding capital stock. Consideration for equipment and services pursuant to the MESA and SOWs Asset Acquisition, Consideration Transferred, Contingent Consideration Noncurrent lease liability Lease liability, net of current portion Lease liability, non-current Note payable Note payable Aggregate sales price Sale of Stock, Consideration Received Per Transaction Debt Instrument, Name [Domain] Additional paid-in capital Additional paid-in capital Sale of stock, price per share Sale of Stock, Price Per Share Net loss Net loss Lessee, Lease, Description [Table] Options exercised Number of Options Outstanding, Exercised Number of Options Outstanding, Exercised Issuance of common stock pursuant to exercise options (in shares) Research and Development Expenses [Member] Research and Development Expense [Member] Research and Development [Member] Business Acquisition, Pro Forma Revenue Grant revenue Summary of Note Payable Schedule of Debt [Table Text Block] Percentage of increase in common stock capital shares for future issuance. Percentage Of Increase In Common Stock Capital Shares For Future Issuance Percentage of increase in common stock capital shares for future issuance us-gaap_GainLossOnDispositionOfAssets Loss on disposal of property and equipment Equity Component [Domain] Statistical Measurement [Domain] General and administrative Deferred Income, net of current portion (Note 3) Deferred Income, Noncurrent Note receivable, forgiven amount us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Forgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. Note receivable and accrued interest from Viewpoint forgiven Interest expense us-gaap_InterestExpenseDebt Represents the Underwriting Agreement. The Underwriting Agreement [Member] Underwriting Agreement [Member] Increase (DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations Increase (Decrease) In Inventory Related to Discontinued Operations Inventory related to discontinued operations Loss recognized on classification as held for sale Disposal Group Including Discontinued Operation Loss On Classification Current Amount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Lease liability Disposal Group Including Discontinued Operation Lease Liabilities Current Amount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Preferred stock, shares issued Preferred stock, shares issued (in shares) Proceeds from sales of common stock, pursuant to exercise of options Proceeds from sales of common stock, pursuant to exercise of option Debt Securities, Held-to-Maturity, Fair Value, Total HTM, Estimated Fair Value HTM, fair value Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Summary of Components of Other Intangible Assets Lessee, operating lease, discount rate us-gaap_LesseeOperatingLeaseDiscountRate Change in allowance for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Agent commission fee as a percentage of gross sales price Sale Of Stock Maximum Commission Percentage Sale of stock maximum commission percentage. Short-Term Investments, Total Short-term investments Short-term investments Operating lease, expense us-gaap_OperatingLeaseExpense Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Common stock, shares outstanding Common stock, outstanding (in shares) Options exercise price per share Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Price Share based compensation arrangements by share based payment award options exercise price. Preferred stock, par value Preferred stock, par value (in dollars per share) Antidilutive Securities [Axis] Gross proceeds from public offering Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity, Total Accretion of discount Accretion of asset retirement obligation Discontinued Operations and Disposal Groups [Abstract] Entity Interactive Data Current Net cash acquired in acquisition of Viewpoint Business acquisition, number of common shares exchanged Common stock issued pursuant to merger, Shares Business acquisition, shares (in shares) Loss recognized on classification as held for sale Gain (Loss) on Disposition of Business Loss on divestiture Operating Activities [Domain] Number of Options Outstanding, Options assumed Options to purchase shares of common stock Gross number of share options (or share units) assumed during the period. Options assumed, Options (in shares) Document Quarterly Report A T M agreement. A T M Agreement [Member] A T M Agreement [Member] Consolidated Entities [Axis] Related Party Transactions Disclosure [Text Block] Statement of Financial Position Location, Balance [Axis] Statistical Measurement [Axis] Represents promissory note for purchasing land and building. Promissory Note for Purchasing Land and Building [Member] Related and Nonrelated Parties [Domain] Fair Value Measurements, Nonrecurring [Table Text Block] Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis Discontinued operations, Provision (benefit) for income taxes Discontinued Operation, Tax Effect of Discontinued Operation Summary of Future Operating Lease Payments and Lease Liability Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Amortization Amortization, Total Amortization of other assets Financial instruments measured at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance Amount of increase in additional paid in capital (APIC) resulting from the assumption of stock options and warrants at fair value. catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue Assumption of Viewpoint stock options and warrants at fair value Unrecognized compensation expense, weighted-average expected recognition period us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Notes payable Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date. catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Accounts payable and accrued expenses Measurement Basis [Axis] Statement of Income Location, Balance [Axis] Indefinite-Lived Intangible Assets [Line Items] us-gaap_Assets Total assets Investments and Agreements Investments And Agreements Disclosure [Text Block] Investments and agreements disclosure. Schedule of Long-Term Debt Instruments [Table] Restricted cash Restricted cash Business Acquisition [Line Items] Entity Address, City or Town Loss on equity method investment Equity in loss of affiliate Income (Loss) from Equity Method Investments Equity in loss of affiliate us-gaap_PaymentsOfStockIssuanceCosts Issuance costs related to common stock issued in exchange for Viewpoint common stock Summary of Maturity of Note Payable Schedule of Maturities of Long-Term Debt [Table Text Block] March 2024 Investment Agreement [Member] March Two Thousand Twenty Four Investment Agreement [Member] March two thousand twenty four investment agreement. Debt instrument, face amount us-gaap_DebtInstrumentFaceAmount Depreciation Depreciation, Total Depreciation expense Depreciation, Total Grant revenue Grant revenue Current assets held for sale, discontinued operations Total current assets held for sale of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Stock issued during period value warrant exercises. Stock Issued During Period Value Warrant Exercises Issuance of stock pursuant to exercise of common stock warrants Share-Based Compensation Share-Based Payment Arrangement [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Lease liability Stock option awards expired Number of Options Outstanding, Expired us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Loss from discontinued operations, Diluted Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share HTM, Gross Unrealized Gains HTM, gross unrealized gains Operating lease, weighted average discount rate us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Fair Value Disclosures [Abstract] Summary of Pro Forma Computation of Earnings Per Share Business Acquisition, Pro Forma Information [Table Text Block] Amount raised through selling of equity Stock Issued During Period, Value, New Issues Issuance of common stock, net BofA Securities, Inc. Bof A Securities, Inc [Member] BofA Securities, Inc [Member] Proceeds from Investment Agreement, net Proceeds from Investment Agreement Net Proceeds from investment agreement net. Issuance of common stock pursuant to exercise of options Stock Issued During Period, Value, Stock Options Exercised Lessee, Lease, Description [Line Items] Current liabilities: Current liabilities: Lease Contractual Term [Axis] Stock Redeemed or Called During Period, Shares Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares) Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares) Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Accumulated amount of amortization of indefinite-lived assets. Accumulated Amortization Document Type Percentage of fully-diluted outstanding capital stock Represents number of shares issued as a percentage of fully diluted outstanding capital stock. catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock Debt instrument balloon payment us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Title of 12(b) Security Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Statement of Financial Position Location, Balance [Domain] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Intrinsic value associated with exercises us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Research and development Stock option awards granted Number of Options Outstanding, Granted Granted, Options (in shares) Program License Option [Member] Program license option. Indefinite-Lived Intangible Assets [Axis] Property and equipment, gross Maturities of Long-Term Debt [Abstract] Subsequent Event Type [Domain] Summary of Stock Options Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Summary of Weighted Average Fair Value of Stock Option Awards Granted and Key Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Estimate of Fair Value Measurement [Member] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Business acquisition, closing market price Business acquisition, price per share (in dollars per share) Warrant exercise price per share us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Financial Instruments [Domain] Business combination, fair value of common stock Perspective Therapeutics common stock issued (13,654,507 x $4.00) Amount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination. Note receivable and interest from Viewpoint forgiven Noncurrent assets: Assets, Noncurrent [Abstract] Sale of Stock [Axis] CASH FLOWS FROM INVESTING ACTIVITIES: Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] VMT Option or Program License Option [Member] VMT option or program license option. Schedule of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Note receivable, forgiven amount, loan Note receivable Note receivable Deferred Income (Note 3) Deferred Income, Current Consolidated Entities [Domain] Series B Preferred Stock [Member] Series B Preferred Stock [Member] Pre-funded Warrants [Member] Prefunded Warrants [Member] Prefunded Warrants [Member] Relating to Prefunded Warrants. Debt Securities, Held-to-Maturity [Table] Represents lease with Energy Northwest. Lease With Energy Northwest [Member] Litigation Case [Domain] Maximum amount of securities offer and sale Maximum Amount Of Securities Offer And Sale Maximum amount of securities offer and sale. LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Additions to property and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Document Period End Date us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Effective income tax rate us-gaap_EffectiveIncomeTaxRateContinuingOperations Total potential dilutive securities Antidilutive securities (in shares) Share-based compensation Share-based compensation Lantheus Investment Agreement [Member] Lantheus Investment Agreement Lantheus Investment Agreement [Member] Represents Lantheus Investment Agreement. Equity Interest Issued or Issuable, Type [Domain] Held-to-maturity investments us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (Note 14), Total Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations {(see Note 13)} Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14) us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of property and equipment Held-to-maturity, allowance for credit loss Debt Securities, Held-to-

Maturity, Allowance for Credit Loss Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total Trading Symbol Business Combinations [Abstract] us-gaap_StockholdersEquity Balances Balances Total stockholders' equity March 2024 Private Placement [Member] March 2024 Private Placement [Member] Represents the March 2024 private placement. Estimated liability us-gaap_LossContingencyAccrualAtCarryingValue Loss Contingency Accrual Debt instrument, periodic payment us-gaap_DebtInstrumentPeriodicPayment Long-Lived Tangible Asset [Axis] Other Liabilities, Noncurrent Other noncurrent liabilities Net Sales Greater Than $15.0 Million [Member] Net Sales Greater Than 15 Million [Member] Relating to net sales greater than $15 million. Proceeds From Prefunded Warrants Net Proceeds from prefunded warrants net. Proceeds from Pre-funded Warrants, net Related Party Transactions [Abstract] Deferred Income Increase (Decrease) in Deferred Revenue Property, Plant and Equipment [Table] Goodwill Balance Balance Goodwill Stock issued during period shares common stock warrant exercised. Stock Issued During Period Shares Common Stock Warrant Exercised Issuance of common stock pursuant to exercise of warrants (in shares) Unrecognized compensation expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Stock Redeemed or Called During Period, Value Cancellation of fractional shares due to the 1-for-10 reverse stock split Represents Office Space With Unico Properties. Office Space With Unico Properties [Member] Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Disposal Group Classification [Axis] Deferred income tax benefit Deferred Income Tax Expense (Benefit), Total Deferred income tax benefit Deferred tax benefit Deferred Income Tax Expense (Benefit) May 2024 pre-funded warrants. May 2024 Pre-funded Warrants [Member] Geographical [Axis] Leases [Abstract] Equipment [Member] Equipment [Member] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Debt instrument, number of monthly payments Represents number of installment to pay debt. catx_DebtInstrumentNumberOfPaymentInstallment Schedule of Business Acquisitions, by Acquisition [Table] Scenario [Axis] Inventory Disposal Group, Including Discontinued Operation, Inventory, Current Interest and other expense Interest and other expense Interest and Other Expense Interest and other expense. The amount of fair value of options and warrants assumed in business acquisition. catx_BusinessCombinationOptionsAndWarrantsAssumption Assumption of Viewpoint stock options and warrants at fair value Noncurrent liabilities: Non-current liabilities: Weighted Average Exercise Price, Options assumed Options exercise price per share Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Options assumed, Price (in dollars per share) Security Exchange Name Loss from continuing operations, Basic Income (Loss) from Continuing Operations, Per Basic Share Counterparty Name [Domain] Business Acquisition, Acquiree [Domain] us-gaap_OperatingExpenses Total operating expenses Class of Financing Receivable [Domain] Proceeds from maturity of short-term investments Proceeds from maturity of short-term investments Payments to Acquire Other Productive Assets Additions to other assets Long-Lived Tangible Asset [Domain] Non-Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arrangement Modified [Flag] Non-Rule 10b5-1 Arrangement Modified Flag. Class of Stock [Axis] Stock issued during shares common stock warrant exercised. Stock Issued During Shares Common Stock Warrant Exercised Issuance of common stock pursuant to exercise of warrants (in shares) us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Legal Entity [Axis] Operating Activities [Axis] 2027 Investment agreement, contingent amount of gross proceeds raised Investment Agreement Contingent Amount Of Gross Proceeds Raised Represents the amount of gross proceeds raised as part of an investment agreement. Subsequent Event [Member] Subsequent Event [Member] Maximum [Member] Maximum [Member] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Underwritten Offering. Underwritten Offering [Member] Offering [Member] Right-of-use asset, net Right of use asset Right of use asset, net Diluted loss per share Earnings Per Share, Diluted Diluted loss per share Leasehold improvements Leasehold Improvements [Member] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Total liabilities assumed us-gaap_Liabilities Total liabilities Fair Value Hierarchy and NAV [Domain] us-gaap_AssetsCurrent Total current assets Net cash (used in) provided by investing activities us-gaap_NetCashProvidedByUsedInInvestingActivities Forecast [Member] Forecast [Member] Shares issued and sell Stock issued during period, shares Issuance of common stock, net (in shares) Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Research and development Disposal Group Including Discontinued Operation Research and Development Expense Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. Entity Filer Category Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Class of Financing Receivable [Axis] Non-operating income (expense): Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Right-of-use asset, net Disposal Group Including Discontinued Operation Property Right Of Use Asset Current Amount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Share-Based Payment Arrangement, Noncash Expense, Total us-gaap_ShareBasedCompensation Share-based compensation Issuance of Pre-funded Warrants, net Adjustments To Additional Paid In Capital, Issuance of Pre-funded Warrants Adjustments to additional paid in capital, issuance of pre-funded warrants. Related and Nonrelated Parties [Axis] Net loss before deferred income tax benefit Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Rule 10b5-1 Arrangement Modified Rule 10b 51 Arr Modified [Flag] Rule 10b 51 Arr Modified Flag. Sales, net Disposal Group, Including Discontinued Operation, Revenue Entity Registrant Name Indefinite-Lived Intangible Assets, Major Class Name [Domain] Number of reportable segments us-gaap_NumberOfReportableSegments Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Loss Per Share Earnings Per Share [Text Block] Entity Emerging Growth Company Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Money Market Fund [Member] Money Market Funds [Member] Basic Basic and diluted (in shares) Percent of outstanding shares Percent Of Outstanding Shares Represents the percent of outstanding shares. Loss Contingencies [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Litigation Case [Axis] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Percentage of ownership considered for warrant exercise two. Percentage Of Ownership Considered for Warrant Exercise Two Percentage of ownership considered for warrant exercise Common stock, shares authorized Common stock, authorized (in shares) One-time payment received for rights granted One-Time Payment Received For Rights Granted One-time payment received for rights granted. Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Proceeds from the ATM Agreement, net Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Accounts payable and accrued expenses Debt Disclosure [Abstract] Financial Instrument [Axis] Total purchase price consideration General and Administrative Expenses [Member] General and Administrative Expense [Member] General and Administrative [Member] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Prepaid expenses Net Sales of $10.0 Million or Less [Member] Net Sales Of 10 Million Or Less [Member] Relating to net sales of $ 10 million or less. Share-Based Payment Arrangement [Abstract] Estimated hazardous waste removal liability Estimated Hazardous Waste Removal Liability Estimated hazardous waste removal liability. Collaborative Arrangement and Arrangement Other than Collaborative [Table] us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Net loss Stockholder Plaintiff Settlements Related to stockholder plaintiff settlements. Stockholder Plaintiff Settlements [Member] Issuance of common stock in exchange for Viewpoint common stock, net Stock Issued During Period, Value, Acquisitions January two thousand twenty four pre-funded warrants. January Two Thousand Twenty Four Pre-funded Warrants [Member] January 2024 Pre-funded Warrants [Member] Maximum increase or decrease in ownership percentage Maximum Increase Or Decrease In Ownership Percentage Maximum increase or decrease in ownership percentage. us-gaap_TableTextBlock Notes Tables Base prepaid rent Deferred Rent Credit Stockholders' equity: Stockholders' equity: Maximum amount of securities offer and sell Maximum Amount of Securities Offer and Sell Maximum amount of securities offer and sell. May two thousand twenty four pre-funded warrants. May Two Thousand Twenty Four Pre-funded Warrants [Member] May 2024 Pre-funded Warrants [Member] Supplemental schedule of noncash investing and financing activities: Disposal Group Name [Domain] Statement [Table] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Oppenheimer & Co [Member] Oppenheimer Co [Member] Represents the Oppenheimer & Co. Write-off of inventory associated with discontinued product Write-off of inventory associated with discontinued product Write-off of inventory associated with discontinued product January 2024 public offering. January 2024 Public Offering [Member] Investment Agreements [Abstract] Investment agreements. Preferred stock, shares authorized Preferred stock, shares authorized (in shares) Equity Interest Type [Axis] Amended two thousand twenty incentive plan. Amended Two Thousand Twenty Incentive Plan [Member] Amended 2020 Incentive Plan [Member] Disposal Group Classification [Domain] Entity File Number Net increase (decrease) in cash, cash equivalents and restricted cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Registered offering. Registered Offering [Member] Basic and diluted loss per share: Earnings Per Share [Abstract] Accrued interest us-gaap_InterestReceivable 2024 (remaining three months) us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear January 2024 Public Offering [Member] January Two Thousand Twenty Four Public Offering [Member] January two thousand twenty four public offering. Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Liabilities held for sale of discontinued operations, current Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract] Operating loss Operating loss Operating loss 2025 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Stock purchase price per share Shares Issued, Price Per Share Entity Shell Company Placement agents cash fee, percentage Placement Agents Cash Fee Percentage Represents the cash fee percentage. Entity Tax Identification Number ASSETS Assets [Abstract] Class of Warrant or Right [Domain] Entity Current Reporting Status Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Notes To Financial Statements [Abstract] Amount of accrued interest on short-term investments. catx_AccruedInterestOnShortTermInvestments Accrued interest on short-term investments us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Total assets acquired Geographical [Domain] Document Fiscal Year Focus Total cash equivalents and short-term investments Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Other assets, net Disposal Group, Including Discontinued Operation, Other Assets, Current Isoray [Member] Isoray [Member] Isoray. Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD Cash, cash equivalents and restricted cash beginning of period Proceeds from Issuance Initial Public Offering Proceeds from Public Offering, net Business Acquisition [Axis] City Area Code Estimated fair value Disposal Group, Including Discontinued Operation, Consideration Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_LiabilitiesCurrent Total current liabilities Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: Sales and marketing Disposal Group Including Discontinued Operation Sales and Marketing Expense Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Preferred stock, shares outstanding Preferred stock, shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] May two thousand twenty four public offering. May Two Thousand Twenty Four Public Offering [Member] May 2024 Public Offering [Member] Proceeds from Warrant Exercises Proceeds from sales of common stock, pursuant to exercise of warrants, net Commitments and Contingencies Disclosure [Abstract] Schedule of Held-to-Maturity Securities [Line Items] Lease liability Lease liability Less current portion In-process Research and Development In Process Research and Development [Member] Debt instrument, interest rate us-gaap_DebtInstrumentInterestRateStatedPercentage Loss from discontinued operations, Basic Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Accumulated Deficit [Member] Retained Earnings [Member] Over-Allotment Option [Member] Over-Allotment Option [Member] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment, Total us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Grants receivable Document Transition Report 2026 Deferred tax liability Antidilutive Security, Excluded EPS Calculation [Table] Proceeds from issuance of common stock and prefunded warrants net. Proceeds from Issuance of Common Stock and Prefunded Warrants Net Proceeds from the issuance of common stock and Pre-funded Warrants, net Amount of accrued vacation, assumed at the acquisition date. catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation Accrued vacation Base prepaid Rent Operating Lease Prepaid Rent Expense Operating lease prepaid rent expense. Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] 2026 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Cash and cash equivalents Limited liability company, Formation date Limited Liability Company or Limited Partnership, Business, Formation Date Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Foreign currency adjustments Statement of Income Location, Balance [Domain] Houston Texas. Houston Texas [Member] Houston Texas [Member] 2025 Other assets, net Other assets, net Chicago Illinois. Chicago Illinois [Member] Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Cesium-131 Business [Member] Cesium-131 Business [Member] Relating to Cesium-131 Business. Loss from continuing operations, Diluted Income (Loss) from Continuing Operations, Per Diluted Share Number of plaintiff Loss Contingency, Number of Plaintiffs Percentage of ownership considered for warrant exercise Percentage Of Ownership Considered for Warrant Exercise Percentage of ownership considered for warrant exercise. Scenario [Domain] Common stock, $0.001 par value; 750,000,000 shares authorized; 67,562,781 and 28,180,985 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively1 Common stock, $.001 par value; 750,000,000 shares authorized; 280,571,026 and 142,112,766 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Increase (Decrease) in Employee Related Liabilities, Total Increase (Decrease) in Employee Related Liabilities Accrued personnel expenses Interest income Lease with Board of Regents. Lease with Board of Regents [Member] Asset Retirement Obligation, Revision of Estimate Change in estimate of asset retirement obligation (Note 4) Change in estimate of asset retirement obligation Change in estimate of asset retirement obligation (Note 4) 2027 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Total lease liability, Total Lease liability Total lease liability Measurement Frequency [Axis] Commitments and contingencies (Note 10) Commitments and contingencies (Note 9) Net loss from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Accounts receivable, net of allowance for doubtful accounts: 2024 - $592; 2023 - $650 Accounts receivable, net us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total Weighted average shares used in computing net loss per share: Entity Small Business Summary of Carrying Values and Fair Values of Financial Instruments Debt Securities, Held-to-Maturity [Table Text Block] HTM, Gross Unrealized Losses HTM, Gross Unrealized Losses us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Intangible Asset, Indefinite-Lived [Table] Notes Payable Debt Disclosure [Text Block] Principal payments us-gaap_RepaymentsOfDebt Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split, ratio Foreign currency adjustments Foreign currency adjustments Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax, Total Current liabilities of discontinued operations Total current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Net assets acquired, excluding goodwill Program Preclinical Co-Funding Option [Member] Program preclinical co-funding option. Number of renewal options Lessee Operating Lease Number Of Renewal Options Lessee operating lease number of renewal options. Purchase price Asset purchase price in cash Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred, Total CASH FLOWS FROM FINANCING ACTIVITIES: Modification of operating lease liability and right of use asset Measurement Frequency [Domain] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Operating lease, weighted average remaining term us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Recognition of operating lease liability and right-of-use asset Recognition of Operating Lease liability and Right of Use Asset Recognition of operating lease liability and right of use asset. Net loss from discontinued

operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Total loss from discontinued operations Building Building [Member] VMT option. VMT Option [Member] Accounts payable and accrued expenses us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Accounts payable and accrued expenses Asset retirement obligation Disposal Group Including Discontinued Operation Asset Retirement Obligation Current Amount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss, Beginning Balance XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 07, 2024 Cover [Abstract] Â Â Entity Central Index Key 0000728387 Â Entity Registrant Name PERSPECTIVE THERAPEUTICS, INC. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-33407 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 41-1458152 Â Entity Address, Address Line One 2401 Elliott Avenue, Suite 320 Â Entity Address, City or Town Seattle Â Entity Address, State or Province WA Â Entity Address, Postal Zip Code 98121 Â City Area Code 206 Â Local Phone Number 676-0900 Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol CATX Â Security Exchange Name NYSEAMER Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 67,587,540 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 226,443 $ 9,238 Short-term investments 41,404 0 Accounts receivable, net of allowance for doubtful accounts: 2024 - $592; 2023 - $650 217 1,165 Prepaid expenses and other current assets 2,108 1,133 Current assets held for sale, discontinued operations 0 5,301 Total current assets 270,172 16,837 Noncurrent assets: Â Â Property and equipment, net 43,792 5,576 Right-of-use asset, net 2,433 747 Restricted cash 0 182 Intangible assets, in-process research and development 50,000 50,000 Goodwill 24,062 24,062 Other assets, net 694 487 Total assets 391,153 97,891 Current liabilities: Â Â Accounts payable and accrued expenses 21,813 6,909 Lease liability 903 46 Accrued personnel expenses 3,976 3,588 Note payable 51 49 Deferred Income (Note 3) 1,400 0 Current liabilities of discontinued operations 0 5,072 Total current liabilities 28,143 15,664 Noncurrent liabilities: Â Â Lease liability, net of current portion 1,676 780 Note payable, net of current portion 1,638 1,676 Deferred Income, net of current portion (Note 3) 26,600 0 Deferred tax liability 4,592 4,592 Other noncurrent liabilities 33 0 Total liabilities 62,682 22,712 Commitments and contingencies (Note 10) Stockholders' equity: Â Â Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 0 0 Common stock, $0.001 par value; 750,000,000 shares authorized; 67,562,781 and 28,180,985 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively1 [1] 67 28 Additional paid-in capital [1] 519,954 227,591 Accumulated deficit (191,550) (152,440) Total stockholders' equity 328,471 75,179 Total liabilities and stockholders' equity $ 391,153 $ 97,891 [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -

Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -

SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parentheticals) $ in Thousands Sep. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Allowance for doubtful accounts | $ $ 592 $ 650 Preferred stock, par value | $ / shares $ 0.001 $ 0.001 Preferred stock, shares authorized 7,000,000 7,000,000 Common stock, par value | $ / shares $ 0.001 $ 0.001 Common stock, shares authorized 750,000,000 750,000,000 Common stock, shares issued [1] 67,562,781 28,180,985 Common stock, shares outstanding [1] 67,562,781 28,180,985 Series B Convertible Preferred Stock [Member] Â Â Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber

of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=catx_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Â Grant revenue $ 369 $ 276 $ 1,220 $ 1,097 Operating expenses: Â Â Â Â Â Research and development 12,028 5,552 28,755 14,231 General and administrative 6,975 4,474 18,367 16,124 Change in estimate of asset retirement obligation (Note 4) 0 0 0 (15) Loss on disposal of property and equipment 0 0 0 22 Total operating expenses 19,003 10,026 47,122 30,362 Operating loss (18,634) (9,750) (45,902) (29,265) Non-operating income (expense): Â Â Â Â Â Interest income 3,581 204 7,868 872 Interest and other expense (69) (14) (121) (58) Equity in loss of affiliate 0 (12) (6) (12) Total non-operating income (expense), net 3,512 178 7,741 802 Net loss from continuing operations (15,122) (9,572) (38,161) (28,463) Net loss from discontinued operations 0 (784) (890) (3,870) Loss recognized on classification as held for sale 0 0 (59) 0 Net loss before deferred income tax benefit (15,122) (10,356) (39,110) (32,333) Deferred income tax benefit 0 0 0 10,500 Net loss $ (15,122) $ (10,356) $ (39,110) $ (21,833) Basic and diluted loss per share: Â Â Â Â Â Loss from continuing operations, Basic [1] $ (0.21) $ (0.34) $ (0.61) $ (0.68) Loss from continuing operations, Diluted [1] (0.21) (0.34) (0.61) (0.68) Loss from discontinued operations, Basic [1] 0 (0.03) (0.01) (0.15) Loss from discontinued operations, Diluted [1] 0 (0.03) (0.01) (0.15) Basic loss per share [1] (0.21) (0.37) (0.62) (0.83) Diluted loss per share [1] $ (0.21) $ (0.37) $ (0.62) $ (0.83) Weighted average shares used in computing net loss per share: Â Â Â Â Â Basic [1] 70,629 28,055 62,293 26,323 Diluted [1] 70,629 28,055 62,293 26,323 [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionInterest and other expense. + ReferencesNo definition available. + Details Name: catx_InterestAndOtherExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationRevisionOfEstimate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 13 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Parenthetical) Jun. 14, 2024 Income Statement [Abstract] Â Reverse stock split 1-for-10 reverse stock split Reverse stock split, ratio 0.1 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Â Net Income (Loss) $ (15,122) $ (12,284) $ (10,356) $ (371) $ (39,110) $ (21,833) Â Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Â Â Â Â Â Â Â Foreign currency adjustments Â Â Â Â 39 0 Â Lease expense Â Â Â Â 100 35 Â Depreciation expense Â Â Â Â 1,585 684 Â Write-off of inventory associated with discontinued product Â Â Â Â 0 298 Â Loss on disposal of property and equipment Â Â Â Â 0 22 Â Amortization of other assets Â Â Â Â 12 30 Â Accretion of asset retirement obligation Â Â Â Â 0 26 Â Equity in loss of affiliate 0 Â 12 Â 6 12 Â Accrued interest on short-term investments Â Â Â Â (899) 0 Â Change in allowance for doubtful accounts Â Â Â Â (58) 0 Â Change in estimate of asset retirement obligation 0 Â 0 Â 0 (15) Â Loss on divestiture Â Â Â Â 59 0 Â Share-based compensation Â Â Â Â 3,327 3,018 Â Deferred income tax benefit 0 Â 0 Â 0 (10,500) Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Accounts receivable Â Â Â Â 890 (368) Â Inventory related to discontinued operations Â Â Â Â 11 257 Â Prepaid expenses and other current assets Â Â Â Â (975) 12 Â Accounts payable and accrued expenses Â Â Â Â 14,937 (683) Â Deferred Income [1] Â Â Â Â 28,000 0 Â Accrued personnel expenses Â Â Â Â 388 1,100 Â Net cash provided by (used in) operating activities Â Â Â Â 8,312 (27,905) Â CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Â Additions to property and equipment Â Â Â Â (39,800) (983) Â Additions to other assets Â Â Â Â (24) (18) Â Proceeds from maturity of short-term investments Â Â Â Â 38,225 22,764 Â Purchases of short-term investments Â Â Â Â (78,730) 0 Â Net cash acquired in acquisition of Viewpoint Â Â Â Â 0 2,699 Â Net cash (used in) provided by investing activities Â Â Â Â (80,329) 24,462 Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Repayment of notes payable Â Â Â Â (36) (56) Â Proceeds from sales of common stock, pursuant to exercise of warrants, net Â Â Â Â 125 0 Â Proceeds from sales of common stock, pursuant to exercise of options Â Â Â Â 896 554 Â Proceeds from the issuance of common stock and Pre-funded Warrants, net [1] Â Â Â Â 288,055 0 Â Issuance costs related to common stock issued in exchange for Viewpoint common stock Â Â Â Â 0 (65) Â Net cash provided by financing activities Â Â Â Â 289,040 433 Â Net increase (decrease) in cash, cash equivalents and restricted cash Â Â Â Â 217,023 (3,010) Â Cash, cash equivalents and restricted cash beginning of period Â $ 9,420 Â $ 21,175 9,420 21,175 $ 21,175 CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD 226,443 Â 18,165 Â 226,443 18,165 9,420 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Â Â Â Â Â Â Â Cash and cash equivalents 226,443 Â 17,983 Â 226,443 17,983 9,238 Restricted cash 0 Â 182 Â 0 182 182 Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows $ 226,443 Â $ 18,165 Â 226,443 18,165 $ 9,420 Supplemental schedule of noncash investing and financing activities: Â Â Â Â Â Â Â Recognition of operating lease liability and right-of-use asset Â Â Â Â 2,115 811 Â Additions to property and equipment Â Â Â Â 16,518 0 Â Fair value of Viewpoint assets acquired including goodwill Â Â Â Â 0 85,885 Â 13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock Â Â Â Â 0 (54,618) Â Assumption of Viewpoint stock options and warrants at fair value Â Â Â Â 0 (7,836) Â Note receivable and accrued interest from Viewpoint forgiven Â Â Â Â $ 0 $ (6,171) Â [1] See Note 3, Investments and Agreements, for additional information. X - DefinitionAmount of accrued interest on short-term investments. + ReferencesNo definition available. + Details Name: catx_AccruedInterestOnShortTermInvestments Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations + ReferencesNo definition available. + Details Name: catx_IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the noncash expense incurred for leases. + ReferencesNo definition available. + Details Name: catx_NoncashExpenseLease Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAssumption fair value of stock options and warrants in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionForgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing

activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: catx_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and prefunded warrants net. + ReferencesNo definition available. + Details Name: catx_ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRecognition of operating lease liability and right of use asset. + ReferencesNo definition available. + Details Name: catx_RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: catx_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481879/410-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationAccretionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 410 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1 + Details Name: us-gaap_AssetRetirementObligationRevisionOfEstimate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_CashAcquiredFromAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X

- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow through purchase of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) 9 Months Ended Sep. 30, 2023 shares Statement of Cash Flows [Abstract] Â Shares issued in exchange for common stock (in shares) 13,654,507 [1] [1] Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. X - DefinitionThe number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards

Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] January 2024 Pre-funded Warrants [Member] January 2024 Pre-funded Warrants [Member] Common Stock [Member] [1] January 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member] [1] January 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member] May 2024 Pre-funded Warrants [Member] May 2024 Pre-funded Warrants [Member] Common Stock [Member] [1] May 2024 Pre-funded Warrants [Member] Additional Paid-in Capital [Member] [1] May 2024 Pre-funded Warrants [Member] Accumulated Deficit [Member] Public Offering [Member] Public Offering [Member] Common Stock [Member] Public Offering [Member] Additional Paid-in Capital [Member] [1] Public Offering [Member] Accumulated Deficit [Member] Lantheus Investment Agreement [Member] Lantheus Investment Agreement [Member] Common Stock [Member] Lantheus Investment Agreement [Member] Additional Paid-in Capital [Member] [1] Lantheus Investment Agreement [Member] Accumulated Deficit [Member] March 2024 Investment Agreement [Member] March 2024 Investment Agreement [Member] Common Stock [Member] March 2024 Investment Agreement [Member] Additional Paid-in Capital [Member] [1] March 2024 Investment Agreement [Member] Accumulated Deficit [Member] A T M Agreement [Member] A T M Agreement [Member] Common Stock [Member] A T M Agreement [Member] Additional Paid-in Capital [Member] [1] A T M Agreement [Member] Accumulated Deficit [Member] Registered Offering [Member] Registered Offering [Member] Common Stock [Member] Registered Offering [Member] Additional Paid-in Capital [Member] [1] Registered Offering [Member] Accumulated Deficit [Member] Balances (in shares) at Dec. 31, 2022 [1] Â 14,211,276 Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Jun. 14, 2024 Statement of Stockholders' Equity [Abstract] Â Reverse stock split 1-for-10 reverse stock split Reverse stock split, ratio 0.1 X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (15,122) $ (11,704) $ (12,284) $ (10,356) $ (11,106) $ (371) $ (39,110) $ (21,833) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Material Terms of Trading Arrangement ITEM 5 â€“ OTHER INFORMATIONRule 10b5-1 Trading ArrangementsDuring the three months ended September 30, 2024, none of our directors or executive officers adopted, modified or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K. Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Rule 10b5-1 Arrangement Modified false Non-Rule 10b5-1 Arrangement Modified false X - DefinitionNon-Rule 10b5-1 Arrangement Modified Flag. + ReferencesNo definition available. + Details Name: catx_NonRule10B51ArrangementModifiedFlag Namespace Prefix: catx_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRule 10b 51 Arr Modified Flag. + ReferencesNo definition available. + Details Name: catx_Rule10B51ArrModifiedFlag Namespace Prefix: catx_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Basis of Presentation and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation and Summary of Significant Accounting Policies 1.Basis of Presentation and Summary of Significant Accounting PoliciesPerspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as â€œPerspective Therapeuticsâ€ or the â€œCompany.â€ All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes as set forth in the Companyâ€™s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K).The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in managementâ€™s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Companyâ€™s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.MergerOn February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.Discontinued OperationsOn April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.Reverse Stock SplitOn June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Companyâ€™s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Companyâ€™s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholderâ€™s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Companyâ€™s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.LiquidityThe Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At September 30, 2024, the Company had cash, cash equivalents and short-term investments of $267.8 million and total accumulated deficit of $191.6 million. The Company has historically financed its operations primarily through selling equity.The Company believes that its $267.8 million of cash, cash equivalents and short-term investments as of September 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors.ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.Significant Accounting PoliciesThe Companyâ€™s significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Companyâ€™s significant accounting policies, and the Company has not adopted any significant accounting policies during the nine months ended September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Loss Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Loss Per Share 2.Loss per ShareBasic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form

10-Q). As the pre-funded warrantsâ€™ exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of September 30, 2024. At each of September 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Companyâ€™s net loss position.Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â September 30, 2024 Â Â September 30, 2023 Â Common stock warrants Â Â 416 Â Â Â 576 Â Common stock options Â Â 7,252 Â Â Â 4,468 Â Total potential dilutive securities Â Â 7,668 Â Â Â 5,044 Â Â Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30 to $3.00 per share. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Investments and Agreements 9 Months Ended Sep. 30, 2024 Investment Agreements [Abstract] Â Investments and Agreements 3.Investments and Agreements2024 At-the-Market (ATM) AgreementOn August 13, 2024, the Company entered into a Controlled Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM Agent, and together, the ATM Agents) pursuant to which the Company from time to time may offer and sell shares (2024 ATM Shares) of its Common Stock, through or to the ATM Agents having an aggregate sales price of up to $250.0 million.Subject to the terms and conditions of the 2024 ATM Agreement, each ATM Agent is required to use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Companyâ€™s instructions. The Company has provided the ATM Agents with customary indemnification rights, and the ATM Agents will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the ATM Shares effectuated through or to the applicable ATM Agent selling the ATM Shares.Â Sales of the 2024 ATM Shares, if any, under the 2024 ATM Agreement may be made in transactions that are deemed to be â€œat the market offeringsâ€ as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the 2024 ATM Shares and may at any time suspend offers under the 2024 ATM Agreement or terminate the 2024 ATM Agreement.Â The Common Stock to be sold under the 2024 ATM Agreement, if any, will be issued and sold pursuant to the Companyâ€™s automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024. On August 13, 2024, the Company filed a prospectus supplement to the May 2024 Registration Statement with the SEC in connection with the offer and sale of the 2024 ATM Shares pursuant to the 2024 ATM Agreement.Â As of September 30, 2024, the Company has not completed any transactions pursuant to the 2024 ATM Agreement.May 2024 Registered OfferingOn May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering.The gross proceeds to the Company from the Registered Offering were approximately $80.0 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering.The Registered Offering was made pursuant to the May 2024 Registration Statement, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024.The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Companyâ€™s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â March 2024 Private Placement with Institutional InvestorsOn March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024.The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses.The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment AgreementOn January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $50.0 million of gross proceeds (excluding Lantheusâ€™ investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024.The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362).The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions.The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions.Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase AgreementOn January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenicsâ€™ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option AgreementOn January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-Î±-NET, the Companyâ€™s clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-Î±-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0 million, subject to certain withholding provisions associated with the closing of the Progenics APA.Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024.The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with Accounting Standards Codification (ASC) 730-20, Research and Development Arrangements, as Lantheus held approximately 19.9% of the Companyâ€™s outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way.Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, â€œDeferred Income.â€ The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public OfferingOn January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024.The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering.The Public Offering was made pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024.The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Companyâ€™s stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company.Â 2023 ATM AgreementThe Company entered into an ATM Issuance Sales Agreement, dated November 17, 2023, by and among the Company, Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (2023 ATM Agreement). Pursuant to the 2023 ATM Agreement, the Company established an ATM equity program under which it may offer and sell shares of its Common Stock, from time to time.On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200.0 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50.0 million of shares of its Common Stock pursuant to the 2023 ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the 2023 ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million.On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the 2023 ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million.On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement.On August 7, 2024, the Company delivered written notice to Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC that it was terminating the 2023 ATM Sales Agreement, which termination became effective August 12, 2024.For additional information related to certain of the agreements discussed above, see Note 20, Subsequent Events, in the Companyâ€™s 2023 Form 10-K. X - DefinitionInvestment agreements. + ReferencesNo definition available. + Details Name: catx_InvestmentAgreementsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInvestments and agreements disclosure. + ReferencesNo definition available. + Details Name: catx_InvestmentsAndAgreementsDisclosureTextBlock Namespace Prefix: catx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Discontinued Operations 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Discontinued Operations 4.Discontinued OperationsThe GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isorayâ€™s right, title and interest in and to substantially all of the assets of Isoray related to Isorayâ€™s commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray.Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medicalâ€™s common stock, par value $0.0001 per share, representing 0.5% of GT Medicalâ€™s issued and outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below:â€¢with respect to GT Medicalâ€™s net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medicalâ€™s GammaTile Therapy: (a) if such net sales for a Measurement Period are $10.0 million or less, 3.0% of such net sales; (b) if such net sales for a

Measurement Period are greater than $10.0 million and less than $15.0 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15.0 million or more, 5.0% of such net sales; andâ€¢with respect to GT Medicalâ€™s net sales of GT Medicalâ€™s GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period.In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â September 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Sales, net Â $ - Â Â $ 1,909 Â Â $ 2,178 Â Â $ 5,239 Â Cost of sales Â Â - Â Â Â 1,447 Â Â Â 1,564 Â Â Â 4,863 Â Gross profit Â Â - Â Â Â 462 Â Â Â 614 Â Â Â 376 Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â - Â Â Â 169 Â Â Â 69 Â Â Â 1,000 Â Sales and marketing Â Â - Â Â Â 855 Â Â Â 941 Â Â Â 2,578 Â General and administrative Â Â - Â Â Â 222 Â Â Â 494 Â Â Â 668 Â Total operating expenses Â Â - Â Â Â 1,246 Â Â Â 1,504 Â Â Â 4,246 Â Â Â Â Â Â Â Â Â Â Â Â Total loss from discontinued operations Â $ - Â Â $ (784) Â $ (890) Â $ (3,870) The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales.Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands):Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Depreciation Â $ - Â Â $ 171 Â Amortization Â Â - Â Â Â 27 Â Write-off of inventory associated with discontinued product Â Â - Â Â Â 298 Â Share-based compensation Â Â 166 Â Â Â 568 Â Additions to property and equipment Â Â - Â Â Â 287 Â The Company previously had a restricted cash account to provide collateral for the decommissioning of its leased facility for Cesium-131 production. This facility lease was assumed by GT Medical as part of the GT Medical APA which included the commitment to decommission the facility. The Company has subsequently moved the full balance of the restricted cash account to its general operating cash accounts.For the three and nine months ended September 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment 9 Months Ended Sep. 30, 2024 Notes To Financial Statements [Abstract] Â Property and Equipment 5.Property and EquipmentOn July 15, 2024, August 2, 2024 and October 31, 2024, the Company purchased a building located in the Houston, Texas, metropolitan area for $4.7 million, a building in the Chicago, Illinois, metropolitan area for $5.0 million, and a building in the Los Angeles, California, metropolitan area for $11.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment.On September 18, 2024, the Company entered into a Master Equipment and Services Agreement (MESA) and statements of work (SOWs) thereunder with Comecer SpA (Comecer), pursuant to which the Company agreed to purchase from Comecer manufacturing equipment for the production of the Companyâ€™s radiopharmaceutical products including, but not limited to, isotope processing hot cells and production suites and related equipment (collectively, the Deliverables) and services for installation and validation of the Deliverables at several of the Companyâ€™s production facilities in the United States. The aggregate consideration for such equipment and services pursuant to the MESA and SOWs is approximately â‚¬49.0 million payable in cash, excluding certain incidental costs such as taxes, customs and duties, local transport, insurance and rigging. The Company may also elect to purchase certain additional equipment and services pursuant to the SOWs. The MESA provides for the payment of certain amounts in installments over the course of the production, installation and validation of the Deliverables.The Companyâ€™s property and equipment consisted of the following as of:Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Building Â $ 1,770 Â Â $ 1,770 Â Land Â Â 1,283 Â Â Â 1,283 Â Equipment Â Â 10,601 Â Â Â 2,683 Â Leasehold improvements Â Â 3,497 Â Â Â 179 Â Other1 Â Â 28,895 Â Â Â 330 Â Property and equipment Â Â 46,046 Â Â Â 6,245 Â Less accumulated depreciation Â Â (2,254) Â Â (669) Property and equipment, net Â $ 43,792 Â Â $ 5,576 Â 1.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. X - ReferencesNo definition available. + Details Name: catx_NotesToFinancialStatementsAbstract Namespace Prefix: catx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Goodwill and Other Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Other Intangible Assets 6.Goodwill and Other Intangible AssetsGoodwillThe carrying amount of goodwill as of both September 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Companyâ€™s Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and nine months ended September 30, 2024.The following table summarizes the components of the Companyâ€™s other intangible assets (in thousands): Â September 30, 2024 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Â Â December 31, 2023 Â Â Cost Â Â Accumulated Amortization Â Â Net Carrying Value Â Indefinite-lived intangible assets Â Â Â Â Â Â Â Â Â Â In-process research and development Â $ 50,000 Â Â $ - Â Â $ 50,000 Â Total Â $ 50,000 Â Â $ - Â Â $ 50,000 Â The Companyâ€™s IPR&D assets represent the estimated fair value of Viewpointâ€™s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpointâ€™s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Held-to-Maturity Investments 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Held-to-Maturity Investments 7.Held-to-Maturity InvestmentsThe following table summarizes the carrying values and fair values of the Companyâ€™s financial instruments (in thousands): Â September 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury Bills Â $ 41,404 Â Â $ 11 Â Â $ - Â Â $ 41,415 Â Â The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Companyâ€™s condensed consolidated statement of operations. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 8.Fair Value MeasurementsFair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:Level 1 - Observable inputs such as quoted prices in active markets;Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; andLevel 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.Included in the Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â Â September 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 224,502 Â There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at September 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023.For information related to short-term investments, see Note 7, Held-to-Maturity Investments. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Share-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Share-Based Compensation 9.Share-Based CompensationOn May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Companyâ€™s stockholders approved the Companyâ€™s Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the â€œevergreenâ€ provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Companyâ€™s Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. On August 14, 2024, the Company filed a Form S-8 to register 4,870,092 additional shares of Common Stock authorized for issuance under the Amended and Restated Plan as approved by stockholders at the Annual Meeting.The following table presents the share-based compensation expense recognized for all share-based compensation arrangements, excluding share-based compensation expense reported in Note 4, Discontinued Operations (in thousands):Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Research and development $ 814 Â Â $ 179 Â Â $ 1,336 Â Â $ 763 Â General and administrative Â 1,138 Â Â Â 239 Â Â Â 1,825 Â Â Â 1,687 Â Total share-based compensation $ 1,952 Â Â $ 418 Â Â $ 3,161 Â Â $ 2,450 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 10.Commitments and ContingenciesThe Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Companyâ€™s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of September 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Related Parties 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions Disclosure [Text Block] 11.Related PartiesÂ In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024.Â On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA.Â On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024.Â For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements.Â On August 8, 2024, the Company entered into an access and license agreement with Lantheus. For additional information, see Note 12, Leases. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases 12.LeasesThe Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.On August 8, 2024, the Company assumed a lease from Progenics for office space in Somerset, New Jersey (Office). The lease terminates on November 30, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.6 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.Upon assuming the lease, the Company entered into a license and access agreement with Lantheus, which provides access to both dedicated and shared space of the Office (Access Agreement). There is no renewal option, and the termination options are available only for material breaches. In consideration of the Access Agreement, Lantheus agreed to pay base rent and associated costs through December 2024 directly to the landlord. The base rent through December 2024 is less than $0.1 million (Prepaid Rent). Pursuant to ASC 842, Leases, the Access Agreement is a sublease in which the Company is a sublessor and Lantheus is a sublessee. The Company will amortize the Prepaid Rent over the entire lease term of 52 months.On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate.The weighted average remaining term and discount rate for the Companyâ€™s operating leases as of September 30, 2024 was 3.2 years and 8%, respectively.The Companyâ€™s operating lease expense was $0.3 million and $0.5 million for the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.4 million for the three and nine months ended September 30, 2023.The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of September 30, 2024 (in thousands):Â Year Ending December 31, Â Â Â 2024 (remaining three months) Â $ 245 Â 2025 Â Â 1,112 Â 2026 Â Â 647 Â 2027 Â Â 493 Â 2028 Â Â 443 Â Total Â Â 2,940 Â Less: imputed interest Â Â (361) Total lease liability Â Â 2,579 Â Less: current portion Â Â (903) Noncurrent lease liability Â $ 1,676 Â Â Asset Retirement ObligationThe Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Companyâ€™s condensed consolidated financial statements as of September 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of September 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Notes Payable 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Notes Payable 13.Notes PayableThe Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered into a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA.Â On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.The following table presents the current and long-term portions of the note payable (in thousands):Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Note payable Â $ 1,689 Â Â $ 1,725 Â Less: current portion Â Â (51) Â Â (49) Note payable, long-term portion Â $ 1,638 Â Â $ 1,676 Â Â The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of September 30, 2024 (in thousands):Â Years ending December 31: Â Â Â 2024 (remaining three months) Â $ 13 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,689 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger 9 Months Ended Sep. 30, 2024 Business Combinations [Abstract] Â Merger 14.MergerOn February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpointâ€™s outstanding stock options and warrants as of the Merger date. The Merger was completed to provide the Company with a new isotope in a larger market.Â The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Â Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right-of-use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Â Liabilities assumed Â Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Goodwill Â $ 24,062 Â Â Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint.Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Companyâ€™s condensed consolidated financial statements.Since the closing date, Viewpointâ€™s results of operations have been reported in the Companyâ€™s condensed consolidated financial statements and include grant revenue of approximately $0.4 million and $0.3 million, respectively, and operating loss of $18.6 million and $9.8 million, respectively, for the three months ended September 30, 2024 and 2023, and grant revenue of approximately $1.2 million and $1.1 million, respectively, and operating loss of $45.9 million and $29.3 million, respectively, for the nine months ended September 30, 2024 and 2023. X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Reclassifications ReclassificationsIn addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands):Â Â September 30, 2024 Â Â September 30, 2023 Â Common stock warrants Â Â 416 Â Â Â 576 Â Common stock options Â Â 7,252 Â Â Â 4,468 Â Total potential dilutive securities Â Â 7,668 Â Â Â 5,044 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Discontinued Operations (Tables) 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Schedule of Discontinued Operations In accordance with ASC 205-20, Presentation of Financial Statements â€“ Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.Â Â Â September 30, 2024 Â Â December 31, 2023 Â (in thousands) Â Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Â Inventory Â $ - Â Â $ 3,148 Â Prepaid expenses and other current assets Â Â - Â Â Â 169 Â Property and equipment, net Â Â - Â Â Â 1,263 Â Right-of-use asset, net Â Â - Â Â Â 676 Â Other assets, net Â Â - Â Â Â 45 Â Total current assets held for sale of discontinued operations Â $ - Â Â $ 5,301 Â Â Â Â Â Â Â Liabilities held for sale of discontinued operations, current Â Â Â Â Â Â Lease liability Â $ - Â Â $ 677 Â Asset retirement obligation Â Â - Â Â Â 225 Â Loss recognized on classification as held for sale Â Â - Â Â Â 4,170 Â Total current liabilities of discontinued operations Â $ - Â Â $ 5,072 Â Â The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands):Â Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â

Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 15: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B + Details Name: us-gaap_HeldToMaturitySecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis Companyâ€™s cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): Â Â September 30, 2024 Â Â Â Estimated Fair ValueLevel 1 Â Money market fund Â $ 224,502 Â X - DefinitionTabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Share-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense The following table presents the share-based compensation expense recognized for all share-based compensation arrangements, excluding share-based compensation expense reported in Note 4, Discontinued Operations (in thousands):Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Research and development $ 814 Â Â $ 179 Â Â $ 1,336 Â Â $ 763 Â General and administrative Â 1,138 Â Â Â 239 Â Â Â 1,825 Â Â Â 1,687 Â Total share-based compensation $ 1,952 Â Â $ 418 Â Â $ 3,161 Â Â $ 2,450 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Leases (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Summary of Future Operating Lease Payments and Lease Liability The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Companyâ€™s operating leases as of September 30, 2024 (in thousands):Â Year Ending December 31, Â Â Â 2024 (remaining three months) Â $ 245 Â 2025 Â Â 1,112 Â 2026 Â Â 647 Â 2027 Â Â 493 Â 2028 Â Â 443 Â Total Â Â 2,940 Â Less: imputed interest Â Â (361) Total lease liability Â Â 2,579 Â Less: current portion Â Â (903) Noncurrent lease liability Â $ 1,676 Â X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Notes Payable (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Summary of Note Payable The following table presents the current and long-term portions of the note payable (in thousands):Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Note payable Â $ 1,689 Â Â $ 1,725 Â Less: current portion Â Â (51) Â Â (49) Note payable, long-term portion Â $ 1,638 Â Â $ 1,676 Â Summary of Maturity of Note Payable The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Companyâ€™s note payable as of September 30, 2024 (in thousands):Â Years ending December 31: Â Â Â 2024 (remaining three months) Â $ 13 Â 2025 Â Â 52 Â 2026 Â Â 55 Â 2027 Â Â 1,569 Â Total Â $ 1,689 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger (Tables) 9 Months Ended Sep. 30, 2024 Business Combinations [Abstract] Â Summary of Estimated Purchase Consideration The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):Â Fair value of consideration transferred Â Â Â Perspective Therapeutics common stock issued (13,654,507Â x $4.00) Â $ 54,618 Â Assumption of Viewpoint stock options and warrants at fair value Â Â 7,836 Â Note receivable and interest from Viewpoint forgiven Â Â 6,171 Â Total fair value of consideration transferred Â $ 68,625 Â Summary of Preliminary Purchase Price Allocation Recognized amounts of identifiable net assets acquired Â Â Â Assets acquired Â Â Â Cash and cash equivalents Â $ 2,699 Â Grants receivable Â Â 95 Â Prepaid expenses Â Â 396 Â Property and equipment Â Â 5,050 Â Right-of-use asset Â Â 10 Â Intangible assets, in-process research and development Â Â 50,000 Â Other assets Â Â 316 Â Total assets acquired Â Â 58,566 Â Â Â Â Â Liabilities assumed Â Â Â Accounts payable and accrued expenses Â Â 2,968 Â Lease liability Â Â 10 Â Accrued payroll and related taxes Â Â 1,642 Â Accrued vacation Â Â 333 Â Notes payable Â Â 1,807 Â Deferred tax liability Â Â 7,243 Â Total liabilities assumed Â Â 14,003 Â Â Â Â Â Net assets acquired, excluding goodwill Â Â 44,563 Â Total purchase price consideration Â Â 68,625 Â Â Â Â Â Goodwill Â $ 24,062 Â X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Jun. 14, 2024 Apr. 12, 2024 $ / shares shares Apr. 11, 2024 USD ($) $ / shares shares Feb. 03, 2023 $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Dec. 31, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â

Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_GTMedicalTechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_OppenheimerCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 7,668 5,044 Common Stock Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 416 576 Common Stock Options [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total potential dilutive securities 7,252 4,468 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Loss Per Share (Details Textual) - Viewpoint Molecular Targeting, Inc. [Member] Feb. 03, 2023 $ / shares shares Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Warrants to purchase shares of common stock | shares 338,709 Warrant exercise price per share $ 2.7 Options to purchase shares of common stock | shares 2,426,342 Minimum [Member] Â Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Options exercise price per share $ 1.3 Maximum [Member] Â Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Â Options exercise price per share $ 3 X - DefinitionShare based compensation arrangements by share based payment award options exercise price. + ReferencesNo definition available. + Details Name: catx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice Namespace Prefix: catx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) assumed during the period. + ReferencesNo definition available. + Details Name: catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross Namespace Prefix: catx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareBasicLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Investments and Agreements (Details Textual) - USD ($) 1 Months Ended 3 Months Ended May 24, 2024 Apr. 11, 2024 Mar. 04, 2024 Jan. 17, 2024 Jan. 08, 2024 Dec. 31, 2023 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Aug. 13, 2024 Dec. 14, 2023 Nov. 17, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, par value Â Â Â Â Â $ 0.001 Â Â $ 0.001 Â Â Â Maximum amount of securities offer and sell Â Â Â Â Â Â Â Â Â Â $ 200,000,000 Â January 2024 Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants to purchase shares of common stock Â Â Â 3,008,694 Â Â Â Â Â Â Â Â Â Warrant exercise price per share Â Â Â $ 3.69 Â Â Â Â Â Â Â Â Â Percentage of ownership considered for warrant exercise Â Â Â 4.99% Â Â Â Â Â Â Â Â Â Maximum increase or decrease in ownership percentage Â Â Â 19.99% Â Â Â Â Â Â Â Â Â 2024 At-the-Market (ATM) Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Agent commission fee as a percentage of gross sales price Â Â Â Â Â Â Â Â Â Â 3.00% Â Â 2024 At-the-Market (ATM) Agreement [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Maximum amount of securities offer and sell Â Â Â Â Â Â Â Â Â Â $ 250,000,000 Â Â March 2024 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â 9,200,998 Â Â Â Â Â Â Â Â Â Â Â Stock purchase price per share Â Â $ 9.5 Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â $ 87,400,000 Â Â Â Â Â Â Â Â Â Â Placement agents cash fee, percentage Â Â 5.85% Â Â Â Â Â Â Â Â Â Lantheus Investment Agreement Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â Â 5,634,235 Â Â Â Â Â Â Â Â Â Investment agreement, contingent amount of gross proceeds raised Â Â Â Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Percent of outstanding shares Â Â Â Â 19.99% Â Â Â Â Â Â Â Â Â Asset purchase price in cash Â Â Â Â Â $ 8,000,000 Â Â Â Â Â Â Â Â Â Lantheus Investment Agreement | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares [1],[2] Â Â Â Â Â Â Â Â 5,634,235 Â Â Â Â Â Lantheus Investment Agreement | Option Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Percent of outstanding shares Â Â Â Â Â Â Â 19.90% Â Â Â Â Â One-time payment received for rights granted Â Â Â Â 28,000,000 Â Â Â Â Â Â Â Repayment provisions Â Â Â Â $ 0 Â Â Â Â Â Â Â Â Public Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â 13,207,521 Â Â Â Â Â Â Â Â Â Sale of stock, price per share Â Â Â $ 3.7 Â Â Â Â Â Â Â Â Â Shares and warrants, price difference per share Â Â Â $ 0.01 Â Â Â Â Â Â Â Â Â Gross proceeds from public offering Â Â Â $ 69,000,000 Â Â Â Â Â Â Â Â Â Public Offering [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares [1],[2] Â Â Â Â Â Â Â Â 15,639,954 Â Â Â Â Over-Allotment Option [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â Â Â 2,432,432 Â Â Â Â Â Â Â Â Â Registered Offering [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares [1],[2] Â Â Â Â Â Â Â Â 5,151,588 Â Â Â Â Â Oppenheimer & Co [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares Â 3,535,246 Â Â Â 123,882 Â Â Â Â Â Â Â Stock purchase price per share Â $ 14 Â Â Â $ 3.03 Â Â Â Â Â Â Proceeds from issuance of common stock Â $ 49,500,000 Â Â Â $ 400,000 Â Â Â Â Â Â Maximum amount of securities offer and sale Â Â Â Â Â Â Â Â Â Â Â $ 50,000,000 BofA Securities, Inc [Member] | Underwriting Agreement [Member] | May 2024 Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants to purchase shares of common stock 146,425 Â Â Â Â Â Â Â Â Â Â Warrant exercise price per share $ 15.09 Â Â Â Â Â Â Â Â Â Percentage of ownership considered for warrant exercise 4.99% Â Â Â Â Â Â Â Â Â Â Percentage of ownership considered for warrant exercise 9.99% Â Â Â Â Â Â Â Â Â Maximum increase or decrease in ownership percentage 19.99% Â Â Â Â Â Â Â Â Â BofA Securities, Inc [Member] | Registered Offering [Member] | Underwriting Agreement [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Stock issued during period, shares 5,151,588 Â Â Â Â Â Â Â Â Â Sale of stock, price per share $ 15.1 Â Â Â Â Â Â Â Â Â Shares and warrants, price difference per share $ 0.01 Â Â Â Â Â Â Â Â Â Gross proceeds from public offering $ 80,000,000 Â Â Â Â Â Â Â Â Â [1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details. [2] See Note 3, Investments and Agreements, for additional information. X - DefinitionRepresents the amount of gross proceeds raised as part of an investment agreement. + ReferencesNo definition available. + Details Name: catx_InvestmentAgreementContingentAmountOfGrossProceedsRaised Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum amount of securities offer and sale. + ReferencesNo definition available. + Details Name: catx_MaximumAmountOfSecuritiesOfferAndSale Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum amount of securities offer and sell. + ReferencesNo definition available. + Details Name: catx_MaximumAmountOfSecuritiesOfferAndSell Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum increase or decrease in ownership percentage. + ReferencesNo definition available. + Details Name:

catx_MaximumIncreaseOrDecreaseInOwnershipPercentage Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionOne-time payment received for rights granted. + ReferencesNo definition available. + Details Name: catx_OneTimePaymentReceivedForRightsGranted Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the percent of outstanding shares. + ReferencesNo definition available. + Details Name: catx_PercentOfOutstandingShares Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of ownership considered for warrant exercise. + ReferencesNo definition available. + Details Name: catx_PercentageOfOwnershipConsideredForWarrantExercise Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of ownership considered for warrant exercise two. + ReferencesNo definition available. + Details Name: catx_PercentageOfOwnershipConsideredForWarrantExerciseTwo Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the cash fee percentage. + ReferencesNo definition available. + Details Name: catx_PlacementAgentsCashFeePercentage Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepayment provisions. + ReferencesNo definition available. + Details Name: catx_RepaymentProvisions Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSale of stock maximum commission percentage. + ReferencesNo definition available. + Details Name: catx_SaleOfStockMaximumCommissionPercentage Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the difference between shares and warrants prices. + ReferencesNo definition available. + Details Name: catx_SharesAndWarrantsPriceDifference Namespace Prefix: catx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=catx_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_TwoThousandTwentyFourAtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_March2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_LantheusInvestmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=catx_OptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_RegisteredOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_OppenheimerCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=catx_BofASecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=catx_TheUnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=catx_May2024PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Discontinued Operations (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Apr. 12, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Common stock, par value Â $ 0.001 Â $ 0.001 Â $ 0.001 Discontinued operations, Provision (benefit) for income taxes Â $ 0 $ 0 $ 0 $ 0 Â GT Medical Technologies, Inc. [Member] Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Stock issued during period, shares 279,516 Â Â Â Â Â Â Common stock, par value $ 0.0001 Â Â Â Â Â Â Percentage of issued and outstanding capital stock 0.50% Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 0.50% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales of $10.0 Million or Less [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 3.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales Between $10.0 and 15.0 Million [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 4.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | Net Sales Greater Than $15.0 Million [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Royalty agreement percentage of net sales receivable 5.00% Â Â Â Â Â Â GT Medical Technologies, Inc. [Member] | GT Medical Stock [Member] Â Â Â Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Â Â Estimated fair value $ 200,000 Â Â Â Â Â Â X - DefinitionPercentage of issued and outstanding capital stock. + ReferencesNo definition available. + Details Name: catx_PercentageOfIssuedAndOutstandingCapitalStock Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the percentage of net sales receivable as part of a royalty agreement. + ReferencesNo definition available. + Details Name: catx_RoyaltyAgreementPercentageOfNetSalesReceivable Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=catx_GTMedicalTechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesOf10MillionOrLessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesBetween10And15MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=catx_NetSalesGreaterThan15MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=catx_GTMedicalStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R42.htm IDEA: XBRL DOCUMENT

v3.24.3 Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Assets held for sale of discontinued operations, current Â Â Â Â Â Total current assets held for sale of discontinued operations $ 0 Â $ 0 Â $ 5,301 Liabilities held for sale of discontinued operations, current Â Â Â Â Â Total current liabilities of discontinued operations 0 Â 0 Â 5,072 Depreciation Â Â 1,585 $ 684 Â Amortization Â Â 12 30 Â Write-off of inventory associated with discontinued product Â Â 0 298 Â Share-based compensation Â Â 3,327 3,018 Â Additions to property and equipment Â Â 39,800 983 Â Discontinued Operations, Disposed of by Sale [Member] | Cesium-131 Business [Member] Â Â Â Â Â Assets held for sale of discontinued operations, current Â Â Â Â Â Inventory 0 Â 0 Â 3,148 Prepaid expenses and other current assets 0 Â 0 Â 169 Property and equipment, net 0 Â 0 Â 1,263 Right-of-use asset, net 0 Â 0 Â 676 Other assets, net 0 Â 0 Â 45 Total current assets held for sale of discontinued operations 0 Â 0 Â 5,301 Liabilities held for sale of discontinued operations, current Â Â Â Â Â Lease liability 0 Â 0 Â 677 Asset retirement obligation 0 Â 0 Â 225 Loss recognized on classification as held for sale 0 Â 0 Â 4,170 Total current liabilities of discontinued operations 0 Â 0 Â $ 5,072 Sales, net 0 $ 1,909 2,178 5,239 Â Cost of sales 0 1,447 1,564 4,863 Â Gross profit 0 462 614 376 Â Research and development 0 169 69 1,000 Â Sales and marketing 0 855 941 2,578 Â General and administrative 0 222 494 668 Â Total operating expenses 0 1,246 1,504 4,246 Â Total loss from discontinued operations $ (0) $ (784) (890) (3,870) Â Depreciation Â Â 0 171 Â Amortization Â Â 0 27 Â Write-off of inventory associated with discontinued product Â Â 0 298 Â Share-based compensation Â Â 166 568 Â Additions to property and equipment Â Â $ 0 $ 287 Â X - DefinitionAmount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: catx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of

business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=catx_Cesium131BusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment (Details Textual) â,¬ in Millions 9 Months Ended 12 Months Ended Oct. 13, 2024 USD ($) Sep. 18, 2024 EUR (â,¬) Aug. 02, 2024 USD ($) Jul. 15, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Property, Plant and Equipment [Line Items] Â Â Â Â Â Â Â Depreciation expense Â Â Â Â $ 1,585,000 $ 684,000 Â Consideration for equipment and services pursuant to the MESA and SOWs | â,¬ Â â,¬ 49.0 Â Â Â Â Â Â Houston Texas [Member] Â Â Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Â Â Payments to purchase buildings Â Â Â $ 4,700,000 Â Â Â Chicago Illinois [Member] Â Â Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Â Â Payments to purchase buildings Â Â $ 5,000,000 Â Â Â Â Chino California [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Â Â Payments to purchase buildings $ 11,000,000 Â Â Â Â Â Â Other [Member] Â Â Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Â Â Depreciation expense Â Â Â Â $ 0 Â $ 0 X - DefinitionAmount of contingent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for acquisition of buildings (properties) whether for investment or use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBuildings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=catx_HoustonTexasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=catx_ChicagoIllinoisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=catx_ChinoCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=catx_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross $ 46,046 $ 6,245 Less accumulated depreciation (2,254) (669) Property and equipment, net 43,792 5,576 Building [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,770 1,770 Land [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 1,283 1,283 Equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 10,601 2,683 Leasehold Improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross 3,497 179 Other [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment, gross [1] $ 28,895 $ 330 [1] Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=catx_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Goodwill $ 24,062 $ 24,062 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Indefinite-Lived Intangible Assets [Line Items] Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) $ 50,000 $ 50,000 Accumulated Amortization 0 0 In Process Research and Development [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) 50,000 50,000 Accumulated Amortization $ 0 $ 0 X - DefinitionAccumulated amount of amortization of indefinite-lived assets. + ReferencesNo definition available. + Details Name: catx_IndefinitelivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) - U.S. Treasury Bills [Member] $ in Thousands Sep. 30, 2024 USD ($) Schedule of Held-to-Maturity Securities [Line Items] Â HTM, amortized cost, Total $ 41,404 HTM, Gross Unrealized Gains 11 HTM, Gross Unrealized Losses 0 HTM, Estimated Fair Value $ 41,415 X - DefinitionAmount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14 + Details Name: us-gaap_HeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Held-to-Maturity Investments (Details Textual) - U.S. Treasury Bills [Member] Dec. 31, 2023 USD ($) Schedule of Held-to-Maturity Securities [Line Items] Â Held-to-maturity investments $ 0 Cash and Cash Equivalents [Member] Â Schedule of Held-to-Maturity Securities [Line Items] Â Held-to-maturity investments $ 0 X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1 + Details Name: us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) $ in Thousands Sep. 30, 2024 USD ($) Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Fund [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Cash equivalents $ 224,502 X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Fair Value Measurements (Details Textual) - Fair Value, Recurring [Member] - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value Â $ 0 Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value $ 0 Â Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial instruments measured at fair value $ 0 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R51.htm IDEA:

XBRL DOCUMENT v3.24.3 Note 9 - Share-Based Compensation (Details Textual) - Amended 2020 Incentive Plan [Member] - shares Aug. 14, 2024 May 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 4,870,092 4,870,092 Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Â 12,500,000 Percentage of increase in common stock capital shares for future issuance Â 5.00% X - DefinitionPercentage of increase in common stock capital shares for future issuance. + ReferencesNo definition available. + Details Name: catx_PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=catx_AmendedTwoThousandTwentyIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 1,952 $ 418 $ 3,161 $ 2,450 Research and Development [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation 814 179 1,336 763 General and Administrative [Member] Â Â Â Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Share-based compensation $ 1,138 $ 239 $ 1,825 $ 1,687 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Commitments and Contingencies (Details Textual) 9 Months Ended Sep. 30, 2024 USD ($) Plaintiff Dec. 31, 2023 USD ($) Loss Contingencies [Line Items] Â Â Number of plaintiff | Plaintiff 6 Â Aggregate maximum estimate settlement amount Â $ 200,000 Stockholder Plaintiff Settlements Â Â Loss Contingencies [Line Items] Â Â Estimated liability $ 200,000 $ 200,000 X - DefinitionAggregate maximum estimate settlement amount. + ReferencesNo definition available. + Details Name: catx_AggregateMaximumEstimateSettlementAmount Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of plaintiffs that have filed claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNumberOfPlaintiffs Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: srt_LitigationCaseAxis=catx_StockholderPlaintiffSettlementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Related Parties (Detailed Textual) - USD ($) $ in Millions Mar. 04, 2024 Jan. 08, 2024 Mar. 06, 2024 Lantheus Investment Agreement [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Shares issued and sell Â 5,634,235 Â Percent of outstanding shares Â 19.99% Â Purchase price Â $ 8.0 Â Lantheus Alpha Therapy, LLC [Member] | Lantheus Investment Agreement [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Shares issued and sell 9,200,998 5,634,235 Â Percent of outstanding shares Â 19.99% 19.90% Progenics APA [Member] Â Â Â Related Party Transaction [Line Items] Â Â Â Purchase price Â $ 8.0 Â X - DefinitionRepresents the percent of outstanding shares. + ReferencesNo definition available. + Details Name: catx_PercentOfOutstandingShares Namespace Prefix: catx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-

10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=catx_LantheusInvestmentAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=catx_LantheusAlphaTherapyLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=catx_ProgenicsApaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Leases (Details Textual) $ in Thousands 3 Months Ended 9 Months Ended Aug. 08, 2024 USD ($) RenewalOption Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Apr. 01, 2024 USD ($) Mar. 01, 2024 USD ($) Dec. 31, 2023 USD ($) Jul. 01, 2023 USD ($) Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lease liability Â $ 2,579 Â $ 2,579 Â Â Â Â Â Â Right of use asset Â $ 2,433 Â $ 2,433 Â Â Â $ 747 Â Lease term 52 months Â Â Â Â Â Â Â Â Â Operating lease, weighted average remaining term Â 3 years 2 months 12 days Â 3 years 2 months 12 days Â Â Â Â Â Operating lease, weighted average discount rate Â 8.00% Â 8.00% Â Â Â Â Â Operating lease, expense Â $ 300 $ 200 $ 500 $ 400 Â Â Â Â Estimated hazardous waste removal liability Â $ 500 Â $ 500 Â Â Â $ 500 Â Lantheus Alpha Therapy, LLC [Member] Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Number of renewal options | RenewalOption 0 Â Â Â Â Â Â Â Â Â Maximum [Member] | Lantheus Alpha Therapy, LLC [Member] Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Base prepaid rent $ 100 Â Â Â Â Â Â Â Â Â Office Space With Unico Properties [Member] Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lease liability Â Â Â Â Â Â Â Â Â $ 800 Right of use asset Â Â Â Â Â Â Â Â Â $ 800 Lessee, operating lease, discount rate Â Â Â Â Â Â Â Â Â 8.00% Lease with Board of Regents [Member] Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lease liability Â Â Â Â Â $ 1,100 Â Â Â Right of use asset Â Â Â Â Â $ 1,100 Â Â Â Lessee, operating lease, discount rate Â Â Â Â Â 8.00% Â Â Â Progenics [Member] Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lease liability 600 Â Â Â Â Â Â $ 300 Â Â Right of use asset $ 600 Â Â Â Â Â $ 300 Â Â Lessee, operating lease, discount rate 8.00% Â Â Â Â Â 8.00% Â Â X - DefinitionEstimated hazardous waste removal liability. + ReferencesNo definition available. + Details Name: catx_EstimatedHazardousWasteRemovalLiability Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLessee operating lease number of renewal options. + ReferencesNo definition available. + Details Name: catx_LesseeOperatingLeaseNumberOfRenewalOptions Namespace Prefix: catx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of excess of rental payment required by lease over rental income recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481178/840-20-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 25 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479341/842-30-25-11 + Details Name: us-gaap_DeferredRentCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_CounterpartyNameAxis=catx_LantheusAlphaTherapyLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=catx_OfficeSpaceWithUnicoPropertiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=catx_LeaseWithBoardOfRegentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=catx_ProgenicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â 2024 (remaining three months) $ 245 Â 2025 1,112 Â 2026 647 Â 2027 493 Â 2028 443 Â Total 2,940 Â Less: imputed interest (361) Â Total lease liability, Total 2,579 Â Less current portion (903) $ (46) Noncurrent lease liability $ 1,676 $ 780 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Notes Payable (Details Textual) $ in Thousands Jul. 19, 2019 USD ($) MonthlyPayments Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 29, 2022 USD ($) Debt Instrument [Line Items] Â Â Â Â Notes payable, current Â $ 51 $ 49 Â Promissory Note [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Notes payable, current Â $ 51 $ 49 Â Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Debt instrument, face amount $ 100 Â Â Â Debt instrument, interest rate 3.00% Â Â Â Debt instrument, number of monthly payments | MonthlyPayments 36 Â Â Â Amount raised through selling of equity $ 1,000 Â Â Â Viewpoint Molecular Targeting, Inc. [Member] | Promissory Note for Purchasing Land and Building [Member] Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Debt instrument, face amount Â Â Â $ 1,700 Debt instrument, interest rate Â Â Â 6.15% Debt instrument balloon payment Â Â Â $ 1,500 X - DefinitionRepresents number of installment to pay debt. + ReferencesNo definition available. + Details Name: catx_DebtInstrumentNumberOfPaymentInstallment Namespace Prefix: catx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -

Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of payment greater than the preceding installment payments to be paid at final maturity date of debt. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteForPurchasingLandAndBuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Notes Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Less: current portion $ (51) $ (49) Note payable, long-term portion 1,638 1,676 Promissory Note [Member] Â Â Debt Instrument [Line Items] Â Â Note payable 1,689 1,725 Less: current portion (51) (49) Note payable, long-term portion $ 1,638 $ 1,676 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=catx_PromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) $ in Thousands Sep. 30, 2024 USD ($) Maturities of Long-Term Debt [Abstract] Â 2024 (remaining three months) $ 13 2025 52 2026 55 2027 1,569 Total $ 1,689 X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MaturitiesOfLongTermDebtAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 68 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Feb. 03, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Nov. 22, 2022 Business Acquisition [Line Items] Â Â Â Â Â Â Grant revenue Â $ 369 $ 276 $ 1,220 $ 1,097 Â Operating loss Â (18,634) (9,750) (45,902) (29,265) Â Viewpoint Molecular Targeting, Inc. [Member] Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Business acquisition, percentage of voting interests acquired 100.00% Â Â Â Â Â Business acquisition, number of common shares exchanged 13,654,507 Â Â Â Â Â Business combination, fair value of common stock $ 54,618 Â Â Â Â Â Business acquisition, closing market price $ 4 Â Â Â Â Â Note receivable, forgiven amount $ 6,200 Â Â Â Â Â Grant revenue Â 400 300 1,200 1,100 Â Operating loss Â $ (18,600) $ (9,800) $ (45,900) $ (29,300) Â Viewpoint Molecular Targeting, Inc. [Member] | Isoray Note [Member] Â Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Â Note receivable, forgiven amount, loan Â Â Â Â Â $ 6,000 Accrued interest Â Â Â Â Â $ 200 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of writeoff of financing receivable, charged against allowance for credit loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=catx_IsorayNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) - Viewpoint Molecular Targeting, Inc. [Member] $ in Thousands Feb. 03, 2023 USD ($) Business Acquisition [Line Items] Â Perspective Therapeutics common stock issued (13,654,507 x $4.00) $ 54,618 Assumption of Viewpoint stock options and warrants at fair value 7,836 Note receivable and interest from Viewpoint forgiven 6,171 Total fair value of consideration transferred $ 68,625 X - DefinitionAmount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationConsiderationTransferredLiabilitiesForgiven Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of fair value of options and warrants assumed in business acquisition. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationOptionsAndWarrantsAssumption Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) - Viewpoint Molecular Targeting, Inc. [Member] Feb. 03, 2023 $ / shares shares Business Acquisition [Line Items] Â Business acquisition, shares (in shares) | shares 13,654,507 Business acquisition, price per share (in dollars per share) | $ / shares $ 4 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands Feb. 03, 2023 Sep. 30, 2024 Dec. 31, 2023 Business

Acquisition [Line Items] Â Â Â Goodwill Â $ 24,062 $ 24,062 Viewpoint Molecular Targeting, Inc. [Member] Â Â Â Business Acquisition [Line Items] Â Â Â Cash and cash equivalents $ 2,699 Â Â Grants receivable 95 Â Â Prepaid expenses 396 Â Â Property and equipment 5,050 Â Â Right-of-use asset 10 Â Â Intangible assets, in-process research and development 50,000 Â Â Other assets 316 Â Â Total assets acquired 58,566 Â Â Accounts payable and accrued expenses 2,968 Â Â Lease liability 10 Â Â Accrued payroll and related taxes 1,642 Â Â Accrued vacation 333 Â Â Notes payable 1,807 Â Â Deferred tax liability 7,243 Â Â Total liabilities assumed 14,003 Â Â Net assets acquired, excluding goodwill 44,563 Â Â Total purchase price consideration 68,625 Â Â Goodwill $ 24,062 Â Â X - DefinitionAmount of accrued payroll and related taxes, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued vacation, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of right of use assets acquired at acquisition date. + ReferencesNo definition available. + Details Name: catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets Namespace Prefix: catx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease obligation assumed in business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=catx_ViewpointMolecularTargetingIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

Z4L)'@ROZ30V7K.20JE!9IY8P,4I:55_JY*D3#P>]? M< @JA^"9P^!2A'[ET+_685 YV%*[92]V#DNJZ6PBQ8%(8XUH9F"+:;TQ?9:9 M?5]KB7<9^NG90F0Q[B+$!$=*\86";N/Q*+8Z&W!
M\4&.1)%AS?XA=VUU*4&'%M0TY7X6W@<3=]],\=QF&'JUS0G;?LVVW\EVA>T$ M4N+6XB,5/;TF.95D3WD!AFA=GC;&)?"HP<;K>9[_C/-+5B>L!S7KP6VLJTVD MA4Z$9']#W$:XQ
P;5$:>_3VC_++="">FP)AUVDEZ(-,4WVLUU#J^J\TM6)Y2' M->7A#92O*O+PO'BAUUKF:RQ/6(]JUJ/;63.EBE;&\VZP3_X?;6F.SL@/1^$P M&(V?[\NY83#VQ][].&Q/__#BJT";6Q.VMN05AJ?
$&W+" U?$ M+[;ER(@]OO=Q_Q#F1DEE]]D V 4>E:BE)G\R^$QG^BND0#+8Q^ M-SJ^-[N(A-J* L#U$Y9YK =HMVZ(1OI%^*#*T 1#3KD34 >2\T M+I5Z"#1E7/7:NL%MR-44Y,[*?
D6L;BH53;U:?UK,K0(_6^_+/Q^ZYT!WBDE M\C%$^2WSCLH=RQ3AL,5P7F^$.R7+SX-RHD5N!?-&:)3?=IC@)Q5(8X#WMP+S MK"8F0/V1-OL*4$L#!!0 ('F!;%D:$N' "@@ .&PO=V]R M:W-
H965T&ULK5IM<]LV$OXK&%VGD\S$%@GP3:ZMF<2B[GJ3 MIIFXN7[H] ,M0A(O%*$2D)W'I$O.0KI5UD\/' ;WE9:D\PCC\ZIY/C,[7A\^]/WI=-\!#,?2;Y MK2A_+7*UO9DD$Y+S=78HU2?
Q^" >!11J?RM1RN8O>>RPWH2L#E*)76<,(]@5 M5?N9?>V>&;@LP$#VAE0TR <,&"= 3,-@@&#H#,(7QJ$L#,(&NY; MLAJF%YG*YM>U>"2U1H,W .:5)5V,-
!!>5KJP[5<.O!=BI^:VH9WI0I#DU>??>:R&U695;E\0[X[N;Z>*ABN?NATU0WMMAT:'1@:(S^)2FTE26&(.6*?NNUG M#OLIT'3DBCYQ=4N=#N_X_I(P[PVA'@V0\2Q>;LZPTY?_]]-/R&#'PF&-
M/S;@[\=J)7:\+Q3RV]M[J6J8*7['4MTZ"W!G>OJ\DOMLQ6\F,#]*7C_PR?S[M?_B1]P/&\SF=I>=TMCR3LY.,!,>,!"[O\W_6&:2AY@^\.G L!ZUYU)CKCO,P
M9]'L>OKPG%H;0^/H%)/:&))]2[Q2T1$#>+#Z"3B(,CQ&&SIKKYJ%J0.C7O9ZU MY!469WC.6CNGL_2B8B@I/RL6CB5%X-BH,0VI4G@VB21R&1NDA#PPH_':BX\1Q^ZMUU=0?&43<)9#
M)R[T;*=E$19S; TAFL7&.!,^Y?A-+!6G,NJN0\NP!GGL>,4#&8YU&SP2"P M(/:I,1LL$1CS6#04^#-)[#L#[]M,":E'P_61,DLB%ICQ(CB8!\S\8K @G'E6 MP B.SF@T4.
^[2.FSL;Z0507:*+5MJ]ZA+^&FVRG<DO/ZFUY+F^G MN>EUMN\4C2"T%>_JDL+F@MFOPAAXIO%:*.H9[8;!!0G46(6HHUW*XJ'WKM>O MOEO 'B/5DZI06UX_S3EHT('],EAR%@/Y5LP8B/IFS
@J3 9B[A6M[Y1I\Q1Z M![01Z+%ETV:@OZ[715E LT6##D?;"0*!:,R0$5!D!NQV=!IP+QQ]MW)LNTKE MG'#>D(JCS=2WI1T+S> 6",J/$Y,!&Q3'@95T&Y5X0QST4M)W:\D/(*':=*]K
ML2,K40$+!TV$.&ZTH-';*@_$C=47%QAN%L96#2 PEH!N-#E <#0)(C9 0R\O M?;>^/*4!Y%7'!, 'B!C7D@CD(DZL-Q]!)3-37&$HEL3>0/R]KO1?("QKOA*; MJOB?
#KHBJQ+D=;$N5JV>SB39\C(G:U$34)[XE#"N,,FZ;M,%]MVSZ0H#WJCO2E]F.S: M+714:=.S[IV>U5MZ5F_+5YFWJ4!/2]/K?K(?IL:6MUC@@+UMS520=@%G4H;&AW MCO9JFKK5]
NH<]6>V_D0>;8FMLB+7T8>#K/(0V&#Y/4:G+HU>-N13KL02I/; MS1!-R413&8I,J%!:9NV0X+!EJWKUQKPO]E\-'#B^\+M]*3Q);F"5@E,UIAUK"[*+$Z@N1^{)0A* 7 M@&OW4_Y]J
=M(=F+LD=YZ3Y%Z7?#"?G*BM*>8F]-]-G9ZIVO-XTI]\DS%L0 M3'MBX7CW>,+N77.NS+A_ZU\M?.1^ZE\ML?MO&;M*&4- ">"7YF39M!]2>P3P MIZS>%)4D)5_#\+S+&+);MZ?
JV@LE]LTIL'NAE-@U7[<\RWFM ?#[6@ OW85^ MP/%LX_Q/4$L#!!0 ('F!;%G&$&$D)0(,T$ 8 >&PO=V]R:W-H M965T&ULE511C2],P#/XK49 02'=+V_4&C*[2;0ÀQ2(AI$_" M>,A:=XV6-
B7)UKM_CY-V92=M0[PT=N+O\^?$;M(JO3,E@'6/E:S-C);6-E/& M3%9"QLM,HX'G'E1%9@%7!A%5&UAR44%MA*]AF)&[\I M/';Q/N"C

;3UZ+)77916@^E]5': *6-4-H8I44H+49I,Y0V1VD+ ME):@M!5*DQ*7K1XS45R;Q;&,J3$3Q;$.+*QI"NN:&C-1'.O"PAJGL,ZI,1/% ML4XLK'D*YI[',?/0Z]+@>ET:V685[ZJ>.:U87NQ2,E/>:
<53=G]S%KMKL#-G M%M&Z%I0V0&DCE#9&:1%*BU':#*7-4=H"I24H;872I,3QJD<^MJZ%Q7587(E[M5H]\;%T+BV-=4R,?6]?"XECC%-8Y-?*Q=2TLCC5/P=SS./(=ZEH:Q8TD18]%
M;%B%)W7/SX2\\L:5DBGR0EYI+\K-6>#NB2OK%=,KQSRT=06EC5#:&*5%*"U& M:3.4-D=I"Y26H+052I,2EZL>\]C6%1;787$E%EH]YK&M*RR.=4V->6SK"HMC MC5-8Y]28Q[:NL#C6/
5SS^.8=VA=:12WG>0]%G&Z^5S\6,02;MX%8K1%I9%M M46DTZPV_>>FEKQ*C32HHK8?2^BAM@-)&*&V,TB*4%J.T&4J;H[0%2DM0V@JE M28F55L^2;),*BV,=4[,DVZ3*XEC3%-8U-
4NR32HLCC5.89U3LR3;I,+B6/,4 MS#V/L^2A2:517#7R[6,1R,+C=2-;F1+XEV$SW=ILO"_[6,2SME4,N&*,-*RAM@-)&*&V,TB*4%J.T&4J;H[0%2DM0V@JE M28G[58]_;,,*B^NPN!
(/K1[_V(85%L>ZIL8_MF&%Q;'&*:QS:OQC&U98'&N> M@KGGUYB,?] MYJ[VGIT3^?6MX= Q=#O-95N:J.GO;[T/,_=9K^^?]A]\WKP7:WW M^,=FM_^T<4.O'^]\OMVL_GKC]\];
[6^N[M_*::^?]07/CÜ_%/)[ZWOX;O=Q ML]FWU_OU3S]\VFQ_WUQO'AYVM??N6^*>..GN_?[ZNENB?D^]UL_>FW>9U]M> MZQ?
K]8[7NK%>7WBM6^MU^=EKR;6I=%7IFCWR6Q/KJ=AO3:W7$[^UM%Z7MM^27TQ%1Q)S)M&=B[EW6:AR:RG]H/5K8*TO M: VMUZ.@-;%>CX/6U'H]"5I+ZW5I!
[H^4]&1Q)Q)=.=B[ET6JMQ:2C]L_1I: MZPM;0^OU*&Q-K-?CL#6U7D_"UM)Z7=JAKL]4="0Q9Q+=N9A[EX4JMY;2K[=^ MK5OKJ[>&UNM1O36Q7H_KK:GU>E)O+:W7I5W7]9F*CB3F3*
([%W/OLE#EUE+Z MC=:0#6M]C=;/>CUJM';6ZW&C-;5>3QJMI?6Z)E%=GZGH2&+.I"E"UV6NN[; VMUZ/+UL1Z/;YL3:W7D\O6TGI=VI>Z/E/1D<2<273G
M8NY=%JK<6DK_JO7KE;6^J];0>CVZ:DVLU^.KUM1Z/;EJ+:W7I7VEZS,5'4G, MF41W+N;>9:'*K:7TO8O6K]Z%M4)5AJ82J3(QE5B5J:DDJBQ-1=HJR2^VYL83 M>SYQ8X@]ARR<=FMJ?
<_3%5M98*#*T%0B52:F$JLR-95$E:6IZ(H]MV)3<^.) M/9^X,<2>0U?LN16;&5H:E$JDQ,)59E:BJ)*DM3T16[N&-K;rCD9 MYQ,WAMASZ(I=Z#&UOJ>QQS-SCRI#4XE4F9A*K,K45!)5EJ:B*W8!R-;
<>&+/ M)VX,L>?0%;L89&I]3X.09R8A58:F$JDR,958E:FI)*HL3457["*1K;GQQ)Y/ MW!ABSZ$K=L'(U/]>1B//S$:J#$TE4F5B*K$J4U-)5%F:BJ[8A21;<^.)/9^X M,<2>0U?LHI*I]3T-
2YZ9EE09FDJDRL148E6FII*HLC057;&+3;;FQA-[/G%C MB#V'KMB%)U/K>QJ?/#,_J3(TE4B5B:G$JDQ-)5%E:2JZ8A>D;,V-)_9\XL80 M>PY=L8M3IM;W-
%!Y9J)296@JD2H34XE5F9I*HLK25'3%+EK9FAM/[/G$C2'V M'+IB%[!,K>]IQ/+,C*7*T%0B52:F$JLR-95$E:6IZ(I=V+(U-Y[8\XD;0^PY M=,4N3]P88L\A M"Z?=FEK?
U\SEFYE+E:&I1*I,3"5696HJB2I+4]$5N\QE:VX\L><3-X;8<^B* M7>8RM;[O3BS99Y;Y,.V-)_9\ MXL80>PY=L]KYO+-S*7*T%0B52:F$JLR-95$E:6IZ(I=YK(U-Y[8\XD; M0^PY=,4N&
MV'/HBEWF,K6^KYG+-S.7*D-3B529F$JLRM14$E66IJ(K=IG+UMQX8L\G;@RQ MY] 5N\QE:GU?,Y=O9BY5AJ82J3(QE5B5J:DDJBQ-15?L,I>MN?'$GD_<&&+/ MH2MVFSYQ8X@]AZ[8 M92Y3ZP?
N\IYJ?<]=X+.O\+E+?/8U/G>1$[[*YR[SY5SG>[[0EW.E[_E27\ZU MON>+?3E7^YXOJYF9*]#,%9B92Y6AJ42J3$PE5F5J*HDJ2U/1%;O,96MN/+'G M$S>&V'/HBEWF,K5+H)DK,#.7*D-
3B529F$JLRM14$E66IJ(K=IG+UMQX8L\G M;@RQY] 5N\QE:OU ,U=@9BY5AJ82J3(QE5B5J:DDJBQ-15?L,I>MN?'$GD_<
M&&+/H2MVFNV&4N4^L'FKD",W.I,C252)6)]<2J3$TE465I*KIBE[ELS8TG]GSBQA![M#EVQRURFU@\UY3*T?:N8*SB*7>:R-3>>V/.)&T/L.73%
M+G.96C_4S!6:F4N5H:E$JDQ,)59E:BJ)*DM3T16[S&5K;CRQYQ,WAMASZ(I= MYC*U?N@^9&5_RLI]S,K^G)7[H)7]2OW42O[LU;NPU8YG[9Z_KA5SN>MGC]P
ME?.)J^>/7.5\YNKY0U=FY@HU<3-X;8<^B*7>8RM7ZHF2LT,Y M3]P88L^A*W:9RJ3Z=&V'/(PFFWIM:O:^:JFYE+E:&I1*I,3"5696HJB2I+4]$5N\QE:VX\L><3 M-X;8<^B*7>8RM7Y=,U?
=S%RJ#$TE4F5B*K$J4U-)5%F:BJ[892Y;<^.)/9^X M,<2>0U?L,I>I]>N:N>IFYE)E:"J1*A-3B569FDJBRM)4=,4N<]F:&T_L^<2- M(?8&+/)VX, ML>?
0%;O,96K]NONHN_U9=_=A=_O3[N[C[O;GW=T'WNU/O+N/O.=\YOWY0^\Y MGWI__MA[SN?>GS_XGO/)]^>/OIN9JZZ9JVYF+E6&IA*I,C&56)6IJ22]+$U% M5^PREZVY\
<2>3]P88L^A*W:9R]3Z=Y;,V-)_9\XL80>PY=L<3-X;8<^B*7>8RM7Y=,U?=S%RJ#$TE4F5B*K$J4U-)5%F:BJ[8 M92Y;<^.)/9^X,<2>0U?L,I>I]1N:N1IFYE)E:"J1*A-3B569FDJBRM)4I-UP
MF&+/)VX,L>?0%;O,96K]AF:NAIFY5!F:2J3*Q%1B5::FDJBR-!77[>U6 M;&SST#WJW8SEQ.NS6U?L/=<&C?<>AN.;3O.70W'=IW';K;#NW[#MV- MASEW'C[?>IAS[^'SS8G^%F\^_RW^
M[JNV^^F'S^O?-\/U]0?[QUWM8?-A_^.;B^^;]3>U[?WO'[_^8? T^<8783*+(%174PHU, YIF5L;6 M BFTZ\@U%D091+6*TCB^BFHA-<^S,#:W>69:5%++8W*+7UK6PSS>@S';*$[c;
M6,AUA7X@RK-&K.$.\+Z96XJBP:64-6@GC6865E-^G4QNQGY]6/!3PM;M]9G/ M9&G,@P^^E5,>>R!04*!W$-1L8 9*>2/"><P.P]^;"E%^[W=^ZW(7?*92D+BA[IID-*7'T'ZWNH12\9G+(W3\4MY1-D-
M*:9#BFGPNWC%;\C%IW*0__?UTJ&E"_+G$&WG/C[L[HMFXAI1P)1353BP&^#Y MVS?)5?SI"/O%P'YQS#U?P(9 @3F/S5RC)!Y"/&Z2G%/QGB21S,_).QR>-1DD6;?8)H[T+[M^&'L&NI'5.P(E4\>G_)
MF>WJK0O0-&.+PU2Q81N14\46+^ YÊ?&X"[P93,\>OE?4$L#!!0 ('F! M;%D!JT:SY (%$+ 9 >&PO=V]R:W-H965TD!!*HW$-OY4GD8=4H+[XYW[1.4N-+OY"D3/V"];:GU?0.$!>,DJV"Q@RS!Y3\]
MJ^[#'F"? IP*<(X![P3@5H#;%/ JP&L*^!7@-P5:%=!]"K0KH-WT+G4JH-,T M0K<"NJHG'OX(X-#!$8)"U/"''HK +7A>CL#UU0VX @D&/V-2,(@CUC>YB"T=S+'*,RSC M."?BN."18!XS,,81BC3\
[#S?/<.;(N7^- Y:[A$^1UPK2_ L1Q/LY^' M_BW I_%1^?Q1T@%;I_$Q\TW[VKP2?/-Z_!I\\WK\-G_W?GYAW, _* 2W?@-< MY>=^Y W0%7IIY^GMY-G48SD,T< 0AP]#=(.,X/,GNV5]U579)B
MF4[4%6:'LKE&YM@=UZUEY9,P]\[7#-&U:LX8"$F!>?FAJ5?K_N]>M3'UZT.[M-[4UZS/1+Y;MW3_[LMD4W]IU@AE(T4J$LN[:HH^@90-73CC)U>G^0KCH%=0P M%CTOKH@(KJ\
(X;N)#%!WT<%?4$L#!!0 ('F!;%GH6J2E* , ,$) 9 M >&PO=V]R:W-H965T*,BMR/@N#<+Q@7 MWF3DQI[49"1+DW.!3PIT611,O=Y@+G=C+_3V PN^R8P=\">C+=O@$LWW[9.B MGM^H)+Q
H;D4H# =>]/PZB8,K(%;\8/C3A^TP;IREO9<07[,9;S'/K1)Q_*Y%O69/:WC8WJM_<2XJXT< MY1TS;#)2<@?*KB8UVW"N.FN"X\)F96D4S7*R,Y,9Q3=!!2O%$BVX,%6*B0U2 MW(T>^9#9VL:O.N%:
[J=2B=]1Z,)?"9!KN18+)W_8^D35XT1[O)NH47.+V#'K! M"41!U._0ZS7NJIQ>[QV]-C=/8/T*,Y'P9YZ4+&_SNA+MMXO:PKG26Q;CV*/* MT*B>T9M_A2>!]<=R/T&N=^E/IDS@XJS'%:H"@TR;WR
19DCA,%Z@IF ES C%R$?C"T/BUP4^;,?6N6I] ..E(:%(_Z,S1(>!!Y&%: M1:8MZ=V"*3*OAP[+KXCLB^"^@?G*H% MJHV[.VB(92E,=< VH\W]9%]=RF_+]\O-G*D-%QIR3,DT.+N@,E75?:'J&+EU
M9_1:&CKQ73.C.Q8JNX#F4RG-OF,W:&YMDS]02P,$% @ >8%L619X\+6% M#0 ^B4 !D !X;"]W;W)K&ULM5IK<]NX%?TK M&.]CG!E9ef3'23:)9QSOHVf;QHV][8=./T D)&%# @P VM;^^IY[
9#4P\YF M=_LAL42"P'V>>^ZE7MU9]]&OE KBOJZ,?WVP']Y[%OC8%RM52S^VC3*XL["N ME@%?W?+8-T[)DA^JJ^/99\V7$MM#LY?\;4K=_[*MJ'21ETYX=NZEF[1E7V M[O7!]"!?^*'7JT 7CL]?
-7*IKE7XN;ER^';<[5+J6AFOK1%.+5X?7$R_>W-* MZWG!O[2Z\X//@C296_N1OKPM7Q],2"!5J2+0#A) ;M6EJBK:"&)\2GL>=$?2 M@\//>?7=KJW[H,J]<'SP]$J1:RK<('>_<7E?1Y2OL5MO+\O[A+
M:R<'HFA]L'5Z&!+4VL2_\C[9&;<\,$L/S%CN>!!+^;T,\OR5LW?"T6KL1A]8 M57X:PFE#3KD.#GZD":(BZ*PK0G:+,65K72AE7]U'" 2;7Q*V:L3B9C,1L,CM]9+^3SCXGO-) _N]=TMI]*]L
MC9&XM,9#U(WSH:U8*$?M9&FT+(2U[BB%+[!B_]FF(L<$"I;H$[#3T55DH8=1_$4ADLS0Z#40M-$',4 MI%NJH$HAJV8E:3TVI&,.;RYNG@@ H+ &^6:7:]R40:PDSJ5M&R011/3@Q4!
MV!B$%!5MAUM-6W6'09-".=' @>&+)SU7M2 $-U4V*RM<4I8-PHZ:%-4;1E% MMUX!&,)*U"I(3]8J1*F] AZ-277L5-BZD69-ZULC\2"I4ECDE?'Q4PI=?%ET
M4>K[*)5.I9/(+8^:=L2>TGCH;F6K"LZZ,]C6MW.O2RV=)OD!K\HY7(91L(/2 M*\7WW[U?#:,O'QH?[Z)2G(#% KK;Z,NHWSW8L*D@^"0YN@7#(FZ)EA2 C MTLYXR17 1X?-E3)"511@RK:
6,4PKB&U$\T6,-"-+ %&+VN, U6RH^&=W^==O[)M56)'0;4[:?U+ M:V)QY-@B$9.ER=#39R]AP_ZHSX4/K.U4Q0L,$L*3MSUH!HX<.IDRQI] F K7.P6N?[BD
M;=Y)5ZS$['DL!.*0EW9[/XE)_LLV7L&/FZDBS%$4>=*RN\H2T09R@W<40WC M2@]AC8-7*>5]-LS/A@7AJ@'(^7E\/18_75Q<0=1+Y0+H%59&$I:1DJQ,*%!4 MUK<(-US
;3HRAPQMOE>'QR3OCAYHVMN'4+#6@61M6N=;2C]"/08.UY)&,1*6 M"<\I0QNM\N-",.^E08Z^XBE=&>H"H&1+-6G%B)WD3 T)2G!5H14R38':1[%Z<)#';3'ZDMD^$)\HK6.7(PL*5E/*5:X-1#*-
$)D"%B M.S]Z61OK=60AL *!A\-;^,$17!HM949+MDM*X1.BP:> HM5#R#= EMV%MU)7N!QI0\48/.XTU$6@3<0W8_%.H:P[\1Y(I>:N)8^> M1"0:;80W5:.*Z01=K>-3T/.MMTZN06<^M3HZ%
(^XADHJP*V2=^0;)"3PL,_T M_55VO14THYB_U+DT%GX'MT9((PV=N&%N TLE:G38+7HB#GT+J!P42NB:"5/4 M%AATM9'K^<:FRMK[%O)-3T9G3T]'3R?/4'0D)3/$)+/#)#5V1T]3?!R!!#EQ
M*ZM6B: _%9#R93"RCB4SDEN633.'NO@0,*-CE](;[)!U!< MK@$C54MV1PN*1#+,H HPN<)CPTI^')%KA+?Z74:#PRH*?8B'SR"O(AAA)8# MUEA<0" M$M:,J8 !?
$H.&YPZP,,12JT2L9L['>4H'46!H$8N??\?4()\D@>/$Q8$;$_W>1-Q8TJ5H:,SQPU MD=G]F7?8/_9XE@RVOT1 X?*>C-E=-!I>2\F#Q'Q ME!KFU%823<9/8][LV32)0DY[.
(<(F;82;LX]W69R<56^8(:!C]4ZQE1?U;8Y M30_I@RK'8?C9(-O@9:0GZ>"9573A/JB7*56_A"-0=:# 3;6T/V<,^E:1#%P! M[]"8,3DK1WQZZWWFV/'0=-OGT/@RGE+)].ANR<33OQ$DD-P/XT/@ *0
MFQ%97#>5#@08'0Q=O(A%EGP@ID<0X6@Z@?!QEQA"GG(D(/ M!&6?'<.2,>HHP_J@F,). ^.R6*,8);A*!*Z+H1M5NQ95"QRF0TYX5@FX%"I M;
(LX!@B6TL.TW)\0+VQ!>YW^E;!JKYBYR]W6M>E:YVBHPZON0JZ(>+)82;-, M XB<^'Y@OHUCMG;8IY'L'%:E) ?:EE@ 1JTIA@BV8=:L>5S/Q&^PNF?, &GG M5[JA="FHH"V[2ON
.0[5/;5*.2W4/8U5^OY@4]R(#[&%\43B\MY#R4'(E;Z- MZ.6Y"473T=+2A8LP3MG%T@"R::PP#"[;]-0:U0'83^01*4.S;89^4/A\%(1& M0P2G^ ?NUN/T7"TKSGC.%.NYLT5<%!P7?+4>.BPYN%%3OZ8
MCWT\)JG2%#'2^47+?0IE%Q_2;%6M[=!$1X9CB#>3'0"X386"\M F]0'UY&A7WOV9/]J!@KW>VAPB#""[HVK#P=D7C)' ZX'+>IF-T>L>@Y"%)PRF[ZN;Z%3QJ96VPB M*A^H5HBG(*YIIA(G09-
]Y8?DH!U&<1^*6R!DYSD/9 Y'9)VD9=?-?RUF9_& MST6-KB^SDHCL)6V;N.$JU205X?XP/3%=\R6']ACDB[8$0/1BFK#UA2U8-YU M;,3#RO&PQ*N*82:FW.:VF\,3VFI;;)XV?
ZGZD;OMFC:VP,IP:ZW#1KR0NPBF M"0C,-L7"PEJ71]CCC-S#>N'Y&OS2:0) Z*2^6767Q*[G=.4-NF3L,>B[E" M@+Z7:A[ZN,0%M%7H_Q.!QW=Z[1+44P8;$.IH,'_6/+1D'.1A:<'K>QE,@
M=XX4YH0ARS[=CW%W:9&.AB#6S , X/NIY$,W=19%;9UL4/. M/#LJV6_,,"3DD^,SSBC\PC2\LD*TURF64-QX{)52P',-J=C0MQG/")]XAF^%W](=)88=-?P9R;&W"STD^&L6,XAMZ$_G'7=J()/KJA?
AT*. M'-+(M;,T_!Z\YPGR7G5J\ZI;F01FKAL!/&9.0>]%5;\=6(U%P4CYUEUV%E39 M5CQT-E0@!C?!,N,;#V@& _?B(X:N.[LT?9.52-7PX;>A'>?84<9.(9T*[:-. MG\N*
<8A ;I'G=7M7;LSU>]N// M*^V8/YQ[2H^$[I/Q,] @1\LU73-;@)Y;F\T78%L M6;)SS+*I! Z@H !D !X;"]W;W)K&ULC59M
M4^,V$/[.K)CQW=P<,R9Q[)#DN"0S0+FYZY260E\^=/I!L=>Q!EOR23*!?]]= MV7%"";1?B"7M/OOV[++SC3;WMD!T\%B5RBZ"PKGZ;#BT:8&5L -=HZ*77)M* M.#]:]=#6!D7FE:IR&$?
19%@)J8+EW- _=F.5<-ZZ4"F\,V*:JA'FZP%)O%L$H MV%["A+ .5]89 M(L;?A^)MX<:'X;A9SFPM4EP$U T6S0,&RP_O1I/H\QO.CGMGQV^A+ _^[&F_K MQX.VH'4?ZX6P,@6A,LADV3C,H-
P*6"\@+:2B3)M2\./JB>0>9$89 T6SP0O3 MI2L0-I[J)"0">T%#G@FJJ%>'HO(6R_'6IJXJZ[LI]!YH%EA'MAG-NZ!)2&D' M4J5EDZ&'E16ET[&N43$)0$S&5DZ(LGUJ/J7DA;4&M!\7OC7P0)4G9 7Q3*-0
M#KXVB.TQ9 ==087B@02CZ.37XP&<6V_Y0#P?WLWBT?0S MX".:5%J6D:DOM-(T2D2Y=9NPQ0FL//)$?/H,)!11.(G 8KG+2Y]'F3VH#3 MK"=-
CQV^YH1'[LJLKZU]X+6'9DSF3WCZC,2]F%24G2]E[D-9W6?Q)1:PG5R57(^ M*('/.D2PFJ8:;713,D_(9R=[XF<-=CG?\K@KKMUU9ZVM+]V ,I VAKZ()B/+ M5F:>E(?S?
W@BA+!]7!M,NG6J=Z@#RAO7L&17G%R7Q&\+'_VS;BPEWAZ?'1TH MR8NKY.CR8&+'HPF<3B?/7[>IGH;Q:0SC<#R9'?VF'5&Z3_G.5[M+QS2<3&9P M&D;C,5Q1@_H6A*;675XH
]RR'2>OT:S)03\(>!^H-14.2/8+KHR?-4FXQZOM MA!$T82I*9Y+,PFGT:1<*5;!N3%K0%O'-I/2VA/IN5+8>X@'TVB_&9C4X3B> MA,DXWI'O?]IX;L ">;CFT'.C*
[(U&B018[V'9!#M61T<^N8%L62801G;_% CT@ M !D !X;"]W;W)K&UL[5Q;<]M&LOXK4XI/BJH" M:5XD68HO5;*=Ü#H;.RK+V7W8VHY?GFVJJK-#T^?ZGBEUE*/BHW*\611 ME&M9X6.Y?
*HWI9()3UIG3Z?C\=73M4SSLUBW+ MW6N5%=N79Y,S]\'+=FJZ(NGKUYL%+=J^JWS5V)3T\]E21=JURG12Y*M7AY M=COYX?4%C>.OGEV?B40M9)U5'XOM7Y3=SR71
MBXM,__%UHR=79V)N-95L;:3P<$ZSGQ@PM1.F#+?9B'F\JVL MY*L79;$5)8T&-?]#M\JSP5R:DU+NJQ)/4\RK7GTH*B5F8BC>Y0]*5Q!WI87, M$W&[+)7BCR^>5EB(AC^-+='7ANCT -$;\;
[(JY46/^:)2MKSGX)!S^74I3@O=J,Q&P**EX>G&$WLSO>L;T9@?H-9L-]BG^<3O750D[^6??E@W%BWZ* MY#L_Z(V,U_7]=Y.K\?,C_%YX?B^.47_U=%.L-S+?"8Q1I4I$
**MFE>%D/@ZK\HBR_#-C_^JTVHG?ETL5)GF2W'_7MS+3.F ^, P\.E]\]TY7*): MB3<2]$KQ4UK>ZE*F27B>[G>/ ?]$6_BX^LW+-)*YD)P[F.Q"^_O!$#)>5
**MA#&6+$A&/*,JE@J,EX9]_U"?BTU=ZAKK88C8KM)XU=K@HBS6HD)HHL?\[UKN M1$&[8KJ(.9G0*PD["/9SSU^<8YQ((6@06R,JW5=%_)D8*(MZN1+8(-%LL2-6
**M\H&DA0W()82RE'!9S7+;E&FLB&*]H7E/Q/1R/!HC3F090MY(W-?SWQ'^'$WH M96TT'A=YDE)8U#2;GNW+/1(DN(81D6J$8:B0E N*M5:\DQ@[466 MB4^!1E:29%$\I
**FQUI8>&X^)I,@Z()*H=%XNTEAR6B@I;&MK$-V9X'JNR*3 M*C.;EKS=5'-2\H*?0>C_Y22Y+ O-[,1*)7:?+$G2F1L4)R@HYJ.Y MV63@E03::
**(+D22;1ICRWM35J'D:B72!7>XB44,$Y0&ELRG(:3:!=Z*&6N MI9$YILA*@!;2'@:S/#"4]#,=/\2Y@(:0+!&+*#"(CS7V ME: ^(DAF5]7#JD%SA1FI,/]H_Q7'KWMG+2!6+6,>J-
**AISEP61CXUS%T)"U8V LX\&+E$V4 MW8_U^^,;6IB)7IB\,7HTEX ([9^\"4]"EVBH"QYA]F&E\ B?;19@? A^N06%
**M_E$0O0,9#U[VK]E!P1BP>IST'2PI;TQ8]T511/LIF(E[]K>=LIBG:US MWO7I]=>VM(]EZ=P8YI8'K$GQ5FR> M%OE3+M^8N2U5-#P_/)87$]JQ0\F "0:FBA%"PA>&"6$[$
**%5I;0)+8U\ JZ:Y[^W3X])T+0<@QC4&)R<15=3"\=[QWV3%0Q^=[:@U]:+ H3 M4HZPO(6RGHC)Y6@R%AM8Y<&A329\9+%C.VN6&]_PW&!;0#KO+K
**M!BEFI9!NR@"VTK/CV!6Q@$*#%K\7<%1!U>VPK/.<6%C+'&7S(^HGZJ']XB/B MZ&Z/KX8\P9JA)7B,WDC\7.1*?RIE0M3? 9&E54VN#,[O4?5 O+K-N400SV5. M^%#(Y"'5Q2,K?-
**K'4.UT9Z'C@1UO\9%04UE\29$+%2+*$W$=P&+@3 4&5#OD M):F.$78JAX\=R#.?8?M,#']]@29U@[(.;J&7-\B#D54WMC^2PN"4\(^,&2"0 M'.3#"-)02KAM!(F2^.[/FVS["5-KI^-
**/C_FU2_7&GQB5ZGJN414$^=AF?I:; MPP0Y^6:QX"*&T%R0[LHYM; ,9BF%+(MX@X!K4SFD&YEN4F\(*JLGP*BY5 M13B??!X,=3 MP3*6]A&I,J+63:7&MHO5B5^9_%
**[;1D5JBB+UP ANX3.0YN63E(J?/#%J3\B& MTCD()BS$#-$H)"K_"18^)QAK1I0JSB3LW95%FI"N3N$QLC1+@K#1I2T[VKD3 M%9^1MS;;)R<->6#-
**:\UA+\$BV4H34@+CIN61J%!2F"5$28!+\3$?"?62IJR6/*WG%62C2;XSR6?K_(?M;HY' LZ,[5WL:7]"CO@E0R;D>]R-%@+BH2'
**M@CZTL2UJU!54\%%$1(&7BXO1S0U5LZ6XX;$Z'$;M8>Z]:Z@4"GJ"BZ;LX8/ M<+THLJS8\9"BY23$"_$WL("80.52\:9*O4HWU'Y(E*F^3!$I8\2 !*E%-0' MM#@L5\>$_96:A-
**52:T.16!)E_ZY6X"G@E=2=DO/'-MI-C 1):J8]P7&Q E*1 M*'FN)@C".VTMFP(.B(-& +NL\1/0!TQT+*8/9!QWF8P#D-[.Q>\\7N,J@":? M5 :D36>T*0)L->@YZ&N?
**VBZ=BTK0##9>/%/WV]P2(2O8FFH['TD29B+W#QOSD=LH(B![4H'26G@54CJ1$!UW,QZD=6S MT<4>LH+[U"95+1'<=:NVE"TC;9!T!R:TSG1N8DD'+8:Z!54QQZ&N0QP
**MC&VIN=]9

**YJK9*Y6W#Q?>'"X$C M]71CRM((K%53]S&%XG(D[FRGZ=@F>QWK!S%(STEK_>HR>9%4*P#\X+H0Y>7H M^O)@"Q3H0F$[G#UZS2[LN1C_>\[2&J3@ WM?P" M7:]4K<-
**#CK[X17'R9YG7A!VO_UBD]$L>B9,-6]EF)"<8X1N M'Y:X&:5,=2MM/Q'A(0OQT#'W 0" A;AN)9?C&Z,Y-Z(C_TD7.Y,ITC(9;B3
**MKRN9Z=M&DJY3$H9Z9[+3:1CM&]S8%0VWD6FWE]'5["*:SBY%)V$YS&)E>P*< MD_Q5QWD0?CHU[E&W.!")8.U4#!!Q05S+HDC$0C+6*T2NEL!*7"61QY-[NC/'
**M5M_;G/!T>YJ.F\B?(#2%#?, 0M1][E+K[Z*W6LR86=KBGZ,39$;&VF>I#C=7 MHL\NVP<>IA?.^-BOZY.]ZT U[3OB)*&RCH-6%;3G,>D6+IN)&Y?5.F< U[.K
**MZ;E9_*C2A,PTJ2@G_PXDK ,.XV.5I[2EM 6W;&)(<'CG@L6\D"4,?,XGZ:8Q MG^;F#DJ@T_8R45B'LM$".N 3$S>]'/RY2N>F5>+7-VE(?N::U.-74P8;U$<] M%-3&!!\44'K""_.191
**TW%2"_YO@D/($$=KMZT!((9C&8X2A"H$6P0'5WJ8E M!"Q-MV],.YJ$XBNF#:I(1Z9M(-)J)?"A7OAT+3]S%D7-4L,U8L%523YTGUPS MB[LY.X(E)8PZ*%@N::
**<*'6EN\N2*/&/;@[Z_($B;.B!&CR$$JDY^P6!/E\J M6YUCAP/^MBG9H9?STY=^5$]_(%9U3L6I?EOLVHK$8I.QF-?P:2H,J>ASIFL. M'KE)JF- *>2#T@2RGHQLH\6!,-
**SN*4*P;J.WE6TJBW?4I*)ZN7OM0H+,LBVQ M8TCU8$?9A)]3>\0&87\H'LQ)V>09QZ.92=+M.R#<:2!4>G(S#I23NO1-AHY\ MNPW8]C&OQY[*'G?V^'T[
**M+/X$R.HXL^+FT_.@364DXVN!7A4Y-A.QKK,JW61I(]D]R7#8Y16=OKP$[UHA MD"\1GG^U_[8DVVK2'5DF:)%56W-EA;L_J(8RN+$LQ4[)D2Q Z-5SMSJGEVRN, M@X1,P5<6*
**(#2&&Y\=VNKBN:[.TA]#30.OP-[C7;IH*M>("$;;\9?IA#" M"O<%HA,6B<0'M14_T]^[(XV:ZP"VVYZO2=&M0>HB* OZ3F)?=D!=WQY=N*"
**M^]%,T@0S>]T)CD%&_[:LEV+P[L/;9;:STC9R M9A^#)Z# HVR,'2SGGR8:G(JWDB MP:K$),A-Q:@OB6Q[&SL"K_:(HWVA@D.W!HM8%]<5)HV"5 0@ZKL9Z-9198
**M67#LO*"3H\,.01<*=+TMT,U&IDFW/V!LB&^2;>3.F><3,;T.CYQ[\"?Y\,HT M9\(2)0B3QJKL-$):T0@@PM\I:YU^'-D"%QVAH6'*(BUU%=R#RJC7D17%9V*N M4F$]1 (,FA6(P4LB[
**.+3I:037-'XKLH5MCFU]F0[7=%_<%5=S%,_FBD.Q M%S[;)7%P'N3+F+T8K%?NC(L.C&HV!UZ8MZ^TXAC.QZ8FY!@(2(<_2^6.7KMG M3;>&%-
**\^H4H3U2K=Z4V:BZ6#V_LWY^+9;#R1NL<]NLHP57L$TD M4&"[W6^GYDS3F^G&T[!7T^[05#93S5KG"WNB\J5\3G'0F7-CG)%("F4OKE$P
**M5N:N9>L*9MB(P4/KNY$Q!S(N@G;4#PG:!9V.#.O"+43U'%*X46ZM?=./HJ+I M/V*5K=R-6"QKA,Y? S!''[(&(\R6DM=(LX2\;=!>@,XF6Q])PHS!X_=HCM% &[@HJ M@GBQS--
**_F\L*>_.50UTJD+*Y?ODNLA24] %+;*%,.T[&]EXU@/@0U%K+U1S M,#]J6IE\C&.:#>%=1O?/Q=71U[>X<%VUR:ZX:ST3-S#AL^/'"?L4/N*.^>_)6YS'AL\%?>9FQOXQLO,![C MYR
**ZZ/>#MD\Y\-2UXJ92B;I-.3$; M#:[W>R\VE+3$YT1/VEK4="[FI.;A7VL3 ;B8M-!%-_8TY5[_:$%Q[Q;6M[Y?<'DUNT84]"<3S;&$U9%]3^ MB@?3%31G M[_0F2/?NHVT@]@VU/N\R>?
**\]2#.]FU>,9(Y'A.X-LO!]$KFHK,,EMH.2VK;K MGWK#\'C#_W_%\ >,?PD/_R)=PR/K]Q_R?#XG;/@+<,VF9XA_^7;Q,>E>K7 M*NT_?*0SUG:AQYA8;W7BL;
**(0X='T:%S''\9ZM33I>BQXZ6O.ET:[.^QYZ1@ M?U"GKH#Ý(4+B+1[KUH\"TYVP'=_??K_"O+X\YM&I)1<$8\\%1950?> M183_44^K.%ET_8C@Y%<%;3?.;)[(^BPQOM>Z^MZ8M-
**F.&7OW -M#6SOF*_\ M3/#M];7'VJW74+O+V^.]UK$GI:H.5)V-QC-S_F6V9Y Y*;P#B'OFCIM+H^8E M4+Z/,IGT5?;,_RRZG%U&TXNK8Z+]G]C5Y&(T'N]MB^"+IG-+OF1PP@8O;D:7
**MK1WR#?/+OOWY%XJ3/?,*W*!K-J=8QB$+/O:"#CU_%Y<3+7=WEY,HC)0I$CA M>A=-%OI?"/S<"D[-Q5\G7(U795W_41NY*6E; M-Y2:']#*T84#7K[O2;5[/JQP?;'T[[?QJ! MM\71?
**C(>_G74]Y,C3X,?B>&./?T4#IUVHI8TOQ?CO_6_MG-K?F2F&6Y^JN>] M+)?4)<[4 E('HV>79^88%L62[&ULG5E;;]LX%G[WOK \W4$".([O=M(D@-M..P7:F:#)
**M[CPL]H&6:)M32=205%+WU^]W#B593FPC+1 DDDB>ZW=NS-6CL5_=6BDOOJ5) MYJ[;^_SR_-S%ZU5*EW7Y"K#RM+85'J\VM6YRZV2,1]*D_-
**!KSDV:Y9TL'FL.71;2J;P=SQNBZAPWJ3E84B0ZBS\E=]*.S0.S'H'#@S* M P.6.S!B*=])+V^NK'D4EG:#&CVPJGP:PNF,G'+G+58USOF;/XQ78B3.Q#OM M(I-
**YG14J%G_FRDJRFKLZ]^!">\^CDN*;0'%P@.*% PZ:R=^RV(5[YX_AW2U MB(-*Q#>#HP3O5-X5PUY'#'J#T1%ZPUKE(=,;']J!W0%,ALYBLD!LG$_'!FB)W
**MXK_SA?,6T/G?/D,$/J/]?"B<+ETN(W7=1KPX91]4^^;77_J3WNLC6HQJ+4;' MJ!_28I^8QPF-NH=\+^[72GRX%Y]5K"/8Y&UBG,Y6PD1182VV(JKFN=6)Z ^" M=\3)GNW
**I3KMBENK'K0I7++I" _";TV:RVP#LV>FR"*0\VOIB>8[%:ETH:R8 M,M5A1WQTQLJ-4)E7Q%=GWN"$LY)TZ(W)OR[12\HZ2(MR9'JGT+G9-^.B)3UR/B"8$/AX3K8]X E8S>UZ

FEWH*,:5%$K-]TQ5VQ^!L? M2:A$IYKD4]\BE0>\D3=19_R:%/:[X(,;.\WW6,\4!7/W>$.F(§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

7[OEDS#8RB3.XYT1LTI3RIQM(V.ZJ-M8W>>+WR)ERNI+W0GXS5=P@SDU_4]5V?=BA+%*60B9AGAL+CJ7-N7@=/3!GF+ MOV+8B;UCHH#5X.94P%3EOP=1W)UU?
G8(1$LZ":17]CN#R@'--"\D"4B_T]V95NK0*- MD"PMC54/TC@K7NEC^4'L&=C]%PRNB7!OUC/0Q*@\&Q M'H:EP?!8@U%I,,HGJ_AT\ZEQJ:23,6<[PG5K1=,'^?SFUFI&XDQ+
<2:Y>C=6 M=G+RF4D@??(;<6,1LDS&V08B\N<:..52$>2]"Y++&B2 /\"@W-/F@VGZ=N>3] MNP_CKE0]T)QN6'J;%MZ<%[SUR)WRL1+$RR*(6NP]L_V%P;ZK1EX-WWD>_HUC
M!%ZO^3FQG3/B6$Z_;3QF\QFLSTG/>M'\!V9S%7]E;K>9 M-Z:B5RFQE_-Z+_!NLY"E0&:22E"Q3IZ1&YK0+%27\iA,L5U4F37*\) M$QL.@LR?].F:"74]X&RS%F=$X9)-%&?
+%Y7][9/J ;E5WL0_+<._*;K;;^^N M3A&78DU#N.JH'"" ;Z$S^?47>VC]WJ8C3)B+"?,P83XF+$"".-=38K]38-]$G M4Y:F*E.J^!M^/R-
KRLF6)AMHTXD1=*I."M@HA^EEQ'9BG5N6/>YN]P6 Z=([MRJ6/Z3)XS65CR@;5E V,4];XGK/J>WY&[CG;QOG:Z?T<,EC$\@-1BS@2%Q%' MTD<0,1-K=`?JQ!:PX?
Z0#R;UU1;>JRW5UL$2(-JS-"PFJ&A<8:"!W('41RJ_M-7_T X2IC"5O&4 3K=_+M#M(Y\-98,:2>.A68,!<3YF'"?$Q8@ 1KR&94R6;T MME8&(TPU8L)
<3)B"",Q80$2K*&CY4:/QJ#V$PO"4@LA!9-M.%:2$HZ,8O. MB%A1WIY++"N9@+S [HXN!/6Q&YZG1]:EBP(1YF# ?$Q8@P1IBN*C$<(&U3"Q MMG.PZ#E<:$V-#D^5 ";,PX3YF+
"=:0@&W5)13+*()[X%*2W0)A"V>(X-. M2FPCA50'.D2$=!U+E85RJ;3IHW1B]PX$,CC0A[DSIPH$E>:ATGQ46H!%:XID MK\YF&T7RA3W11#X1NN20KV)TTMB33:86,FJ5HM8L'$*
(MW2>M(:1TLWK,C%V MYV298-(\5)J/2@NP:$V9.+5,'(1;)/(?^:ST,LOUHL3SSE82('=QDNB[7'5K M^PF$,-Y0F;MQZAH6E>:BTCQ4FH]*"[!H3;'5%5?[C95<;=2:*RK-1:5YJ#0?
ME19@T9JJK"NOMKGTBI8I"S>VWOK%T MB5H61Z6YJ#0/E>:CT@(L6E.5=7'<-E8[\=+EJ#5=]@_3)6J]&I7FH=\)5%J M16NJI"Y:V^:J]0~DRX"#"G:2.BTCQ4FH]*"[!H3;G5
M97'[XHVE2LQZ\Q25YJ+2/%2:CTH+L&C-9_WJ0KUC+M1CIE!5BTIDK2KUCKM0?G2KW&A8_"IO2HMGIJ0$(E>:BTCQ4FH]* M"[!H36G5U7W'>5MIT4']&0*5YJ+2/%2:CTH+L&A-
5=8_ SC&@N[$$S).E2(C MLJ"QX0F&$K/_=*%CZ;_#O(=:=T>E>:@T'Y468-$*&73W-H6DP)?Y?A]!0K;) M9/%4?G6UVE-TG>^D.;@^M2]=N^6Z9U_ZQ8ZA&E]L8+JC?!FKZ)/
0KFRSD>#_M#N'%G]#B1+)UOB5ESJ1D:7ZX AH!UPW4^PO&Y/.)=E#MS)K\#U!+ P04 M"!Y@6Q9SS^8PC0(_#,;_& &0 'AL+W=O<*PF=*W'SPHI/Y9X0#CYG:5]>SO:<'Z[G
M\W*S)UE2A(G%1.63I'CN//LYCFL_5-=>VA6-^P M(T]I3AX*4!ZS+"Z^W)&4O=S.X.SUPD>ZVW-Y8;Z^.<0{\DCXKX>'0GR;GU 2 MFI&\I"P'!=G>SM[!ZP@OI$-E\6]*7LJSST#>RA-
CG^27GY+,F2-,1%*RX1(B M%O^>R3U)4XDDVO%[SH[Q92.YY]?T:/JYL7-/,4EN6?I,S3A^]O9<@82LHV/ M*?_(7OY)FAOR)-Z&I67U%[PTMLX,;
(XE9UGC+%J0T;S^'W)NB#AS$#AZ!)0X M(-7!'7# C0/^V@ANX^!^;02O0N":2Y[UB,OQ*]4^/'UOQ@GP 57(*#EAN62@)\/I(AEYDOQRZ/H MS_[-FQC/.DO)EST5P9=+YI MFG97-PT--
V##R+4O@1AGI!$XQ^8_5<&_[F@Z<05>N7J#AD!"\GA++#.&X <-MY&K:<__U[EAW.W\N>OCGHD=F]X!LA#O4N7>XQ*=^ARL\/(#WKBP)+\&>I D0 M\R,HX[J#)>
<=C)TZV!LQ%HJ"Y%S7C>I(KCZ2G}JORT.\(;6I'@FL_7? M_P9]YQ^Z'-H$"VR"A3;!(DM@G=R[I]R[)O3U+XS'Z6M"03RM)^@Z0!W.K\+) M1^GSVKF9/Y]GU=B@J5D=#1?:#!?
UPWG8@:>(G11XIQ1XQN'WGL9/-*6<$DMC MT+,Y!FV"!3;!0IM@D26P3@?P3QW GS+T[/N,&WHU5$\P] SMF-J,D?#A3;# M1?UPGK- ^J&W.#&_,#(?
$!%Y0RM*=8P:O:>.))M@P:+'!O26GL+_HC=;^4NW M:Q-9:E6'_N6)_J61_G<9*SC]8Y!^H_=4^FV"!3DX:,Q0 M4U-A%2UHT#J# J.%D@^=E0/5C-AJ63N)*&UWN9,#@SQ9.9B^.0)
M(+\?Z2$;6)N942=GQR9:T*!U>%\M'76X:,Q62ZQFQU++NME!;7:0^<&NKX\ MD463 Y/#2,QZ3U_ HUQF_^<#R9Y(\5_P/W!/2GK,KB"&X.Y8"M"R//VL3:>Q
M&9/3:1,ML(H66D6+;*%UNT=;\(!_7<4#6BUY6$4+K**%5M$BC6VC=+M#6/:"Y MV'3ZY)'FU-W5$]9J2X0Q;6O>,!PRM:HPT ?V%/T!Q6Q" YHK S]5444\1P^3VI76/7*MJ?SQ@:#5@ MI
GH>@/"OW8EBOIB6QUCYB"3TS4:,+0: M,-($]!>+@2'6%@"0N0!0*3Q0$$X+(E=#@#VE=#=8-&O0C#1;%>?C 4.K 2-- M0(0&GBFH%=+(J-+6[UE9"I8W;)?3/^1\E8--
*AXM=$LW<7U<29GBM.SC2*S M\ORQD//LH6!;JN]HXW)38^+Z2*5,(^I@C[&^$3Y3?@UAWV)?&;4Z$IEUY$>! M&1>;?5422<@S2=G@E@P:EY,;D_.Z34->WTBU"75
CKK#*$IEO[E+R6J&(S$*Q MFM0JYK*X^"264/E.R]NX_-.8+#U/Y:UOM'*A2IQFD]939\#(?&,7$H=;78?- MV[%<& 9 M%_0_DEP\9=.*NCC):$Y++I^ZS]I5#^YOMQLA=J8-68^3[*GWF
MV[N4OE8.8,,'E0IT MS?=[*9]GQZ+-XF;L=)C9??)A9]NGG<<5CL8$+J":@F^Q2>=;@8/- F?LA)C9 M?7(*K&H6PT!EJ+CPJ M9D:=G!NKVXVX?[2X-
U3Z)FC9F]RLRL3YV;MW&2EVU5N21I@$QYS7KT.=K[> MQ'Q7O7^H7+^#U_=08%L M6>/LHZLQ!0 ;BL !D !X;"]W;W)K&ULM9IK M;]LV%
(;_"N$.10MTT<77I++:!Q+IE6!8C7M8/Q3[0,FT+E42'I.($Z(\?*J7#Z'"XI>P'7Q,BT%,2IWS46@NQN3 ,'JY)@OD9W9!4 MGEE2EF A=]G*X!M&\"(7);%AFV;/2'"4ML;#_-
B4C8M00LMR!)GL;BCVX"4%]15O)#&//^+MD7; M?K>%PHF+FI1BV8,D2HM?_%0.Q(' ME\1V*7 /E;0+@7M+M9SM M!=UC
M!;U2T#M6T"\%_6,%@U(PR.]N<3OR>^E@@<=#1K>{J=:2IC9R0^1J>0NC5'EW M)I@\&TF=&/|%!4%=]#N:,OD\,/&,<+I [D,6;:1#!?KD$(&CF*._R9/(H,F?:,?
7+UF#^R6/:1^R;&.^+2VN:;&/]X3%N#"?08 MAX028^DP-1^TJP>BG7/;KW!WS\$7-(VQ? #JC\/W/V5S="U(PO]MZ/-5P>XT MLU4>NN ,')))12R8:3M@C:8T_?K!ZYMIR=WCV.H.NJ9I
M#HW'0S.];-<;=%XT"X#Z5K-)M[))5VN3B4R_T8*PPB=R+HM(;)2KRX5+B1$W>1+!>=4")KD MFVN"%X2!O+\DE*QVU$!JB6VX_\ 4$L#!!0 ('F!;%FFW5)*M00 %86 M 9 >&PO=VJR:W
H965T[,ID>]G6KTR1"1({%.4\)?;B%AVZF!C=W)[J*I1XP M9Y.WO4 7D:;R0):+X1=O*UC)0N!:2I9G5I#2K/PGSU4B MJARP<\+!KASL0P?WA(-3.3C_U\&M'-
PB,V4H11[F1)+9A+,MXMI:H>F+(IF% MMPJ?9GK?GR17LU3YR=D?3 +RT'OTR)66N'Q!)(O0;]_6-%>[*]7$4ZD(Q):G M;-[.01*:B'?*^O/3'+U]\PZ]031#?
\5L+92MF)A2<=4KFF'%ZZ[D99_@]03Y M-7*L*V1;MMOA/N]WGT.HW''A[K3=396A.DUVG2:[P'-.X.TBOT*/"5$AMQ/P MY4&9HWU)J?BW*]02V^W&UD_VC&_;GGM
M6WE>X'<3]6NB?B_1VS5-(IJMT)>/D"Z =XJ] M%^)# _1L,Y-ZE-H/V? L?BO78S/9/BK4I3'!_9?(ZD@5LR1"JVG.V08T6]&O MW%[$L[=K(+1V_$V]@_U+*G?
04F@HM'8JFF((]Q89/Z#V\\&0FN'V]0]>'Q)F0Y.%@V%UCZF-W61W5ML MG"W3VU?PON#N%[UU=&2U1Z.Q=Z#N#C/'.5'EVKK@:8_L=2?ZBPK%$G5'CC(F M49ZHA$>Z(Z,33D- A
.B6A%(QD2B5'<8U3.#0I)321+ZO3@FJR&U1_K]?X48 M1]N8AC%*2496Q8< +2"AL &!MC1)&I#:"Y%J@*:@^T-C'+&\GRHJVW8%*R MM+B,@43 M8&:7S(F=S=Z@;J5//L/4$L#!!0 (
'F!;%GNH&PO=V]R:W-H965T$]NVPGBUK1#1YXB7WM>X{//?U MVBK]8$IS"[M*2#,EI;7U):4F+[%BYES5*-W.6NF*61?]#36U1E8$4"5H'$43 M6C%N29.&M87.4M58P24N-
)BFJIC^=8U"M5,R(H\+MWQ36K] L[1F&URBO:\7 MVD5T8"EXA=)P)4'C>DJN1I>SQ.>'A*\<6[,W!U_)2JD"]P44Q)Y02@PMYZ! MN6&+,Q3"$SD9/WM.,AS1@?
OS1_;WH797RXH9G"GQC1>VG)*W! I"\^7*V"""%]H^-R*0-\:JJ@<[!167W#]<@ZG)V=P ES"7:D: MXQA,2JU3Y\^@>:_DNE,2/Z%DB?4Y)-$KB*-X? 0^>QX^Q]S!1P&>',*I\V0P
M)AZ,B0-?\@3?@1]_C'G)A2*-!KA^]7*6.WNXX]C17>GC(^?XGOTM0LOREQ M36A0,Y%D+U^,)M&[8Q;\)[(#0Y++!D.0Y]L&08T5VR$E_C>G=CF\7C:!*G=+NO
M_F]9G2RZ=YG]0_*)Z0V7!@2N'2XZ?W-!0'2-V056U>%^KY1UW1*FI7O/4/L$ MM[}6[H[W@6^9X87,?@-02P,$% @ >8%L61W*6U;? @ FPD !D !X
M;"]W;W)K&ULO59=;]HP%/TK5E9-K;0V(7RJ@T@4 MM@ZIW5!9MX=J#R:Y$*N.G=D.=/OUNT[2"-I .XF-!V([]QS?<^)KN[^6ZE[' M (8\)%SH@1,;DYZ[K@YC2*@^DRD(?
+.0*$&NVKIZE0!C?0PEW?\SIN0IEP M@GX^-E5!7V:&,P%31726)%3N NUP.GX3P.W+!E;R & 13NH09F-MTJK#G M5BP12T!H)=51E!@XP\,YG?C^\X!O#-9ZHTVLDKF4]
[8SB0:.9Q,"#J&Q#!0? M*Q@!YY8(T_A9"S-$ ZY)1<2AFM&>>$ MBHA\,3$H,A&&BB6; R&,JY/$'P[M&Y/CHQ-R1)@@7V.9:9Q,]UV#0FPZ;E@F?5$D[>](>@;I&6EZ[XCO^:T:^&@_
M? PAPALYO+D-=]&^RD. \M#/^9H[^"@"UPT3S,#I%:]J],:%NRO$D(F!1/^H MTUM,T*J?P%,RN4YI" ,'2U6#6H$3O'W3Z'COZ]0?B&S+BV;E17,?^VN\./[P
M$/(L8F)9+;J3.D^*B3KY1*8S6@5M#W]=[4I]G6+H16M2D5KKXIA&&9)QJE! M <-$*L-^4[OKU*59,+4W$GB:XKZ(K?3:57KM%TPF4R5#T)KD*HSSLAW# M"K?
E%#=90^ZN(9F#JEUMN>]G_=K4=B&S+B$YE1.=?5U[GD%XC/'V!,H&X/N%Q!.U[-@#NKJ/!7\ 4$L#!!0 M ('F!;%FHD[+FK@(#,& 9 >&PO=V]R:W-H965TN,FUM7#LS'9: MV*??.0E1-
P)(>]/X8M_CWW..K\.MTH]FC6CA*1/2C+RUM?F){YMDC1DS'96C MD)FETAFS%,J5,W*-+"V3,N&'03#P,\:E%P_+=S_EQ2U?K:U[XWVB*_$8EY1E*PY4$C6"
M.XY;LS,&YV2AU*,+KM*1%S@@%)A8I\#HL<%3%,()$<:O6M-KMG2)N^,7]?/2 M.WE9,(.G2OSDJ5V/O"\>I+ADA;"W:GN)M9^^TTN4,.4U.:.NU@0=)8:S*ZF0B
MR+BLGNRIKL-.0AB^D1#6"6')76U44IXQR^*A5EO0;C6IN4%IM3;~H2S*,1S!)8KTR'JC";.%YO89KN0&C:7Z6T/3T^K00"WAE&G]S.4* M[I@HT "3*9PSKE]B6G+.)9,)9X)4C-
5%I;)_AI9Q80Y(;]Z9=F!&GY$I2'7, MA3!PA%L@?H!]H!+F*U584C;#'U+1AVNG]2FQI6I\ U34\P[T L.(OS"",;3 M,]C?._A;QJ_BKN&)R5F"(X_NF4&]02_^_*D["+Z^XZ'7>.B]IQY?
SB:'P#*E+?^- M*23*V$.8*Q%$W"J*AOVE!B!]$Z&.$"ZV,@;FD3T^4)!?4 M05K/NA+K[S!TN^T_0:@_Q\ UQ1C*T'_%4'0#C!H 8? WPWEE-;P=W;T[;[
MH.T,NOU_"/R='N#:Z83I%144!"XI+^@<$[ZN6E056)67;6&A+#69NTS3_$_$?4$L#!!0 ('F!;%F:?+S\7@(%<& 9 M>&PO=V]R:W-H965T077)1> M$KNQF4YB5:,4)\KV::,K]C
MR40!I1&J9!J68^]=_V(2V75NP628W=T$4RMG]E$2)K^>@/% O2WV$?29G?P MTU;'I-$1'M QA;3'!OW7+ S" ;N?3]G)R].?:7RRUOD+.W^AXQTFXBF,/7H:!O0:O.35BWX4
MO#WB8=!Y&!QC3[:ZBZUN\.;T^[0V;)%CLX]RG02QO]XC8-@)&!X5<,E-SGB9 M,1>\?ZS%FDMW,8X5_"CG'Q[9J%,\^B]E'_T##U'G(?]K98]^6W9_IT_8EGO# M]4J4ADE8$B;HG9-
=W;2Q)D%5N=:Q4$B-R(4Y=7[0=@'-+Q6UCS:QW:C[+TF^ M U! + P04 "!Y@6Q9U7CGO*4" #E!0 &0 'AL+W=O]H+<^>Z^N",.OF2M]
(,I$"T\E4*:85!86YV$H\)PPY>%=0=AFE1LB3.TM]6U)BWR>C M@?/W#G<J/4%MGP.'5ZFA/%?6+>^40!9;:PJ MVV"JH.2R^;.GM@^=@#C>$A"W
;&ONTGDJSQCEJ6)5FO0SIO0G."I^F@JCDLW ME)G59.449],K91&.X3.<,Z[ACHD:88K,U!JJ]=:09=;,"]0"IDKB,TR9?J#K MZSYB@D/-W%N,J>I4@Q)1@F> M,TO*B
DF,X29OXMM#3DPVRW-S1%N,*NUYG)),88,V#U#R[@P>[#@ROA>J-I0 M(99VXU1TXUX2S=F6!U /]J'.(H'<#L[@IV=O3]A0FKPILOQILNQ MQQULP;W$%0KHP?
T4RSGJG_"K0VJ_0ZCC\&^O7XQO\7HWOWO9)Z9B&0X#>KH& M]0J#]..'WE'T]1UV_0V[OD?O;V'7I?]J#-*8W>PO.9MSP2U\SI.&N K6^=U MI:3^.Y[WEY0
)A9+\R;7_G_@.MAP';P[27^A\?5"OU5?@W#D$=Q27*5Q/#B, MXB1<=3.'G5?K%B"->LFE 8$+"HP.OAP&H)NETBA65?XASY6EM>#%@O8P:N= M]H6BQ]PJ;C=L-GOZ&U!+ P04 "
!Y@6Q9=L8[/M0" "I"P &0 'AL M+W=OZHPWCSV(% M(-%+0E,Q=E929]>N*Z(5)%@[<$>6*ZD7W"'4X27,0-YGMUS- M7,L2DP1205B*."S&SEGG=#+4\2;@, EH@+ZB"TPX>L T
M!W0-6.02 AU,06)"!?H!+S+']+ 2>X3N(,HY)^D2/5Y#,@?^I +N9U-T M\/VEPY$J5HC[CWZV!3YKA4X@4O&/@017N*F.L M.[YUQS=\P2M\NT+/A #E!TYC=$7PG%
B"8BM63%2=_*O%SKJAJ7<+IQC001Z MO%('H$L)B7BJ,Z?(IEN?C2[H4Y'A",..JE@!? U.^.53I^]]H[.J);**<8$U M+FAB#R](BM.
(8(I*B$7]B[N4;+W"$BVTM6MM;9T1C>S[&E&0]0V9_JNM0V_D MKFO4=:VZ;J.Z'U@#!;Z]\74*&AGV5=2645LSXKM?:@:Z+5I7$MD%>/ZUKC^ MN]9
O^':%NH:S_]/=2=6W\=GZC_"2\:PV(B669Z MJSF3JE,SPY7J8'K +6_8*J_*B>Z7;/=>?@'4$L#!!0 ('F!;%DY'Z,* MT@(.0' 9 >&PO=V]R:W-H965T>*%T",O-
Z8\\WV=YL"I[LD2!#Z92\6IP:E.^+I4 M0#,GXH4?!<&1SRD37C)T]Z8J&308VW@5\9[#2&V-B*YE)^6@G ME]G("VQ"4$!JK /%RQ(F4!36"-/XV7AZ[9)6N#E^=O_L:L=:9E3#1!8_6&;R
MD7?BD0SFM"K,K5Q]@:8>EV J"^W^R:J)#3R25MI(WH@Q \Y$?:5/#8<-01AO M$42-('HMZ&\1]!M!WQ5:9^;*NJ"&)D,E5T39:'2S \?&J;$:)NQ;O#,*GS+4
MF>1&&B"GY)#Q=@*"LT^0I/IJ+%/@:/\3UF&!@% M44 N10K"O@PR+:(@#]J?-9Z >,$Q;3SWT#29JE_/3)JGS.JEH2U+C:M$C87Q@ M_>,.^62W_)JN23_L4OM(IT44M8@B9]??
8K>5S%@I*A: + R9K5\0G-*UNSU> M4961^RNT))<&N'[HHE&O'W>O;[_C,UW2%$8>?J@.U!*\Y..\"CXU,7F/YF] M0-5O4?5WN?\[J@-R4]G=0^2_(;4$L#!!0 M ('F!;%G\I6L!MP, "L1
9 >&PO=V]R:W-H965TY.5%"'L0'EF.I;EFSE."V,Q4VMW=#$C!YZE!=Q1Q YY MCNG7%63D-#=LXW'A/MTG7"Z8BUF)}[! JF\HV)F-BQQFD/!4E(@"KNYL;1O M0MN2
"7Q1PHGUAHC:&Y8\$600<4F!Q=\1U!EDDF&+/%#-8D^S.->3(W)@:*88_#!,'XZ@#=%/)]@.(]!63F#A!LHKY%K M72"\ZR?#W?[S/E_VL/_K+WC#++?)4%?
QN4_QM1+S#G^5&=/.GJO'U(B1 MB#Y:XS+E.),)>(66.3D(Z<^_"TKTGD/_NK+CDJ_UZ]?5NH;5N((YH8HQ0SH M$8S%RU]LWWK,%QJ=9(%.LE 362>(7A-
$;XA]T7ZNH]9SW1>.BLE73/(]=US8 MTY$S,X]M-U*>?:D*Q-%PDLAQQM9C5#'VE%C[6C0VGOA/TRC1&5D M $?Q.BY5WGZ^A7P+M#<+!RE_- MUD@4ZR4)-9)VX^$U<_)]
<2GR=0=1)%N@D M"S61=8(X;H(XUE9**J91Z^&>V-Y9);F4LL!_)+@&HV MO]-7GQ%=,VG!4,9[(0JZWHLBA^M.O-JPDFI6L\MX:*15<,$< Q4"HC]'1'M M9SV1*I%KO(XM_%|+ P04
"!Y@6Q9_6A7T^@" !:"0 &0 'AL+W=O MM I@"&/ M@F=ZXJ3&Y&>NJ\,4!-6G,H<,[\12"6IPJA)7YPH5+H)[OJ>-W %99D3C,NU MN0K&LC"<93!71!=*4/4T!2[7$Z?C;!;N6)(:N^
&XYPFL !SG\\5SMQ&)6(" M,LUD1A3$$^>\/9@(!#:*P"Q:3K.E==P>;]2_E.S(LJ0:9I+_8)%))\][((1'$M.#F3JZ_0LW3MWJA MY+K\)^O*MH_&8:&-
%+4S1B!85EW18WT.6PY=_X"#7SOXSQS\0P[=VJ%;@.E-1 ME5@7U-!@K.2:*&N-:G90GDWIC30LLUE<&(5W&?J9X%8:(!V/?"0S*00SF"'C M*&90ED(0--3B[
4,8U^0:/IJ#_=@UN+T5<<-ZJVFUE7]@JT_D!B53 M32ZS"*)=?Q?#;F+W-[%/_5;!!>2GI.M](+[G]\C]XH*$^$ MLW;!"PA1L%,*=C>"+8%VFT/NEKK=_[K74NMGY_GS&FW(E0&A?
^"[RDJPMU_0 MEO:9SFD($P=K5X-:@1.\>],9>)_W41]);(>]U[#WVM2#VT(L01$9DWR3&/*G M-4G32K!?"MJWT"H8C-W5-E#KEO\)U&^_^JU YTFB(*%8-EB&3!2"@#9,V 4-
MQG"P)42HD$5F]M&UJK\VLY788.NH\/6-O^:\=A '#>*@%7%A9/B02AYAXD,MD45#I_=QM4J^ENM(8COTPX9^>.QJ'1Z3_4AB.^RCAGW4FOG+^C&^E&.~T%3=G
M3_MX1R\]=A7)BV95C.Y6^Q*@DK*K:Q+:"JHZ6;/:?#B?77<4)6P M3!,.,;IZIT,L%5U\FIB9%XVPZ4TV%K+88H?/Z"L =Z/)3,$>F(W:#ZG@K]0 M2P,$% @ >8%L6726G1:- P -A(!D
!X;"]W;W)K&ULM9A=;]LV%(;_"]$50PMTT:<=*[4-!!:&94@&(TG;BZ(7C'QL M$:5(C:3M!-B/!RFIBI3*JEVP-Q8IG?:4R9F3*55< MN*Y,,\BQ/.,%,/UDS46.E:Z*C2L+ 7A5BG+J!IXW=G-
,F#.?EO>68C[6T4) M@Z5 $?DJT3LW_X0J0[Z,_T"U0K&^% MEE@H A*]3D!A0O6=>WA46TS?Z*/=PEZ_>H~H4(0S>$4OW?R:FK=$^,GYO6 MK;ZO6@T.M'J#Q1GRHK0'#4G,=&.
<-C//C,OTE+3*,[C,0N'AZBZZO%TV>1_^AGU\0!IL_E:5-L\2 M60?[!,$^^44+PL0F3YMFB26S#L^XX1E;6A#B[W)XK$\4SF^V'_4Y]?VJW^^?[@X%-7!= :.[/0#P,0? .,I#]!+2\'$]&P MT[?
O!+\I&OM7]OE6WQ)9,%^KSEM\?W $?I&PO=V]R:W-H965T'B^1T;SH&Q M#_;%*HQ_) O&.'GVO2"Y["PXC\ZW62R8#Y-3L.(!>DSLS#V*4_OQO-N$L6, M3O-
!OM=5)&G0]:D;=,87^6-W\?@B7'+/#=A=3)*E[]/XY8IYX>JR(W=>'[AW MYPN>/= -=7T1TSAX8_QK=Q>F][D:9NCX+$C<,2,QFEYV/\KFCY@/R)?YRV2K9
MNDVR37D,PQ_9'7MZV9&R-6(>F_",H.F_)W;-/"^3TO7XIT [FYC9P.W;K[J1 M;WRZ,B\T8=>A]\V=\5E9]0A4S:C2X_?ARN+%1O4S[Q2"7Y7{):+]L?=,AD MF?#0+P:G:^"[P?H_?
2Y>B*F!Z]$!2C%_V1F@] \,4(L!ZNX Y<" 7C&@US1" MOQC0;QIA4 P8-!TP+ 8,FPX8%0-&30><%0/.F@Z0I===W3LHS:/V6Y_FB44[' M%W&X(G&V?.IE-_*DR\>G:>(&67T\\#A]UDW"\?
&GD#,B*^0/XUQ MZGH)^<*>^9)Z"\@[X@;DRR)<)C28)A===GH;-!G%X_$XSOHN[V6;E=9NO%"'X<3D_)=+HA"B2TB-?'S3R_MT'YRBKV[JM%*,/++#HEJE1%:QBM.:,*&!VS-
@9F;CPA&DLF ML9LG)?E^DRY++,[\Y.^:%;Y:P[UZ./NF/4\B.F&7G?2K-&'Q$^N,?_}-]-DA_ MUJ4[$M.0F({$#"!TF(C$+=B=E(S %AE?+H;5D0SZ6/KN?RE[HR$)M MRV"-
#7(LFVP^C97^\.RB^[2=WLB(>I.(!C*BB<0L)&8C,0>$5=*VOTG;OC!M M\QT/$L[(,LU>FG["\[K,%1M,[>_GT<[5=W)7&1$O4E$ QG11&(6$K/W7XMA
M;UA]*1Q0P$I"#C8).6CP.,?!*<_9SQ&+*W6!.O/7$>I4?.F%30I_29^:,Q"P[GI0M M<:@JA!':?CR+5UH="J-=B8PR)!ZHY &
M,J2)Q"PD9B,Q!X15$OMLD]AG[1*;/4"SO3F@*DD[^;N_C-+*[MC+Z_3']W&6-_F=[N,B9RXRPD9,Q!X15^."%6&^,@84F3!T-&E)O$M* AC2AF@75[*8OAX,*64W9 MK1Z0+-
X7I.E9TDY+^C??:KPNYO[X15OR^OQ>%; M%P"T.PG5#*AF0C4+]ME0S4%IU0(HFY2RN$MY2Y]=?^EO9D]WO_T) O:SH1J M&E33H9H!U4RH9D$U&ZHY**U:.66?
5.Z_V20+VCZ%:AI4TZ&: =5,J&9!-1NJ M.2BM6BEE U<6=V&OL@9N*D?4G6;SK-I?%!3&]N$'>??PP[4X4.M4AS9MH9H! MU4RH9D$U&ZHY**V:ZF7O5C[2O)W-W
DC#UD(\LWE"_(U<'; H%[>!"-0VJZ5#-@&HF M+.@F@W5')16K92R,2R+.\,-?DPL%EI7!%+3H)H.U0RH9D(U"ZK94,V1]QOY MHZT)>_6$I{(IK8B,TLU^?
BQ&VN8Z5--.@F@[5#*AF0C4+JME0S5'V>^.'<[WL M9BM'NMG]"?<_=G/T9^OB>'6^0_M9T,U':H94,V$:A94LZ&4VB'?VJ8K8*R M4:T(VWO%M&:5[2=?A32>9A_\]VS.
B[>3Q:SK?,?VJ6&:CI4,Z".="=4LJ&9# M-0>E5E53.];#\KB/-TQ4CK9(=V MFJ&:#M4,J&8]^^?8UB4[M(,,U1R45DWVLH.L'#L'^*?WE)'=Q6NHHD$U':H9
M4,TLM"/GJUG0H#94E58NB[!\K,]8_5J#]8ZBF034=JAE0S81J%E2SH9J#TJJ54O:/ ME5_N'Q?"]MD,@[T?X(G#M$YT:%L8JAE0S81JEM+(@?&T;&M)!:=4K#99M8171
M%E;WVW3[*2R.U#:%H9H.U0RH9D(UJ^:MVD]A:$@'I553N.SVJF_5[56/==^* MQ(:V<:&:#M4,J&9"-:O9FV5#@3H,9W:VK-/LGN=7!4{GJ3KR\-N'MU< M>?QC?
KWMG<>OY7--KGEC'D//0SV\N&)VR.%L@?7X6AOSU3A9@<_WV\?]02P,$% @ M>8%L6>6_ZY)% P Z@L !D !X;"]W;W)K&ULM9=;]HP%
(;_BI554RNUS2<)=!"I'ZHVJ=M0:;>+:1<&#L1J$F>V ^V_WW$2 M4AK2,*'=0)SX??\\QP2?X9J+)QD!*/*NB8XRY?Q)#[[,1X:EB2"&F=(6%+]6< UQK)V0XT]E:M1K:N'V]<;]M@B/
M8:94PC6/?[*YBD9&WR!S6-.\5O=\.1FJ0#W=.@F@W5')16K92R,2R+.\,-?DPL%EI7!%+3H)H.U0RH9D(U"ZK94,V1]QOY MHZT)>_6$I{(IK8B,TLU^?
BQ&VN8Z5--.@F@[5#*AF0C4+JME0S5'V>^.'<[WL M9BM'NMG]"?<_=G/T9^OB>'6^0_M9T,U':H94,V$:A94LZ&4VB'?VJ8K8*R M4:T(VWO%M&:5[2=?A32>9A_\]VS.
B[>3Q:SK?,?VJ6&:CI4,Z".="=4LJ&9# M-0>E5E53.];#\KB/-TQ4CK9(=V MFJ&:#M4,J&8]^^?8UB4[M(,,U1R45DWVLH.L'#L'^*?WE)'=Q6NHHD$U':H9
M4,TLM"/GJUG0H#94E58NB[!\K,]8_5J#]8ZBF034=JAE0S81J%E2SH9J#TJJ54O:/ ME5_N'Q?"]MD,@[T?X(G#M$YT:%L8JAE0S81JEM+(@?&T;&M)!:=4K#99M8171
M%E;WVW3[*2R.U#:%H9H.U0RH9D(UJ^:MVD]A:$@'I553N.SVJF_5[56/==^* MQ(:V<:&:#M4,J&9"-:O9FV5#@3H,9W:VK-/LGN=7!4{GJ3KR\-N'MU< M>?QC?
KWMG<>OY7--KGEC'D//0SV\N&)VR.%L@?7X6AOSU3A9@<_WV\?]02P,$% @ M>8%L6>6_ZY)% P Z@L !D !X;"]W;W)K&ULM99=;]HP%
(;_BI554RNUS2<)=!"I'ZHVJ=M0:;>+:1<&#L1J$F>V ^V_WW$2 M4AK2,*'=0)SX??\\QP2?X9J+)QD!*/*NB8XRY?Q)#[[,1X:EB2"&F=(6%+]6< UQK)V0XT]E:M1K:N'V]<;]M@B/
M8:94PC6/?[*YBD9&WR!S6-.\5O=\.1FJ0#W=.@F@W5')16K92R,2R+.\,-?DPL%EI7!%+3H)H.U0RH9D(U"ZK94,V1]QOY MHZT)>_6$I{(IK8B,TLU^?
BQ&VN8Z5--.@F@[5#*AF0C4+JME0S5'V>^.'<[WL M9BM'NMG]"?<_=G/T9^OB>'6^0_M9T,U':H94,V$:A94LZ&4VB'?VJ8K8*R M4:T(VWO%M&:5[2=?A32>9A_\]VS.
B[>3Q:SK?,?VJ6&:CI4,Z".="=4LJ&9# M-0>E5E53.];#\KB/-TQ4CK9(=V MFJ&:#M4,J&8]^^?8UB4[M(,,U1R45DWVLH.L'#L'^*?WE)'=Q6NHHD$U':H9
M4,TLM"/GJUG0H#94E58NB[!\K,]8_5J#]8ZBF034=JAE0S81J%E2SH9J#TJJ54O:/ ME5_N'Q?"]MD,@[T?X(G#M$YT:%L8JAE0S81JEM+(@?&T;&M)!:=4K#99M8171
M%E;WVW3[*2R.U#:%H9H.U0RH9D(UJ^:MVD]A:$@'I553N.SVJF_5[56/==^* MQ(:V<:&:#M4,J&9"-:O9FV5#@3H,9W:VK-/LGN=7!4{GJ3KR\-N'MU< M>?QC?
KWMG<>OY7--KGEC'D//0SV\N&)VR.%L@?7X6AOSU3A9@<_WV\?]02P,$% @ M>8%L6>6_ZY)% P Z@L !D !X;"]W;W)K&ULM9A=;]HP%
(;-BI554RNUS2<)=!"I'ZHVJ=M0:;>+:1<&#L1J$F>V ^V_WW$2 M4AK2,*'=0)SX??\\QP2?X9J+)QD!*/*NB8XRY?Q)#[[,1X:EB2"&F=(6%+]6< UQK)V0XT]E:M1K:N'V]<;]M@B/
M8:94PC6/?[*YBD9&WR!S6-.\5O=\.1FJ0#W=.@F@W5')16K92R,2R+.\,-?DPL%EI7!%+3H)H.U0RH9D(U"ZK94,V1]QOY MHZT)>_6$I{(IK8B,TLU^?
BQ&VN8Z5--.@F@[5#*AF0C4+JME0S5'V>^.'<[WL M9BM'NMG]"?<_=G/T9^OB>'6^0_M9T,U':H94,V$:A94LZ&4VB'?VJ8K8*R M4:T(VWO%M&:5[2=?A32>9A_\]VS.
B[>3Q:SK?,?VJ6&:CI4,Z".="=4LJ&9# M-0>E5E53.];#\KB/-TQ4CK9(=V MFJ&:#M4,J&8]^^?8UB4[M(,,U1R45DWVLH.L'#L'^*?WE)'=Q6NHHD$U':H9
M4,TLM"/GJUG0H#94E58NB[!\K,]8_5J#]8ZBF034=JAE0S81J%E2SH9J#TJJ54O:/ ME5_N'Q?"]MD,@[T?X(G#M$YT:%L8JAE0S81JEM+(@?&T;&M)!:=4K#99M8171
M%E;WVW3[*2R.U#:%H9H.U0RH9D(UJ^:MVD]A:$@'I553N.SVJF_5[56/==^* MQ(:V<:&:#M4,J&9"-:O9FV5#@3H,9W:VK-/LGN=7!4{GJ3KR\-N'MU< M>?QC?
KWMG<>OY7--KGEC'D//0SV\N&)VR.%L@?7X6AOSU3A9@<_WV\?]02P,$% @ M>8%L6>6_ZY)% P Z@L !D !X;"]W;W)K&ULM9A=;]HP%
(;-BI554RNUS2<)=!"I'ZHVJ=M0:;>+:1<&#L1J$F>V ^V_WW$2 M4AK2,*'=0)SX??\\QP2?X9J+)QD!*/*NB8XRY?

S"3O^-K$+'ZPW-U7:@ MSB4/#.35@;Q]@7IMW*6JM\5MV[;3 .^T/A"\5X/W]H'[;>"]'7#?"QKXO8';X.YT/I [J+F#?=S]-NY@E]MK$)5FN8(Z'A@)<0[5%&>Q$.7-]
MNQ&E<[$##H]C6Z]%J[=\&$A?G8[PY"T_)N[M3V;W9GEXP:&3J7O304%O]@KUW MA[Q$0(;))QH9NQUC#V[@8-K.9;4LW:/BO./+^>]);Q]7BV.\]#;&K2#6&C M^]VDS@Z#
[0=^DW1W5M"W&J3F5B.FN^"O5"Q9*I%B@2KK/,!RB+*Q+ >*9T5O M-N4*.[WB,L)F'(2>@,\7'/NS:J#;O,]#_\"4$L#!!0 ('F!,%GD*NQ$ M@ 0 +$< 9 >&PO=V]R:W-
H965TQX\:ZC1]FL##wXV?Z MQ_+A]<,LB*0WG/V5QBJ9.I<.BNF"+$Q]X=O?:?U 0;!7GU2YYJ(0X"@LL3 7X=X!\%/Z)@*.'"%X;,*@#!]\-&-8!Y:.[MU;.7PH5$D=Es\"T2IK6FF8-
2_3):ZY7F9J+<*Z'OICI.S3YS11$.T'MDCB2: MDQU9,(K>AE21E$GT0)]40=@[] :E.7I(>"%)'LN)JW3OAN$NZYZNJY[\$SW] M4;!SA,=GR/?P&'V]#]';,^_0'<]5PG:Z6SW[5!?
VQHZ]HYMS%'@&ZP^>L1V8 MT(X)Z5)C<(D)+)CH%1B_?$C?[\.XVJ'&)K^QR2^YP4GN0J';"I1&)W0MT^Z M ;I5-)-_=UE1T0;=-)-\KN2&+.G4T=E%4O%(G=FOO^"1]UN7 9"P$!(6
<%: ME@2-)8&-/$O>ETWUOISI=U4([4R7&59.7S,JV*B$Y?E?<3;$$_?Q4.*730;C M=I,(:$@MX0:-< .K<'/!LU1*+G9ESD'?[FBVH*)S'EM)?:6#A(60L @(UK)C MV-@Q!$TM0TA+
(&$A)"P"@K4L&366C(!2BY73UXS1SU/+RR8O4@O0D%K"733" M75B%,_O(#4_U++[C>BM:,"+0 Q%KJM)\?:9GN5Z=G],-^@?UR436COLJ#0D+ M(6$1$*SEWF7CWB5H)KJ$M
02%D+"(B!8RY)Q8\G8^D*5EJ2-)6=HI7M").-% M=SX:O\@/V//:">+&VF-?I2%A$1"LI33V]I68UT]KG<>H[D@A013M++@J(,8' M>GOG7G DN+W?
OHJ#TB(H6EOS@^H7]],\+\P*@/@*955E:I;ALC35Z\7/B]7K MNK_A@2/!Z-@/ZYAZ^P%)BZ!H;3_V92ZVEFRS#V5FT1,^E31&*A&\6"=(4J8;
MKHTK$>1JEVG\GY7[CE.//O;^>VL/6LU"T=K:[^M9,"]H_^?F:<4%FA=BF1!! MO/I$\AB9O^LB9;&Y8MM=V8?6=RT'I86@M B*UC9Y7WOC >@>"X-6X*"T$)06
M0=':QNRK<&RM*'OOM.RXWL: %N*@M*BFM1+[Q4%B;PN^K[&QO%8>)I3$ M5)@&^OZ*Z_6[/C':2E)JOE+-_ 5!+ P04 " !Y@6Q9PBM3GLH" "9"0 M&0 'AL+W=O
M,OXL,@")7B@IQ,C)I"R'KBO2#"@6UZR$0LTL&:=8JI"O7%%RP L#HL0-/"]R M*,M),Y8\\ZN%V,'$\+ @*I MU Q8W38P!D(TD9+QM^9TFE=JX.[XC?V;\:Z\S+& ,2._\7,1D[?
00M8XC61 M#VS['6H_7BQ"F,'-5H O@&G.3S M)S_ROMBLMD2V9SQLC(>GV),[$&*HRHYS;;MD7++:S7%%$QD:_;&)%==/W8W MNT8L.9U!D[.GK]/HZYS49PJQK
KQ$A%6K*XD<'I*:478W5'A1V'_G51;4B^R M:^TV6KLGM4XYH[D03+60D?UT#W0.W%I)YG^MX!:(MLS'36FHU8[)VK3>$MD
M>\9[C?'>ARO39K1GJ;#^X%T96I)Z0==>AOU&6+^=ENX?O/RPI2TYQUIZT.@;_MM-W2@X,?BZ6E;4D'+>WN,)SZT'*/^2HO!"*P5##ONJ>L\NH@4 62E68OG3.I M=F8SS-39";A.4/-
++INS4@=Z>F]-8\@]02P,$% @ >8%L6<1"L+=K @ M @8 !D !X;"]W;W)K&ULA51?;HP$\/JIZR. M6FEM0B"AZT*DMFC:I'5"A6X/TQX,',2]8V?V >VWG^VD$1NA?2%W]OW^7,)=
MME/ZT12(!$^ED&84%$3551B:18$E,Q>J0FEO5DJ7C&RJUZ&I-+*E!Y4BC*,H M#4O&99!G_FRB\TQM2'")$PUF4Y9,/]^@4+M1T M>#N[YN8V!$.99Q=8X17JH M)MIF8E_P@^/.
[,7@.IDK]>B2K\M1$#E#*'!! MCH'9QQ9O40A'9&W\:3B#5M(!]^,7]L^^=]O+G!F\5>(G7U(Q"BX#6.**;03= MJJT7;/]'-]"">-_8=?41@$L-H94V8"M@Y++^LF>FO>P!XCC(X"X
<3>=RWD M78X9L3S3:@?:55LV%_A6/=J:X))E"EI>\LMCO+ODA!Z?3@"%QF8L&8I"_?]+-+HT^OV.ZW MMONOL>?^+9QJ=&/%Y1JHT(A0*DF%,>LR6].EGLX-XC;O];-
PVV%AT%H8O&4A MZ5*J44A)W*R6M4O*64MJEE!PJ)=U*::N4QJ4T[%)*#Y1Z2?JQ6VO8.@U? MU9HI8J)+,'CXJ=++_\7"O9%VV_&.Z367!@2N+"RZ&%JSNMXX=4*J\E,^5V1W
MA@\+NZ11NP}[OU)V<)O$+8YV[>=_ 5!+ P04 " !Y@6Q9B]Q@J)P% O M)@ &0 'AL+W=OA2IA22K=-U-:WOW8KH7)AB(FL3,=F@GW1]_=I*%!%RO,;\;2)SG M^?
C'\\5V'CQYHNR1;P@1Z#E+CW;'PA&>;G=$MR^61%68:%O&7K M/M\R@I>E4Y;'B-407\ZV>(UN2/B8?
N)R;M^0UDF&ND>K*@M)'=7.SO.Q9JD4D);%0""R_=F1&TE219#N^UM!>4Z=R;%]_IX=E MYV5G%IB3&4W_299B<]D;]=\"2K'"1BL_TZ0.I.^0I7DQ37GZBI]K6ZJ&XX()F MM;-
L09;DU3=^K@>BY6"[+S@XM8-SZ."]X#"H'0.OK<&M'=S7UN#5#MYK:_!K M!_^U#I/:85@&JQK=,C1S+/!TPN@38LI:TM1%&=_26T8DR944[P233Q/I)Z8? MJ2#(=M%
[=$O8FC#T=DX$3E*.[LFS*'#Z3CYZN)NCMV_>H3>HC_@&,\)1DJ.' M/!\'3!;*Z_L-+3C.EWS2%[)5BMV/ZQ;,JA8X+[1A@@&YI+C8[ZVH/ M?JWV\-
=JC\SN^'GN'#E.Z>X80C%HU#DH>8,7>-<%ER6JHX+Y)4PM^KOIP!]/^KMV MT{MG*'?M0F.,6S'L;I&H<;(&@^'L5T%(&@^'L)M85@D^1JEE.M6
M@FNC_ZF#7\&\UGB\MT?^P#T8?XW9>.@=#&Z@L7*]L>4\6<(;D2Q"07\F46T17:T7)5D',2D0T0M2W3[O:OJ^ILN[W.=:?7 MF;%%IVH$$A9 PD)(6
0$ZVADW&AD_!,:R0NU!BE]Q#3+Y#Q3OUJ2YWB#\[5> M'>.C!=@>^)[K60<,H9FQ1:=J!!(60,)"2%@$!.MHQ+,VF0CK=2J1W1@3C,+3E5':"T)06@M(B*%I7(:U< ME?
T3\T6LWS;4\D)A]@$VK(DUK[YU'"V-MQ#71CK/UD7D+0 E!:"TB(H6E<7 MSEX7CE$791*3D9@D.[Q(B9PT*%LG.Y(CG-$B%UHU.$=]\!W+.2$P<*3!0%)
M"T!H(2@M@J)U!,%/&]K&'-./LT!F_U/?66I:>U?B'DIHC€$:'!H%&B/[2)6A MSLH^M(J@^MB-P3X19YLS<3_.!D!)P?A.#^F\D"<=#8C4'D=*8J8S042PT M=L[X*+(15&>
[T=BGYFQS;NZ4K!#Z#]UPRO W5$ZLIF21N=:30PA)FX/2 E!: M"$J+H&A=;>T3CK8/GS2R0?.,H+0Y*"T I86@M B*UE7./MMH&U-3/]RXGMLHJW6TM>5Q3ZE:)MSBE=QS
JR;!*&6@% M9L=FH+7BE@M*BF=?[=/(I_OW4)\5.G3:)(Y7FD;_PZBQ 4]J<;KHJ MS_0I;N46)\DY2LE*5F6=#^5*R:K32=6-H-OR M<;R"'D&S\G)#\)(P92"KZBF&2
[&:Q*GM0/?O=^S0C*XI-^"O M_HY[[&=R4[(0Y4A:G@I\E)-G4SKZMQU59)AP51?5%C2S%K(@FGJRHVK*HDL MM4%%[@:>%[D%XZ433^S80L834>N9-@-N M/*G8!I>H[ZN%I)
[,JJ2\P%)Q48+$]=2Y\,]GD5EO%_SBN%,';3"9K(1X,IV, M=.IX!@AS3+118/2WQ4O,ME_5KVWNE,N**;P4^6^>ZFSJ MC!U(<F*$LM:993G(Y_"HW@#^$+
MS%%N4%)CV=0'Q!J^*ITS"7>,1#4O-SVX*9,^/,RQ6*%\A'=QEHE:L3-7$U92+(7*3/?>L MX0X^X+[&51^\00^]+QC _?(*3D_.WLJX9$7K1]#Z$5C=P0>ZLUK1B%)PD3S7
M7'&;Y<,/&H,;C85Z[$)M)(?=DN9:G:N*)3AUZ-XHE%MTXL^?_,C[>@1XT (/ MCJG'"Y2J0GNVR4^J2X6UYHF"1!0%L=,)2IZ *U53%4_]02*A[W0&\$+G $[MGG?6E5"S962W--=Z&X?
#R!]/W&'T'Z, E'1XEO2"&HK*&TM'Z=UH:0F%G%-!Q M@!V3DI6:.AK6C$O8LKS&+M!FQ_-=#0>1-V<8V"BMY5-AI'0?@?E7OPH)BW>4[7F%-Q>^:CA:5?6-60M.+ M99L9?
2)0F@4TOQ9DZKYCGJWVHQ/_!5!+ P04 " !Y@6Q9#B"UF7D" !3 M!0 &0 'AL+W=OXT&"JF+ZUPR%VDZ#8?!LN.7KTCI#F*4U6^,=
MVF_U0I,6]E$*7J$T7$G0N)H&%\/S6>+.^P/?.6[-G@RNDJ52#TZY*:9!Y(!0 M8&Y=!$;++!B]1"!>(;!Z[F$&?TCGNR\,1KWWM5,N2&;Q4X@+D2QG]AVYV- L@;8U75.1-
!Q66[LJ>N#WL.H_@%A[ASB#UW MF\A37C'+LE2K+6AWFJ(YP9?JO0F.2W,7R*JQ M.8!H=)Q%(_@+81@2D(PW?)WP)#:TO6[+$9>=> R_#S:I+:!-,?8IW$AOLN%H,D[&T5D:,@[
)3U<\A]PM>8Y M0DT_GB?RE(42]*N8G=4![R[X$'2;>K('G?Q#&^[-B!MNYO0C)_3N:_0%02P,$% @ M>8%L6&UL MM9E=;]LV%
(,_"N$50PLDL;ZLV)EC((W1+D#3!4V[712[H.5CFR@EJB1E)_]^ MAY)B6Y,"Q@.3BUB2=5Z2CP\/7U'CC9_ U+1 DX>49^1GM](ZO^CW5,*"E*HS
MD4.&WRR$3*G&4[GLJUP"G9=!*>\'GA?W4\]RWF1<7KN3D[$H-&<9W$FBBC2E M\O$]<+&Y[/F]IPM?V'*ES87^9)S3)=R# _I,?23SK;U7F+(5,,9$1"8O+WI5_
M,0U"$U#>\3>#C=H{)F8H,R%^F).;^67/,ST"#HDV$A0_UG -G!LE[,?/6K2W M;=,$[A_J7\H!X^#F5$%UX+_P^9Z==D;]L@<%K3@^HO8_ GU@ 9&+Q%YK[*MIL9_4_7I?]2MXIE\?
8'9&O/"$!%X0=H1?V\/O(3\C MH5>&1QWA4WOX%!(,|[M:[R/@+>5@2SDH|<)G]-X7"J\H1:Z2GP53K,3V_1-> M(S<:4O5O%Z!*,NJ6-/?@0N4T@3G@%
<@V]R>^_^;'W1Q2ZP2BTLQ4SW7DR#RXF#<7^^C^-5=C3%&%V5%&UC&: MZI8+EFER*[! %IQ*\I7B]-0L6YZ0FPRS_LMI#.0G9EC53^6@TNQJ2.Q!M7! MENK_20DW5BF!A)XDY
,2YIAPRW5GHX_84B4>C MYCRZMK9W+!I'8@TTYULTY_;Z)"ER0$N4 $*9<>A"4DD,JI",!@= K*T<"\21 M6 /(< MD: 6"'B*G,$[@ ,VJ@LX4&;9XA*/X (BUE6.!.!)K !EM@8Q^ 01=
MN]2/Y00RP#O@8FWL6"Z.Q!ISWK[5CD[^TBM\K*G M=3(VL7'/RP^]C:.)O(:!MK?.6C?;J&_"DUY300?O+$"]@M#GW&G;Z3(OMV%!*$Y
(P*WA.'VDYY7!:T22!=C7L%IW!U8PBH>'K)S: M:5=J358[0^U;3>,D$YC] ,[HC'&F'SNI#%Y0K)WZ8E=J328[9^S;K?%5G2J8 M/E)P7J:/!$XU7M/TX9GSLLF_W MRU-
8@)35]/E%L6D;YO,@:B6,4\?L2JVYK[BSS('=,E=K^1,5ALF#ZWJ1=J_G M08=SCCSO$)"]R:,W"U_#/ <[\QS8S?-GT(=6YP37\807(6+J=NV95:$]?>1K7=+5?YE#_M]>?
E7G\B,L7F()\MU$';0\?#.#C;QM;V%HWDX-<[]O7=*Y@W@+95+EBG"88'RWMDY M_MBR>JE6G6B1EZ^99D)KD9:'*Z"8-
>8&_'XA<&VK3\R;J^VKS&POVS?)$X'A5IQ>CNG5#G+E(MBZ,Z5RC]X7C&=TY04%UE.A4:2 M3*9$Z:Z<>44N*8D+(*7.CZ MX7O7,7+C+*9#]_[L[8]%IJ[>..9X\N[DI'-_?K4=/RN!
<]>SBE[N(7K1Z>#"_M &+BX7[BN[0QZ=ZF='6Z5JJ9&+*%O(9XVO%,,%NTY3[LG"G/5ZUB'TS(&'8SL M[^5MAS%,N&L7_O/K-U)S:Z15=5Y5WJ-!DHEUE0>N">C,)*7.
^%#=TPXFT@& MK(2DC*],N N:!<8SZ2A]>6DK/D2*1P/[I@=77J63,I'),K?)8'XGU>E;0-T# M@XSSQF#7-8'1("=*42FN=:<\N0P^@9RJ?;?*M<.9)"N_>^FN">5!)YED,J:R M2>.
[=6@TX#0!.Y+-YG!46>X!J%26ZD;,R"P3I/10,ZJ&EIU2SF_AMO0]V=!> M)JTU+>M,-$UMJ&H:&=,!_;::T6[+AB_2=7+VD*E/"ST<4?:A4NB-I E;EOUE MTAC
U'U0Y7WWD;"92:@:_=\+1@-0\9YY)]JBS0:E,=8!*UWF@4K%I._)3 MDOR.+E5=3LL$]]P]0L__=IYG5%!)>-NTKOU#GN47.PYZKV6YO*ML&[9ZK/8:
MAV[R\AA,AH=O,H@.WV.UXSMTD_UC,'D,R]U[M3O[Y FO6I/V=JX M;FQ;FZ@#KP=#]QN\B/!U4F>R8%PQ4?7F+(ZI>+)[U?**3/2K^H:^/C^F"5EP M==> 0W?
=_DICMDBCYJP;F(CJP'7["PQ/,X7K=Q.=BXF8+FD\KKIR-BF;CF[H MK-4'"-O(=?FQ(QC'8'8$,"P/Y@#C&!:6YW\:3Q\=C\$P,WTKTD$KWU]L*LD"*+(C@!F=Q $&)7(XY@#L
#A@1!^1S< M>AYY]7/*6___>O074$L#!!0 ('F!,%F7BKL

-8?20$3; M8T.P6BP^0"X99K>]9!:G8%L66';SFKH! 62H M \ !X,"]W;W)K8F]O:RYX;6S%FDEOVS@4@/*X=/,(6-KS8*Z0"9+:Z!I MC";
(=S:=ZM6&=53_);=,P)FU5!TUL*N>IGJK&&WTAC'3M=-\-JNG'>5B M\O'#KJREFOH[TK"5X5+ 07O@@;,7_7;>[I)GKODC;[EYG4_<=LLFI.."=_PG
M:^:3V83HC7SY+!7_*6A=[=U*R;;=3[+AQ -3AJ_>';ZSD/?T4;LCACY^HP R MG]0S*'#-E3;N"E<^!<9G!A[V1U[PU3%U2PSXIV6^Y++%P%,,O<=P<=C}
M#D$\4_\GC'*]YBMV*5=]QX09XJA8:P&%WO"MGA!!.S:?["XAYZ(A5\) D,A" M#$?!M?9)X:\7S?#4!G"]&*HS#B?4HG'@XT%>2-$PH5E#8$O+EC? T9"_:4O% MBA$/,D<@\P-"_I-[D
4"61P$\L[BP*T>9(E E@>$#")9(9#5(2$+#]&(.M# M0I8>Y#$">7Q(R,]#/$$@3PX)67N0IPCDZ;B02_I*GC59,N5NMV/C)=>K5NI> M,7\HGV%C^6Q ^9FUS9&11S?4]&K(?
J&Q^IB8=;*1M>,P3P#SFG)%'FC;,W+#]!W/ M_UOIF'>RD<7C,$\!TXT_1S!J.E%V4*2&J_T$'5-//K)ZAF%]!IS UG%O1+JP M_=['Q.R3)[&/U<\W>QI"N:0P
PU:98[.=%)X)W/B@;88F/*Y,+/D(YOE+4?\';DP]?$Q,;/D*$4283SSH=[M1LP\'T^18F;C>7%O'#'S%"G,$UL."-LC9IXBA7GV"!+Z$93>^)B8>8H4YMGG
M\4MF*&]]3,P\10KSQ%8O@DHO,?.4*@2,T^9PCQ13'\ENL3,4Z8P M3S0K"J*)F:=,89XH9A!-]#U."O]$D[<@FIA_RA3^B6(&T<0L5*:P4#3'#**) M6:@\Y,I:&$W,0N4A5];":&(6*E-8*
(KI1[/"+%2EL% T8_>C66$6JE)8*(H9 M1!.S4)5D?2VR3AF^ ,_;#]#XF M^CU!DEF0APFMM.\ZJE[MA./:Q\0L5"69"^V94[[+WBO,0E4*"^W!_!U4'Q.S
M4)7"0C',L*=C%J26"B8H<>Z4(U9J$[R?L'##+K0E8^)6:A.\GXG@AE4>HU9 MJ$YBH5@TESXF9J':66BZ^Y2Q86LN6/,5_D+#\15M5TM%,_P.459V3>9Z[YM M+^#8K?
@B:;/[,G+W5>?'7U!+ P04 " !Y@6Q9)V75I0P" "$)0 &0 M 'AL+U]R96QS+W=0IN MW]?%Q_%PJJMF-X[]CY3]>E>.;;WK^G(Z7]ETP[$=S\MAF_IV_=YN2]+E,J?A M=D;S_'0[<_'ZV9?
F=AM-OMU^=FM?Q+:?S'X/2G&]{KKI2Q6;RVP[:,JR9] M'*ZG:[H5-FC1WD$*0SA]D$&3S!SD$^?Q! 4$Q?U"&H#Q_ MT#T$W<\?]
!!#_,'/4+0X_Q!LD09EP1}$ZP)M!;D6@B\%@=1,";06)%L(S!9$ M6PC4%F1;"-P6A%(Y!:D6PCL%L1;"/16U%L)]%;46PGTULG'-H'>BGHK@=Z*
M>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z&>AN!WH9Z&X'>AGH;@=XV MV2PAT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#; M46\GT-M1;R?
0VR>;W01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z M!^H=!'H'ZAT$>@?J'01Z!^H=!'K'Y&@>!WH%Z!X'>@7H'@=Z!>@>! MWAGUS@1Z9]0[$^B=4>],H'=&O?-
WZEW'ST.IUYZO-3[_.ZD>S_>6Z^,ORZ^3 MDU?E@G.ZK:C/?P%02P,$% @ >8%L6>[5[1CF 0]20 !, !;0V]N M=&5N=%]4>7!E&ULS=I=3\(P% ;@OT)V:UCIU_R(<*/>JA?^@;H=9&%;
MF[8@_'N[28:)11,?&]8H.UYSWJ2YXKKIZVC,-JT31>FV2)&=\58*!?4FI!; M1UU:F5O?FIB^^A?F3+DT+\3$9%*PTG:1NCB.?8UL=GU+<[-JXNANDWX.=VF MF:8%L60=!36*! L0 !
M (! &1O8U!R,W!S+V%P<"YX;6Q02P$"% ,4 " !Y@6Q9V-.>/,T M K @ $0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$" M% ,4 " !Y@6Q9F5R<(Q & "<)P $P @'+ 0 >&PO
M=&AE;64O+&AE;64Q+GAM;%! + 0(4 Q0 ('F!,%ES[R3EZ@4 .I> 8 M " @0P(!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L! A0#% @ >8%L6721$GCV P ML T !@ ("!:!8
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >8%L60Q/NO_X#@ >7X !@ M ("!+R4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ >8%L675[N&UL4$L! M A0#% @
>8%L6>A:I*4H P P0D !D ("!H'$ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >8%L M62801G;_% CT@ !D ("!FX< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
>8%L617,P$/;! O@L M !D ("!"*T 'AL+W=O&PO=V]R:W-H965TV !X;"]W;W)K&UL4$L! A0#% @ >8%L6:24+YHE!0 30P !D M ("!A[L 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#
M% @ >8%L62[5]Z# !P CA@ !D ("!I< @ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ >8%L69+V MC=" > P &P@ !D ("!$MT 'AL+W=OMC-LH" =!@ &0 M @('GX
>&PO=V]R:W-H965TCC !X;"]W;W)K&UL4$L! A0#% @ >8%L6;LE77=_ P =0< !D M ("!1.D 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ >8%L6=*Y@*3L @ =08 !D ("! M&O,
'AL+W=OPAC@8# ;!P &0 @($]]@ >&PO=V]R:W-H965T&UL4$L! A0#% M @ >8%L63:*GW$K P A@< !D ("!NOP 'AL+W=O&UL4$L! A0#% @ >8%L69(39]H_ M P ! P !D ("!C@T!
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >8%L6>?C73(]!@ I34 !D M ("!E2&PO=V]R M:W-H965T&UL4$L! A0#% @ >8%L6:,=4DJU! 5A8 !D ("!R3L! M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M>8%L6:B3LN:N @ ,P8 !D ("!.D8! 'AL+W=O.>\I0(.4% 9 " @;1+ 0!X;"]W M;W)K&UL4$L! A0#% @ >8%L67;&.S[4 @ MJ0L !D
("!D$X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >8%L6?UH5]/H @ 6@D !D M ("!DE@! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ >8%L6>6_ZY)% P Z@L !D
("!R6&PO=V]R:W-H965TR@( )D) 9 " M@?QO 0!X;"]W;W)K&UL4$L! A0#% @ >8%L M6<1"L!+=K @ @8 !D ("!_7(' 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
>8%L60X@M9EY @ 4P4 M !D ("!EGX! 'AL+W=O&PO=V]R:W-H965TT8Y@$ /4D 3 " M 962 0!;0V]N=&5N=%]4>7!E&UL4$L%!@ !' $< :!, *R4 0 ! $! end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0;
} /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 194 302 1 true 63 0 false 8 false false R1.htm 100000 - Document
- Document And Entity Information Sheet http://www.perspectivetheoryanalysis.com/20240930/taxonomy/role/statement-document-and-entity-information Document And Entity

Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100040 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited- Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100070 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Parenthetical) Statements 5 false false R6.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited- Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Statements 7 false false R8.htm 100100 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited- Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 8 false false R9.htm 100110 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Statements 9 false false R10.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 10 false false R11.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 11 false false R12.htm 995457 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Notes 12 false false R13.htm 995467 - Disclosure - Note 2 - Loss Per Share Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShare Note 2 - Loss Per Share Notes 13 false false R14.htm 995477 - Disclosure - Note 3 - Investments and Agreements Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreements Note 3 - Investments and Agreements Notes 14 false false R15.htm 995487 - Disclosure - Note 4 - Discontinued Operations Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperations Note 4 - Discontinued Operations Notes 15 false false R16.htm 995497 - Disclosure - Note 5 - Property and Equipment Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipment Note 5 - Property and Equipment Notes 16 false false R17.htm 995507 - Disclosure - Note 6 - Goodwill and Other Intangible Assets Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets Note 6 - Goodwill and Other Intangible Assets Notes 17 false false R18.htm 995517 - Disclosure - Note 7 - Held-to-Maturity Investments Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestments Note 7 - Held-to-Maturity Investments Notes 18 false false R19.htm 995527 - Disclosure - Note 8 - Fair Value Measurements Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurements Note 8 - Fair Value Measurements Notes 19 false false R20.htm 995537 - Disclosure - Note 9 - Share-Based Compensation Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensation Note 9 - Share-Based Compensation Notes 20 false false R21.htm 995547 - Disclosure - Note 10 - Commitments and Contingencies Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingencies Note 10 - Commitments and Contingencies Notes 21 false false R22.htm 995557 - Disclosure - Note 11 - Related Parties Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedParties Note 11 - Related Parties Notes 22 false false R23.htm 995567 - Disclosure - Note 12 - Leases Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12Leases Note 12 - Leases Notes 23 false false R24.htm 995577 - Disclosure - Note 13 - Notes Payable Notes http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayable Note 13 - Notes Payable Notes 24 false false R25.htm 995587 - Disclosure - Note 14 - Merger Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger Note 14 - Merger Notes 25 false false R26.htm 995597 - Disclosure - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies 26 false false R27.htm 995607 - Disclosure - Note 2 - Loss Per Share (Tables) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareTables Note 2 - Loss Per Share (Tables) Tables http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShare 27 false false R28.htm 995617 - Disclosure - Note 4 - Discontinued Operations (Tables) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables Note 4 - Discontinued Operations (Tables) Tables http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperations 28 false false R29.htm 995627 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables Note 5 - Property and Equipment (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipment 29 false false R30.htm 995637 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables Note 6 - Goodwill and Other Intangible Assets (Tables) Tables http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets 30 false false R31.htm 995647 - Disclosure - Note 7 - Held-to-Maturity Investments (Tables) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables Note 7 - Held-to-Maturity Investments (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestments 31 false false R32.htm 995657 - Disclosure - Note 8 - Fair Value Measurements (Tables) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsTables Note 8 - Fair Value Measurements (Tables) Tables http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurements 32 false false R33.htm 995667 - Disclosure - Note 9 - Share-Based Compensation (Tables) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables Note 9 - Share-Based Compensation (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensation 33 false false R34.htm 995677 - Disclosure - Note 12 - Leases (Tables) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables Note 12 - Leases (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12Leases 34 false false R35.htm 995687 - Disclosure - Note 13 - Notes Payable (Tables) Notes
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableTables Note 13 - Notes Payable (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayable 35 false false R36.htm 995697 - Disclosure - Note 14 - Merger (Tables) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables Note 14 - Merger (Tables) Tables
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger 36 false false R37.htm 995707 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Details 37 false false R38.htm 995717 - Disclosure - Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSha
Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details) Details 38 false false R39.htm 995727 - Disclosure - Note 2 - Loss Per Share (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual Note 2 - Loss Per Share (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareTables 39 false false R40.htm 995737 - Disclosure - Note 3 - Investments and Agreements (Details Textual) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual Note 3 - Investments and Agreements (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreements 40 false false R41.htm 995747 - Disclosure - Note 4 - Discontinued Operations (Details Textual) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual Note 4 - Discontinued Operations (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables 41 false false R42.htm 995757 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details) Details 42 false false R43.htm 995767 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual Note 5 - Property and Equipment (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables 43 false false R44.htm 995777 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Details 44 false false R45.htm 995787 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextual Note 6 - Goodwill and Other Intangible Assets (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables 45 false false R46.htm 995797 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details) Details 46 false false R47.htm 995807 - Disclosure - Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstrumentsI
Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details) Details 47 false false R48.htm 995817 - Disclosure - Note 7 - Held-to-Maturity Investments (Details Textual) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual Note 7 - Held-to-Maturity Investments (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables 48 false false R49.htm 995827 - Disclosure - Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details) Details 49 false false R50.htm 995837 - Disclosure - Note 8 - Fair Value Measurements (Details Textual) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual Note 8 - Fair Value Measurements (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsTables 50 false false R51.htm 995847 - Disclosure - Note 9 - Share-Based Compensation (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual Note 9 - Share-Based Compensation (Details Textual) Details
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables 51 false false R52.htm 995857 - Disclosure - Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense (Details) Sheet
http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForShareb

Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense (Details) Details 52 false false R53.htm 995867 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual Note 10 - Commitments and Contingencies (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingencies 53 false false R54.htm 995877 - Disclosure - Note 11 - Related Parties (Detailed Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual Note 11 - Related Parties (Detailed Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedParties 54 false false R55.htm 995887 - Disclosure - Note 12 - Leases (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual Note 12 - Leases (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables 55 false false R56.htm 995897 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details) Details 56 false false R57.htm 995907 - Disclosure - Note 13 - Notes Payable (Details Textual) Notes http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual Note 13 - Notes Payable (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableTables 57 false false R58.htm 995917 - Disclosure - Note 13 - Notes Payable - Summary of Note Payable (Details) Notes http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails Note 13 - Notes Payable - Summary of Note Payable (Details) Details 58 false false R59.htm 995927 - Disclosure - Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) Notes http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details) Details 59 false false R60.htm 995937 - Disclosure - Note 14 - Merger (Details Textual) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual Note 14 - Merger (Details Textual) Details http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables 60 false false R61.htm 995947 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) Details 61 false false R62.htm 995957 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals) Details 62 false false R63.htm 995967 - Disclosure - Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) Sheet http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details) Details 63 false false All Reports Book All Reports catx-20240930.htm catx-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "catx-20240930.htm": { "nsprefix": "catx", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "dts": { "inline": { "local": ["catx-20240930.htm"] }, "schema": { "local": ["catx-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 251, "keyCustom": 51, "axisStandard": 29, "axisCustom": 0, "memberStandard": 25, "memberCustom": 36, "hidden": { "total": 11, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 194, "entityCount": 1, "segmentCount": 63, "elementCount": 650, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 675, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R3": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "longName": "100060 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "us-gaap:RevenueNotFromContractWithCustomer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R5": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "100070 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_40e935e0-1b15-4ec9-8352-a86b37b2ce7e", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "link:footnote", "p", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R7": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals", "longName": "100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_e0061dee-5f67-4e39-88ef-33371679b2cf", "name": "us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e0061dee-5f67-4e39-88ef-33371679b2cf", "name": "us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-", "longName": "100100 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_ff7af04d-cab6-405e-a335-bf805b1c79c2", "name": "us-gaap:SharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3a03805-a934-4de4-b99e-68d1c58cf6fd", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R9": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals", "longName": "100110 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "C_40e935e0-1b15-4ec9-8352-a86b37b2ce7e", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "link:footnote", "p", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies", "longName": "995457 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-

gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShare", "longName": "995467 - Disclosure - Note 2 - Loss Per Share", "shortName": "Note 2 - Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreements", "longName": "995477 - Disclosure - Note 3 - Investments and Agreements", "shortName": "Note 3 - Investments and Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "catx:InvestmentsAndAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "catx:InvestmentsAndAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperations", "longName": "995487 - Disclosure - Note 4 - Discontinued Operations", "shortName": "Note 4 - Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipment", "longName": "995497 - Disclosure - Note 5 - Property and Equipment", "shortName": "Note 5 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets", "longName": "995507 - Disclosure - Note 6 - Goodwill and Other Intangible Assets", "shortName": "Note 6 - Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestments", "longName": "995517 - Disclosure - Note 7 - Held-to-Maturity Investments", "shortName": "Note 7 - Held-to-Maturity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurements", "longName": "995527 - Disclosure - Note 8 - Fair Value Measurements", "shortName": "Note 8 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensation", "longName": "995537 - Disclosure - Note 9 - Share-Based Compensation", "shortName": "Note 9 - Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingencies", "longName": "995547 - Disclosure - Note 10 - Commitments and Contingencies", "shortName": "Note 10 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedParties", "longName": "995557 - Disclosure - Note 11 - Related Parties", "shortName": "Note 11 - Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12Leases", "longName": "995567 - Disclosure - Note 12 - Leases", "shortName": "Note 12 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayable", "longName": "995577 - Disclosure - Note 13 - Notes Payable", "shortName": "Note 13 - Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger", "longName": "995587 - Disclosure - Note 14 - Merger", "shortName": "Note 14 - Merger", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995597 - Disclosure - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareTables", "longName": "995607 - Disclosure - Note 2 - Loss Per Share (Tables)", "shortName": "Note 2 - Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables", "longName": "995617 - Disclosure - Note 4 - Discontinued Operations (Tables)", "shortName": "Note 4 - Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables", "longName": "995627 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null,

"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables", "longName": "995637 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables", "longName": "995647 - Disclosure - Note 7 - Held-to-Maturity Investments (Tables)", "shortName": "Note 7 - Held-to-Maturity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsTables", "longName": "995657 - Disclosure - Note 8 - Fair Value Measurements (Tables)", "shortName": "Note 8 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables", "longName": "995667 - Disclosure - Note 9 - Share-Based Compensation (Tables)", "shortName": "Note 9 - Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables", "longName": "995677 - Disclosure - Note 12 - Leases (Tables)", "shortName": "Note 12 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableTables", "longName": "995687 - Disclosure - Note 13 - Notes Payable (Tables)", "shortName": "Note 13 - Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables", "longName": "995697 - Disclosure - Note 14 - Merger (Tables)", "shortName": "Note 14 - Merger (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "longName": "995707 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_532745f4-5399-4a24-809b-7519505784d3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8c106a12-28a2-40a6-8baa-15457f90789d", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R38": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh "longName": "995717 - Disclosure - Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)", "shortName": "Note 2 - Loss Per Share - Schedule of Securities Not Considered in Calculation of Diluted Weighted Average Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "longName": "995727 - Disclosure - Note 2 - Loss Per Share (Details Textual)", "shortName": "Note 2 - Loss Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_f6c321fb-defa-4ddb-b9ce-7547f7a6926f", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f6c321fb-defa-4ddb-b9ce-7547f7a6926f", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "longName": "995737 - Disclosure - Note 3 - Investments and Agreements (Details Textual)", "shortName": "Note 3 - Investments and Agreements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_532745f4-5399-4a24-809b-7519505784d3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3846d597-2f1b-4db2-aafb-87d3c42706c5", "name": "catx:MaximumAmountOfSecuritiesOfferAndSell", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R41": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "longName": "995747 - Disclosure - Note 4 - Discontinued Operations (Details Textual)", "shortName": "Note 4 - Discontinued Operations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731e", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R42": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "longName": "995757 - Disclosure - Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "shortName": "Note 4 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb119013-eec0-44c3-873f-136ce323c149", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R43": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "longName": "995767 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6e84f13a-9997-41c9-9362-6f5580000d0c", "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration", "unitRef": "U_EUR", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R44": { "role":

"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "longName": "995777 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextual", "longName": "995787 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails", "longName": "995797 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)", "shortName": "Note 6 - Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "catx:IndefinitelivedIntangibleAssetsAccumulatedAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R47": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments "longName": "995807 - Disclosure - Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)", "shortName": "Note 7 - Held-to-Maturity Investments - Summary of Carrying Values and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_a74807af-0371-4d2e-b88c-4b217abc3bc0", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a74807af-0371-4d2e-b88c-4b217abc3bc0", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual", "longName": "995817 - Disclosure - Note 7 - Held-to-Maturity Investments (Details Textual)", "shortName": "Note 7 - Held-to-Maturity Investments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_ad48417d-59c8-44bd-950a-d8c9c8b65070", "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ad48417d-59c8-44bd-950a-d8c9c8b65070", "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu "longName": "995827 - Disclosure - Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Note 8 - Fair Value Measurements - Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_8860cc95-f9d6-486f-aed1-89ef82159eaa", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8860cc95-f9d6-486f-aed1-89ef82159eaa", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual", "longName": "995837 - Disclosure - Note 8 - Fair Value Measurements (Details Textual)", "shortName": "Note 8 - Fair Value Measurements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_a39cde7e-b9aa-4bcb-a496-9d355da84c59", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a39cde7e-b9aa-4bcb-a496-9d355da84c59", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual", "longName": "995847 - Disclosure - Note 9 - Share-Based Compensation (Details Textual)", "shortName": "Note 9 - Share-Based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_38547cc8-8d99-4152-97ab-ae7b5c3ee3a2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_38547cc8-8d99-4152-97ab-ae7b5c3ee3a2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel "longName": "995857 - Disclosure - Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense (Details)", "shortName": "Note 9 - Share-Based Compensation - Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731c", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731c", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual", "longName": "995867 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "U_Plaintiff", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f32d4c68-8da9-47c9-aa27-96548499a595", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "U_Plaintiff", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual", "longName": "995877 - Disclosure - Note 11 - Related Parties (Detailed Textual)", "shortName": "Note 11 - Related Parties (Detailed Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_6dd02eb1-5f96-42a3-ab9e-2994b487f1aa", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fa8c760c-8cfe-4643-ac21-f9cbc03c37ba", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R55": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "longName": "995887 - Disclosure - Note 12 - Leases (Details Textual)", "shortName": "Note 12 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5b22851e-3e90-47cf-a2fc-c86788654324", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R56": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails", "longName": "995897 - Disclosure - Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details)", "shortName": "Note 12 - Leases - Summary of Future Operating Lease Payments and Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "longName": "995907 - Disclosure - Note 13 - Notes Payable (Details Textual)", "shortName": "Note 13 - Notes Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:NotesPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": {

```
"contextRef": "C_42168cba-49d3-4f3b-9485-1288e209a533", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R58": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails", "longName": "995917 - Disclosure - Note 13 - Notes Payable - Summary of Note Payable (Details)", "shortName": "Note 13 - Notes Payable - Summary of Note Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:NotesPayableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2bc0d3f0-bb52-4f3e-8335-4f26707b3dcb", "name": "us-gaap:NotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R59": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails", "longName": "995927 - Disclosure - Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details)", "shortName": "Note 13 - Notes Payable - Summary of Maturity of Note Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual", "longName": "995937 - Disclosure - Note 14 - Merger (Details Textual)", "shortName": "Note 14 - Merger (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_5384934a-0e22-45a8-a5cd-c32d5d12731c", "name": "us-gaap:RevenueNotFromContractWithCustomer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f6c321fb-defa-4ddb-b9ce-7547f7a6926f", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R61": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "longName": "995947 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details)", "shortName": "Note 14 - Merger - Summary of Estimated Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_880b4de0-422f-417b-88b4-f0021b286bca", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880b4de0-422f-417b-88b4-f0021b286bca", "name": "catx:BusinessCombinationOptionsAndWarrantsAssumption", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } }, "R62": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "longName": "995957 - Disclosure - Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals)", "shortName": "Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_880b4de0-422f-417b-88b4-f0021b286bca", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "longName": "995967 - Disclosure - Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)", "shortName": "Note 14 - Merger - Summary of Preliminary Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_1ffadbf4-db2b-4096-afeb-cad9ff1f3a96", "name": "us-gaap:Goodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f6c321fb-defa-4ddb-b9ce-7547f7a6926f", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "catx-20240930.htm", "unique": true } } }, "tag": { "catx_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ATMAgreementMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "A T M agreement.", "label": "A T M Agreement [Member]", "terseLabel": "A T M Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "verboseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r72", "r73" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for doubtful accounts: 2024 - $592; 2023 - $650", "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r924" ] }, "catx_AccruedInterestOnShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "AccruedInterestOnShortTermInvestments", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest on short-term investments.", "label": "catx_AccruedInterestOnShortTermInvestments", "negatedLabel": "Accrued interest on short-term investments" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r31", "r163", "r583" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r827" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r82" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r610", "r912", "r913", "r914", "r916", "r1014", "r1081" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r840" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r840" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r840" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r840" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization", "totalLabel": "Amortization, Total", "label": "Amortization of other assets", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r8" ] }, "catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the assumption of stock options and warrants at fair value.", "label": "catx_AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue", "terseLabel": "Assumption of Viewpoint stock options and warrants at fair value" } } }, "auth_ref": [] }, "catx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfPreFundedWarrants", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Pre-funded Warrants, net", "label": "Adjustments To Additional Paid In Capital, Issuance of Pre-funded Warrants", "documentation": "Adjustments to additional paid in capital, issuance of pre-funded warrants." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r36", "r37", "r377" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:", "terseLabel": "Foreign currency adjustments" } } }, "auth_ref": [] },
"catx_AggregateMaximumEstimateSettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"AggregateMaximumEstimateSettlementAmount", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Aggregate maximum estimate settlement amount", "documentation": "Aggregate maximum estimate settlement amount." } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate
Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present
Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r873" ] }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r799", "r809",
"r819", "r851" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous
Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r802", "r812", "r822", "r854" ] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension
Adjustments Service Cost" } } }, "auth_ref": [ "r874" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]",
"terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r840" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r847" ] }, "ecd_AllIndividualsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r803", "r813", "r823", "r847", "r855", "r859", "r867" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All
Trading Arrangements" } } }, "auth_ref": [ "r865" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel
], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based compensation", "documentation": "Amount of
expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r406", "r411" ] }, "us-
gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": {
"terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss,
Ending Balance", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "documentation": "Amount of allowance for credit loss on
accounts receivable." } } }, "auth_ref": [ "r170", "r227", "r270", "r273", "r276", "r1046" ] }, "catx_AmendedTwoThousandTwentyIncentivePlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "AmendedTwoThousandTwentyIncentivePlanMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Amended two thousand twenty incentive plan.", "label": "Amended Two Thousand Twenty Incentive Plan [Member]", "terseLabel": "Amended 2020 Incentive Plan [Member]" }
} }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "terseLabel": "Total potential dilutive securities", "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included
in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } },
"auth_ref": [ "r210" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r28" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not
included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [
"r28" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative
applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r433" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "verboseLabel":
"Purchase price", "terseLabel": "Asset purchase price in cash", "label": "Asset Acquisition, Consideration Transferred", "totalLabel": "Asset Acquisition, Consideration
Transferred, Total", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity
interest issued by acquirer." } } }, "auth_ref": [ "r753", "r1011", "r1012", "r1013" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Consideration for equipment and services pursuant to the MESA and SOWs", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
"documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1011", "r1012", "r1013" ] },
"us-gaap_AssetRetirementObligationAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetRetirementObligationAccretionExpense", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Accretion of discount", "terseLabel": "Accretion of asset retirement obligation",
"documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and
incorporates changes due to the passage of time into the carrying amount of the liability." } } }, "auth_ref": [ "r304", "r305" ] }, "us-
gaap_AssetRetirementObligationRevisionOfEstimate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetRetirementObligationRevisionOfEstimate", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-
operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Asset Retirement Obligation, Revision of Estimate", "terseLabel": "Change in estimate of asset retirement
obligation (Note 4)", "negatedLabel": "Change in estimate of asset retirement obligation", "negatedTerseLabel": "Change in estimate of asset retirement obligation (Note 4)",
"documentation": "Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the
settlement of the obligation." } } }, "auth_ref": [ "r306" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets",
"crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [
"r122", "r135", "r166", "r182", "r214", "r218", "r221", "r222", "r267", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r434", "r437", "r467", "r574",
"r648", "r725", "r726", "r768", "r790", "r976", "r977", "r1031" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang":
{ "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "us-
gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } },
"auth_ref": [ "r159", "r171", "r182", "r267", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r434", "r437", "r467", "r768", "r976", "r977", "r1031" ] },
"us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current
assets:", "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsNoncurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent
assets:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current
assets held for sale, discontinued operations", "totalLabel": "Total current assets held for sale of discontinued operations", "label": "Disposal Group, Including Discontinued
Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one
year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r51", "r67", "r105", "r107", "r157", "r158" ] }, "us-
```

gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale of discontinued operations, current", "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]" } } }, "auth_ref": [] } }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r862"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r863"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r858"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r858"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r858"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r858"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r858"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r858"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r861"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r860"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r859"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r859"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r303", "r1050", "r1051"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r43", "r44", "r303", "r1050", "r1051"] }, "catx_BofASecuritiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BofASecuritiesIncMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "BofA Securities, Inc.", "label": "Bof A Securities, Inc [Member]", "terseLabel": "BofA Securities, Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r106"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r289", "r290", "r291", "r292", "r293", "r429", "r747", "r748"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r38", "r40", "r289", "r290", "r291", "r292", "r293", "r429", "r747", "r748"] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, number of common shares exchanged", "verboseLabel": "Common stock issued pursuant to merger, Shares", "label": "Business acquisition, shares (in shares)", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r119"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r429"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, percentage of voting interests acquired", "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r39"] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Pro Forma Computation of Earnings Per Share", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r881", "r882"] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, closing market price", "label": "Business acquisition, price per share (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "terseLabel": "Net loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r427", "r428"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfProFormaComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Grant revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r427", "r428"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "totalLabel": "Total fair value of consideration transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r0", "r1", "r12"] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails",

"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Business combination, fair value of common stock", "label": "Perspective Therapeutics common stock issued (13,654,507 x $4.00)", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": ["r0", "r1"] }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Total purchase price consideration", "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": ["r12", "r14"] }, "catx_BusinessCombinationConsiderationTransferredLiabilitiesForgiven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesForgiven", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination.", "label": "Note receivable and interest from Viewpoint forgiven" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger"], "lang": { "en-us": { "role": { "terseLabel": "Merger", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r117", "r430"] }, "catx_BusinessCombinationOptionsAndWarrantsAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationOptionsAndWarrantsAssumption", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of fair value of options and warrants assumed in business acquisition.", "label": "catx_BusinessCombinationOptionsAndWarrantsAssumption", "verboseLabel": "Assumption of Viewpoint stock options and warrants at fair value" } } }, "auth_ref": [] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued payroll and related taxes, assumed at the acquisition date.", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayrollAndRelatedTax", "terseLabel": "Accrued payroll and related taxes" } } }, "auth_ref": [] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation", "crdr": "credit", "presentation":[
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued vacation, assumed at the acquisition date.", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedVacation", "terseLabel": "Accrued vacation" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "totalLabel": "Total assets acquired", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "terseLabel": "Lease liability", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "terseLabel": "Grants receivable", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued expenses, assumed at the acquisition date.", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "terseLabel": "Accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, in-process research and development", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "totalLabel": "Total liabilities assumed", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired, excluding goodwill", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "terseLabel": "Other assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r41", "r42"] }, "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets", "crdr": "debit", "presentation": [

"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset", "documentation": "amount of right of use assets acquired at acquisition date.", "label": "catx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Net cash acquired in acquisition of Viewpoint", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": ["r20"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r23", "r161", "r717"] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Member]", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "totalLabel": "Total cash equivalents and short-term investments", "terseLabel": "Cash, cash equivalents and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r901"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Total cash, cash equivalents and restricted cash shown on the condensed consolidated statements of cash flows", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD", "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r98", "r180"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r98"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "totalLabel": "Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r896", "r1044"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Supplemental schedule of noncash investing and financing activities:" } } }, "auth_ref": [] }, "catx_Cesium131BusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "Cesium131BusinessMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cesium-131 Business [Member]", "label": "Cesium-131 Business [Member]", "documentation": "Relating to Cesium-131 Business." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r838"] }, "catx_ChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ChicagoIllinoisMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Chicago Illinois.", "label": "Chicago Illinois [Member]" } } }, "auth_ref": [] }, "catx_ChinoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ChinoCaliforniaMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Chino California [Member]", "label": "Chino California [Member]", "documentation": "Chino california." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r835"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r833"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r150", "r167", "r168", "r169", "r182", "r204", "r205", "r207", "r209", "r216", "r217", "r267", "r318", "r320", "r321", "r322", "r325", "r326", "r356", "r357", "r359", "r360", "r362", "r467", "r602", "r603", "r604", "r605", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r635", "r657", "r680", "r695", "r696", "r697", "r698", "r699", "r877", "r907", "r917"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r34"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price per share", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r363"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase shares of common stock", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r363"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected

Measure Amount" } } }, "auth_ref": ["r839"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r839"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r433"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 10)", "label": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r78", "r125", "r577", "r634"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r109", "r308", "r309", "r701", "r966", "r972"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r780", "r781", "r782", "r784", "r785", "r786", "r787", "r912", "r913", "r916", "r1014", "r1080", "r1081"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r81"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r81", "r635"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r81"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common stock, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r81", "r635", "r654", "r1081", "r1082"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 750,000,000 shares authorized; 67,562,781 and 28,180,985 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively1", "label": "Common stock, $.001 par value; 750,000,000 shares authorized; 280,571,026 and 142,112,766 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r81", "r579", "r768"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r844"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r843"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r845"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r842"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r185", "r434", "r435", "r437", "r438", "r501", "r706", "r975", "r978", "r979"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r185", "r434", "r435", "r437", "r438", "r501", "r706", "r975", "r978", "r979"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r183", "r184", "r331", "r358", "r499", "r519", "r572", "r718", "r720"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayable"], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r110", "r181", "r298", "r299", "r300", "r301", "r302", "r316", "r317", "r327", "r333", "r334", "r335", "r336", "r337", "r338", "r343", "r350", "r351", "r353", "r479"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r17", "r72", "r73", "r123", "r124", "r185", "r328", "r329", "r330", "r331", "r332", "r334", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r737", "r738", "r739", "r740", "r741", "r765", "r908", "r967", "r968", "r969", "r1024", "r1025"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "us-gaap_DebtInstrumentFaceAmount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r328", "r479", "r480", "r738", "r739", "r765"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r75", "r329"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r185", "r328", "r329", "r330", "r331", "r332", "r334", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r737", "r738", "r739", "r740", "r741", "r765", "r908", "r1024", "r1025"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [

"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r17", "r185", "r328", "r329", "r330", "r331", "r332", "r334", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r737", "r738", "r739", "r740", "r741", "r765", "r908", "r967", "r968", "r969", "r1024", "r1025"] },
"catx_DebtInstrumentNumberOfPaymentInstallment": { "xbrltype": "integerItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DebtInstrumentNumberOfPaymentInstallment", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of monthly payments", "documentation": "Represents number of installment to pay debt.", "label": "catx_DebtInstrumentNumberOfPaymentInstallment" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, periodic payment", "label": "us-gaap_DebtInstrumentPeriodicPayment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r17", "r48"] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument balloon payment", "label": "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r17", "r32", "r33", "r47", "r111", "r112", "r185", "r328", "r329", "r330", "r331", "r332", "r334", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r737", "r738", "r739", "r740", "r741", "r765", "r908", "r1024", "r1025"] }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity, allowance for credit loss", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Total", "documentation": "Amount of allowance for credit loss for debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r250", "r270", "r273", "r276"] }, "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity investments", "label": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r233", "r251", "r253", "r568"] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income (Note 3)", "label": "Deferred Income, Current", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r880"] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income, net of current portion (Note 3)", "label": "Deferred Income, Noncurrent", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r880"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "negatedLabel": "Deferred income tax benefit", "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "verboseLabel": "Deferred income tax benefit", "label": "Deferred tax benefit", "terseLabel": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r8", "r149", "r910"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r414", "r415", "r575"] }, "us-gaap_DeferredRentCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRentCredit", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Base prepaid rent", "label": "Deferred Rent Credit", "documentation": "Amount of excess of rental payment required by lease over rental income recognized." } } }, "auth_ref": ["r144", "r1029"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation", "totalLabel": "Depreciation, Total", "label": "Depreciation expense", "terseLabel": "Depreciation, Total", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r8", "r30"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r375", "r379", "r407", "r408", "r410", "r750"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Net loss from discontinued operations", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r55", "r56", "r57", "r58", "r59", "r65", "r90", "r1047"] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations, Basic", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations, Diluted", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, Provision (benefit) for income taxes", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": ["r56", "r57", "r58", "r59", "r65", "r69", "r416", "r420", "r421"] },
"us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] },
"us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale [Member]", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r5"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r157"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] },
"catx_DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligationCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligation", "label": "Disposal Group Including Discontinued Operation Asset Retirement Obligation Current", "documentation": "Amount classified as asset retirement obligation attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":

"Estimated fair value", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66", "r158"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "terseLabel": "Gross profit", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66", "r158"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r51", "r67", "r105", "r107"] }, "catx_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Disposal Group Including Discontinued Operation Lease Liabilities Current", "documentation": "Amount classified as lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "catx_DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationLossOnClassificationCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss recognized on classification as held for sale", "label": "Disposal Group Including Discontinued Operation Loss On Classification Current", "documentation": "Amount classified as loss of classification attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net loss from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Total loss from discontinued operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other assets, net", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r51", "r67", "r105", "r107"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r51", "r67", "r105", "r107"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r51", "r67", "r105", "r107"] }, "catx_DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyRightOfUseAssetCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset, net", "label": "Disposal Group Including Discontinued Operation Property Right Of Use Asset Current", "documentation": "Amount classified as right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "catx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Disposal Group Including Discontinued Operation Research and Development Expense", "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales, net", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r66", "r158"] }, "catx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Disposal Group Including Discontinued Operation Sales and Marketing Expense", "documentation": "Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperations"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r50", "r104"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r747", "r748"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r794"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r826"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r837"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-

gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": {
"terseLabel": "Basic loss per share", "label": "Basic and diluted loss per share (in dollars per share)", "totalLabel": "Basic loss per share", "documentation": "The amount of net
income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r177", "r191", "r192", "r193", "r194",
"r195", "r196", "r202", "r204", "r207", "r208", "r209", "r213", "r425", "r432", "r447", "r448", "r569", "r590", "r721"] }, "us-gaap_EarningsPerShareBasicLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "label": "Earnings Per Share,
Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r204", "r205", "r207"] }, "us-
gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": {
"terseLabel": "Diluted loss per share", "label": "Earnings Per Share, Diluted", "totalLabel": "Diluted loss per share", "documentation": "The amount of net income (loss) for the
period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding
assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r177",
"r191", "r192", "r193", "r194", "r195", "r196", "r204", "r207", "r208", "r209", "r213", "r425", "r432", "r447", "r448", "r569", "r590", "r721"] }, "us-
gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label":
"Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r201", "r210", "r211", "r212"] }, "us-
gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-
and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "us-
gaap_EffectiveIncomeTaxRateContinuingOperations", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit)
pertaining to continuing operations." } } }, "auth_ref": ["r417", "r752"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Employee-
related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued personnel expenses", "documentation": "Total of the carrying values
as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and
bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } },
"auth_ref": ["r73"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfShareBasedCompensationExpenseRecognizedForShareI
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": {
"terseLabel": "Unrecognized compensation expense", "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "documentation": "Amount of cost not yet recognized for
nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r409"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Unrecognized compensation expense, weighted-average expected recognition period", "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "documentation": "Weighted-average
period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r409"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"verboseLabel": "Common Stock Options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to
purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address,
Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or
Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-
document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } },
"auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressStateOrProvince", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": {
"en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index
Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [
"r792"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"],
"lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of
registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define
each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument
[Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCurrentReportingStatus", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-
information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to
file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent
filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables"], "lang": { "en-us": { "role": { "label":
"Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some
examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical
segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging
Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r792"] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional
suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-
and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large
Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on
the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r792"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation,
State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data
Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r876"] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant
Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r792"]
}, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r792"] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small
Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r792"] }, "dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax
Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned
by the IRS." } } }, "auth_ref": ["r792"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text

```
Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r831" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r872" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r872" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r872" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r156", "r174", "r175", "r176", "r186", "r187", "r188", "r190", "r195", "r197", "r199", "r215", "r268", "r269", "r296", "r364", "r418", "r419", "r422", "r423", "r424", "r426", "r431", "r432", "r439", "r440", "r441", "r442", "r443", "r444", "r446", "r472", "r473", "r474", "r475", "r476", "r477", "r481", "r483", "r493", "r588", "r595", "r596", "r597", "r610", "r680" ] }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Equity Interest Type [Axis]", "documentation": "Information by type of equity interests that are issued or issuable in a business combination." } } }, "auth_ref": [] }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Equity Interest Issued or Issuable, Type [Domain]", "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination." } } }, "auth_ref": [ "r119" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r841" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r799", "r809", "r819", "r851" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r341", "r466", "r738", "r739" ] }, "catx_EstimatedHazardousWasteRemovalLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "EstimatedHazardousWasteRemovalLiability", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated hazardous waste removal liability", "label": "Estimated Hazardous Waste Removal Liability", "documentation": "Estimated hazardous waste removal liability." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r847" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r450", "r451", "r459", "r754" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r450", "r451", "r459", "r754" ] }, "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Nonrecurring [Table Text Block]", "terseLabel": "Summary of Money Market Fund Included in Company's Cash and Cash Equivalents In Condensed Consolidated Balance Sheet Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)." } } }, "auth_ref": [ "r1016", "r1017" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r341", "r366", "r367", "r368", "r369", "r370", "r371", "r449", "r451", "r452", "r453", "r454", "r458", "r459", "r461", "r506", "r507", "r508", "r738", "r739", "r744", "r745", "r746", "r754", "r758" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r341", "r738", "r739" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r450", "r451", "r452", "r454", "r754", "r1019", "r1022" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r341", "r738", "r739" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r341", "r366", "r371", "r451", "r459", "r506", "r744", "r745", "r746", "r754" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r341", "r366", "r371", "r451", "r452", "r459", "r507", "r738", "r739", "r744", "r745", "r746", "r754" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r341", "r366", "r367", "r368", "r369", "r370", "r371", "r451", "r452", "r453", "r454", "r459", "r508", "r738", "r739", "r744", "r745", "r746", "r754", "r758" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r450", "r451", "r452", "r454", "r754", "r1019", "r1022" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r121" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
```

```
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"Financial instruments measured at fair value", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel":
"Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance", "periodStartLabel": "Fair Value, Measurement with
Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance", "documentation": "Fair value of financial instrument classified as an asset measured
using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r455", "r460", "r756"
] } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to
measure fair value." } } }, "auth_ref": [ "r341", "r366", "r367", "r368", "r369", "r370", "r371", "r449", "r451", "r452", "r453", "r454", "r458", "r459", "r461", "r506", "r507",
"r508", "r738", "r739", "r744", "r745", "r746", "r754", "r758" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value
adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r754", "r1016", "r1017", "r1018", "r1019", "r1020", "r1022" ] },
"us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r236", "r237", "r238",
"r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260",
"r261", "r262", "r263", "r264", "r265", "r271", "r272", "r277", "r278", "r279", "r282", "r283", "r284", "r352", "r361", "r445", "r462", "r503", "r504", "r505", "r506", "r507",
"r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531",
"r532", "r533", "r534", "r589", "r733", "r754", "r756", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r769", "r885", "r886", "r887", "r888", "r889", "r890", "r891",
"r944", "r945", "r946", "r947", "r1015", "r1018", "r1019", "r1020", "r1021", "r1022" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "terseLabel": "Note receivable,
forgiven amount", "label": "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs", "documentation": "Amount of writeoff of financing receivable, charged against
allowance for credit loss." } } }, "auth_ref": [ "r136", "r275", "r281", "r731" ] }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of
Financing Receivable [Axis]", "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and
method of monitoring and assessing credit risk." } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r152", "r153", "r154", "r155", "r226", "r228", "r229", "r230", "r231",
"r277", "r278", "r279", "r728", "r729", "r730", "r731", "r732", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r925" ] }, "us-
gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Financing
Receivable [Domain]", "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and
assessing credit risk." } } }, "auth_ref": [ "r140", "r152", "r153", "r154", "r155", "r226", "r228", "r229", "r230", "r231", "r728", "r885", "r886", "r887", "r888", "r889", "r890",
"r891", "r892", "r893", "r894", "r925" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Foreign currency adjustments", "terseLabel": "Foreign currency adjustments", "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
"totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign
currency transaction." } } }, "auth_ref": [ "r468", "r469", "r470", "r471", "r677" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel":
"Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r803", "r813", "r823", "r855" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r803", "r813", "r823", "r855"
] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r803", "r813",
"r823", "r855" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r803", "r813", "r823", "r855" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r803",
"r813", "r823", "r855" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r836" ] }, "catx_GTMedicalStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "GTMedicalStockMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "GT
Medical Stock [Member]", "label": "G T Medical Stock [Member]", "documentation": "Relating to GT Medical stock." } } }, "auth_ref": [] },
"catx_GTMedicalTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"GTMedicalTechnologiesIncMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "terseLabel": "GT Medical Technologies, Inc. [Member]", "documentation": "Refers to information regarding the entity GT Medical Technologies,
Inc.", "label": "GT Medical Technologies, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": {
"label": "us-gaap_GainLossOnDispositionOfAssets", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal
of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r906", "r964", "r965" ] }, "us-
gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-
us": { "role": { "terseLabel": "Loss recognized on classification as held for sale", "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Loss on divestiture",
"documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing
return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r436", "r906" ] }, "us-
gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on
disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and
timber property." } } }, "auth_ref": [ "r8" ] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": {
"label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Loss recognized on classification as held for sale", "documentation": "Amount of gain
(loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from
their carrying value to fair value." } } }, "auth_ref": [ "r906" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-
condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of
expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the
manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r93", "r659" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel
], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expenses [Member]", "label": "General and Administrative Expense [Member]", "verboseLabel":
"General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r93" ]
}, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill",
"periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing
future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately
recognized." } } }, "auth_ref": [ "r164", "r287", "r567", "r726", "r734", "r755", "r768", "r951", "r952" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label":
```

```
"Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill
and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." }
} } }, "auth_ref": [ "r950", "r953" ] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecurities", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "terseLabel": "HTM, Amortized Cost", "label": "HTM, amortized cost", "totalLabel": "HTM, amortized cost, Total", "documentation": "Amount,
before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r139", "r249", "r277", "r949" ] }, "us-
gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "terseLabel": "HTM, Gross Unrealized Gains", "label": "HTM, gross unrealized gains", "documentation": "Amount of accumulated unrecognized
gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r142", "r259" ] }, "us-
gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "terseLabel": "HTM, Gross Unrealized Losses", "negatedLabel": "HTM, Gross Unrealized Losses", "label": "us-
gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured
at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r143", "r260" ] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Held-to-Maturity, Fair Value, Total", "terseLabel": "HTM, Estimated Fair Value", "label": "HTM, fair value",
"documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r141", "r258", "r451", "r458", "r568", "r573" ]
}, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"HeldToMaturitySecuritiesTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsTables"
], "lang": { "en-us": { "role": { "terseLabel": "Summary of Carrying Values and Fair Values of Financial Instruments", "label": "Debt Securities, Held-to-Maturity [Table Text
Block]", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r926",
"r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943" ] }, "catx_HoustonTexasMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "HoustonTexasMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Houston Texas.", "label": "Houston Texas [Member]", "terseLabel": "Houston Texas [Member]" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "In-process Research and Development", "label": "In Process Research and Development [Member]", "documentation": "In process
investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of
knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r954", "r955", "r956", "r957", "r958", "r959",
"r960", "r961", "r962", "r963" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": {
"totalLabel": "Net loss from continuing operations", "terseLabel": "Net loss from continuing operations", "label": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "documentation": "Amount of income (loss) from continuing
operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling
interest." } } }, "auth_ref": [ "r87", "r130", "r134", "r570", "r586", "r723", "r725", "r918", "r920", "r921", "r922", "r923" ] }, "us-
gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from continuing operations, Basic", "label": "Income (Loss) from
Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding
during the reporting period." } } }, "auth_ref": [ "r89", "r131", "r177", "r189", "r191", "r192", "r193", "r194", "r195", "r204", "r207", "r208", "r425", "r432", "r448", "r569",
"r1048" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from continuing operations, Diluted", "label": "Income (Loss) from
Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share
of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common
shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r89", "r177", "r189", "r191", "r192", "r193",
"r194", "r195", "r204", "r207", "r208", "r209", "r432", "r448", "r569", "r1048" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on equity method investment", "label": "Equity in loss of affiliate", "terseLabel": "Income (Loss) from Equity Method
Investments", "negatedLabel": "Equity in loss of affiliate", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } }
}, "auth_ref": [ "r8", "r88", "r129", "r214", "r220", "r222", "r266", "r585" ] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-" ], "lang": { "en-
us": { "role": { "totalLabel": "Net loss before deferred income tax benefit", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax",
"documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing
operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r91", "r902" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } } }, "auth_ref": [] },
"us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ],
"lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r747", "r748" ] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": {
"role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" ], "lang": { "en-us": {
"role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not
limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } },
"auth_ref": [ "r11", "r16", "r18", "r51", "r60", "r61", "r62", "r63", "r64", "r68", "r70", "r71", "r108" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel
], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated
amount has been reported." } } }, "auth_ref": [ "r297", "r303", "r307", "r456", "r457", "r460", "r592", "r594", "r664", "r714", "r757", "r1052" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel
], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount
has been reported." } } }, "auth_ref": [ "r303", "r307", "r456", "r457", "r460", "r592", "r594", "r664", "r714", "r757", "r1052" ] }, "us-
gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "The
increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but
not paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel":
"Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the
credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"terseLabel": "Deferred Income", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to
transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r715" ] }, "us-
gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "label": "Increase
```

(Decrease) in Employee Related Liabilities", "terseLabel": "Accrued personnel expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r7"] }, "catx_IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Increase (DeIncrease (decrease) in inventory related to discontinued operations.crease) In Inventory Related to Discontinued Operations", "label": "Increase (Decrease) In Inventory Related to Discontinued Operations", "negatedLabel": "Inventory related to discontinued operations" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r7"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r288", "r292", "r294", "r735"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r288", "r294", "r295", "r735"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, in-process research and development", "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance", "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance", "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r286", "r294", "r735"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r288", "r292", "r294", "r735"] }, "catx_IndefinitelivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "IndefinitelivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of indefinite-lived assets.", "label": "Accumulated Amortization" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r803", "r813", "r823", "r847", "r855", "r859", "r867"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r865"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r795", "r871"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r795", "r871"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r795", "r871"] }, "catx_InterestAndOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "InterestAndOtherExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "negatedLabel": "Interest and other expense", "terseLabel": "Interest and other expense", "label": "Interest and Other Expense", "documentation": "Interest and other expense." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "us-gaap_InterestExpenseDebt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r95", "r347", "r355", "r740", "r741"] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "us-gaap_InterestReceivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": ["r899", "r1083"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Write-off of inventory associated with discontinued product", "verboseLabel": "Write-off of inventory associated with discontinued product", "terseLabel": "Write-off of inventory associated with discontinued product", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r285"] }, "catx_InvestmentAgreementContingentAmountOfGrossProceedsRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "InvestmentAgreementContingentAmountOfGrossProceedsRaised", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Investment agreement, contingent amount of gross proceeds raised", "label": "Investment Agreement Contingent Amount Of Gross Proceeds Raised", "documentation": "Represents the amount of gross proceeds raised as part of an investment agreement." } } }, "auth_ref": [] }, "catx_InvestmentAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "InvestmentAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Investment Agreements [Abstract]", "documentation": "Investment agreements." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r214", "r219", "r222", "r725", "r903"] }, "catx_InvestmentsAndAgreementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "InvestmentsAndAgreementsDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreements"], "lang": { "en-us": { "role": { "terseLabel": "Investments and Agreements", "label": "Investments And Agreements Disclosure [Text Block]", "documentation": "Investments and agreements disclosure." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestments"], "lang": { "en-us": { "role": { "terseLabel": "Held-to-Maturity Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r133", "r151", "r232", "r235", "r463", "r464", "r1040"] }, "catx_IsorayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "IsorayMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Isoray [Member]", "label": "Isoray [Member]", "documentation": "Isoray." } } }, "auth_ref": [] }, "catx_IsorayNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "IsorayNoteMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "documentation": "Relating to the Isoray note.", "label": "Isoray Note [Member]" } } }, "auth_ref": [] }, "catx_January2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "January2024PublicOfferingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "January 2024 public offering.", "label": "January 2024 Public Offering [Member]" } } }, "auth_ref": [] }, "catx_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "JanuaryTwoThousandTwentyFourPreFundedWarrantsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "documentation": "January two thousand twenty four pre-funded warrants.", "label": "January Two Thousand Twenty Four Pre-funded Warrants [Member]", "terseLabel": "January 2024 Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "catx_JanuaryTwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "JanuaryTwoThousandTwentyFourPublicOfferingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "January 2024 Public Offering [Member]", "label": "January Two Thousand Twenty Four Public Offering [Member]", "documentation": "January two thousand twenty four public offering." } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": {

"role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": ["r983"] },
"catx_LantheusAlphaTherapyLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"LantheusAlphaTherapyLlcMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lantheus Alpha Therapy,
LLC [Member]", "documentation": "Lantheus Alpha Therapy, LLC." } } }, "auth_ref": [] }, "catx_LantheusInvestmentAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "LantheusInvestmentAgreementMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": {
"en-us": { "role": { "verboseLabel": "Lantheus Investment Agreement [Member]", "terseLabel": "Lantheus Investment Agreement", "label": "Lantheus Investment Agreement
[Member]", "documentation": "Represents Lantheus Investment Agreement." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term
[Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r492", "r883"] }, "us-gaap_LeaseContractualTermDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term
[Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r492", "r883"] }, "catx_LeaseWithBoardOfRegentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "LeaseWithBoardOfRegentsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Lease with Board
of Regents.", "label": "Lease with Board of Regents [Member]" } } }, "auth_ref": [] }, "catx_LeaseWithEnergyNorthwestMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "LeaseWithEnergyNorthwestMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Represents lease
with Energy Northwest.", "label": "Lease With Energy Northwest [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease
arrangement." } } }, "auth_ref": ["r106", "r491"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": ["r486", "r492"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r486", "r492"] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating
lease, discount rate", "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "documentation": "Discount rate used by lessee to determine present value of operating lease
payments." } } }, "auth_ref": ["r766"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Future Operating
Lease Payments and Lease Liability", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of
undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in
statement of financial position." } } }, "auth_ref": ["r1028"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for
lease payment for operating lease." } } }, "auth_ref": ["r490"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following
current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": ["r490"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year
following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }
}, "auth_ref": ["r490"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following
current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": ["r490"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year
following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }
}, "auth_ref": ["r490"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "2024 (remaining three months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having
initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1028"] }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": {
"en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of
lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r490"] },
"catx_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal
options", "label": "Lessee Operating Lease Number Of Renewal Options", "documentation": "Lessee operating lease number of renewal options." } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Lease
term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1027"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating
Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity
analysis of operating lease liability." } } }, "auth_ref": ["r482"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-
gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic
benefit to others." } } }, "auth_ref": ["r17", "r72", "r73", "r74", "r76", "r77", "r78", "r79", "r182", "r267", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326",
"r435", "r437", "r438", "r467", "r633", "r722", "r790", "r976", "r1031", "r1032"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-
gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the
portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r86", "r126", "r581", "r768", "r909", "r948", "r1023"] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES
AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-
gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during
the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r74", "r160", "r182", "r267", "r318", "r319", "r320", "r321", "r322", "r323", "r324",
"r325", "r326", "r435", "r437", "r438", "r467", "r768", "r976", "r1031", "r1032"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current
liabilities:", "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Total current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r51", "r67", "r105", "r107", "r157", "r158"] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities held for sale of discontinued operations, current", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent liabilities:", "label": "Non-current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessFormationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyOrLimitedPartnershipBusinessFormationDate", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Limited liability company, Formation date", "label": "Limited Liability Company or Limited Partnership, Business, Formation Date", "documentation": "Date the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r17", "r124", "r340", "r354", "r738", "r739", "r765", "r1042"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r10", "r185", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r10", "r185", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r10", "r185", "r345"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfMaturityOfNotePayableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2024 (remaining three months)", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r911"] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Note payable, net of current portion", "label": "Note payable, long-term portion", "totalLabel": "Note payable, long-term portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r17"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r310", "r311", "r312", "r315", "r412", "r736", "r973", "r974"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r310", "r311", "r312", "r315", "r412", "r736", "r973", "r974"] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Estimated liability", "label": "us-gaap_LossContingencyAccrualAtCarryingValue", "terseLabel": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r310", "r878"] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Number of plaintiff", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": ["r973", "r974"] }, "catx_March2024PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "March2024PrivatePlacementMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Private Placement [Member]", "label": "March 2024 Private Placement [Member]", "documentation": "Represents the March 2024 private placement." } } }, "auth_ref": [] }, "catx_MarchTwoThousandTwentyFourInvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MarchTwoThousandTwentyFourInvestmentAgreementMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Investment Agreement [Member]", "label": "March Two Thousand Twenty Four Investment Agreement [Member]", "documentation": "March two thousand twenty four investment agreement." } } }, "auth_ref": [] }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaturitiesOfLongTermDebtAbstract", "lang": { "en-us": { "role": { "label": "Maturities of Long-Term Debt [Abstract]" } } }, "auth_ref": [] }, "catx_MaximumAmountOfSecuritiesOfferAndSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MaximumAmountOfSecuritiesOfferAndSale", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of securities offer and sale", "label": "Maximum Amount Of Securities Offer And Sale", "documentation": "Maximum amount of securities offer and sale." } } }, "auth_ref": [] }, "catx_MaximumAmountOfSecuritiesOfferAndSell": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MaximumAmountOfSecuritiesOfferAndSell", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of securities offer and sell", "label": "Maximum Amount of Securities Offer and Sell", "documentation": "Maximum amount of securities offer and sell." } } }, "auth_ref": [] }, "catx_MaximumIncreaseOrDecreaseInOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MaximumIncreaseOrDecreaseInOwnershipPercentage", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Maximum increase or decrease in ownership percentage", "label": "Maximum Increase Or Decrease In Ownership Percentage", "documentation": "Maximum increase or decrease in ownership percentage." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r373", "r412", "r454", "r535", "r591", "r593", "r600", "r625", "r626", "r686", "r688", "r690", "r691", "r693", "r712", "r713", "r728", "r742", "r749", "r758", "r759", "r763", "r764", "r778", "r980", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038"] }, "catx_May2024PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "May2024PreFundedWarrantsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "May 2024 pre-funded warrants.", "label": "May 2024 Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "catx_MayTwoThousandTwentyFourPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MayTwoThousandTwentyFourPreFundedWarrantsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty four pre-funded warrants.", "label": "May Two Thousand Twenty Four Pre-funded Warrants [Member]", "terseLabel": "May 2024 Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "catx_MayTwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "MayTwoThousandTwentyFourPublicOfferingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-

consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty four public offering.", "label": "May Two Thousand Twenty Four Public Offering [Member]", "terseLabel": "May 2024 Public Offering [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r839"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r839"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r373", "r412", "r454", "r535", "r591", "r593", "r600", "r625", "r626", "r686", "r688", "r690", "r691", "r693", "r712", "r713", "r728", "r742", "r749", "r758", "r759", "r763", "r778", "r980", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r858"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu], "lang": { "en-us": { "role": { "terseLabel": "Money Market Fund [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r984"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r866"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r840"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r179"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r179"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r98", "r99", "r100"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r92", "r100", "r132", "r158", "r172", "r173", "r176", "r182", "r189", "r191", "r192", "r193", "r194", "r195", "r198", "r199", "r206", "r267", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r425", "r432", "r448", "r467", "r587", "r656", "r678", "r679", "r788", "r976"] }, "catx_NetSalesBetween10And15MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NetSalesBetween10And15MillionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Net Sales Between $10.0 and 15.0 Million [Member]", "label": "Net Sales Between 10 And 15 Million [Member]", "documentation": "Relating to net sales between $10 and 15 million." } } }, "auth_ref": [] }, "catx_NetSalesGreaterThan15MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NetSalesGreaterThan15MillionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Net Sales Greater Than $15.0 Million [Member]", "label": "Net Sales Greater Than 15 Million [Member]", "documentation": "Relating to net sales greater than $15 million." } } }, "auth_ref": [] }, "catx_NetSalesOf10MillionOrLessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NetSalesOf10MillionOrLessMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Net Sales of $10.0 Million or Less [Member]", "label": "Net Sales Of 10 Million Or Less [Member]", "documentation": "Relating to net sales of $ 10 million or less." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r839"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r803", "r813", "r823", "r847", "r855"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r830"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r829"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r847"] }, "catx_NonRule10B51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NonRule10B51ArrangementModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Modified", "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]", "documentation": "Non-Rule 10b5-1 Arrangement Modified Flag." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r866"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r866"] }, "catx_NoncashExpenseLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NoncashExpenseLease", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Lease expense", "documentation": "Represents the noncash expense incurred for leases.", "label": "Noncash lease expense" } } }, "auth_ref": [] }, "catx_NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Assumption fair value of stock options and warrants in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.", "label": "Assumption of Viewpoint stock options and warrants at fair value" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Additions to property and equipment", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r24", "r25", "r26"] }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Shares issued in exchange for common stock (in shares)", "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r24", "r25", "r26"] }, "catx_NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Forgiven of notes receivable and accrued interest assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.", "label": "Note receivable and accrued interest from Viewpoint forgiven" } } }, "auth_ref": [] }, "catx_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill", "crdr": "debit",

"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition, including goodwill. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Fair value of Viewpoint assets acquired including goodwill" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (Note 14), Total", "terseLabel": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations {(see Note 13)}", "label": "Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14)", "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r24", "r25", "r26"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "totalLabel": "Total non-operating income (expense), net", "label": "us-gaap_NonoperatingIncomeExpense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r94"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Non-operating income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "totalLabel": "Note payable", "label": "Note payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r17", "r124", "r1042", "r1043"] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Note payable", "totalLabel": "Notes Payable, Current, Total", "terseLabel": "Notes payable, current", "label": "us-gaap_NotesPayableCurrent", "negatedLabel": "Less: current portion", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r72", "r73"] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Note receivable, forgiven amount, loan", "verboseLabel": "Note receivable", "label": "Note receivable", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": ["r280", "r643", "r924", "r1045"] }, "catx_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfBusinessesAcquired", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Number of affiliated predecessor companies acquired", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "us-gaap_NumberOfReportableSegments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r724", "r727", "r919"] }, "catx_OfficeSpaceWithUnicoPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OfficeSpaceWithUnicoPropertiesMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Represents Office Space With Unico Properties.", "label": "Office Space With Unico Properties [Member]" } } }, "auth_ref": [] }, "catx_OneTimePaymentReceivedForRightsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OneTimePaymentReceivedForRightsGranted", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "One-time payment received for rights granted", "label": "One-Time Payment Received For Rights Granted", "documentation": "One-time payment received for rights granted." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Operating loss", "label": "Operating loss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r134", "r723", "r918", "r920", "r921", "r922", "r923"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, expense", "label": "us-gaap_OperatingLeaseExpense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r1026"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease liability, Total", "terseLabel": "Lease liability", "label": "Total lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r485"] }, "catx_OperatingLeaseLiabilityAndRightOfUseAssetForNewLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OperatingLeaseLiabilityAndRightOfUseAssetForNewLease", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Amount of operating lease liability and right of use assets for new lease.", "label": "Operating lease liability and right of use asset for new lease" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Lease liability", "negatedLabel": "Less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r485"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesSummaryOfFutureOperatingLeasePaymentsAndLeaseLiabilityDetails", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Noncurrent lease liability", "terseLabel": "Lease liability, net of current portion", "label": "Lease liability, non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r485"] }, "catx_OperatingLeasePrepaidRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OperatingLeasePrepaidRentExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Base prepaid Rent", "label": "Operating Lease Prepaid Rent Expense", "documentation": "Operating lease prepaid rent expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use asset, net", "terseLabel": "Right of use asset", "label": "Right of use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r484"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r489", "r767"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining term", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r488", "r767"] }, "catx_OppenheimerCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OppenheimerCoMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Oppenheimer & Co [Member]", "label": "Oppenheimer Co [Member]", "documentation": "Represents the Oppenheimer & Co." } } }, "auth_ref": [] }, "catx_OptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OptionAgreementMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Option Agreement [Member]", "label": "Option Agreement [Member]", "documentation": "Represents the option agreement." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",

```
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies" ],
"lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } },
"auth_ref": [ "r49", "r101", "r102", "r120" ] },
"us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, net", "label": "Other assets, net", "documentation": "Amount of noncurrent assets classified as other." } } },
"auth_ref": [ "r165" ] },
"us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r77" ] },
"catx_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "OtherMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Related to other property plant and equipment not specifically disclosed.", "label": "Other [Member]", "terseLabel": "Other [Member]" } } },
"auth_ref": [] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } },
"auth_ref": [ "r839" ] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } },
"auth_ref": [ "r801", "r811", "r821", "r853" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } },
"auth_ref": [ "r804", "r814", "r824", "r856" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } },
"auth_ref": [ "r804", "r814", "r824", "r856" ] },
"us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Over-Allotment Option [Member]", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } },
"auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } },
"auth_ref": [ "r828" ] },
"us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "negatedLabel": "Issuance costs related to common stock issued in exchange for Viewpoint common stock", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } },
"auth_ref": [ "r22" ] },
"us-gaap_PaymentsToAcquireBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBuildings", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Payments to purchase buildings", "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use." } } },
"auth_ref": [ "r96" ] },
"us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireHeldToMaturitySecurities", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireHeldToMaturitySecurities", "negatedLabel": "Purchases of short-term investments", "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities." } } },
"auth_ref": [ "r21", "r234" ] },
"us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Additions to other assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } },
"auth_ref": [ "r96" ] },
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"terseLabel": "Additions to property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } },
"auth_ref": [ "r96" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } },
"auth_ref": [ "r838" ] },
"ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } },
"auth_ref": [ "r838" ] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } },
"auth_ref": [ "r830" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } },
"auth_ref": [ "r847" ] },
"ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } },
"auth_ref": [ "r840" ] },
"ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } },
"auth_ref": [ "r829" ] },
"catx_PercentOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PercentOfOutstandingShares", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of outstanding shares", "label": "Percent Of Outstanding Shares", "documentation": "Represents the percent of outstanding shares." } } },
"auth_ref": [] },
"catx_PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PercentageOfIncreaseInCommonStockCapitalSharesForFutureIssuance", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in common stock capital shares for future issuance.", "label": "Percentage Of Increase In Common Stock Capital Shares For Future Issuance", "terseLabel": "Percentage of increase in common stock capital shares for future issuance" } } },
"auth_ref": [] },
"catx_PercentageOfIssuedAndOutstandingCapitalStock": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PercentageOfIssuedAndOutstandingCapitalStock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "terseLabel": "Percentage of issued and outstanding capital stock", "label": "Percentage Of Issued And Outstanding Capital Stock", "documentation": "Percentage of issued and outstanding capital stock." } } },
"auth_ref": [] },
"catx_PercentageOfOwnershipConsideredForWarrantExercise": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PercentageOfOwnershipConsideredForWarrantExercise", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership considered for warrant exercise", "label": "Percentage Of Ownership Considered for Warrant Exercise", "documentation": "Percentage of ownership considered for warrant exercise." } } },
"auth_ref": [] },
"catx_PercentageOfOwnershipConsideredForWarrantExerciseTwo": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PercentageOfOwnershipConsideredForWarrantExerciseTwo", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Percentage of ownership considered for warrant exercise two.", "label": "Percentage Of Ownership Considered for Warrant Exercise Two", "terseLabel": "Percentage of ownership considered for warrant exercise" } } },
"auth_ref": [] },
"catx_PlacementAgentsCashFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PlacementAgentsCashFeePercentage", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Placement agents cash fee, percentage", "label": "Placement Agents Cash Fee Percentage", "documentation": "Represents the cash fee percentage." } } },
"auth_ref": [] },
"us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } },
"auth_ref": [ "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010" ] },
"us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } },
"auth_ref": [ "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010" ] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } },
"auth_ref": [ "r831" ] },
"ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } },
"auth_ref": [ "r875" ] },
"ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } },
"auth_ref": [ "r830" ] },
"us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEq
], "lang": { "en-us": { "role": { "axisDefault": "Portion at Fair Value Measurement [Member] [Default]", "label": "Portion at Fair Value Measurement [Member]",
```

"documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r465"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r80", "r356"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r80", "r635"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r80", "r356"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r80", "r635", "r654", "r1081", "r1082"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of September 30, 2024 and December 31, 2023", "label": "Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r80", "r578", "r768"] }, "catx_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Pre-funded Warrants [Member]", "terseLabel": "Prefunded Warrants [Member]", "label": "Prefunded Warrants [Member]", "documentation": "Relating to Prefunded Warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r901"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r895"] }, "catx_ProceedsFromInvestmentAgreementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProceedsFromInvestmentAgreementNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Investment Agreement, net", "label": "Proceeds from Investment Agreement Net", "documentation": "Proceeds from investment agreement net." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from Public Offering, net", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from the ATM Agreement, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "catx_ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and prefunded warrants net.", "label": "Proceeds from Issuance of Common Stock and Prefunded Warrants Net", "terseLabel": "Proceeds from the issuance of common stock and Pre-funded Warrants, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from public offering", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r4", "r602"] }, "catx_ProceedsFromPrefundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProceedsFromPrefundedWarrantsNet", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Proceeds From Prefunded Warrants Net", "documentation": "Proceeds from prefunded warrants net.", "terseLabel": "Proceeds from Pre-funded Warrants, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Proceeds from maturity of short-term investments", "terseLabel": "Proceeds from maturity of short-term investments", "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r19"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of common stock, pursuant to exercise of options", "label": "Proceeds from sales of common stock, pursuant to exercise of option", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r15"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from sales of common stock, pursuant to exercise of warrants, net", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r904"] }, "catx_ProgenicsApaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProgenicsApaMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual"], "lang": { "en-us": { "role": { "label": "Progenics APA [Member]", "documentation": "Progenics APA." } } }, "auth_ref": [] }, "catx_ProgenicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProgenicsMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Progenics [Member]", "documentation": "Progenics." } } }, "auth_ref": [] }, "catx_ProgramLicenseOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProgramLicenseOptionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Program License Option [Member]", "documentation": "Program license option." } } }, "auth_ref": [] }, "catx_ProgramPreclinicalCoFundingOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ProgramPreclinicalCoFundingOptionMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "Program Preclinical Co-Funding Option [Member]", "documentation": "Program preclinical co-funding option." } } }, "auth_ref": [] }, "catx_PromissoryNoteForPurchasingLandAndBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PromissoryNoteForPurchasingLandAndBuildingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Represents promissory note for purchasing land and building.", "label": "Promissory Note for Purchasing Land and Building [Member]" } } }, "auth_ref": [] }, "catx_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PromissoryNoteMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableSummaryOfNotePayableDetails"], "lang": { "en-us": { "role": { "documentation": "Represents promissory note.", "label": "Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r9", "r491"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipment"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r104", "r146", "r147", "r148"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [

"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r106", "r162", "r584"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r491"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r9", "r491", "r571", "r584", "r768"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r106", "r491"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Change in allowance for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r178", "r274"] }, "catx_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "PublicOfferingMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Public Offering [Member]", "label": "Public Offering [Member]", "documentation": "Public offering." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r828"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r828"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r365", "r373", "r402", "r403", "r404", "r412", "r454", "r509", "r518", "r535", "r591", "r593", "r600", "r625", "r626", "r686", "r688", "r690", "r691", "r693", "r712", "r713", "r728", "r742", "r749", "r758", "r759", "r763", "r764", "r778", "r782", "r971", "r980", "r1019", "r1034", "r1035", "r1036", "r1037", "r1038"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r365", "r373", "r402", "r403", "r404", "r412", "r454", "r509", "r518", "r535", "r591", "r593", "r600", "r625", "r626", "r686", "r688", "r690", "r691", "r693", "r712", "r713", "r728", "r742", "r749", "r758", "r759", "r763", "r764", "r778", "r782", "r971", "r980", "r1019", "r1034", "r1035", "r1036", "r1037", "r1038"] }, "catx_RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Recognition of operating lease liability and right-of-use asset", "label": "Recognition of Operating Lease liability and Right of Use Asset", "documentation": "Recognition of operating lease liability and right of use asset." } } }, "auth_ref": [] },
"catx_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:", "label": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets:" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r796", "r806", "r816", "r848"] }, "catx_RegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "RegisteredOfferingMember", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "documentation": "Registered offering.", "label": "Registered Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r225", "r372", "r497", "r498", "r576", "r582", "r628", "r629", "r630", "r631", "r632", "r653", "r655", "r685"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r225", "r660", "r661", "r664"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r225", "r372", "r497", "r498", "r576", "r582", "r628", "r629", "r630", "r631", "r632", "r653", "r655", "r685", "r1030"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedParties"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": ["r494", "r495", "r496", "r498", "r500", "r607", "r608", "r609", "r662", "r663", "r664", "r683", "r684"] }, "catx_RepaymentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "RepaymentProvisions", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Repayment provisions", "label": "Repayment Provisions", "documentation": "Repayment provisions." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Principal payments", "label": "us-gaap_RepaymentsOfDebt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r905"] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Repayment of notes payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r97"] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r183", "r184", "r331", "r358", "r499", "r519", "r572", "r719", "r720"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r413", "r714", "r725", "r1039"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel
], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses [Member]", "label": "Research and Development Expense [Member]", "verboseLabel":
"Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have
been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement
Determination Date:" } } }, "auth_ref": ["r797", "r807", "r817", "r849"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r798", "r808", "r818", "r850"] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does
Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r805", "r815", "r825", "r857"] }, "us-
gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": {
"label": "Restricted cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as
noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r23", "r145", "r180"] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],
"lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "verboseLabel": "Total accumulated deficit", "label": "Accumulated
deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r83", "r113", "r580", "r598", "r599", "r606", "r636", "r768"] }, "us-
gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": {
"en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." }
} }, "auth_ref": ["r156", "r186", "r187", "r188", "r190", "r195", "r197", "r199", "r268", "r269", "r296", "r418", "r419", "r422", "r423", "r424", "r426", "r431", "r432", "r439",
"r441", "r442", "r444", "r446", "r481", "r483", "r595", "r597", "r610", "r1081"] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueNotFromContractWithCustomer", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-operations-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue",
"label": "Grant revenue", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": ["r884"] }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": {
"label": "Modification of operating lease liability and right of use asset", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease
liability." } } }, "auth_ref": ["r487", "r767"] }, "catx_RofoOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930",
"localname": "RofoOptionMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "label": "ROFO
Option [Member]", "documentation": "ROFO Option." } } }, "auth_ref": [] }, "catx_RoyaltyAgreementPercentageOfNetSalesReceivable": { "xbrltype": "percentItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "RoyaltyAgreementPercentageOfNetSalesReceivable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Royalty agreement percentage of net sales receivable", "label": "Royalty Agreement Percentage Of Net Sales Receivable", "documentation": "Represents the percentage of net
sales receivable as part of a royalty agreement." } } }, "auth_ref": [] }, "catx_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "Rule10B51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"],
"lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Modified", "label": "Rule 10b 51 Arr Modified [Flag]", "documentation": "Rule 10b 51 Arr Modified Flag."
} } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel":
"Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r866"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1
Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r866"] }, "us-
gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate sales price", "label": "Sale of Stock, Consideration Received Per Transaction", "documentation": "Amount of consideration received by subsidiary or equity investee
in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } }
}, "auth_ref": [] }, "catx_SaleOfStockMaximumCommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930",
"localname": "SaleOfStockMaximumCommissionPercentage", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Agent commission fee as a percentage of gross sales price", "label": "Sale Of Stock Maximum Commission Percentage", "documentation": "Sale of stock maximum
commission percentage." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": {
"en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private
placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockPricePerShare", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"
], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by
subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],
"lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": ["r374", "r915"] }, "srt_ScenarioUnspecifiedDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],
"lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r200", "r374", "r878", "r915"] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could
potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r28"] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Securities
Not Considered in Calculation of Diluted Weighted Average Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table
Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic
earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share
amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r28"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Schedule of Business
Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
} } }, "auth_ref": ["r38", "r40", "r429"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Estimated
Purchase Consideration", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business
combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } },
"auth_ref": ["r38", "r40"] }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Change in Asset
Retirement Obligation [Table Text Block]", "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes
such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation." } } },
"auth_ref": ["r970"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],

```
"lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Note Payable", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r11", "r16", "r18", "r51", "r60", "r61", "r62", "r63", "r64", "r68", "r70", "r71", "r108" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r27", "r29", "r204", "r205", "r207" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationSummaryOfSharebasedCompensationExpenseRecognizedForSharel ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share-based Compensation Expense Recognized for Share-based Compensation Arrangements Excluding Share-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments ], "lang": { "en-us": { "role": { "label": "Schedule of Held-to-Maturity Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265" ] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table]", "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsSummaryOfComponentsOfOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r288", "r294", "r295", "r735" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote6GoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Components of Other Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r735", "r961" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturity of Note Payable", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual", "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9", "r491" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-tables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Preliminary Purchase Price Allocation", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r45", "r46", "r660", "r661", "r664" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Options", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r376", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted Average Fair Value of Stock Option Awards Granted and Key Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r116" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r791" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r793" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations [Member]", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r6", "r52", "r53", "r54" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r223", "r224", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r622", "r623", "r624", "r687", "r689", "r692", "r694", "r700", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r716", "r743", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r782", "r982", "r1049", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "catx_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
```

"SeriesBConvertiblePreferredStockMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label":
"Series B Convertible Preferred Stock [Member]", "documentation": "Series B convertible preferred stock." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": {
"terseLabel": "Series B Preferred Stock [Member]", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r897",
"r898", "r981"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation",
"crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-"], "lang": { "en-us": { "role": {
"totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Share-based compensation",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r7"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r376", "r378", "r380",
"r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402",
"r403", "r404", "r405"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based
payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by
Share-based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment
arrangement." } } }, "auth_ref": ["r751"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Intrinsic value associated with exercises", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "documentation": "Amount of accumulated difference
between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r398"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Stock option awards expired", "negatedLabel": "Number of Options Outstanding, Expired", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "documentation": "Number of options or other stock instruments for
which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r390"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Stock option awards forfeited", "negatedLabel": "Number of Options Outstanding, Forfeited", "label": "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "documentation": "The number of shares under options that were
cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } },
"auth_ref": ["r389"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel":
"Stock option awards granted", "terseLabel": "Number of Options Outstanding, Granted", "label": "Granted, Options (in shares)", "documentation": "Gross number of share
options (or share units) granted during the period." } } }, "auth_ref": ["r387"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } }, "auth_ref": ["r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393",
"r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405"] },
"catx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePrice",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Options exercise price per share", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Price", "documentation": "Share based
compensation arrangements by share based payment award options exercise price." } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": {
"verboseLabel": "Number of Options Outstanding, Options assumed", "terseLabel": "Options to purchase shares of common stock", "documentation": "Gross number of share
options (or share units) assumed during the period.", "label": "Options assumed, Options (in shares)" } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue",
"crdr": "credit", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual"], "lang": { "en-
us": { "role": { "terseLabel": "Stock option awards grant in period fair value", "documentation": "Fair value of the options grants in period.", "label":
"catx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" } } }, "auth_ref": [] },
"catx_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted
Average Exercise Price, Options assumed", "terseLabel": "Options exercise price per share", "documentation": "Weighted average per share amount at which grantees can
acquire shares of common stock by exercise of options.", "label": "Options assumed, Price (in dollars per share)" } } }, "auth_ref": [] },
"catx_SharesAndWarrantsPriceDifference": { "xbrltype": "perShareItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"SharesAndWarrantsPriceDifference", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel":
"Shares and warrants, price difference per share", "label": "Shares And Warrants Price Difference", "documentation": "Represents the difference between shares and warrants
prices." } } }, "auth_ref": [] }, "catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock": { "xbrltype": "percentItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "SharesIssuedPercentOfFullydilutedOutstandingCapitalStock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],
"lang": { "en-us": { "role": { "terseLabel": "Percentage of fully-diluted outstanding capital stock", "documentation": "Represents number of shares issued as a percentage of
fully diluted outstanding capital stock.", "label": "catx_SharesIssuedPercentOfFullydilutedOutstandingCapitalStock" } } }, "auth_ref": [] }, "us-
gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"],
"lang": { "en-us": { "role": { "terseLabel": "Stock purchase price per share", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of
equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesOutstanding", "presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-
stockholders-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances
(in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Short-Term
Investments, Total", "terseLabel": "Short-term investments", "label": "Short-term investments", "documentation": "Amount of investments including trading securities,
available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r127", "r128", "r900"] }, "us-
gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label":
"Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r150", "r167", "r168", "r169", "r182", "r204", "r205",
"r207", "r209", "r216", "r217", "r267", "r318", "r320", "r321", "r322", "r325", "r326", "r356", "r357", "r359", "r360", "r362", "r467", "r602", "r603", "r604", "r605", "r610",
"r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r635", "r657", "r680", "r695", "r696", "r697", "r698", "r699", "r877", "r907", "r917"] },
"us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis",
"presentation": ["http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-"], "lang": {
"en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r81", "r84", "r85", "r156", "r174",
"r175", "r176", "r186", "r187", "r188", "r190", "r195", "r197", "r199", "r215", "r268", "r269", "r296", "r364", "r418", "r419", "r422", "r423", "r424", "r426", "r431", "r432",
"r439", "r440", "r441", "r442", "r443", "r444", "r446", "r472", "r473", "r474", "r475", "r476", "r477", "r481", "r483", "r493", "r588", "r595", "r596", "r597", "r610", "r680"] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual"], "lang": { "en-us": { "role": { "label":

```
"Geographical [Axis]" } } }, "auth_ref": { "r223", "r224", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551",
"r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r622", "r623", "r624", "r687", "r689", "r692", "r694",
"r700", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r716", "r743", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r782",
"r982", "r1049", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069",
"r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r186", "r187", "r188", "r215", "r483", "r536", "r601",
"r621", "r627", "r628", "r629", "r630", "r631", "r632", "r635", "r638", "r639", "r640", "r641", "r642", "r644", "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r653",
"r655", "r658", "r659", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r680", "r783" ] }, "us-
gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-
us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } },
"auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "us-
gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOperatingActivitiesSegmentAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureDisclosureNote1BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r200", "r374", "r878", "r879", "r915" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income,
financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r186", "r187", "r188", "r215", "r225", "r483", "r536", "r601", "r621", "r627", "r628", "r629",
"r630", "r631", "r632", "r635", "r638", "r639", "r640", "r641", "r642", "r644", "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r653", "r655", "r658", "r659", "r665",
"r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r680", "r783" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or
TSR Estimation Method" } } }, "auth_ref": [ "r800", "r810", "r820", "r852" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares
equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-" ], "lang": { "en-us": { "role": {
"label": "us-gaap_StockIssued1", "negatedLabel": "13,654,507 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock",
"documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "us-
gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in exchange for Viewpoint common stock,
net(in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." }
} }, "auth_ref": [ "r80", "r81", "r113" ] }, "catx_StockIssuedDuringPeriodSharesCommonStockWarrantExercised": { "xbrltype": "sharesItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantExercised", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "documentation": "Stock issued during period shares common stock warrant exercised.", "label": "Stock Issued During Period Shares Common Stock
Warrant Exercised", "terseLabel": "Issuance of common stock pursuant to exercise of warrants (in shares)" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Shares issued and sell", "terseLabel": "Stock issued during period, shares", "verboseLabel": "Issuance of common stock, net (in shares)",
"documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r13", "r80", "r81", "r113", "r602", "r680", "r696" ] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote9SharebasedCompensationDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "verboseLabel": "Options exercised", "negatedLabel": "Number of Options Outstanding, Exercised", "terseLabel": "Number of Options Outstanding,
Exercised", "label": "Issuance of common stock pursuant to exercise options (in shares)", "documentation": "Number of share options (or share units) exercised during the
current period." } } }, "auth_ref": [ "r13", "r80", "r81", "r113", "r388" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "terseLabel": "Issuance of common stock in exchange for Viewpoint common stock, net", "label": "Stock Issued During Period, Value, Acquisitions",
"documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r13", "r81", "r84", "r85", "r113" ] }, "us-
gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "terseLabel": "Amount raised through selling of equity", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common
stock, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public
offering." } } }, "auth_ref": [ "r13", "r80", "r81", "r113", "r610", "r680", "r696", "r789" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "terseLabel": "Issuance of common stock pursuant to exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised",
"documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r81", "r84", "r85", "r113" ] },
"catx_StockIssuedDuringPeriodValueWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"StockIssuedDuringPeriodValueWarrantExercises", "crdr": "credit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value warrant exercises.",
"label": "Stock Issued During Period Value Warrant Exercises", "terseLabel": "Issuance of stock pursuant to exercise of common stock warrants" } } }, "auth_ref": [] },
"catx_StockIssuedDuringSharesCommonStockWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"StockIssuedDuringSharesCommonStockWarrantExercised", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during shares common stock warrant
exercised.", "label": "Stock Issued During Shares Common Stock Warrant Exercised", "terseLabel": "Issuance of common stock pursuant to exercise of warrants (in shares)" }
} }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-
statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Stock Redeemed or Called During Period, Shares", "terseLabel":
"Cancellation of fractional shares due to the 1-for-10 reverse stock split (in shares)", "negatedLabel": "Cancellation of fractional shares due to the 1-for-10 reverse stock split
(in shares)", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r13" ] }, "us-
gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": { "en-us": { "role": { "label": "Stock Redeemed or Called During Period, Value", "terseLabel":
"Cancellation of fractional shares due to the 1-for-10 reverse stock split", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price
or redemption price." } } }, "auth_ref": [ "r13" ] }, "catx_StockholderPlaintiffSettlementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "StockholderPlaintiffSettlementsMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote10CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"terseLabel": "Stockholder Plaintiff Settlements", "documentation": "Related to stockholder plaintiff settlements.", "label": "Stockholder Plaintiff Settlements [Member]" } } },
"auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total stockholders' equity",
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81",
"r84", "r85", "r103", "r637", "r654", "r681", "r682", "r768", "r790", "r909", "r948", "r1023", "r1081" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
```

```
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel":
"Stockholders' equity:", "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split, ratio", "documentation": "Ratio applied to
the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r114" ] }, "us-
gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals" ], "lang": { "en-us":
{ "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also
provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r114" ] },
"us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the
balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r478", "r502" ] }, "us-gaap_SubsequentEventTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial
statements are issued or available to be issued." } } }, "auth_ref": [ "r478", "r502" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote4DiscontinuedOperationsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote5PropertyAndEquipmentDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements
are issued or available to be issued." } } }, "auth_ref": [ "r478", "r502" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote11RelatedPartiesDetailedTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-" ], "lang": {
"en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote12LeasesTables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock",
"terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]",
"terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r846" ] }, "catx_TheUnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "TheUnderwritingAgreementMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Represents the Underwriting Agreement.", "label": "The Underwriting Agreement [Member]", "verboseLabel": "Underwriting Agreement [Member]" } } },
"auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder
Return Amount" } } }, "auth_ref": [ "r838" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total
Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r845" ] }, "ecd_TradingArrAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang":
{ "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r865" ] }, "ecd_TradingArrByIndTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r867" ] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or
another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial
instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244",
"r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r352",
"r361", "r445", "r462", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r521", "r522", "r523",
"r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r589", "r754", "r756", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r769",
"r885", "r886", "r887", "r888", "r889", "r890", "r891", "r944", "r945", "r946", "r947", "r1015", "r1018", "r1019", "r1020", "r1021", "r1022" ] }, "ecd_TrdArrAdoptionDate": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } },
"auth_ref": [ "r868" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } },
"auth_ref": [ "r869" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel":
"Expiration Date" } } }, "auth_ref": [ "r869" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": [ "r867" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel":
"Title" } } }, "auth_ref": [ "r867" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement,
Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r870" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us":
{ "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r868" ] },
"catx_TwoThousandTwentyFourAtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname":
"TwoThousandTwentyFourAtMarketOfferingMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel":
"2024 At-the-Market (ATM) Agreement [Member]", "label": "Two Thousand Twenty Four At Market Offering [Member]", "documentation": "Two Thousand Twenty Four At
Market Offering Member." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfArrangementAxis", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ],
"lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r433" ] }, "us-
gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote7HeldtomaturityInvestmentsSummaryOfCarryingValuesAndFairValuesOfFinancialInstruments
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote8FairValueMeasurementsSummaryOfMoneyMarketFundIncludedInCompanysCashAndCashEqu
], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury Bills [Member]", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes
information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing,
and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r1041" ] }, "catx_UnderwrittenOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "UnderwrittenOfferingMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Underwritten Offering.", "label": "Underwritten Offering [Member]", "terseLabel": "Offering [Member]" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r864" ] }, "catx_ViewpointMolecularTargetingIncMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "ViewpointMolecularTargetingIncMember", "presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote13NotesPayableDetailsTextual",
```

```
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfEstimatedPurchaseConsiderationDetailsParentheticals",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote14MergerSummaryOfPreliminaryPurchasePriceAllocationDetails",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareDetailsTextual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-note-14-merger-details-textual" ], "lang": { "en-us": { "role": { "terseLabel": "Viewpoint
Molecular Targeting, Inc. [Member]", "documentation": "Represents Viewpoint Molecular Targeting, Inc.", "label": "Viewpoint Molecular Targeting, Inc. [Member]" } } },
"auth_ref": [] }, "catx_VmtOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "VmtOptionMember",
"presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "VMT option.", "label": "VMT Option [Member]" } } }, "auth_ref": [] }, "catx_VmtOptionOrProgramLicenseOptionMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.perspectivetherapeutics.com/20240930", "localname": "VmtOptionOrProgramLicenseOptionMember", "presentation":[
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote3InvestmentsAndAgreementsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "VMT
Option or Program License Option [Member]", "documentation": "VMT option or program license option." } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } }
}, "auth_ref": [ "r834" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember",
"presentation": [
"http://www.perspectivetherapeutics.com/20240930/taxonomy/role/DisclosureNote2LossPerShareScheduleOfSecuritiesNotConsideredInCalculationOfDilutedWeightedAverageSh
], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Warrants [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to
purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r780", "r781", "r784", "r785",
"r786", "r787" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted",
"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are
used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r203", "r209" ] },
"us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing net loss per share:" } } }, "auth_ref": []
}, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.perspectivetherapeutics.com/20240930/taxonomy/role/statement-condensed-
consolidated-statements-of-operations-unaudited-" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Basic and diluted (in shares)", "documentation": "Number of
[basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of
time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r202", "r209" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in
Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r832" ] }, "catx_statement-statement-note-10-leases-tables": { "xbrltype": "stringItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "statement-statement-note-10-leases-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } },
"auth_ref": [] }, "catx_statement-statement-note-8-sharebased-compensation-tables": { "xbrltype": "stringItemType", "nsuri":
"http://www.perspectivetherapeutics.com/20240930", "localname": "statement-statement-note-8-sharebased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note
8 - Share-based Compensation" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" },
"r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-
1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic":
"205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic":
"805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r17": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))",
"SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r23": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r25":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r30": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r33": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-
55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r41": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" },
"r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B",
```

"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481774/310-40-40-7A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "b", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(4)", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "c", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r181":

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481879/410-20-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-

{"r313": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r314": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r315": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r316": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r317": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r318": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r319": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r320": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r321": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r322": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r323": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r326": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r327": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r337": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r338": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r339": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r340": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r341": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r343": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r351": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r352": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r353": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r354": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r355": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r356": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r361": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r362": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r363": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r364": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r365": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r366": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r367": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r368": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r369": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r370": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r371": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r372": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r373": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r374": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r375": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r376": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, r565": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-11" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",

"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r877": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } }
ZIP 80 0000950170-24-125399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-125399-xbrl.zip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

**2B>0!\833.L]-"CWC5?75\KL+M)L M6(9Q>K0+67G>.@'=(U(,9S-P:8@"[@54.035#GWF\EQ>MYVIO#Q]BK->N.M MK_;K[\"8TS?3(:&?G;U[89<]-UP#8&O%B#>]#!.H9*@LC9>^_.D[>S6O*"W MUMG3<;YL#C1,ZNUP8/&=$Q>+^:P;H;;%E!N3^0U*"2:E\]2FJ8EB"TXCR&=.EV MY;,7KSKO?!N+;U@@.?M!.W+0/ ODR\.MC% (E77SNK>#\O)@-QW4VV\F 5[,A MP98-7?8?P_KF<#*$SIR,P)*C."T5IWN5U.FE*#;08#JG$Y<5A=R&<7WWV?%. MEHVAFYR_N2+B"F+#EI%EJTEC\T'E@!**<6=;>X#7${WN*S$_98=_(W7XZLWD MU?YD,8OC\NH-GG_T:(#Q*7#TK#LOV)J9?(?A00IZX!+ /YH<'$[&W<'$]WC3*3VX M4TK'?7'T(@[+T_&C>#B^Q:S=+\N9I?(41\#?<\/.Q5VSE==>V'YNS82HHK4*,"&R)?AE M<,E2 @!3A8-9/-"7$C>5(_JL=>B<=#+N9OQU:AHM36B%1>ERK7B@+5.,ZV 6OT6 >$-59:>P^6OD$(I&]/"M)>9]TJQQ+D62WJ8<^TK+'I\&* K:X>H\Q#PU]&+:$M#SG8%@+A3PUVUBL13 ? M:O-2F%!C;XFYC3-1L;4ST76XY%-8N>GBG=>V'O ;K/(17(4_Z_S)8EP^=6_S M);OPS1S&1@X}(P1+IBJFM2G 9JS5HN%_OA}]}6T$]JC MXG>CT;L+N$M&*L0OVTP1_)2Y>;:5U\-,Q,[O8ASK[>5F6>3Y,H_JBJT\\K>621.YR'.YD=37% M)RK H8!/>69).\&D3[S4+A(OP"ZV8;7/FHSH:+ Z'$ M^MIY6TQY8D(=-L&VG!78=_84EU\G6?FYDZ=>A2ELZUHTA6*US9PIZRO3FEI,MN199_7:%I$7RC$LDGBE]L#KT0SV3I,KQ:YD.&VLFML-""91G,XHK"'[/L&\|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{9:?)MWCY^@GR;0R]$ MOB"=<@GR%BV\?0-E&@R\A9:]+\VW9$1OQ:\WIS:7A,.C2DY7RUQQ=+T5*PLM M-^:]D5%H[8W(?25-#^.SMTN93&G:K'3HE?/&HH,)BQUF'EV32M?4VK+,7SL@U M09#4G =X9+& B#I6D-,WN#I-BN*2#2GV-]R^ASI0;B]"H^268I2Q:VM*<31T M-1P42SSFVIP4-O6VDOUM /O5!|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{GF./ M$4)?2JRJ+,69XP#43E&9BBRA8A64;6S>,&-R$*+I%GL\OQUG>Z, M11/..5_>_UR%TW3E!.QW9S M'4>L=T.6GM4YT77VUVG%H.FK_3@6YK?A:/1(EX4J/[UU6^UT5@+:$\KFCL0::X% M=4DI+"G32BS"Y=;;5F_G@B!GA\Q^U0 D!>-T:2P[!P#B2Z R=X%Y76Q5+EO5 MXWZ<^+2V>3: M#0*,DDZ;IIFAXELZ4@,Z'A)S1e3#C8,>O_2CGL]=_-8BP2@\+R@=&:]24HZ(`MIYKEA64EBRE"..B4NO?S!S8#\QAC1J%)SM@4RHF-CB3)\?772:BF+;,V-9'PR M',=QAFI\67,=OJ;,3_PTF1;*BEI;]I^/5J%!9XS>4+Q/X2#$K7@(_>S4=+(}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}>5TQ!>Z4 U8 TP7'K/29^.H 5?NK3?9KTO3'H3A.9&K MH_(?*5*C;Y$]"S4"@5!+=J$4+_ZFW0Y=5G[T>6M*_USG;VH="PZ?09A5=>F; MDA?M9,BUZ<244PI<8"1++.7#FC#1%9PPHH]JUP]\$[Z$'2A--*9Z4:RTKS5>BF MXY49X:M,SK@H>FMHO}(2A==3K]MEHWR4C56A{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{(=?$HZNU78]&C>)3'&L(^4$ M+&9CM? P &WU^1UG"GF$QX&\#%'I'N ON6[7.R0,BH5[MF'=]OD[6$]2%=VB@1X2$1NF6<$ZC5[)NKL*TPN32OL%SB0%X5_E]:!0.-YT_ M=TZC=TY'3!)+/U@$3(U M%^-@,$@ NI]S")0(V>H&ZESL$-WJ'.K%)'80=!!4KMB?*V@!B) #F/Y%-2T MW#89S]EL^#_U@>"'\X<'<;HW'+/YY/ !?]A]UN++!<'3TX-7PH,X&S^J;P&3[/]<'AM+(WTWBXG,&;2C%L#}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{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{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

(;Q+]L4S&@S'2\<"G]Q=9L#_?=&U9!T=#99U M-J@(W!.,&0C._C[X[OC'[^]V?E$##&<2/ZPS(_'(-W%:V&@R^7-U#3E? M%B99)T?2+2;&TZGM08WCU>DO_?IB.GQ-MUX;E5A^Q3]
[R\Q]^$CT_N.2+,$, MOGNQ^^O+G>_O#5[1[(}?13=BRYK3M1R70ZEO#[MV!(>+*X70R7T+*XV/G66QU *<--F]YS3K, M_+2;W0=3/.^.T6X%:2NXBGCL6 0VJ¥K_%L<
B\1YQS<6OPQG>;'L*T]IPSOC M.#J.#3O.>'\6P^ MA),&O.RSA:C>3?D^6%=PD7BX\$+".7@*7@1W#V0&Z+W M85G[@"M+_,VEVSFCZM&[8D?J+AT=QH-E6,)W[X];U28Z?
IYX?,XJ2N_^-1- M],YHM+F.U5J7U)CS$Q18-86<[W>,. MNHT"T >]Z*=>5\ )BJ;[YL$QYW1Z:O6^S>#^12;MGI&M_#5X/JZ MFWBD>7ZO'^Y!D0UFDX,ZR"6\=BCR6)
]=B&RY:.1Q_CI827URG$ F*V=W1W M6;@$9%QI_%1'0TSB=#X]]"T6^EX:/MY&G6#F[XT?DIR5]YX"@3\X8S2F6[&4 M]YX/)?S/,UY[${]._RE/%J/W7G= J.N]9X)X[U4+V#_KZV^&H]%
[?Z.!Z[^M M;-&X[L55$QSZG>* L,&;Q)V!/4=QNK9:2UZ((^+=O?TN@(BJG7V$:"O!63U^_M3>:NK VJZA)T8>^^[ZHK:PIG P(=E821Z^_[O**]8^V+>-$RF\]8"-H&Q8
M'75;U[T9PGO<-V3S%E;?,]+_V\EC}(U-L9CDF>-W?G)PVX#&+UQ]B!!AI=W M0*>C!(\7@I%Z65NJ&K$Q]_1X0 JJ*@L8;:)3LZT;N\F=SP- M:#FRL]-EK:P)3
[%6BS&JW:_L[O+PE5+9=2]'KP.S(NYT>M@%N,QENEB%NNZ M3_-Z5.3]EFM9;L.H2Y&$^KNX GHC..3/[L,;R]C(%?5N);%J)>A;\?[URUC M^4C2O8-
4,QFY#MC3,=@2IM#R*4:IV2X\(<"> S6:''9V=[5YLW=R?O)8\U;> M;^7]7/).7!:?43#D:$]29W^)W0[P0_?+AFP=RTX'_#; YOO"?,N9MYQY8<[$ MYPMRAI;*-,?
#):NNC7*XO/<;'QWKPW4&)QU5M*X0[=' [MK'G+F;>2J[BHA:^E<=0D@47E0';VIW+[Z$$?2-/?A7=#;6 M(8/5NP=M.CD@B2@+#)K%T:TPW
K#%HZA7M&QV!KHK5A'M9Q/CYIS7%&;<)F M^#G3"=>DX^(3UX/KZ[Q5+ F>]3*/5]PB2D)2>Y3)O##ZZR>!V#I1$/"-FC&N(/H*@MWM -CAN[3A^4;6 M\+T\,,B[RE<
2HVCV:K6\X26.UD01JFNMSM MVQW38=_^[+(V)N\ ,04(3Z:'D^G.;5@QR;"L)Y2=X)\TJT[#55O 4^? <\M MXKE%/+>(YUM%/"\>OQ]\?C1JZ?_\7CPZF^/?^Z\>/S[JZ>/=N\" 3WZ@C.'
M;:C!KG+CI^7U*K=I+8 7J5>_Y2F]KPN^@;.3FU'\6GQ!BW;_!=_Y]'L^5? W MQ?SGWA1@M; 5&^?6_G_VWK2YC>1:$_XK%9I[8]H1.'+NBWKL"%I2^VJF+6F: M\G6\GQ2YBAB# V
:LF__LTL<)-4A)8 (&JTQ$M421 5"[G>9X\>1:2 [:: MVT(+]!=`0UK7@VEON^: KNJK_+^QKGEQ^78C]?*_N75ZZ/?SU\=_?KKJ=[M MP5+XM6_M:H?M++NDU!]0L0- E;Y,US
M'V7'#F5'6U".[LV. M?SS9<1UIL!/5<55.[OCJE\ZLYC>9+XA_;*_$4*%Z^@[2LX:I5'T2H(1@A&0Y^N_;#VCF8090EN M[<>3)=<^C_>S_/XZX^01%Z5BNH4?9"HW#4*
(A,.%V'9.VH47!K'^IT76F46BQB^7E_!$I, MAJ*M-'.\G(5_GLPFM:[(17&)YF7[M.AIV5<5(S"D!7$,IVN EH\A+;C'}V.Z MKJ3-=+9,B_?A4G;4KZKLV(76>5T_^K)2PM\OQ49SAP3"4-
MMHY-$78(@A-,U M0,M'77(0^3VW7M'W>?*N5,IU1=?W<;P(YVWQS5UHE+]=??5Z4?FZ] MO._SY%VIEW^=UR+SR[;BVONV%/[JZUT(F/]{X[+,?)_KS^_E3*3V>)\7H9V
MY&N)S+^M.KO^-E{\$_5)I^&U%O4)$BY.UP!-'_7)0>B36Z_E^SQYUR&XY??, M9Y/%^[/Y+*18Y<".8EW:CVUER=NKCT;=@;ICK^RD+T2*TS4LTT?=L>^Z8U4L
M=KC58L_CE_KAZ[<'"L/1;G1:6HP0;V!!(K3-4#31[UQ&'KC:&^V M_*X%1YFJT_?4O9^/%_]\GUVH_3MWH3EJ&&?SR^KS4&Z@W-@KZ^@+?^)T#/HP7Q;12?
+]PD[1XO[L")G^_\>'-7#Q"_?R"$68U$>XH4]0BZ 6V2O;Z0NYXG0- MR_11BQR$%AEN\DN9EO1^X7):?FYKBUSDP^ZDN$BMQWKA/6ZM.]GGR;O2'H^3]U(_M'EU_;&H-
SK5&]_=!1CU1L\) M%*=K6*:/>N,@](;.FQV_:[V1/IV,_7AYCW,CI:YDQLN+ST)UT:FZ^.XVO:@N M>DZ7.%W#,GU4%]LGR,7XOF30[LCQN'RZ6^Z=1Q\A95B0P%N]MJ%O^=GZ2VB_W
M8EM\]=GW?MSW[] ZN#C^V(2)6RSJWOF08#J+Z?(]Y;GJCR\>Z]\P+K;]Z1GP MG_D?8(XGJ?0VGQ9A?/3Z<]QO#B;N, /ZD_7-U/=-/7)+A":/!7E&__O?+$< MY\^7']B^%=
(T_GPV6[0M!)[-TZ2MU_NSGWVJXR^_\YDOR)SFY5=_^LY-]^TI MNWN%KG?W#VZ\#E9L/!Y_L4G+:ES\69?NY(KU+AY_/*W^XNEFR^?
N?/E[.*L2IN/J7EWDLK'!/.BE1>CYM4T/&VSMX[/-6([1,K4)T?-RFK3FN$[:8N<+ MMQ<3\=.K:,,\F9TOBDT5\TJ?0CI;-HL3-[_(DCQS\^:CFYRG)KJE^\,CS]). M#V;M^?,K@=^>X%L%?
Z'YZK-4"5@>O;XN+-%>K9(96[++1KR<@]7!OOW=3[YVJGT<+\9^/!DO/S^[?\MO'5QRGU-MU%K^GS?UZ<5 5P+UCW>\CSY5;(-W;? 6]M2831YPB&.ZQ\5J;_6PYO;_'_&P MKMOO
M&K=8I.7B&0+$]UK,O6D+W0W]UKR%QT"(08P7-W)/%[9?X]WXP/>=M-8.HZ83 M3)?/Y%U)T-_@OILQ9_5WW/R=Y.=#8$.W.&FC"$/]HK:!^.@F7^1GW+$#OV>V
M>H(WM_S*Z6S/QOOE%KAKH/_1X:KN1W+CU_[%/X7^-/95VGO\Q=F['71FW_ M\CY;,;9UQ#HB- 434&FQ@'6?WH=LO=7J2=/^ED_+WVJBUO/W-&<?7180?7TE
ML0I<3AZ"BS9GFKFSY3U3=UH&<+Z #\Z=/:N&>#2-]:^7UU9XM'SNYO//X^F' M_ZX1OD^:\^EX]2E_?__WXQ>%_\JZE-_"GS0QA?&IFRS^] 3*OU:Y.'|Z,OZT M?
#8]/X4X:Q.^ZBN>_)DQ-1*"_Z_?CGB/Q^T!71GW AGCSY>A+,MP5E0P0@F M<\$B9T DE\!H;4"S*$G@T43#OH8SR9D6LL"9Y-:"<$R (=:#EM1*(K41D3\F MG-
D1XV;H8+:Q9PC5\O?;U/');+Z$ @ZGS7CZ,2V6IRB5!V!;2"RFK3FN$[:8N<+ MMQ<3\=.K:,,\F9TOBDT5\TJ?0CI;-HL3-[_(DCQS\^:CFYRG)KJE^\,CS]). M#V;M^?,K@=^>X%L%?
Z'YZK-4"5@>O;XN+-%>K9(96[++1KR<@]7!OOW=3[YVJGT<+\9^/!DO/S^[?\MO'5QRGU-MU%K^GS?UZ<5 5P+UCW>\CSY5;(-W;? 6]M2831YPB&.ZQ\5J;_6PYO;_'_&P MKMOO
M&K=8I.7B&0+$]UK,O6D+W0W]UKR%QT"(08P7-W)/%[9?X]WXP/>=M-8.HZ83 M3)?/Y%U)T-_@OILQ9_5WW/R=Y.=#8$.W.&FC"$/]HK:!^.@F7^1GW+$#OV>V
M>H(WM_S*Z6S/QOOE%KAKH/_1X:KN1W+CU_[%/X7^-/95VGO\Q=F['71FW_ M\CY;,;9UQ#HB- 434&FQ@'6?WH=LO=7J2=/^ED_+WVJBUO/W-&<?7180?7TE
ML0I<3AZ"BS9GFKFSY3U3=UH&<+Z #\Z=/:N&>#2-]:^7UU9XM'SNYO//X^F' M_ZX1OD^:\^EX]2E_?__WXQ>%_\JZE-_"GS0QA?&IFRS^] 3*OU:Y.'|Z,OZT M?
#8]/X4X:Q.^ZBN>_)DQ-1*"_Z_?CGB/Q^T!71GW AGCSY>A+,MP5E0P0@F M<\$B9T DE\!H;4"S*$G@T43#OH8SR9D6LL"9Y-:"<$R (=:#EM1*(K41D3\F MG-
D1XV;H8+:Q9PC5\O?;U/');+Z$ @ZGS7CZ,2V6IRB5!V!;2"GW48K*3&G' M-1"5"]4(I<$QELKS"\NTD4%FVX5";HWO7;&]5]>FUQ&#"'#H21 R=0A"S<#$' M@EE:D:1U2,!,@2O!*0?
G>/DGBX)K*Y/PI@L9W!UFM>FJ\.\TGSWY,PP=J?KD M&MZ+G/6;JWQ7B% (94:7BV:>0BH'.C])HV::EK6HCYM,9K^WF?IERS9Q=NZ7 M^7S2N(NW/&MJQD(#S=6!?:?&[A4MJR\
(I*@9"!HS.$456!&=4L$GXE,7 N7H M_3QHC;KV,XMIS1P"XG[M=1!G!)*6 V M*1I"U,76.X'K-9M^G987D4)=7,10/72IAL"%BSD0X(I),Q.]A9"5 U'@"XP6
M$:)0OF@6SUF2G0B4[0,7'5$EAPY=>*6R@RN5M_?YL:Q29_:BVZ54FSMN]9 M$[ZVD5RZ;FY(;G<1RX\K$\SH:9)4 M>2V2GJ>B MG<_2JI#*N;-3>_Q*R<]*B-]>_@#X2PIB*
(Y.#"N_"$T,V!3#L"R3\($[5WL MYNJPM>LW^<5X<38K1OW?@IAGKZ9AXZ43(BG@"/O.BV[47X$BPP'7(VGJ1(_&=N,)WC)OK81@C3B@"Z'XY MT^_N:?
P#YX3VEQS<0>'=;.DFZ#D?UA$<_4[W^IU\XM$Z IP72A&\B'+O(P%E MG6 BED_QH3L-W[&/?),1U7='^N$&1[0:R&(.!:VD)MI+"LI["L(*#U8$ R3+ MHIDI%>6/[I1SQ_YP-
3)\\!%O>U2H]/%3]W_((E[/I@$KM6&!*QPO;N1^+VR_ MQHN!DCL)E*PWN\O/;8!D++1V5K-)VQ0\/#+U7%+BD>F^(U/BQ$06(QA)#8BL M23DR40)&.<5\-,&HCD(C5Q;X=N*FRZ-
I'\EIA*]35R@L-TA@9#UB%R[F0+"+9\<%<1)L3@Y$ M$!QLD+*F.-)RNB^3JG07,G@7V*4%7H&B0W@'*C@MEO-Q6*95\PYDD)>2 \Y%#L]
[&H+GW43Y75O=[27NKV,8]CHS!]=,'O&K M1XLY$/PB2H@L) <5. 3AR\'=:1O!R:2X2\;G]?H>FRC@;>/7>E"@&?Q]%CJ% M=R"''7TV7;OIA["
<7+N'%J"FO/)O/0EK4HL6+Y.9AU>LNIH]I,FNO/Y!U>FY[MR#KWY[?+K(D(X(DOK*.4 ,^-KG^P)*W24J[Y7391S:*D.1QH9/TZ_ACBM>V MN@I#?
GI(F/SK1U)4E&9:*&3C^(9[B8 \$S:P1A(D?0M*;]Y6 M+P !KD2M]A\BCYWXD1'/#DE.HW?YQ^WK.'HV/ +-4@ M! M@F*2@C7&<%OOB78Q?QC)&R\WEOF[8!W!A)8L
M27!"% :QA(*O198HY90I$Y,V:V7^-@HYQ[@W?G]I+);;/SL&E[MV#U)CTI17^Z,NR;C/[;&5;?/Q$#8BA@E0Q() M#(T.A% $''42LBC?Y3(I&SM)'5P154?TQ"T=4;G%+,%[-
\B!D12B(Z(CHN.& MR8DA>:&8!F:TKLT,/'@F;/6M)TI-R"1VV,R@(W2T>F3LSCH3'#8X8L7630VF MP;J6]PZT7W4>AU;7$C?
R8!>V7^/=V$75(<%5C]0M.WNKNK=Z]>'C=\KU\TQ^_>/|___7FUQW,@]7=A^C1?3Z'9 CTB"2I**6I>2.[#!U"2B:RD MU]13H('=HY!:F2)'3JD8>K>#D1T6ZS[RL/T&:FEYT:%C'(?
HRA#"!-2@[F M@(C!%<5+&9@BD)-4BIAN:K9]62O_DD8^=TLBEJ 1N@:_&(.!+JL%I:K1$$H M7X1M"IZ\3@YDBHZ3K*@WIOLV'UN"+H'-
[M"#O!,/VL7YZ05%Q&X91H$%08LC114\M%2PX36:RG6F^C@EZ=GD]GGE'Y+$[?< MHC^%CRSV3T7\PL4<"'[I**3FG@/-JISC34C@6":0962$:25\-VEEN\,O:($K8R18Y0.D' +A
MA&7-.BE3O#VX$XACR@%[?[4O<%RFGLFUC\VH:9J>1^:G5O/P/R!\]MR[DC_OX M@]FHO=$*K(ZJ%BICY:M@@0L:10S!,Y*ZD+N7YK>ROFX9A(X$]G!"S,+%' AF MA42=%T0
MSD5S-(2G"N:EPO#')F93C'S O58H/Z!T1..!4Y\@N IR9V &K*J:FD)30A9TRX59W MTMCNQG7CF_QBO#B;+=SDKP4OSPI/K9JDOKAAY&\N;?P0^*L_->P1/!$\$3R_ MOR*P+
A(I(10Q#B(P!(8[AC80%FJ'-AYZ$32/PIXKM_0C8C>8H^^_J#H3CN! MD"XZ@9!#/"NL.H&$]1,#,EO/C^+H:+HWNX8XFH4S0*Q1(#15X(F31:VG3"4C M,3+;L:3ON$J&&5&!^8"(6(-?
S($@5BK6!6$8I*Q-0:Q(P%E!(-ED:2;:2-%) M<8RM(1:5(Z6VV#_T,#8YED[=,(QY>HN(Q>]H]P^T7T48AU9T$C?R8!>V7^/% M*,C=%WX:-.TK-?"E[1Y-
IM7O86GJ)X+3#Q%W7>*,L;'&O\(+K/::]QF\$$$ M,$IPZ8T-RK,M%H3JO.\X'2E,A$?\PL4<"'[%6.!+$ JL-ED5F5,PU'#@42>M M5>3&K(6B=%@5JG/\TF;PX=T8,[GC-
'B4QD@M2"VWU%@A2FA6&*)P# @5'3@7 M-*C$@]%$*1%5)U>BL^F'=VE^>C/OM#LUS =?5@4A"Q=S()#%=:,6<]$U/+. MO("7(SR $'Y!YP*/1.>TTO]&=Z%8A"P_PZ"#>?
9K\72H8T^>'8G7(+?(69M&C1_B1Y/#2?<)^68.Q+22/>WW MTLJHE0&FJD/%"0M.%F V2C"A#.',=Y+I_B5Y0*-2;D2=OTZ=U1\<2;O%9,Q> M;WA$KQXMYD#0BQ0)RXS-
]:!>D$@5)++"Z%!"BM@@BXI-:]W^'BY]$;WV20]C M9_C'K>G-\B3-F^FM*39(*5@!!2N@/(R6"K_(S%FAI4"+0(X9/*,&O"'"4ZIJ&M?,M]BOGE_*IL@.B(ZC(I^?T1SH#IZJH":E$ 8X<%
[28!% M25((P3F[5]9ZHXCFCM%1Z^,ML5>;=]'EZ4&*^57%)U3PR%'(49W%@B1*&/$% MAJ0FA6*43G!RS^%%ED+ZY7O)C3ZVFH[DNR*C93!@H0HVQ$2$1*[=6H(*H52
MP!QU(%)UL]M@H>:)L"+/G8MK'<4?6(ZJJX@X-M(4(7&;SO>'U*I:*]S:^QJM M#1;_N7>@_2J&,[3B/[B1![NP_1KO?E=N[$Q.WF8M7R_55S^&10HP_@0GXUA8
M]UDY+UOFJ8T"K"8!RODX@N/:@(O&&E=;V=+TS5]B! D^!P922E84IG=@J52@ M(Y>9):XCD1VR\//9Z>EX>5K^L6C<-#:K3@$?TC3<]*'=]M; +VZ_Q/LJ1>7\!D_!B N("
[B1<6'[.M[]/@7O M+;L=+V?AGR>S24SSQ?]LTK_Q\O/V+U@2(8S-*# C3S8A>W7>+=@O2]88JW M#7>;CN#_=[Y8CO/G#4CP>SV<;^>7.?B+2H^CYC]N@3"4@O#:
M@+>6@Y$Q^!".%TPQ9G#<>4:I\IHI1B";4/:ABPPLRQ8*5 42168LKNU=+V22+#J@LJ(\D;[L!A4@4V=K M37V=U7[L7:C=)K"3'4I428B\ \BR#J!K:& M2 B$%OHBWF=&=CPXN6=[-
Z9%4365;IKC0B-E&_^E3F(KM/PD-6=?BI%'VMDV M2$ZU2!5+ M9]CC(X;RPP6; UQAS8.G!UM;-?+1;G/[SP]=J^+GX5MXLTO3-< M4>D1"=<0."GCDE2#,2P766J+I9O&\?
3#=@8G%$F6%V&HA>+E09T!*Q2%X!W35M'$ MV=86KK28 P$J9QV16A2-[TA164E*,#*4\UX,U@=O0W"= M%$! H-J+'*D?K&K0\>U =].W^?7 ?
1'8L^F]=P'=&Y\B,:A,@"JGRW&EJ(2B M%%(YQ&5E,L]!V$Y4PFIL>^,X3Y'2,@0"SM?!)U?..B(%D"80KK*)VG>"/(\\ M^.UZ_1_DY>_>?Z2)
<3J$5GTO/!%SY/:P]F;:)WC.EC:\6;MWI\OR=:]HIUX\#O?EUE*KPJ@0+.I M0(W++&APl.Y0$RK4T3!8,WLJ^W,CY]]U[TF0F'*V72Z%ZX'DR6!Y(A@DJ@@ M?=?
L\5#OV"TE0O1(*C;2YK$PLGJO=@2.15-K&2$E5Z\\C0*OE88"!IQ:JVDT M82L0LM5-R%@HP!X3*$YLW5!%PL@Z2%]0,1M%N.RD)?16-R$S(VK(R!KYN,#8 MB>=UU)1?
=9;*TWY,D_??MRJPT$\%5+>6;;L6L&KIUS5EYW-%N,Z'<_F:>+] M)]TY0(H.EIX?0M'!RCE))? VB&"%9D6Y=BSFNL0J-OCN MZ]BP8@?95$>2LHR VM$(:.<
M''BE*62NHK3*9DLZ<8E=0\#;@@"OIL]7]G^#USJBM$*B(RO%'T(-0P7YMX?U*['ML]I.D.8A MG>^>3]H\BYCR.(R72"=8;;W?U=8[S /XZ5'2CE2)9.,EYD=PV,!!6% M6VS?
1!^UW/N7>^2N[?#-LJ((S@C."/Z/"LY!>%)@3(/.V8"0M7]H5@:V'Z-=Y>N*D8Z<%6Q@^P?NW)53:X;);=9:>BZVN+YC#UE M57?&V7DM'?F8)[3O\R3_Q]...K?/Q$ ..U#[(U-2(&FJU1:,
)>\!^:CI590 M:MW.86T3/]:-)NA'T[@]KY:E(RKYKLYN7VV= SN](6XB;B)N,H:,QB0JVR?8O#P3E+]=>?[VRUVWL_Y& M#(@I'WWOIWWOH!]C;#\4[;+I2.G3*P]" 9%WTC&7 @\Z"?-
I}/)LXF;?OC3DS2%OQ\-3LOI<[FHUMV< MSEO.9NZMZT;A8*^:5%RQGY2=YDL*R M69ZD;Y2-_];37B'YZ_V[-EEPP.3N5>9E[?Q(C05H07\M :G4A F",W7&QZ(
M6KQ,%EU*/2VKD((%PR4#9^KZ>!92[2/PK5N!WU++!I$5:E7TY*UCZ*/L-R@H! M)0^?W)MO7.LXSWUD-,<(E@4#(BM29XP6;N(Z.]D6>WH4>YNO%F%UIN^X"?VF
MS]0LZFZX>HHO=NTC/E7*N5AB,IU91/2LS!K)4U&^<5&M M]/(#V[="FL9,,KO]|%.=VO({GUT)KT_?J<._O1K[N1F^S%HO.W'Q9UVXDRO? M[<7#CZ>3\,0\Q,)LC6?N?
#G[^7^L@U)_/*B?^CP.?[^E!WS_%=K=C;)_A]M:-\XS(:?U&XR71ALUUB:)?6T<[C4UHL MX89UK5E)M\:P2\V^\:S>XWMV$',_"V2(N+8G5-(87R,>F\'$(7 MH^;5-
#QM[Q*.S_UB',>NMDUZ"+5W_3-SL]:K1R_YKCWL_Q^5HX,+00LJF,Y MGU]1]/-+BMZC)6O;,UW-7T6S-U?SU_QT/G7GLE=9^_L,>/?+N=]E>#/NGBX+;
MJ\O$B^J8TZ(#9^>+\]T"#^E32&?+U>&Y$$/[FL:MCM2X@(] 73BX0QYMYW_UNY]\':3Q<;P8MX[SS\\NWW]+^,7JXX1^:LU_WA2*%^-<*<4_
MWO$VNINWD+U]LDT&\U2KW7S24\9V\D'VJ>S=B-@V1G1/*%6+0G?'4NTJ6'CO M-%#'P<.W/.$V9^%V;]!6@C#5-X(P?R@WX_'FILL]\NYDGE+SM_+ODT7SLARH MXI?
?WS?,0M^3NK 74_D0\:[&"T:U=U&]7H\19O:8DPU"@$4 EO-QA@=@9M6, M8P0F)'LTG!\WG&]VH$?#0<-!PT'&>=PS9,/C0@YN\S5[\?(<;3]
M'2WN:AQM_T:+NQI'V[_1XJ[N_6A__%;K!WOS;%(9:'~NM.Z:T+_.W739U.S MZ7G:>I&*0SN@;,WVZ@ZWQ>X+5.QO#=;.RU$(QE@.C@-1O):C#@E\=@Q$4I$G MFYSEMS1=-
L)RX8#4PM5".@-.A@)/G$49*=.![(&-4Y\1B]<8\&CDPK!$<$1P1' M!,<'@Z/RAI7_#0AA. BO SB6/&BFI0XI:"K3U^"8BT(401DPT16UJ8,%YY@&
MJZ0HFM(Z:>6C@2,=,;;7 ;@0'A$>$1X/#!Y),CO9H:M#:MB&"HU, X+VHR M>>_.IFG9,A'@:4P*9J]X,Y41N3,K .=#4:>M9R(\(C\1JA$?,4CB,UB8'0RR= M-
X38+E#N73^(G@P7=W$OEW5@P\5=W,MEQ>$>^'!Q8P]@N)M?D4G1X\CB\2)*+ M*GS3#TWZ=%;+!RZ>(?D-QF@&AA&XBP>ZK_,;+N[B7BXK#O? AXL;>P##W?P*
M9(/NM[7'UT.,W];?1#7BQLNY7[@2_<1FE%';C,'E8D'H0(%G{($SU6TU$AIN.DF?'UE;$?3^.+: MU%ZN_ 5=7;"S$6%F>S?L?=[>B%2]6(A57+ M#)-@",2 (R6#]']$DGK-,
M43#=32SY]!%*CJ1D"%0(5(->RIX'E8]$!6LB%%CU83#GP6B1@:487(^QT"Z MB>O>/E Q,}2(E(=[O9&\.KSZG8.7M*;3*CAH+W.Y3RH28&D6+#,14:DT)0[
MT4W4]0[.@V+$.!TX>&V].@:Z$I_\^:]IFFK#X^I)=+&\:KQ8SMLFJ*A\>VU= M2!XWR2,9(KR4A2V23^6X'0L19,\@!R]##MD&LD8>FS@3+\RM<,?1%\;6+7VH MD=4H?
1&JAKV4/84J'Y4U(K-R*I<.1.*^P XQ4$[:TJELDUJ_]]C$F[@;J!(C MH05'"%4+5H)>RIU"EG"'&BP2!V0B"9PW6< Y"2^ZTL%*QM0ICF_@3=P-5U(RX MVF(:-
&YP]"CBZNX1?!4E18ACHD" *2"5&0='E .;7&+1:I5NU=CN>I>LR;F2\?[EI[M^^GUK+O(_'5<.^M#^GE"WKA@OBBD,$&60[E60GPKO"%)\$+Z54YRW?
B1.&8]6=U*A%M$*MSCZ'G%U'P!@/UU.QE8!,4>;C1 2$L% M$&N?%Y>)A<3*J9&&Q&CV7?@RMPZ(ZW[-?D6Z?%^=YEL]91@PN0/GYJ^SQ:(I M9A7'B[/9PDVJ:_-L/CLKH_[<1E&F?
YV/,1N[?P74=\9H@ZV;KK,A+$<*A*E8 M^4:"]Y2#9IX19ID)6G82A.G&TVK&,Z8O6B,>+UM>:JEKL=5TA$'$0<1 M!^^Z& I,)2TE")(3"&,(>$L]6.X"T4Q$8M>T^D81GHB#!VH:B(.
(@_W'0:&5 M-*2@7R:DMAD+'IP*##A-) CFE;>=.'$1!P_5-/9CXR,T(C3N.K(^2NIT$7E$ M4 ,B.@6N]>YZ*Y)**@>=.PE-[08:%V5FRE??*MFQQ<)"O4'*G4:PMK_QH5[>
M]I<0!A'JBN#@F$Q M@S7,DF28$.N9L)NX=+>&@F1F(41!1$%$04W+@QND_!&AH@)&5!B/*'-RF" M'\22X*+49NV"?
Q.'[K904.@112<%HB"B(*+@YBAH0Y*9%12D*;J"@CR!IRD! M5R:G1&,PW?ANMX6"G(RX0A3<9@'3VS;9ADU9]R62^8<,I\'.?_>-M3$B+2(M(NW^(VWT7%%!/? @68U-5
4_O0%M,]$Y>L)E)P7R=H"T MS(Z8VF)5O/XA+4;J8*0.7J+A)1KN8ES6P0T7=W$OEQ6'>^##Q8T]@.%N'JG3 MX85W67I,7RXO2" 0";7D?V^?I_/V"E^_:<-DIB M+ >E> 81HP6?(RO_-
$12X;3QH8M(_5?3C\7":C.NU6W[I.NG"LV6,8F2+:41]WM:(M4+U9RIXBE K4)9),)F& U".(<..89Q"RL(]Y+IW@7P>%,1B@]LH@1AWNQD;8
MZO/J=@];2A7QY"UPPVKO&I7!:RI!6RTM/EN>I/EE+QK4NKVVKJ&2QF[2?8HV+H2B*,AD. AE%3A."/#:8%/>SMAZT@$B(2/B(2"B*H M]-*#C;Z<8%568)Q70*SQ!>XT$>%!KM<=
(*'LUU71HQ2M0/?K=]O1RW^=CY>? MF_&T+?'SG$36 MKGQ.-U&?EY65?IG/3E<6_+>T/)G%ZRO!#9NAY?&G%.'?.3Y[\F<87(4EC+U"
M/$0\W%]USW*@]8;1')!.$?!4B8A6XYMU$S3$D\IR(W(C3_ 98X()W5,H()TU3.3P45/P29!")-9>BFZ\):_MGDUG7_8DZ/;"EH_D)D+7>4(A@B&W;FV.9-$"0U4J Q":PO.Y "19Q(MS=FP
M3HHQ;!L,J=YB^_I"(4(A0F'?H3 0F1QS$CAWMS!A-F"]BF"T8M09ZD)>\W%L MXFW>-A3JD19;#&I&,$0P1##L.Q@:RV*()D!.68!(11(ZFA5$SP(E26G'.W'X M;AL,S0
[H^ZR+FV'S3+V)5;\AZP'V_3=.\[]0$IEGD^.VU/[N/I>8TJN3A_ MSZ8+])(=4((SE@#8KQ#)Z)/14AN@,0H0U#%P) 0(C 01M;11L.Z3,)]?V?&; M*S/^2\JS>5J]
[IW[E:8O/RWGKL#C>.KFGU\MT^GB]6Q:GV0^FTQ:Q]N/%G#] MSL!*..*L7\5<,74(D121=,O!YLQ+F:D IV(&83P\%VB$2&56HMXE,-=]NN5> M(ZD=R9Y5Q48@12!%(-
WR)2YAV@L3H$R_+_(R&C#,%7DJC'%91WCJOO\R;T&#4FY&5&')/T32_5Y31-+]0M*BB,4V,U MI0#+902MM5!!9R7DT1,O<+,AF7)%--0 99SM+
<<-#:"G":>BMB5J&;7,D]A4P^,AI!$^.9=^P' MKEN^F:VB6<9H;%'UH+0B-#8)VC,7XN]V\0CO3VH_3X_BK2#0U[T3B,$(P1OH<2],Y8KJB!X5I6F+\B7 MM0#C
@V"R\0J_#W<(XWJ=!^M93]CD>_KT'*0#NBK0&3?WJ^4#9S3?){B99N6 M?M4?C1-Y5U(8 =T^X/7J_NE_S-ABLBD@#LM063APE&=53@**2IVC9U1WTJ_E M^B:U?
#4YC^/IA[>S>7V0H^5R/O;G2^@VD>P1++#<2["T3'@B 7*M:]BS,K&(_D1!*R4L\\XYO1:^][#:&7L!EF3&Y18;ZB)8=(E@B6/8.+)70/$4E M0(?J6=;2@Z\-8)CS.?G(O"%KZ2$/JX^Q#V#)
[8A2#-A#L-SO-46PW"^P9$II MK0F%1&0!2U(.Y,9S 8R9I"DQF71= F,OP)*-RL,B6.YS='/O/,LOT),.5Z%X M%=H),?%*.#IY$%%$$(P2\,E;R"(SD6K&+PLW_>)F$YJ7" 2'JQQ[,?61W!$<-
PQ.!)N M0\&THO9T+C)1*PI6. ;6RIBR4,HPW4DUBZ[\;M#!"39XJU7;_!RM]'#L@L? MKSQ '^]E]#"*]VXLCCVMVZ"\LW_28_)4-]WO?(?6Z.JVR?BX,EJ-Y>>0©
G2ZA1N"9_;Q%M8U2'S=6?,)F[I[4+NE@.0$7(1$> M^'!Q8P]@N)M'_3SDF/*-4\G^'SO^XA;CT+AI;.)X.IQ^:V64#V<6WKTCK8$ \5<;>_.:.&;V>$?54EQ>=$I:_3 M^DG/YFE2/O)CNO-)*
<8U;']J^NA'ZUW$+.P'_.U]/$(2BI&L*-_8 P@6%7AF M)7 AI4_!&VY)MT75:WOJYU?@O$VS5LORG'UEWP9L5"^3/%XZ99M:Y'3 M-"_+_6(VF;CYXN+5%_$,Y&8_O>
<(8[ZMSI,B]9*U"):7 V$O">>A)U MCCRM16IL;69>K+Q*NY\;\I316P(]L P>TLW!KRG2S<[I)C)"4C "K&>I@&JT M8"*U!2^=,;#0F;=<;4CVL+/VAT
VU)JA:>9I1HB$8PB8O)4X>D&Z:.7:XIT MLW.ZT3RZ,4@WG25(:#>&%[QS4Z;.%Y:$X<)[IG68Y"NBEZ^$4%X07HYW:X$S&[G.6!$ MOX,+N1.*!P,:I3)?O/":$XZ#L8Y+ES-
3<:V4]R/-W*.YI4!9L+O)?CHHB(A8*M-D 4[HP(9,< M'-&_).4[^3HXWI&PR/-W*,Q(97(A(]2Y7*#2]SV-SZT:10]Q"J7WRHW@U>X M_1-,6'_ZWHE]?

1]C:THS:F<>B&X5#WJ48&C3I7#L5))RD+GJI/[X9=N/AU/ M/J1@JY:86\3: PVD+:&9R2)@* \@HHC@C*0@4V8Z$T]C3ML8_X44['/N9A^K M=B-
1(5$A43W*,9\E:VERX(WWA:A,^2J6PVJ.TK!RQ/?*T2ZN,/>5J!2A7@5! MP5)"0%0'MI?60?29$1^R86R-J+L8_^,0%==(5$A42%1(5 ='5,%))^MQ0$I9 M3@?*%]!U.0*WY8CA'.%2=-
)$;1^_^H[2!4I3)F."1,K12'CIP 2:07+FK+!& M"+66VM/%#.R>JLE3=5L_920J)"HD*B2J_28JSH/DBD>(H=;><>58X6)AJRP#
M5UYQQN@:46UR_;>_1)6]UZ)P,C!:QBV8$N!M^N^##Q8T]@.$^ M3JOP@^_!]X]VBE)6J'!F*^Y!6H9"+YGQ1OC>>%MLY/3M?UH86T[3$_GR()CA< MW,4]7M:!#1=W<2^7%8=
[X,//%C3V X>YE\<[[TKX.L7+G6M87IGGM(Y/W)-;C MD3+C>QKB<4=_"I*LS!U35@6Z::D9TLN$!"-DE)RSN1CGGI&CE:>49>GY_Z M-'^3VTB#Q9OSY6)94&4_; >J++#RH5Q%
(_";T0C -XK"B%IDYP4%$I4!$6(MY[T 9H51T2K)V%!!E@X'?3,I_^;8NQNV)B/%+(9?8'E-I RDC(XI([N">0,I RD#)Z2QF,I"RT >IKS0=ORRG#&08RF6!LC(J; M-?
3<)#_GT=#SKE+_2M&<-"DSP!"ID|"""8RQ)FPH;;"8V\9*Q4J,,8I#W M+C%D/_!6019V!%8Q%(KE/0,1(RD0",U8!,*D*CAGFKJ_'KEG$V29_;,1;SP MF3D?
0!M3&"'7@DG6.Z#E=&&2$DJL=RSO<-C;9A&F1HPABVR$(9>77N5O5QZ_ M_7(OCA1???:]'_>]HWZ,P7T'AET_B=EPI/3I5,Y2V?-Y-EM.9\NTLO[7[]Y+ M):,@+H(WV=3T?@,^$0FTS
_3@;(EO-9M>V/:?*Y]8*1H[M,4>SSUP$^S6B"I(LEXF4(PR5Y3U%EQLN&3BC/-<%3Y-.7R/]\7(6_GDRFQ2X M6;S\U_EX^?FW5#!ID=H?')]-QLM'V6]05@@H>?CDWGPC+
H5CS_!R3C&-'U6 M9CEHK51FH%F@A:Z%!R>2@91H,L(1[EQ\%'N;KQ;A"EJ^^&OG3U,^K&R&9E%W MP]6S?+%K'_'94BX"JYIE42/_^WR:&BI-,/&V.4VI>5YRBK<'"M'3CR>+I
MS2%<0ME.X/M:Z?:2G6X?W@_M@HT'^ZX L0LU>MU-'[?AZV51%7I4UYE'%Y MV8>YFS1G;KYL9KGB]B\)5^"PX4"/R>M:M36E7-U>3]TTC,O+%S7W_+1\PHU-
MLYK'./[8A(E;%/EX5I0H3&&#?HB4(@\%>4;E8C&^?/E!{9O MA32-M\2B^-FG.K7E=SZ[4I6?OE,Z?GLU]G,SL"^$:%F+BS_KPIUQ5^Y7,;VS$U^=\Y\7/S_YX^6.V(T>
M=\W)O!+^_RB@_+X^U-US?%>Z2_L$OZ]VE"_DO_J8AW^U M.R]FPT*$W1BL/4T4$WQ^>I;5QV5_^ANK-NEJ5T,[=(ZVGE\2HLEW+"N-2OI MUA@.\T1R/8W[>BZYN0VO'\UN.
%OBVPZ2ZUD;PHGE$)Y^6 O1@UKZ;A:1L7 M>'SN%^,X=O-Q^HXVWKMZ\&;GQ\CVI!'WY%R,]0$O+^K-+Q ME2!HH:M,7O-+F;QP\!/YU)W'6J_F#_OSM%O>4_PR/'C?
0."G5].B\&;GBV+N MBS]\-0FM&^JV:.>6Y"]HH3YC98EB-O7E4!AP=G[1&/KGU4=20IZ2_[Q\0ZAE MBI>?9Q23ZWE M_WF3PBX&O.*P/][Q/OI4L@W>M<%;V%-K-GG (8[IGE0
TU'R\KIE/B1%S-2^ M.WMP2KP)%#LIK;3M@6\EBTA|(XMHTRYSA[0+7I?C2O.W\L^31?.RR(HB_-)9 M(6^?Y@TGH\WVR.;_J YD'R$P(3]8GKC$("I^J81?3I-8#^DX:$M?&D+'&VA
M&R;>0F75N^L;=3>)7;D-[O0I'1W_5_/+KV_^<=S\\MN;OS5OWK{\|>C=]]=_M;8Z>OWOUWZ_>O7IYW&EEH^U.S5Y7'>ANZ(=1=J GX\6-W-.%[=:=X-SZ<[F']
MC$178X\/*CX;N/+YEVT77D8$+XUY;@KFNC;P0;MF_N/&4@ M!6Y5CAE(L!D$HPF\-K7P ZW!\XERKK(P"IV_6H:9J?IUV+<7_;9.'YQ=V#\ M][72X'9$*=E>0/S^6M3V^S0X$T0IL+?
&@EOK/S4\75<'_T,S.4HT,G7YHVG28\7*<%N@T&]+9 M>VB^!MS(@UW8?HUWETZS5L(^U&O6_I*#8]E?9O,RJ=,FG,_G:1HNTT5/OTAM MP"/B(0C:@95*V?
K)C1"1:28&LA3E%$:C!V]8]$W0B=)2V\ Z\?!=F.#*S"PM\ M-W?3Q>I!_NK&TWJ<'TLJH/TSGWJW0_5KS/=(Q>80SP[R,4=")YQ(JP*5A1L
ML@2$#/4KI\$X8371+J:T5!MA$T_45O#L)HRUZ2SP[S2?/?DS#!W -O9%H4[^ M$9/Z-,E%.M*GLYKGAT32SV;5L?NRY7%M>:W&5NLB5Y*>G;CBZH7P0K!Z@ZP8LQ&0B('
M(711L)8&L%0702LYH2G&0#A]B.K=,ECQVPK'#V[HR-X)P+W12HO">.VC@IJ MW('8%E+'O3K7"Y*%I^!8IK7(O /+E 4=DP\A>)\)XZ<(!?-/TNM*X(VD&SQP(M5;B8 X$JR1QUY>P-
1<\R$.4$7FL:4U",NNA%HI:O|!:A21@P=J-"' MNQ.)^X]Y??$LYUH$;3S]6+X[FW]NW&(QJULZQ>;W\?*DB>-%?<]X>EZ^SWS3GG"L]$%G5@TY<1<)_W!1!6]:E+@(D>_U@UO$QG<
M%4ZM0)]I8,W2X0G_O;@(::@9-,9Q:*'VV<).JB8O8/2OC_MS6FT[_.A^?U3A@ MY)2>6QQRRGV)/?7ACCVXF;+E]>&B/J8=3#B%V(7=^'7316..P52*Y#T;:TX%"0 2)Q/O#(
ME?"Z"SW<-79]9U8Z&SJ4H>-X-ZGHI[,RPG^O8B.*3IXM3]*\^HT3)LGUWL:0 M8>XM \4%K6V4P6I9U+&*#(I65H4W@N91>NJUZ4(=7U>#^&4VOVF/?05,#)Y+
M$++1P,0<"6E3K($@R(!4OLEAD"4;)#"I1:Z(Q1M-.HB6V#5I\\(D,Z"S>C0 . M89XNU6^K>VN3\?&\[2G7S'SYS'9?(Z_TW-Z05^X5PS9;R7WAE:1]$<.60!' MA2AT%
(09XJ(K)&##XJ%K@;U<&^.;*_J[L]"(3!,W%*(L1OA"^@@^^=\4>*%! M6U&@2&D.AJ@,7H:BB0/)1/E.9/%VX6O=3ZR&#F+H)]Z)3*XW'<9>UZ";^^!&
#"_!T)^\,W_R>5NCOP!%VMYXS]E33&=EZ(DP>/DUO'L6RY429(\%$)$(0;<$QJ M2$(22W+D*CPHHF/,.(97;NBMWK4(?W[BIA]2]5:[R63VNYN&5/=D$V?G?IG/ M)XT+H&]Q!<\OA:_
L"9/,0E(UA}JY",YF \2$*)P-U!K7A6_\;6V1 MMRB?^\ML_N+"QH\N3+QK3Y+L61H[JG!$RH-'RATD@VC#:"00)3,@5$[@=.*0 MDI:!9FIE?
E"MY6Z1#/4W.L'W0W^7LV/9E\N$T=7(+L@N=[&+4LK3%#P0SC@(`MZ7B-KI:%8H0BBA2"V7)T]6]IQ3IO\LL+@T6RP=@1!+"> -C!.Q*(M8$(6_2V
M3@J$**+::EN4M0LA<^D3C6N5BCJ-W^X*(-<#4WI6R_X![@1TCN^X/%ZV1DO MS^<8PGU8-C8P]MHZNT3ME5&! J$F%_D=39'?-H"@,GN1 G61;Z,.WE_.%^-I M6G3OHNY9H
A*,P0O!*^[/-.*Q:!E!.L-*9!5D[(==Z #-S8R3EC:2B&\'P_QB2LO\6Z18K&'TYJ'B\[G(=@7$LA]!!*8,2RU'5 \+P3B,ABF M.<1@F!/.\5MRXS=1OZWY_:5:W_,QM=5O:@19WKH/(*@A8LY$-
"B03(NB83@ M;%&]1<^"H<87=H]$<25L?%A4]{Y B]"> 19-A2/2>BM\7*:?YO$U,K.FWS=)] M:GR:IO(JI)*>FQA2R;T)-BY9JW@$(4S1LBR&PB(F@TZ@):!QJP$56@HF@O((X5@.-
:@16B)R-M-8"M54 .?UPT6&E[48X&3L_GHR7X[1X]JV-N#^[KDL"*Y-;?_*G)^S)_0/] M7G#0;NBWHOL6R!O'BQNYQPO;K&BRVI7I;3:O+=FGD(:?W1^@H&*AR5-!W;J MV_JI3
@A@R$2,*J!BBDSL"9$L,RHI3&1@43ZHM6-$HT%GQ;I15K]_6IZ:8N_ M79EBUT 3MTRQ6+5,CL%+,85GAP)AMZ\SC:,74.@I<1 G"1PV&4 9*\A"2
M2\%Q]N"ZL^NTXNNL!=ZGFDGIX;&U+/O35J?({&.5^"S"0@(I34X2G3YU:.6%((J9,2 M W??QKY=&6?AG(M61[}1UUW5"=$8F$8+V4D#,/ M(2CX (G!7&
M'Q[X4VN4O&O2KHMY5Q"8S{J*W;&,\$2" M(8#=I=A%CH[G D$FUU]\)H+-)(%V,1 G38QI+?:O&\7>"8!A,1ETGS^"^[SU
ME)^E^6(VG:8)^LP?;F&^;+DTOWK4.LYF,9N,8W.Y1H=A@QLN]]>'/Q_^,I)P M4OLD!>)5];L[,$Y("'"I%J1C7+J]5\>E&4+\\/9O,/J=T$;'9O;>=FRUF0]VS
M@58H3WB_+0+0]I*%SB(!)>0J:* ;1!@/":PZ.9 }9\:+?E5;4J>T(^*F#)AW1 M;?HB^@.9.W6^W^E'_A'A?Y!ET5ZG91/+MD3Q'VZ6 M2BL[]6-K"4AP2'!(< \B.,ER2EQ&(PX#
(4@E.IT);TTB;.L[*FBQ-!L>[G MQ;C?7MCV7S[_?5&+?+ZYM.JC*Z/NB-[,B&\SY+,_]{: B8#9\'\^" ?35U, MC'C@IXX#+%@A1- J==,!44TZ:1]WS8 ^3NS:/7(DBUF'.TK-!]:7>;]P?T'
M&%F#A6?O'6B_"K$.K? L;N3!+FR_QKNQCZU#@OO:I;9'[-9^VN^K^?"S2;R[MM\#1\7\UO_SZYA_'S2^_O?E,\^KU?[\\?O?]]5^;H^?O7OWWJW>O7AYC4X$A M6=;0D 0W\F
7ME_CW66\61>W3@=YZ704XWA5K70YJQ=/9V6\G]N,[?2O_'9 M:7D5^DQ['MAYT"',!^_O=)P:QZ(%?A,!D8T!3[F%)!U3*0;-UR,L-KF >NL^ M5VM>O)L=A6+:_3VPMK?3MQT>32-
+R\-OJN -#LR?4OVP,)*")D(F8\-F4E$ MP4),P!@--2C-@DU2 -&\3)4&X)YIV<46T<\BTF/+]*%%G*/^K_%^55\6RJ@=H M9\A@A5@L9YT2 ;)+6P,@% !.QP+S@FDF1?0I;$?O;A$]*
MGRT*?OR?#Y>?FYFN5FTDZ202[\15CE<:&1 MOUT8YM$T/I]-)JE]IC?YN-IH-=%7UQ;:6=;XB+&>=3_%!"$-H2VNYH>,)>E M"PZLUZS %)'@J!=@B(@Y>56T<2<5F1X?
VA@;:=4SE\1^)V\/5UZ?S\.)JVW* M4%$C[1P@[1R\ERB0HLN]4^!8VZ?,4G">9# ^*D%2T*F;PDYK7J+_2I/X;G;) M;L.:#033255$(2MY2A2)>%!AIBU)%3 M[>V#6@OO"-
&PA"KZNA^ICI);[>=:/FGU]:KM0-7H_SU.OY_-QAC."HF+U*AU=F_1> M4].^EN-- SD"(P+C5BL9)26LET!4)69@F"22>4$D%(WH6"[QP8UUW1 M(V4M(N1^>=NS;K)C?*H-
XNFKMSN6"H5^6Q(?';P/GP9?70T6^#!9A!29/#, ME\2)K-.W'&UEM;582G65Y>HL;W*2X;.,!L@D:+"S$;,7H7&$I\HLHZ Y1+ M4\M9ES.')1ZT+,<'$YE6ZY&+'59/?1"&?B.Y:"04UK/>\
S2]P*I6#L+:V=A M[2S'$C]WQA^S5>#"+;P0W3,^EL M%1=9H\6FLV5YC/(-YR<)G90]#]\Z+#D@[\$(C'8I#F%H+0"H;,#ZT*93€
MF7"96">5D:X,?/$FOZ[V.79EWEWE5:M^Q3KC#0Z"(X+C8X.C"(X,PC-0JF*- M*!-@5.20#=,Z,"!$6 /'36YWM@R.$L$1TL;?K?K1HNS8-E$[S$Y/9_7WS\(_ M1\W9^7QQ[HK@7\Z:]"G-
PWB1ZJM^=_-Y^?9BU$P3IHL7IAD9Q7XL.H1 A!!4%N'QFX$R.X+RD)"I50&TM1^VA58^Z 2[,GT;7]P&IY=E9VTX
MZ:;GEHAT=?">7F2FO&BBN20OM;/;8/=M^7WY3+E*3;_N,W'?/=3U4$#?VJ-NG.N MKZ=+/E6VONQLMBH)\&R>)]XVM+AS'!3YK^=P@/QWK[.(^QAS"! 4+5Q6$^FL
M=@2BT#1S;@11^B'J/;CEIR_([]4%3+)SUN0:,GP:!H+0]P XA(?7J>N.DTR M8T9$H@L<46WPBSD05&.1>N**H&^.U:.Y@A>$LJMF6EEHH6)ZD O\@$ -?>/H
M&]^MQ+_[;ZZJC7[P:>0FK M7F#5BP=QFXJ29Q!*4O"14XC*Y&2BSW:]^/-#NA1T MA[QK+A&U16_(ON+O@42N8ZG3DR*G.;QM.Q^+'"*9#DBLMQ>^A4IU.5(.1)H M6\/;HP"GG
:BI?1*>)O\6L'N#@N0_G)IU=T7SS-V1,06VXCM*[_A^0(A$R%S MF^V$2?+9" 4T,0G"D03_/WOOVMS&D:0+_Q6$=^>$'8'DUOTBGST1&MG>T+XS MEH_EF?TX45<)>T"
@P9TV5__9C4 $F23(@D")("NV35% NA&5V7FDYF5-TLM M VFRC3RC2<\Z)R\[[#>Z/\@4G%>XW&/4X33ZCCY!G@:U2=4W%W!39OZUZ]2 M,G)O"7M:ZJW,3K.&RS.MJ,_%
MZ!,.9Y-YTZ;$SE(SGXU"":F7]ZM_=N(Y*S5CZYMU&%EPJX("A_^@GU1*VXH M1)Y,SC0G?&57@S7+?S]?2>/OEX+8#I>;Q.LO;'SRMS0;3=$36PKX3RM!Q[_'MBXA^V<^K)??
W3S]G/&1=Y, 2O60L#WZ:" PDO;^,N-PC^R*3;$_4. MWCS8!1CXA,\T*:'N:1Y2,V>#130B,@7""HVLA!41O
M/%%*F\P[:5N2,RUD*B"Y1=?",0&&V#):CEI)H#8B\]WJNDNM]M.HN9@V;OP? M""47> 7^71YM-%FD^ XQP;5EXSMR+.Q0L!HKZY'A=P*N3NMO[.,2TH5>)4B
MNAYA]6Z,1._8WVF|[Z#BTX: =BO;S__W;V[^__LO/O_[Q?O#ZUY\&O___H_? MW[[YX^>?5N_C:.^]^&?SV\^]OW_U4]>".A)=L2*%<;KPX_2BFO!AWO^_[DTE
MWKX3/5&*BEBKF47=YFP"820#5(>NG+[Q3+70O#NNFN;LHL_%66$>/VD5N)P\ M!(?*,M/,G56GH!29&@KQ;$EH-]CPR/1BQ>"*P16#MW1,5$HJ*41190H0>PI.
M1HY_,A>"IU*QSED04XY[[2Q^*"(&R_8WFA"\J:$RH7.3[E@,#5#^GQE@<<<- MP343N&8"UP3*FD!9&;D2]B37N_79VPX5W &?O=T]21E_#Z/QJ+7,VDZX#X_^
MSZ=M'U\\0TR3HKR*QETYN6W;;GDW;IMQ-1]3FC>O*OKT2!K[ACZ5D7M+V-:- M,^U3^4P)=JU"O:EEZ^'I":.F[O)@M"^'GH(FR@@MPYDRB)0>.,=\.B)(D$8 MPM6N
D^O)S=/,U_/W[C9[.MH\N'O;KS8U5CMO4>,CN,@LL+9P1*SPMG>VK 8 MSYEPD!6"F-!;@TM<@L_:VIBMT3KO*H;S7'!&]=":WJ-9G=ST+&=4M>Z\9CO7 M;.?=*22=>4R.>E!:6S2R-
0=/.0FP_42A:8W85]W-D[>D M3K$*EX=U&MZ*RI.[J)-C-/#_F,[=^#&!Y^;C]/-D@&+ZC?!S,\=_VJD$ZZCV M((^GG^L9>TU0K@G*.]21B2;ME&/@2':H(Q-%?
9"*R3N:EP.5%'4"F*N\'7%Q?C]D#,C=&4^ICB M DV4:1Z@6=2>CHTFG]!T:\<63N*M0PQK#+>4L'[EOI>&;FWA#VM]=:DM& YC0@,E%PWGEPG^A #?7"=
9$/69BRJFO[G9?/7'ZX!"V+0"^DNIQV@U3-.^.DN1[BJ.KX:2 MFKZKFPHE9@]@;00*66I%*4%R4O+<8V0%B3D0*FCP@OK=S+P[]D@[9F*U8Z#
M]^L9]3/8S,^XT6SPJ13]ER/JOX_2YXOI:#)?GD W [?BYS(*?)F9-_@PG<;/ MH_&XZIX3E[^]>[ZE>ZQVC%CI0"@N0429P8L0@;*(*HE3HY5[\JGT/8JG;=;Q
M+E]7/9DC]#;,V[1+'8^),.PXT2P*>04N! :>^\B% M)NCE/H<7NWKEEV52IQN_FY7"G/G7MY-F/EN4_0WTTDSBJOBF_GZ+&R;GZXVS(G#=;5AOH6HBCDOA*1@ M1=+%-Y-
@//ZF&0TBH)2LZ=2;;Q/J>%]D[38(K%Y6];(J0ATO0CVTJ&9SY^_8 MH>]OLQ[XCH!.&D$8C67:N 2A(GIQ%@$Q64<8T3$JVVDGNXU-^70$[)B": :J M4XOB/BR!
[H<:!7FI[""DX/.+=:+^E4V]-+VG%\O,HD)-]-G-9J[M.34?Y,O8 M2=5F1R6./=-FSW!F: 0C >UMR=!V]HJ"2T*"HUHD1XB1KM-;9->QD"L1?I=, MK?1N*,6O)_&_5C);3?
1JHE=0.Q%0.WH3W4B6%2,60$0[7?C(P7@3 ,&2.!#PU7IP6CSVG=U[#+X^7OU^D\#68H-$G5WIN M%3O>A3!;GJ_C#ZE"95"1Z5*/9,">X_RTE{KQGUD VG M(+)2X&
((H(211@I+4!'MV[{OXMO\?BF^})M>+X7W[4IV?UG):K7OJWU?H>U$ WH[7MO ^"9"@@D$Q".E8:K"(,L"TZE<=:H)Z5UO!!T/LS*5T.J3ZSP=P=6 M/OY;R-
#^^@"!4OCG\UK0&WMYWW??L7YZ=MGG%(F?I)Y!%C?K4C\^L<_T ;P M1L4 C(H$0AD&+A@"(5%&.8TLQ_3=X,OY^-7833[\^W=I G||_Q+K>)_2H/4; M^'"P9?
[/PQ]B^C.1(PW/E8;]L&?.>74R]>?YBEY02+O3_D78\T;/-M^K^VHV1!!__YU=BD-&\S0RL8#1>!%6B4^:3O4B*5),MR0(2/+BH0AA(P M.FE(25P!!>>1ZH,0@-?GT\72#QY>S
M:=L",HV_(B?\]Z(I[\^G^$X>IS!O9[#0IT1QO*EE!DN4R$:">2A]_1/#)0*149YK5+%)IUOC MW!^GXYAFS3(M\O>$JJE)[1OO+\.C^8N@+2!]@)*G;^[FA="D *,O\$48Y]\ M^N4?
@7M&DN# M(OH!1*#FR4$^*2%5I)EX^6+"-ML281+E+GVS[,_S2IZW_:$_,OKX#_B"KQ"\31++5.T2LD_,)\|F,<(6ZXKZ_*NS]>%'-J M\N%]/AX?+9]L%1L@9P)?*'IVE+^NO["]%-
(DWI+;[J=?ROKQGJ\NIU%\>:!? M?_^6'2:O\VNN&-)B],.0[N-EM&7U*/)>#3!IY@CY{]RB_GTQ^MOX+8N7VI M MO(RYN(QK>^7&G]W7YL?O_FW-$?
L]+%D;MF[P<5;LF7]!G?.^\E!WI_%=G<[; M)CL"]Y^#?KPTV6)QZL%LNRL+/^2.U>[X<>HZ':"1VU !'FS?*EJ]%[;H-N M:U%;+6TM'>T^GE&4A
WIZDC);H5A_T>8^\"]JVT\5)]KDPVO'LUNN0%WE=0, M:I\\GX:SUG-\O?#.*(S<;I2?YSKM]\,$SZL\EN5I"K4NS4&0[LVEL?%FT]AX M7TR,PZ'3Y=#0-VTI5E/JLC9]Q/_U+X91_>-
@Z2L.OE],W"+BH\4?#F<-S\]K MA[#J[]^6D;#318,@@'B0OH149@^WU7@_W-B1]K3VMC2(UA)8Z8[RR$65X'K+ MQP'5Y'2Q"BO^N'P"2L@9^=/Z
ESWV%TTZ563T,Y&MEYO7!L'6=[[NYM){9]& MS6C9J0/5^O1/TCV67\?%&= R3YMZ;K7=I.+[MSNNHV=,\"TNV^(2M&B-LAO_
M>YZO?;8%VC/+U(FM"8E&GFU1A+"ZJ_VYSS"Y9^EZAIE+7?WQ!DL!W%\\Y Q M3+N=%/C\IRU//3VC[AD])BE1WT%K*=XWW?9H..#-LI;__4-J^1^]1_=- M'#T:ANF'-
&PYE/!H%EH7=ZR+JRQ:%W?@BZLL>N2+.X31KN>C&,?ICEVTQY7B M?&_*[_HYCI5A'B?V][L2A[U.YWQVYYT/KBIFI;LFSW5;C^VV,K2=;$GMMC*TB>^ MV&_DH-
A=CIBGK\R62@/*$IVI_=V$U":@ M/+'LG"646XZ_1< M]I2H% RPP!#B7$[@E43T,B2*))DE^?:QAWN!*T6&4I&*616+8#HZ0?<6L1W6K ML]OWH=\+(E(;4]*
_>"@[">@9=&@PP,_]_Y1'C'X8P^:R,C!1>3141,&9S) M>(O,:-1>6>]VBH@/:RE/B1Q:SDX)&I_04KYBY!%3]/0PC;_;O'@XF*1[D]:K#CJ8U=:(S4XC-D:9,DT"#-$*A"JQ&^71(LXL*R%"
M0NUR4_4X[@@W1(*S7("(28"W-H$RD09I0E9E*L4MJJ?(;XH_+6:CR8??VGD; MRT#.QDBGYNF1'#Y4J(\DT?W61[V$KUN25:K$7Y=XZ6G,L4SG(3RBX1@#..T=
M*)54UIZP*#HS+W)5YSI9+>Q._M:+0\>?P0(24\K(,#8ZV&P#F7A(A T^V3_:&7R\Z?/PDF+VBUHD0LA>H9;6C MVJ#5I2@KITE*H05%.7A..2/$$ZK\3=0J8\0U0E8=
(A:GFM.$WX%T:L8QQ3-MWVKG8=\0W/KO9 MS+6CL^>#[$:SR:D8 M*3J\7GEPTB9(5FDN)2-*/BDL$=S\RZO7L0P5;J<;_C&]:DQ9^E*^G:RZ4EYI MX7>YM3/?+17OZTG\KY6"?
3W_!=5K:VU6O[B"6P6W"F[WI"EGQ1AQ$CAU! 0A M%DQR%*SR0?K{J=5/BD8<%+AUW&<]-+R6U5:4ZS$A^X%R,3)5<\OTJ1QA=&]TCEAN:HA
MC$KDPUE:E=9{FYM(DJADN4*G* 41(P2O% $,LN,Y[2)YWV+-M45CS$2FQ5 M::M)WVPHTM_3,CTJVCT [1R/.5-& M06?'002FP4N;@5IM+%,JP%[}0^%$+30 M(N&
(8YQQL)P[2%$SXQ))DI!=%&8<)NQ5(Z^B725D?]!.>>^#R@9HB@'=4VK M>>*`):J=8S(XU4&[;0HZ#A/MJI&W@S!(K0-YK"C^FN:#\;1IJM;94H[N'R%\ M#)*V):D?
-3^YYZ&3AXQ//F%6]:A04>'1J'#4]BQQ6I"<&3C#+ CK*#A]&.2@ M T<&,O0/4M=Q&TJ!!Z)7%0(K!!X8!!XU#-)C**.V631LJ2EV$]E\(1) MT%$2,T70RCRI#.:) /NP<213ZWE5;B<<
MNJV)#G>K#NUT4HP3B$I*$%('<()%T(P:YP/1.O&;JH-$[0Q'&]EHD$D_+@5 M*4.4>"E-CA@G]C^YGNFA47*H3<\;5%:8.DA"UI&!^^-FTZ[E//">P/E 0FENP
M01F07%I*=&0D=!*SML*K?8T,9#W/HZIP=9"$K"UGZ%3)AB$) 7H32L03%AP MCGHP*L>$R!,3Z9Z)"I("'1I-,K3&1%8<'"<&>##HEDNO."?/!U=,/##FD)E,%
MK,,C9%\QZZC/*IF15A&>(%,A"R(2L-%D\)('11SS7'3.*JVW(9:V:C(Z#\)Y MC@#J2A@^.!6H]<;9EYA M0RYWCJZ_6,S*._/!?#I(7](LC)ITQWP7O'0U!*8JGA.6QJIOOA&FX8DR8260 M&-
$"9JAJ3%8>/$75XYE/FG7R]W6V+A"C@7*J4.EX :Y,O19)2<4UE83S1XVK MW^RZ^?-*9./3Y]8;-J2RYYJH@EB_"=D+$$LDI>+@@Z&Y'(9&-(!MI)"H2SYR
M3K/IN{X!+&V(/Y^#NT+/T3YOH*7R=*R%[5TQ2H=]O("MC2Y:E!FL,\-B M.,0D4ML.?-&80Q260% 4KZ'>E0K,!#Q(:G+TB7/_0O+5G?;*646QBF+|)60O M4$Q(F55* M!M1$1R
3W)(!DX$H@3R3)A.@E_CE*>2H:X-TR"L%2#9XE#P-=I M3&B>$5J-L"/E^@I?)T+(7L!?CLD88=$(,R44K"EZDT$GD%$$1I4VS'82.JQU M*3I'(,I(0 @$#)^=
^T$H=00:5RGU*4:8<<2DZGC9NJXF:I47EJIG'[/M!,F MQ7V^DO(M7L!>2I(H'A&XO! @B,/?J-!@7);$)4N#VTF8XC!AKQIY%>TJ(?N#=DX**CA7 MP$@I$XXR@(_6
(F"$V6Y"]CTFX3U3A,M*M&W@["(+4TI8Z,J8TMC[&Q\>F' M3@ZS^V*U12L]"XJ'+4]2VA62E$&D24#(C@*:) R())(FAWS-H=A&CJK(4C MD8L*@14"">P:I21,3HH<4RP$F=QI<#
P895E0&47,'0C<)FY3(?!(Y*)"8(7 M-Y/ HVXDIJ0/.I,$1C(-0BH++FM7YAD8[S/-0MA=1(CV.O2 TB$EJF^86]N, M5?"MX'O,X"M:U'ZTO4LI.+@;Y6]6H05'MM]OO8@B,1
S.4@O!EO&+*'+RE 6W?%'1**OBT&[RJ,V!+-<*6? ,QW1-V<1G.,<2F->60&\15$9*=B(!ESF)$8IF4L\OL#,&:J'@IQ4;GP-!E6,/ V,W'M292C% MX!&X+*-/N4U@C%/ M$]9:D.-
ZLRR,ALJ!&(..O],(84YG(O+V+-`)0EAM=GYH7%_AZT0(V0OX,MX9 M3[P%@9886F!"@?.) Y.$VLB,SK'C\4?'@Y+X\:C0[1>$9' Z67"$,>V9%^F. M2,X+-
#MG/>]U7D&LWX3L!8AYI5SDDH.E%NVI4'JZQ4S 6Q4Y&EK4DDXXFEA) M>%9XC:8!A&0"3,0?W"HEVGFG[*5 K-I@%;XJ(?L#7\J98 5+8$-&0TR6E#XJ M I"
<1'11AL!8I])%.QIU4."%1?ARMNAPB$49T3C]$;5VVPP^#].F]F[_&8 M.F^FZI1=ZY33,YIVPD2NTGHBA.R%!+4FI MLV:.3>?4EI9UULP1-UVLEFA%A<-
%A:.V9K54E+O,@'7'!043AP5CK(%,I0V2, M4+U$9ZI@Q:.1"XJ!%8([:<$,LI9U(P!Y=RB(P%"@/464?;(8NI$YS?)EQ5 MP?>0P+U?.FME"@#9GS;Q/%_-T[M.L#IS9K7"Q,U:D*TX7?
ISZI^5N7_YAZ+D] M:Z(0C$A,,K"4H28*I'33] 2H%ESD9+U+XJ8F2DSPR)@&$8H;$N/=>DH4$H9 MHXQ0+KJUH'L97"/UD)(]ICI\DTWJJ4L%Q<.Q.';9>[BBXSH0%ZC6NG2)U G1
MD1L&)@E:FA<96[J "--)*]L*'8]Q3$X%QPJ.%1S["XZ42!6=E:"\-PB))I<# M"0N4::&R42D*?A,&O^,;\28&DJB*T)6
MA*P(V4N$/.I#Y"2UBL%$,*ZT<1)&@;$(K5XDGIQ16;G.P/)@+4L>05H&2D 0 MB9BM+8*&QJ]!QW,N6XU%Z"4]&7=GGE-YK 1&JH3(2$=!OW]'W8K-8,M=[C MG(=#1UGO0BN_R
MWM_=C&I^&C4C/QHCV[]:7W];O++].B[.*%7E^[Z472D/MUHH;O.7'[_[MSNN MHV=,B"TNV^(2%W@;F46QBF!N',_I& MYH7Y9N;%?
C]T'2,>\OQUQKC%JUD=J24KBRY;=S>S\LM\FC'W*F*!O>9'H_Q M0W:U['W{(;B!Y9U__TY]]^UE/BJ;[B3XXT;17BZT,?'HT[=5B*P.?'DU/:+&'X-Z-G%M&F[O;V:I;&;CSZE.Y^*5N^I
MBFT5V[O%]O4YJK1Y%=LJME5LCTEL+[NF#DK;5!A-!JO&J564JRA743XF40YA M<;Y *4IQ\%/*HS":5Y&I(E-%YFZ1^6.ZH>BJD#SR4.M93K+N;I'P_+EBSX% M9,KZN\%7@4K*>-
*0@YM?U^%!DT2&ECD%G_A0I+.**RM\.H8._!5N*EPQ\ S'Y MD."*\"OV"0R"8@@]JG1GLCI C()OF0[RAH0-77E!%A?2@13NVBN,U^.%BEQ'O MI5+6Z6?LB:>'TO9\>G3%K(,D9%\QZZB[U
62 M7!@Y.EXZ*)Z\-C::LIB!2=&"4=Z"BHDKYD Q7+]"E3K*A$'OLO72H$E7[SYT: M14\/(_>,8CX+8;PFD)A%1*(V@Y710J:^Z$8(3=1#')F18R"Y# ML6CF26HED=J(R)_-KM-

**R2+4])>QZAC#*^(^(JJTUH M^[:5>VS>D]Q4\X<7=`G;-(L2=1E,,TI#VPFF*2P]N%C,RCOSP7PZF'],_]O/ M_FU%J!0&[W).L]'DPW P20\M\!)GC-%O5H6T^Z;.'"!4$0BKRN^$ M(:'JO+MUGLXR:V$E1",)6NZ,@$L^ U'DT)!4\-^!,0#VI$P!(\:=%$?O?4/BG<1E!PMUIWVJ>'#^B"60; QEP$=&C%+24A>2DQH]7'HT9[_M=).S4EHC!K_A91EW-L7!?[G9S$WFS6,".? S,&G7GEE[MBCQ35M903M5RSZ/E M=K78,3.\[MH0J$2NTOK2JSTX.3UJFU03H4E4&8+++'(24!&W2+,"B&\VCMD++ MSAD@#PEM3Z6 M=4PE!%*T)WFAA7O6CMP M(E/P5$4C.6?)=*J-(PU6^IR ,,I "%:<<<^!R;K163)DI-/Z M54SK,2%,[@6F,Z1RXS>!=5B"HCV!=)]F RZVB9.>*3ZD9HM33CZEI= ,7G^8I5P]\4P55=67? EBNC({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z&ABY9Q1SG%'KK04KB$4;+7!PE*)+ MR5-,*7?HB5&=HEB'1HN-7* MG@,,N=1Y,SU5/#5,L],L'1]=Q!"C8)@FBNO@)+AL M2Z(X1@P3T05O4\JI, [!AAQA66YT?=M=7^#H10O8"OB2)F5FC(&I*T 13 M'IQV"HB(0:<8MQ*A2Y_$@Q,R"DZQP4"XN&T.C<5Q2J* M]9>0O4 Q3VAD*0C@.5L0P11$R@)82MQ[&@(- OI,_(XTPQ&4P3)F2+>[1^>0$ M/%$F!*XY<:(:84?*]16^3H2OO8 OD[2,SC @-#L0,954/HYHAN97(,;&1#O1 M8R8=R9Q&(!Y-+^$0N9S!WWQVGB.B&:Y)-<(.A/GKO)EG#62,SIRR452-]H_:=&_P_\#+TBC$Z@#>: ,496J24H%(^913S>#F M7[%=EGG3RF/{D?]:2N,.@S-L*$C/LP0JC/6;D+5Y9 ^(7*7U1 C9"Z,C4LNX M4PEB,&A V%C:Z+ (M4PEB)&4C9*GQ"*<972T/O -0V/+;F>WN+^\VAH5O?I+ MR&IK](#(55I/A)"]L#4"C\9*ZB#X1$!(+DI_*0[!21=MYHJGSHCWQQRY5UOC M6([:._7#7JH?YA_O*GQX_<=?AX-)FM]6IGG]J$XZ2T"8ZL-92$- (6GP]=0..$CI+:"W'WB()K31N SJ3F2%0D0Q.2 F)Z<03 MU0()\>+V5L^=Q5I(<>C1G=_3AU&#J)+BX%W.JU*T64@/ M)J9R9.I0*0JN061C$[5.>\<[6954!DX(WQ;@"#&@5 M.:22#J7!>45AA:Y^${(7I*5R2)!1"D%2!8*SDJ2E!+@ H D<[07M)|@A=>['B MA#W<6MBE0)60O<$MK'@GW HB2# TME\#DF']2IET65O3P2VOF_29D++\ K6&NY\!2(1=P27%*P M1* (!Q;/-Q)% 3"(M.!L<<),D"=(1J3K!FNES3D+D(*C;^G1Z'+41M!" M<1=]RE[?/K?D.>VMGA]RU5J>G45[KA[$G)7'?$CTYZ_N:SM&?O ;WB7C- J42N\6FM^Q$2NTGHBA.R%>2],,X%Z#P%]:!#46##2!O23H_6$ MBVA")P*+]BA+/F:@5)98+3-HGIH(UOJ<'"%42W?!KM>:OXW\OFODY/D?SQ_1U MC*T.=>/? W"B^G;QQ%Z.Y&Z^5^[N,&OV75J&O]7EUM"N2522K2/9M)..12H8 M ,X%!:$S*2T^&4A/-.-21Y8Z@8U,A9(&K_':H*,MB0#KE %\R3EC7=!*OSR2 M=7N$##HFHQ2T5TGI,R'Y &E':L4S!E/{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{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{&0I=^/CIPD,QF%V(DT76:#B::DQ! M@ZA>#S \3{

(SN'AX:-1J\[8L:ÐC) MCN>O?^<4]P=P/WT;^;$=]O M2'N7M>&OZ'O;K AO7U#/3]#W1%;[>C"HSP.)XEHD[>041@R/;3L'#_!U/>R8 MQJ_%B#HH?JL\O=Q;

<6R6=4Y@KL7KGHTU61<3WV^.&OLA@X:#EY.0 NN)Z] M5]^+),<5"6D:RF\1 M&24R2F24A>7ZX,;}J^GAT#_0G1I9Y.ZJ%Q=O;V2.KN_50ZN3'_O?G@4<7-Z MW{] Y9VAU^.O]? D\7=#,FIJ#.9(&MSC*)U3PIGB1"B5 M$I7YU+N4BV(UISPMTC*5JB!*86QD81D15[>$V]SEN8?OZ$HIX]BA-Y\,X.) MK8,'/PPAO&;>)#V

A7J2!51BEGE$SXB>=XN>V@M1!"H)Y2(CW#%/E$DS(E)> M<;X<+=E*U>[KH*=1XV\+T#E8!YT+!R.+YR(W]0\D?^[9KZI{^3"}L1-B-L M1MCB,(;8KDIE](R%QF_%9%_K ML11$#TFL)!4K2=V1P#*TY#EW@H@LY]@#4Q'A749*EAEJ!36:K=2>O4DV2),1 M6_^^O%14^".&1@R]5F--RAQ36*ZTE)9P1PU1>9&2E!FI->"KRE>4_NM@Z-/Q ME43PC. 9P?-

)@2=3NI!254%%I&!?0I8>C:^J9[_M 8],*}]PKDIL9!! M!*B8CQJK&3P$DHE,\928(E8SB(P2&256,]@3]396,XC5#&*F;,R4?7@2.>9^

M1XJ.%!TI.E)TK&:P!'X[V(U@ST(E8J)94\QL1@@QICZ,B>6!8#32-Z M1O2\,GI2R5/C)!$4]QGO0DA*MC2$FLTOEPE+&5]K$?O<]GTZ$?H3-"}L1-I\(M;+K,E\M.@9]QG$:@8/P$,2D\F>

M:C*9<=;F..CXA?*6<(&]8D%&$9>GBEIO&>,KR60W:0?]9 36@T\FBPI_Q-"(MH=>]9I"5N2LL)}(]"@J\%Z#T,TJ,$IYQ1C$[]S88>G1\)1$\(WA&\'Q2X"ED MP:EABA2L!/

T>4&$3"G)G2VH=;G)$H6NK&?0+^&%RZIK*P-^V.KO2 MA'Y<=V#SG/YWTHXK?W'3F.+,U3WX>N*25_4IO/?B/_\B4E:^;)-WGS[_ISH= MO7S=QQLGC1MA8,EPG(SA<@?

#/0UY)%Y537*&(?))[9-_5.Y\5%?#\>Q!HVH$ M>L0P?-LH6]5P.XS[(ADUM9V8<6+4T%86GM4FROQK4C4AW#EYZW0S4-&DQQ%_A:+3JBBKT$=IA M&*8^A6>,X%ME3@X2V

%SDMBJ-?5D""]QWT,-A% Q!/&P53:D\0/ZO,V&=?) M=,'"0+LIP(/^M[M<=NEL6BWR]S57\+A1HXL&>.Y@%%]U*8L $F5K'6?[H\+ M7);)G2MD>BW748M/!R>'H_B\:=N2$L+

<8/X0R'K8-[QNI/O %&5L.JA@4(M*]R.U7$8VT*HT717QLZ<#(&&CR^F^_'>-<>NZ;8"GQ^NJDZ[/V"]ZDEC8#!# MYRS, 5X%.S :P'XM/OYPB:'7\2LP]9UBT

9^O<_*)'\+N+0T^6EW#6,SIDM+ M+)6&<*V[X6NGQT=#^UXU?[J I&^ \<877YR9-,!^KH4O7W7T^!6I>'C< MBC10%R_\P'U;0?5^NZ<[$BXB0/C- M^&6@!X+/;U\@XR&GKE#.?

%^+PZ(H?]XB]"-FD]R(TOH1+1P!_.G<" 8W>#E= MDVJ[6N=]"5$> ;V@6 MWM122D886(W*Q;3T!5@%(<=Y&:W,/B:A8>HMB@T2Y6DJAS+M@#R M<B86K7>/M/ZWFU+)417A88.9

***:4%D9EPI-2>:RE=6?]5V+&, M\"I.\FL]G>*<*SGP] &,4]VO\#0YA1'#8]L@E\PT S-(M\#:(J+GFT4Z%W&%75"71_325&H"L;&$Q R$EST .CT_J20M/:9^_>'Q5ID!+ MDS*_W[I"-[R-**

\='+Y[R:7[O:V$"18/8J0WO$T<4G;/$SSD]_S"_##/BH4B8?(1 M%-"Z3CV:-2,_P\XJW]_Z-/>:._<7XK0L,/#K2^.)&X{Z>%@WUM/C=%AS8BP7<

MFVRSN\&OG9\!1+2ZAUS5)PA6,;&OL\G=5]G:B\6\+B=Z1>;,%/+\V==LFOP]! MI@P"#_VJN$MRKE$)HI,%)GH-_C;12Z*7!2YZ.I<[&9VGOX6O=KW4.=N+Y9P MYV9G3+KI%_?

WPR^'R5>8>SMI+I)?JL'@2A >PQV_%Z.U]41X2^&(G!UPRN\V'/!!!I&]-KC+8WHM47T*AUC:>$5 (&GA#,EB"JH M)"9SOJ2%ISC=XE>"]DI:!Z.^GB(!N)_@1Z,

(=>JNF&BR@J^,1:Q+6+;OF]I MQ+8M8IM*LTQC+V&1L9)P^(MHKS,BO:-64FJ87$D@N3]L0Q?8WB?A152+[!91 M,;]0C?JBU%261)9:$LXQN[C0.6@Z99%Q9F56WJF]B;['X'K6@ M)

[P&@+!N0DF&Q.@V29DVES*Y-&8\;&5+(]0LU#[%7WT=Q_KQ;V;?X7 M9B*0:.4Z2%!,# :Z[S*"3U5(G*U!6\!<8A SM4V.X18 F&\ A.2-+$,R&' M2&K7,

(J=RE<._FR3]J1NQ@23DA=?WJ4,KWE]]P35-.'V<.)F 7FF;L?A'5GSUZOE"' MR;LN43L@1)-L-;ZZH^7=A[=+Q@HG4&#!0_Z M6S?\Z>_#>J.=,)?W\+\F%4B+

<"UNZ7@CS&HUP/4$.>G<:OG'1,TFUG]X^X>GG@+M>V(R Q2> M,T6DL)X ?4NFI=%YOE)1_R8YY3//S?L@8H,L!/.ZPEH\1H59>-"7UG0E($!!OB44#:.%DD;=Y6M>W<]YT@;-

***A_7$.IJRX5;!6\X'@"L@IE%(@_10',3K!B!%S5.$= .V@6 MWM^2V.+MHMI22D86(W*Q;3T!5@%(<=Y&:W,/B:A8>HMB@T2Y6DJAS+M@#R M<B86K7>$2MD,-B"0?=>N:L^**

***(Z[>M)Y;D7Y,:M9? FL&5@*QRYGHZ,5\^\6U+ M=[IMG::2A&IJG8^F)Z9^OPXV;",B0UO!VU0SK36W@"(5WKBR[_V&)^?5^ 2K MPDR\!R *M>'P^,#A$ZJA;T C#M@WA]4V>3,**

***IH[+E/\ .\XK:T;$-O %\. M"9WS 5_8H0IH"3#4XV$%;P,PG)(G.F#J.=$BTJEA!J)-D HP\"'BYP @WC?U M:7B;J9NFUNA:ABMP(@>+#^FA%]1U]1(U_"=.VCMT] !I_SZL5S!I1A1 I.-N**

MUX?UXK:A&M&..\'6.*!R5!.P'F,O%&GZ'R!?26^8+#5YTMR^/!N]WVO*DB] M"T44.P&-,ON6SI$-!<*8="PKE",V+3/"&9IH

***@TS3],RSVEFQ5.*^Z.IV^JXP\G"W<_]:M>'RX^)PYP_I^)1^W(>? != MXQ)%+F5,UXTUHO8P63>"5 2I^%)?!JFU-05T\]?+GKH(6;&^P)W7%WA_V1*+ MV1X/,/(]9GML-**

***3^W9$IDAE#*%>&<2:(R61!5I+GFQC.SFL,F1$&-D3GQTA:$ MB\(3Y2PC0CHO4I9+I]1E=}(KU9Z\F?M1CL:O^OC ;;9ZI"D_R&D:7Q>\OO&5_ U&/:'P6OK%Z50>4F#NYJ7EO**

***RU0!'7A%I39XKQH2P:@63J!7: MJIQ(P#/"'76Z(+EA*\LPYQZ1EO"P?R**LC>C;GQ"__JP6#XSZLZT-'2ZNY=L> MKV7-^YG29D?*+L*RI\'VT]!L6^U?**

***G*TK,I#_QI:,.0:BHQ(!Q#$2^%3IQWC MXP./8)9%^^5$-X7C /I"X"[<4X_V),Y\;!FH(S!Z*D!U1N]D/NP&H/>=6@ M3X+RAC2X,W1#P?[C0!U$I+D**

***Q4!AVU;J258Z+;V15M.5HD.Y,E06U!"92G3Y M<$,$+7(B9.I880T3^8H?[-9TLW5J8>E!3H%<*-TG,MQXWJLNP5;D)[)<.\KS"U:0("5@7'_N!B!MQH#0^W&H8.\PP?ZQ0,\,*I**

***MID}QZO.FW+]05(%=MG<<)'..R[0@7/&<<,\IP?J$Q*>P-[GT5B(WW!QYC1I_M>_')-2@UU3'HXN_ZE7LW'8J;-0K-4+[L.,2L&K?A@[R[WJIML0L(_ABYG\A**

***MZ2+7I#_@FUI_X(OVC;._)LIZ,@2Z'-JA)P\6R$+-J%}>GSE9 MND"C(T%'[<&>GS63O3_C-&*NSX,"3(J9')P(4=7P2-*0'-&OG6$*@M4Q3 M5<)U[?.>2X%?**

***#I*3^AQY^&#.EY=UJU]JX+50R"+4NZI!%SL%Y1 VHHM1Z M72#Y:$!!-*7&@'G@4Y+:HK#4.%JBU^?VGJ{OVL39R0!DTYO3T."^<.Z+.\XJ**

***MXS:0YF!0F_#;1_]Y5@/H4RC6%+Q*FWU{C]D7C<6;NCSBD%X2E*X^A[R=HW*? MH6T6UC-QW_!WMUA0*9@=@\'F>]0<\'!4=M]03PSYU3]^R:AN^C(BP0_.]\L/**

MCF[+NL]_2C[.*D'M$&\V)-01=[6SE81,*>R2Y1;P\9,5=]GM=2]_#W29N\">K_4@133*F(.4M7 MSUF*#+:.R?!^J8>2OF&7YT$5GS$9<6;F8)!W%8TSIO3T399&(}A-%)HJ2*#)1 M9

***(HB1X.26VRQIZ !,8SQGQL-/1$@?CIS3A2>)SQXYYQI/ XX\<]XTCA3V;& ML3CIC?7:MP\K9(9:V+VF/88D/O7A4+)>VQ6!Z+,GDA,^(%IR8M-=,YRRZ',O>QR8YM=B5CN67P8Z=**

***QDH9@2P"V;YO:02R M+!0*93SDH9-02Z5P*0)9[(D3.B)6EHKX4)3,K><]&% R^ @6.>0$;&?Q0CEG" ME.&ERUWIB]UJ9.P@RXH(91^]GU+(Y1M$(G8O8R30WN06+U.3HF"N%**

***(DH4*9JW ML:7*23Y9:O8&>;>IU)10FCG'=]#*1C.3%IH3-NO MYCY/_6X-V32+'KF(7W%+GP!^6>NXSJ*49!(,5TY3P"_K/-&"TDQ)HU*U6<}U[?.>2X%?**

***#I*3^AQY^&#.EY=UJU]JX+50R"+4NZI!%SL%Y1 VHHM1Z M72#Y:$!!-*7&@'G@4Y+:HK#4.%JBU^?VGJ{OVL39R0!DTYO3T."^<.Z+.\XJ**

***MXS:0YF!0F_#;1_]Y5@/H4RC6%+Q*FWU{C]D7C<6;NCSBD%X2E*X^A[R=HW*? MH6T6UC-QW_!WMUA0*9@=@\'F>]0<\'!4=M]03PSYU3]^R:AN^C(BP0_.]\L/**

MCF[+NL]_2C[.*D'M$&\V)-01=[6SE81,*>R2Y1;P\9,5=]GM=2]_#W29N\">K_4@133*F(.4M7 MSUF*#+:.R?!^J8>2OF&7YT$5GS$9<6;F8)!W%8TSIO3T399&(}A-%)HJ2*#)1 M9

***(HB1X.26VRQIZ !,8SQGQL-/1$@?CIS3A2>)SQXYYQI/ XX\<]XTCA3V;& ML3CIC?7:MP\K9(9:V+VF/88D/O7A4+)>VQ6!Z+,GDA,^(%IR8M-=,YRRZ',O>QR8YM=B5CN67P8Z=**

***QDH9@2P"V;YO:02R M+!0*93SDH9-02Z5P*0)9[(D3.B)6EHKX4)3,K><]&% R^ @6.>0$;&?Q0CEG" ME.&ERUWIB]UJ9.P@RXH(91^]GU+(Y1M$(G8O8R30WN06+U.3HF"N%**

***(DH4*9JW ML:7*23Y9:O8&>;>IU)10FCG'=]#*1C.3%IH3-NO MYCY/_6X-V32+'KF(7W%+GP!^6>NXSJ*49!(,5TY3P"_K/-&"TDQ)HU*U6<}U[?.>2X%?**

***M&^=,F1*C'=R324&$]E@SUED)5B^H/RMUQN9 Q/IYFJ#D=PC@NW)E".';<'_MYJQ3V-).>@%HE%-&I)49<.jT$I2KHM K?:>XT-J47!*J/&AM3.0$3$U+E,PI**

***M0)O4+O<[1K!"E!';N&!BQ%RT\(SH7KXILI5R&I/N4J3&I-@MJ5*6XY=2L] M3/%9MY@D;?IPW.^MK'8+E%YFV.X MBR]4D0O%5[HKYIG@,N.*4)?B>,(21.4&P"!+;6Y96F;,**

***!C0P;2_$:!OHJE9 MMN-V^&_VN +R/>*RLM8QGJ?$^Q(4;5"[B522$9?F3J6YM8:F MEW%9EHK9TA1$<1ET_XC*$94C*D=4?IBH MS"3-'7,%D7DA"4^Q^'[J,^)=6M#",YME6RG3?**

***Z^HG!VP@D5\B[A\2^\V_(XM+/Z^OM?U;CI@[[H1R&+GYSZ=F18 M@^'9W_/34L^C?Y-j:-VW%R1{&3H9V]#N#"@4VW5,3H<+)NA?3FJV]**

***'ZD7H^EZ=N<6&!#;._79%0KQ-WZ';56R[MW8ZQY4IN\^[*N',GLZ.:?O1}[^G08;KKL[++\!.QK]W'8Z.Z\1GF8W LU.%<7 M;=_&C63NCOZ%?;O4.G[*AUB,V'"%!?9.89/M M.**

***<8I+;/5")T;&'C8 MPZX*32G;HZ%%4H&]8H.V6[>]fT>T M<"3]IW,C&-S@,NN'=?G.4@#PTEGGOP5JF[6{^OG2$W6:"QD!&R1&4S M5H+D4??**

***LF :F1_$M8EV#GLN)ZT;CSN^28;NN!Y770^ZY+P:GR0*6^AU??T' MSH9>??O6O%!,3.+E&9%E80DOLI(H!T#D<^HZK16S&X#LGZKVW9.0A?3EJ2? M!JJ"#[UOE\R>V]M]6V?**

***VH\N= 1-1M,));YJ3EML MV>B.0_O'!>C,J\Z1S++#!, P-^_0.L?/OJ*F_8<=1N#C0 M7NC0>PYT"4C2.KPH= ZODZ6FI%&/XUG7926E:3KK]'VY";JVI:>=FU+DQ,W M"$T@9TV4\>;#)-**

***BOV%P9'M&ZC:P H[PG.7^O@YX&;,1M=W0JW'71+A[1AC7 ML$Y.ZR8T'^ZZ@Q\?-^X8;D'EZ#_VC8N,,K9P94%*7H+@%\82X:PB6C J2LN9**

***MT2OG;7F6ECSWG.09M@6*2>"2DW*G&&G(}5PFRWU!C^.+1%[],TZG9R^Z1?Q MRVSECT(+]8T.A.)Z/7WIX5YU\X6K!Z&AZ= >=)VM8?1 5]@;M>E:],[HRB:#**

***M2G7]_>27GRJF,J\)D6)BJ+3!9$RA[WG2]N"EUDF5E)1J/6Y1)8353I%,_]2 M(G2N"$LU%WAPJ_6/4/?(F 8X^VC\2C7-!7SX#S68;'8X+=$+R7] +AM'/D&L M"%%2DO,<:W-**

***1]*V!Z"A,2I6!J3*[TAQ,**I3P1C1N<.&VCGH8(Y3XITM!-4@ MHZC;Y4S7,\8>+V[@^^.O*U9Q<8:F5M1$"&Q.[D08!"7 M A A$Z62WCCJM])B?G9!>_H$5M2%UT8-VXX3[\\D#@L4K>**

***(K6L7L(5K%/8TE M2&0WMX,?J--L!ZAW/X+JW1#A9]B=0'3&.XJ.W)00_IFTR;OA&4BG8-L<@0[> M63G!E1]D#Y@XX9[9]?"0_U9@0X&I)CK9M6S^*Q(9Z"Y05=P PRWB5M^:S@E**

***M;(/,3(;!7D:Y>.EK()RS00:#NG8YKLD)YFQ+/4H!P!]@OLAS,'9/1E"E6&+-R MJLJ*U&4*%$4F,TS1!F-*))R)=^?Q>V? 3B?Z;NDW10Q[_F/\@'DH=R<9'__N_XS MP@ B13V?<9GL**

***6!+7I=^A(8'>X8U*/$NO54/_Y PBP)) SB4U.# M85R9-CGZ=-2)jJE'!\'!YGTUJ'H'VU3(' 17G$J >\!8:UTR K5^/UUP DP& MSKD B"FQ8BX'V,D8(Z6V3.FR-(**E?I$6FO#,KC(HW**

***/,R51@N?$N)12FLP&_MZ[H2Q-.V;GQD_C6INF/45V!A5-9U)\3!{/"N:=*BV8JO01QN#N+9G6OA, $"_M?!^*^;-UY(?VULPYG(P7C+%N!TY1JM+U:),Z+38T"GCCCXE;"INQ8O7*JI**

***M5Z"3GU3F9(,.W:G.J$0';7K?@"GSU$M74@)@@QI0O !]J#3$VI0ZES.JUT1] M*V'*@AHBC'>$%PCRJ2,>&FTH9G)2KV2BW-/>K \2"D]D')S+LXNCMK6:C^' M"W),)2VP1>4K**

***Q\M'3$1CYTZ_[-P1:ZZAN:!J'(A&^K> 1 MYT/7M"!?5*!EU"JDZ=GB9&N%A77!L#B[VCC99.3.C00"J'%US&2CG*G>.E,Q; M0:EFI5S-$S.%M,PK(IC//"=*$$%Y0=!?5Q2VQ/8=6],0?**

***YBQ"QKZ'!CSU.7 MJ&2K?#T8U.?3XUX4COA[3UD_0K]Z"J9%U-X?B7Q\BTJUM4%_5 -.@EHZZD2_Q MA+>Q4U+YK@?J8(UBCU+P"D1U *+2)1]JT/:S@WLX(>HNQ2>_J,.P >8[KKCI**

***M.+NPH]F0VJWQ<^2X!\]QH)$>38YA!%F(-+RO&H+R>S2^ZB#_8/%D=1C MIAJI=T'O+_4H'&C-?;9'..B>9!\&?=^\'?UN>I\X .E@SI0>X\>**

***M\#"11(V[!U3U/^#&"3H(7H5W=8>VW7O@SRXB-T3@SA3SXC#Y?00*?[@>]?W> M'5,U^[X\ PQR/!["2ED,*T?&**

***({4G$]1+T!_=:2KA=4N!C\O>A[WSV=N<:H$\HP1KKPCVEI%O,QE)@IA>+G2 M4V!9QGW&Y?OH?V]=\.7?:?ACYJA,T\(1FKD"FV$,B. ?50&^EYJ29'23)5<%$IMA;C6 M*8JO^\7Y#-**

***!R53=>^J.SKCVBJ9JGVY\T* PF[=0GT_2RH0!'>YS+Q;+ K^KR> M#&QRHLZ"!QCH"_2 1==/4YTBB"GO&X_E7 [+UWRs"M074K\]<$]54,$[5!+$1 M3-$0TY^X?V%*1G](#TB'|C% Q^G5V'PB*87I*QH0;GE5-/0PFJVH7[K.UP_#;_M,::1G%46CTZ2ZG0$4J/2;"518X>ZF,]*[Z0@&1,@+BGV?W'8T(IY MDTMC|>/MSW#;NA@]7-?N;V_DYE/5Q8HT? MH!&4-LTI ;N3**

***F258#X6&K0$GQ4:2Y_DJQT\#)/>"$N)*P3%Q%6#H2.+9R-G&W,G3]W)PV2E"OB"D$G]'XG B5,M /"D8SZJG-5_2#V_M;C0@ M>KBNN_G>(/I3U1*DU05G/L4$2(^]#RP!**

***(<_A_2HW6IL\)54)N06-02HI;P MN+6$((F#+C#=Y34R^/*YS524 QM<]Q$>ZZ,Z#O] XWZ]V^GE@2K@.NML%2IY**

***M=F\"&,QH>WVCQZ=.NTB>'74WSGPDSZR)M#2>E9)0P0&=4E<0)6U& ME,6C&5,JL9JH;8616D@-<"0*1"=!="YRPHQ37-I4B'FMAA -N@Z:IM6 /KNA M.U>#CZ.0*K $4DM?**

***7:LJT+#>(Y "M3#,(ZE'7830-&!OJGH&H=C-/\$"0.I, M 4B$HH##P450;U$W,"IX!@8*FI,\?^T26.=Y*%,JO$Q}!_.(PGG\/,)=D*-- M -!YDCK:M3:6ZH@GM&*&HJ2?')TLE@'C2%>T<7,Q**

***#NZ%1;2=2CU_Y/J[@JK< MMEV%G[U3=(7SREKF0%)3 ,Q D:Z= (8HE/P6--RMO+:=>E"0=_C5_!OM3T-<'-5]ATJ?,'-6ZD*IM\|L#PTZ1**

***M)QB2#S2TQR$.N_1LKV-DY!{0(+"2,K+9V@R9^27 SDU@[!GW+W[G7,>P,V4(M2M&!$M.,8>!]C/%\SSJM)Q1L&8ZK9M%TWE1MYAJKL*&$2)*)6Y!=., M:J)#G-**

***M//I]6)D:'5.JJ(L2]\+3E*18>7 0A.A6$Y424N<9)9FQ?;G=E>.JG4^A/W3 M6YZ8HRH%"U#H0A+'D5Q8#B1F*'5YGDG+RU11MA7V>9J.JMV]^WLNLAURV96R**

***M06)WB7WN+L%C=XG872)VE|A>=XD^X4HM2.4K)UT1J9GMKIR5MXQ'2XR$D'EU M>(QJ.&P$ENQHW*FJAD$MZO;"7CI6W%0%TOVEGY]JL-.TK4UEC'>H9FVA3.6&!!YV7 MJ2FMS-**

***&95BV3X'NKQFQVC&6*9MGY4KL!/->6>W\1->I)IS* F2\|T\0H*[UG M/E.R^+Y)^L]^]XZZS?L\W;N9WXZM====.-7LA.(R+!R^9]ZZ!%>C"^3>-R,T M-**

***SPW1>J)R;"HF0%JLNEI,R4@A)DI7*E=OS6B6K1&NTKV3Q*HQ1KB;.C+AEA M)NJWN?JBC/GNJVNUN^:.3QG7Q2:#&**

***MN*0[20.E'GM<{),FN2PL#O:34[B7LBAR3_*"'"4#&/">BP$XT.5.2+3+5W52 M62J&O72{YM(0KG)*M =DI" 9O,NLU6*E\.+=R-3C;QQPCAH-VN VVGC?{7[S?=SO!X:,V9+ZNM5F-**

***@7W7FIH)DM>Y'&P2 M76#7-A"_):>NMR^4U0R.[?[\M5T\ M=[VLR_\9^O"&F;]I/H#77.%CE%)T[>$Z=UT5_0+[8Z35O6(Y%E(GJXG+2Q* M^_S%4REW'^\EX,^_==2S?**

***$*%!PC=$51_,(*CP3,_F*%>3@;JHIZ,X17?G'TY M*ZYU2'^>WA#\O:/6O6C=2"K<+H4(<:F>_9/TS' (&9G9&=56W4$^6+ZC(4+ MX4J[7--**

***+@)*0%3\O'K3TD^Y.6O{ZG7O9H>0WO/.&M^6'(LWN\)5_ ^^NX6;>J M_2E5H!ZMS)_'33T96M+SG__K>>YA:)LW4DD?K!A1\XPF L$?T_A'=7OXK#K M)E7<-C'._SC5)&^Z/B.+/?**

***V6CKS&}AH+LF;P=[E ZP_&KZ5RKCGDNSQC6'+\ M-OC]GM[LG]2,;PB9RQOGJ5;7P9.V8+ZTQ+-6>(LRFQ>V4CH6CMJ#<=SK]\ZM0 MV56697?8>T>LM?C88;U?**

***4UXFADUS_8\M[^U:EK_+J0?5;8N,L"&^5Z1Y;EQ*.M"J$9=LX3>*PJB7=&,RO30JVZ]&]R[O5=&_-3;RAUAZH6T_/>5NC30&U@H[F;AX/7$?X#5?S]W@S+T/&MV6A**

***4[8&SS8("REE1L#,**Q-,R9S?I_B NV) MK^?UEJ1$PF>!$>]0K,%D: MJ=-,92N=!>Y<1J"3>$M2@LO- :=/B^ZC)7%,*2&BE'@RW!*EQ%+J06&=Y580 MSPN0$AF**

***O4RSDGB7"102]VQ*A-'C;=-P_"' MAJ'$;"P&<.$5N?]+1;[:%(;5J/U2#*E YK03AWKY91%.WEVS,0<8)--'1/0);Z/6^GE5EY IJF[T7LB,WPZ M=+V=WH@/?=.C{(RB>YPG=/"AA[?'-JV(.**

***ZQY6!/<;Y5^*#8SSG#/9A@I]M',,%:ENF4)COG95"RZ\0!KN<56ZJN, M\BD*GI=E29@N,XR?9T3Q,B7,E,Q;I9A/5XIEI-I0FWE*M,Y3C)-V1&09QL.F**

***M14E+G5FC+Y^PA[2@/BMH>W4Q1*Q4& %K[[*(A4TTX3Q C,U"'LP1 M3PVAG!NC*C/-,U<(0I6BA)=,$2U]00#>,.Z4R@],'+L'P"K3S,%= M#Y6Z]RCTN-48F-IU5A:-996W>?**

***2JIA^6A0R)R(7H%BK#&0.2"YBAP,;E$E:RLP3@^C6@+VYN"\"Q- MB\SNTI?0K50!N:Q1L%VSY'7FR'B?81E?XUESA!ZO['%$Q9+4L23U-N23Y#E7 M.F6D9"7FI%E-**

***I+0E|4Q[GPDAE%]H#7038^ W8&',4+P;,WLF8A7JZ)./,!EA M\]Y\-THIK84CU-I#RCNJY%P7)\6"1]Y!7=B5ZFTW4>/0%B9CL?Z'6*Q_I^G" MZ^?;EY6=EET=J6-**

***'AK5UTR?]M)1M_^_0!^?,"Y*]#&$$;=6X0'V8ZCLY';Y< M*LHZ4A:KE,P-PJSJQMN;3O20PP=KZY.ZH7TYJMLJ/#N4$Z_.W&(*Z8Q OUV1 M"F^3+G^[6.K;**

***[2,6$G8PWF14]RYDYDUVH^+_P:RKMV:=K+7\"Z=^A'<G>Y, M4N5A*H0M+&.0[XN%P*]1"WM6;7K]0GUOL!NJB&CN/5O2+_-Y6-**

***?,8ZE"2=>M8W=%=M8TT]A1T91=UQY\)'53!#U;L^*F M=40DO}\Z(OFA2&]:Y&6?:H=<*IM8;7,]3;:R2[:B7/[\;,FD$?_:>I:?0Y M*K%9@-O*W13HT:P+0?V'3=1?Y!^Z1BA?A:IDD?**

***A\62X)#+=$@;'4+=F5 *A%2EA),>&IET12 1*@U#:G!;=&WJHM](T$ M!EH57_K;-F!4/I:C]4@2J68"! 3 ,9B#A5I9@KC M22&L!W,H+8F"GR0K?**

***9;G4@/N;/W,Y>%4)7NZ"0!_O116NA!U^LBCXF91M2O1 MK9XZD7+G"-_"$0Q.)4)ZC*DM7:E=X4S&MA'=^LNDK8:N;5_5I{H:AN5_7;78 MKWO2;(QI3?**

***K="T"\3P7R+BL.B*!^^BS"O&U%,/YP%S>M/YT8P MLL'E0/JP*-]9!X L/NO@N!!W/0N@_/G2$W> ^:8}?,N&2>?/NDK@_ M#I.W3C<3U5PD68@5AI\+ .Q"C^Q]MHSIEK$M+PTA1:M**

***D00W$^K.'I,JD:.$-]W9%.@!-,>.HN*)]Y2:"$Q\92F M3*<",EM)*5U#=6_"TLXH[5W8@(_HLZ#DAQC1$\7\)Z=]\N46&W$=]B?]D9Q2Z218(Z5,.OZF%;@:H? OC.]&'K70-@M9:R**

***MCH9V2EI;ZD2=\|/-JSAAWLE^1*P$##KDF9**F]{@EBCA1G1>(F&>E'9:9;+:A7_,%B= MN7EWZ\895YV%-*7@> &*!$E9HT#\4)_U#=)fF@;1&M[>MK6I0DZ.;J:9=#<$**

***M#NZ0<'YNQR<*/E, +F6_5<-V;#Q/,JANC[S%11_4$;L5Q5F=N&&[?.Q2O*LM< M"?1.:?* 3C,BBL*@@AK=41IAYB?N#;NGD% MNU6-?ZO;UK7_;&!6'[W?' YU/= L#C?'0^T.,P^**

***:OILRR[$W^T?<62^T-*B MER^U.6RT2(E. >RHS3+/+<^T7:F8FNN/-%*ET2X,BV 8&SA MUU=,G1/&!{?9]7?=K=\K_)N*RT$-KT84VKL=9T9R[ZTEUA89FH2&"""9SDHO4**

***M>2D8E4QM8\>GFM)\T[>TXW0OF7U%OG1R8N8A&+0U2J/)*8JBP6#)U)LE2"\. MB6U0U^L1SJ\-I'2N&E!QVV?.CV7FIU@W>$.?)T/!46@@4D/7)\(/FKJ,]"G MEP1[,X0,XF(!D5*)**

***{%1J19V!+:J 6ZD/@

*MK@M+S8,Y}:7W?D{!?3;ZMM{¥M_T*SBG8-IE)26D\Z+,R*XG25A/XRRLC5):K·M-!YR_6!H8]&=AY@,&(ON;/,L2$G,3tJ)MP8PH>"}>*.Y9*/)>TH(*G\]'$G1Q·MS319?E"P.VZT\2!#PV.J[+5YZPC]H:.IAW7N8_O>>6MXE2,&G];)WL^=BP)4N6?/4/.67A+·M\]4\$-D=-RAY,$0?G0BW;Q^X$ >'@F06TN:,^G1!Y$SCTJ)(B94,8N6&FX:BM<\FTD@[,H!SEC$1)P!,GQFBE2N-+KE,28K<*,DXL?@S·M*XS,^:WDV0V\?&Q, DP<%.D=5[Q[*G4@UE1\N(I34=[RZBOE2A""09X(8!X·M"U.FA.?<$,DD)T66FE(PH8IT]8S&E&$GYVICXZHBZ/\?K>R&+·6?5 [=BX-:/ K?FK-=@YG2(5\B·IDR)Z·T)88QQ7C-.Z·M&E. ^G0OV:0\.57K#'44@B4 2@21ZP*YIH+]2[4DXP#'X"U8%.@.K=[%;=O1V·M,9[TOAV'QEBT,<:TYM)FA)-5R"A*Y3EE1#$G2A ;J? K)>9V+F$F30,W=%?."ZML M2\[(V"THVC5;8+A/C0ME)·RWD1NV+IHS3X=SHHQ9"FF6UA69+8@Q949X2AU1M.:4$1(CR0HF29L5>RYB>D]JTC S7?QR?N*;[;DM")Y,Q,C];·EN1.O4(YM#5 MU49GV@C[%D39\V3X)\]>1=GCI"XR:L"@H3G8·ZHT1!=6$9OIO&2%$33=._MF MRL*?!@HD4.=*"UR\K3S/ YIOSB1_6MP2;9Q;_=UG7"52>}^SIV4=(\&=Z) MDF:I,D!J;,M80;Q@)!>%2,*+-/"?·.4·MP7·C5B**KR-I·F7(W%C,!-[JZ']O MW58M&19%2S1DML!E[X9C·3RN0G9GH,^#!*X<-,7!,K-89%,U!@LIH MZ#PM_HKB9RE!TY2N) M&OY:U .\&@RV9?#0 _J=VEE/BVVBQ7,K[@LTVDND*&QB18%84>"FL6T\TR97M&3%,9X3KHB0Z52G\)D2;2Y:S,.*J\!H^WS=QME7YE8N# MO(@B[+X,L2WG\^Y+PLBU.#&Y"G'MS41CCF',,8S)RGN2K/S;.N^V""813)[&ME*,+^':US;LVGFTR4A>SZK/3QK9)M+G X^S,-.D^&2 MSQT??U7?MB5T#@J>1KD3#9OMR9TS90+51S'S9#@GBIFE_++2:)5I*R[#%H*S(YPH59X,VT2I·MLF2\&)X:K"LK?0$2PK*42,$8*15GSK&RY 7;-W_9/ !_X,O?ZN'Q5]>2NWVVUU(KBD,?%7?%K[<6GOUE-^Q,13C'Z/]MQ"-KA9*&V4 M·E&J!·FV3)KEN+!WAGFDBK,A(YJVR1BB?YGL7O[!]4<,X :51ECW0 M])"82_;@)%1,_WA'4XZ*[^T.#E:,YAXD[IL93&PU/$Z.^]I540U^,L[1>*2P MJ,+JK*14O0@/,#O(A'U-M0 M2Y^\I.E<+*-)8TXPNV/45,8AX[056"XQ&BKZ6J*OY5:^%N],H55)!,T\5XR·MHJ031,@B3ZV45F7I94$E!(@VZRCA:0KWL%(3(30GGM*4Z504VJ@K"%I7BTS\ MM5'#MCL8>#?LU4CL^3"^>(>+ [=KQNV$OO=Q-N8'U%1U[5>>!S;DO JQ$&1 MWG'I#N^AWB35\HM[N^AWB35\HM1E^EVBWR5JP]=:W%^C8^5.1 !'ZF*(,MO4$:YGL4.M=IHU-·MZ_$+-2*CH>KE^,_8"BK2O·A4EMX:0@RC)'..6:Z·1ZXGR1<7O9=JGC8>BK\CEZQOT\7\,/DU#65@;]M=;8G8'CIW=]JW947Y"YG·MJK^3=ESYBQNP[!:F.N6OI&H3H&0SZ=*R59N,3UQB*P_&1IL:EV@V/G=N&#X. M9Q=M%>#PO6)5U63G*G!Q"6U#YE/N-/,)CD;L.[-]-E$VXNA@PV'L6-1 M+S/N!J&;JH67-_7IRC+"$_]1N?-170W'ATNLN([3@!W_!O\F9@!3_+]_&JEC M1X.U=.-!5+"KWM*C>B3+T&REW[&OA5+8PZX[0)H,'(Z?&FK=C10%R_P MVYRLZHCGU[?I(<.;+&31^NR+ ^9BN-_/57-S>)/KA%0?Z%/0SH.-NYDYGZWH^^&@Z ?$@[51WXMA9J,ZY?+7\"Z=A^'C>YT>.5A]!_+CF8"Y40 (:T*P3E9R?U ,0CO4Y2N!VHD%.5ZJYF-[Y"IZEAET3\&H<MVN5-!O O?(V]A<,&M,F).D.= !2"*OB=X5'5]VO-O·Y+A10#.·.W/#3JE3HU%3?P,K:NR >*8;=?]+]Q_K·M7GV-YVX_N5ZESN9I1K3BEO!,>B*%5426ON ^*WU]5H^"]*=*L1IDDI>$.RV(ME(4F"H LS32WPI27+>'/W5Y\],=O08%$D87C^&KC11BZ6;.3\ M!S8R2*Z-!O+]W<"5P^F-L3#):MK$-KRA#:175K0PCJ!F4O*@?!3CC("%B2' MSICU.C-\)?N6,]H\YBF1052E:XDDBJ@/:>$+:EW:6%V2';,0U]V1W8'B.!H MP8'N-K@X"%38 S&@-H!W@.9(E_.L<,>4*I@GVI44X% 9 $;1$>9T:2FUAJ9T M&W*X<;H)[X:@_;C?8">N3HCH?H#?:I1*(XW-Z6)2+@O%)>FJDR]!.HQFA.> M!T#3C*1"\3+/4\=7*>XF2'@/%"-<<@I_G{2)M&Z+U\<6-0(_5KDDR>I"D-.6!3^'"7K$/M1ZO1;IVAO)=*^Z(D/L/T:.,5!M]5* M$ET"SVB9NURN))(7DC!N"8 _1@0I8&AX&*2Y3KGABM5&KR7U2K?A MF\#A/>@7/#^4>7B2$0DOJ4$tUXWSQ)*2%A*T4PLV%/.1:-#TFD/$%/.1:-#^$6;]E7898*.^NT>YNF"MGTXOG,O%T^H&<3!?0-#+8>]3L?3Z>5EO)<8MKR#AX6*@2CQT^P.HQTS:%HL_)*_???GU^Y*Q0#6[D#Z6D?3>/.' MW3XC/C_3!: 4)?))_#"7D"0WT+BFK"%/D_,W7O7]U5FQ6N9[-[GA_/*83 MP<58F,85!K\\<-P/50V[8WM\V-$05*C!FK^/[.Q7C@U">AK9_IQLC#.#-Xl M@,]GB_S%F4G3QTI"RJ\,R=[>!RB·TZK;G^?:?GSZCF^Z;UJS$F2BNE,P_-F MKW\>'@ SGTT],"F\#^BE3/V.5X?)43LE)QA9$)?ANQ.@.B0UM9.*4OGP%F@,,!^-/L*HVK,"Q:L(%,(1S^)7\5M=_XM]?9@MZ$.X%= H[O4"S M_;*VN&;AWD%_[\)FC$\4>H%!(S3CL/0@O(?M0>* *=$5W*V8=H/*^?;@CXDX MJP=G\,T0@S#K29LT5?MG=>D%R#+\?%/N@I$E^J)^,0C3JH3]OO--2U;C$,.MM35-I;^W*)_A\4Y=W19G.J+A*C)BU&E(Z1C*;\", .L(G@3 MG%D#9 G\[T=?+@\%G]XDU>D(@VSQ^B?B^^LXF'R^W" .\YJ[" ^B6T<9YQCA·MVK@0%]NBE=7'#[=]@$H[X^%Z.MN%L)79SO9??7+-U$J[_-7YRB>3V5KAQOO? MPII-/W7?##!XTN'$XL"GPYW/H!\X#G)A"!@D###L@&(-S V,YL-9E-0LCJK" M:.+/\VG/Y[D4W(,#FKUC'J3UO@:ZG·R T[^" '%HFW*FI$'G).% KQN$/1B+9 #S;-0Q7ASD M05./(@(O'*))@\"@?QNCB.D!AIZK3@*K=TG2S)0X0/CC/&T#Q&CYI3F·4O*@?!3CC(\"

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j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l;G-M^:W])> MV!=^E!M_;5MNJ_-TJ)\;<=2VMN$%H@W'(R\>"M9.'9'EX=C+4,9\,'"_ +!+:.* MR\-44*5#"TH>/>WF8Q.I_UP0>ZNS:(.1S\N1Q& 21V(R+>E^>+-><V\3RY9HIYM8X[97N)M/EU[B=_$,=M+O.VG:R_Q.Q_S6_%GO(&CM##?V31RSO;%;K7LY5VCY<K+>^>HWT;?75NIL):Q@R])ECE)[1A-DDR M+|++(P21-)K#]*94OB'\6(2$EV5C!O64+V]>DWG(&RQDL9_CO MUA. R%K68%F#90U;QQIVMH\W/"(2_ ;(E,33B UF1Z>^@<38MMG69Y!C0FFO. M>A_WT>9OH&7UEM4_7T["@=MH/%U-XYIR>ZL)6O9@V<-#V$/#;,2>H 6!90^6 M/5CVL7L8=\V'LZ|"'+'2QWL-QA>[A+#9)]M;K\GR;(`RQXL>W@ >V@WW';/ ML@?+'BQIL.QA4;B7][AV_O&N]4\-O-K=Z!GGV<&;TQK9DPJ47>Q?L7;!WP=X%>Q?L7;!WP=X%>Q?L M7;!WP=X%>Q?L77CDEKOLOOE3(/\T-Q%(Z9M.,X^2[`XIYIN]9^L3Q6G56WB;M@Z3H1^(UXSAWJP[YY=D".HLW8CVXVJ/0*_?=7OOI^EZMW+0-K2ZRT5_+-RS? MF.$;[^Y>]fE"P99M6+9AV<96LHU]=W_?:AN6;5BV8=G&/=A&I^L>-)XK,=7RM###M]HMQ>^[G*:+>#;2>8&/RO!^N@ M?]¥A^O3S U?PCR++P\'T 0<1,Y]5W^=<>3#,(?O^DNWY;?4BW/G7%R)N!#& M%FW+3BP-RQ6IXT63D5?+1P+&G&K]{@MCD65.F#GXI93W!)N=N(]G^T#^83R, MIJX3)S%U4HB+P2G29AR8]'C_S7DPIU^R,|_%# ^94K5=.W\MP MOV7GJZ'PG&L!7.F79]O><&#D"'"A,LY-|E KAC&&P4>8((+O N1"37(SIP+S; M#==I-5H=U_&3\0186X LZ9=NO?>@<<=K >F.GC/U4>!DQW5]Zl8X;JN[<=2&M M_?K^W 1BN"WW7$>S4V\]9]P%ZX"A>N5"+F$<_>/MOF^^(&70Y=&E$Z3%$,7/,!7&(!{@>U&:0LT9@<>)XDP5FF"5Q+")8=)9G].U\ M%*9!#78@GRZ?U$"(I &"Q#*=60.9U!L#06==.U!$(1PSJ!4C+{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fT!N[?'M&ZR7ZL'ZFBY5$E6]JRYD?=-@ODMU-?]WF MGGN'Y(K-[_*SFIQE%Y9=/-I-WG8,3=O5Y!E@/S>S?&K-H1>6(S.C^*G,H-X M/#9*@=-D?%OBV+,7]"_TK"[:$T^GV" 1*112UQTKP!3SX$$>?"B9$$22KA=WG8#@EOI]Q8673UH]]1V"T-@O471< MIR_R:R%BI^ .;R\P_$C #T<(PHJUXPC"ZCI?OAPOO.0[,>+L*\TXXDWI=I# M N+P_;00@4;@MO>K!WQW/93&AKSJ-5M/ HB32J?[= +@D&@QP#QDT ;$, M~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f[5W\%G]J#,Z M!SD+9WV"VRXBOU65N 6.TYC5VFNTOM#WI.T>TKL^)H.CPSASG=/8KY-9E@K9 MX<[B4EM3(^%1E7LC=FODHHP=A>I=>CO,5()O#A."FHU!,>!=6ASTME9<)+D MY^NZS6[3[>]O:V_@@B=7.091K:091J$H\('E!U.$2F:8ZO9&F#PF:MAV"5ZX M]E+0,F!!.YH$OY=__5/^=1<'TBD8S4/[/,2Z:O[$'\OI<;LB=D)*745_6O%99)9]8,W5E3=*3N,. M*XRP818^\TNCWF@:(^BX83D4NJ4PV7%'UC'+%WW1CQ+T*RK[Z$#91TONRK?)M1,0@G\8PI=*#CG];[48')9438_Y!\<9^DORLI447FH,3)W'/VTBL7 MM&QW#>L?DP-9]X&4;+P\\S_Q]N&[$?>W8_?>SRI[__]M!I_NA]O7DTJ62&\WWC1;-]_O%W]O=@P|PWMR,_^/MDYW&_\J.ESHC!G.7U8=EWV_'AV="+ NH]*GTG'Z.>.CM,0<&?3C'G)H/-##, M0DZC7X01=L<#=J,.XY7]Q)7+?USI*[_TGG'QH?Q=EPGZ4_9=)RX0IDNI#IY M@KXT2:CA'\@/T'.Q=<=^1,%4,/!6W"&1^S/*R)=%::DJ711Y2@0W-\,.BM3H M#\YF.ZX;PQ^]3;I;-IRFJ2-M1+5 {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lE?(\Z,T\NU^~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{[QB)G)UF/F\Y'5..5ZY]?<]LPU).MYF&-#//9/5.>/ C2L>VTW8 MH8(>4<3^OHF'IF;'.)+R>)ATD5BU<"W?H%L&XLI29$;2^XHMND MB|&^2A<^;,>)?!O3V*T3Q*<:,$@59P]43S7]D)X?N 1@X8^..KJZ@6-C*Y+ M3)GBFGI!-+'#Y8$OV.EQ+0(A4A.LV-%NPXU\Q-A00?X8;_>Z^W]6HUV&931 M@X-9&-.BN,P'(H$;?C$[1&V4/,2SQ%(>7KL.6N^OKT@I?]WKlG8[S3W6YU. MN|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}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|&,V+B9WC!5)2H M+\K:3RKG^.,3K@I.4OD088

_HCA'5VCGRR>IL'[0YURY8M$"KC7S#TL--NZ+35"R_M-M>[-(:M|N(C%5H[0:#0L08$7"FUF9%78/$'8M^S6Y5#GA5UK#83=YQ"[O&-7-M;ROLWN;=L"M;PY5987=O8=?*

Z#ROKUN5,9V7=.DBZ>;,,,,3N F,^\X?]8OZ M<5W+K&:[V[A5L!TT>E:P6?9O5V8%V\.#@\WZZ=<+*]RV[%Q/J5N3\[\?S[\X MIW&6>QCT^B3[K=SUZEAI8,_"!J_.IH7N)$3V6B)B70[*

*,M?MN$A6E+R(M*+$)AJ^]LD<.V5/>+/P/E,;]$BD NT%2_SW)GY+ M_:^]LL=0?Y'&83;R-^ 1>_B?&T(F,\[J?HRQ *L"=_)?+@8E,'%-H#N_#[R MP'+H8U&L;@H_,0+7[D8.[U& <\?;W>3GN8H3Z_R+B./I%[6_U;^1}>U7H=1 MY SX$CI9,9E$5%I$_ >0l,#LF4QR!*F#EM[82&4V8)*V[A,F*8 (MD6NLF,|_4O'/0F1Y=29C;ZK^@,,.(*

RPM;T7.3GB!N&=)]Z=>B$6PI0YHD*,*1C*]P'O>UX6"W+++N G$2MWU=L@SDRRI4>_M+ ^0.J _2]S701SY,$FY?>Y@*9'M7XD,_N<'UPYB'?6!2(H6A,Y;0[>P)W;YE*

MRP_)%^B\;YJ;LFEZ;N!^UCO0E7P;A> M<[?D;6 #\]\NKYV!6Y38^_Q=,/C+NRP<9J]RZR].?_MZ=/G'^0#:,;KBBAA>HO& BXZ2%-9;,85?AC9?*

M45<@K6A&Z."D6(H/1S0:8$4\|?':\!RDP(D>W@C@@_]6:C46_]EX ^H]\ M228.,T;]%FH/2#/EL=_-&C97809665A3FTT/U_@*SA3_7I6[3RD7R0SS_9)W MFO=_]7-PVSLK+,#0Z])S'!*

[^8OX0]&, M35C8&Z:|2P;MK!'<*OO)^<7WT^.+T__?N)-_GYR?O3]Y(_+T^,+USG[>EQW M'<_Y!+KZM9<*Q^B,]f;EB291Z?:X852Q8=.U?&SSK_O++$S;X]+QU9WD3I9$*

M8;!A'(XWX'WVWGD@U^(EXN.'")(8^DL_]=<$<#EGYW(4_B/;=2XF29+;:NV?O MWD8L[!$WS)+!UE/'UB[L,:'S42@&\|\ 5_]5/W__WS@ILBS7+[!+=T8Q=F[0M+ M M:^>)@8>"'+

(O9RU+)^+^X.0&'OF[UOFZI<68+?8KK8VH4]VIJ8!{JC]E?T-MMR/?3^ RA/%0FQJOZ(=^Q%)W5@'[58'_YM>\TG]R&8^)S7A8%L62;5?7%N6 $ '1 5 !$ M

!C871X+3(P,C0P,3,P+GAS9.RI>W/C,)8O^/_]%-C:>B>BL6"G3%OSL]J8 MIAOR\[L]3HC]ZMNWXZ-#]$)'93\HJD,*LW]KLO#EXS*;Y)@3\+$S%=3ALX MP % X#Q_YS__Y\O&0T\XC-S*

__-WI^]/OD/8MP/!]5=__NI;PW3V<'Y]_=W__M_,Q_^,__8SI%%U?7M^@6/Z.9';M/^.;:^(=B%&[QZ^?H_^U\G]#7]PUWAC MH8O WFVP'Z,I6L?0$]N/ F\7D^&B]W:P^8*F4T[\/,06_!Y=*

M6#%&/W\\^?C#]/1T>OIQ'D,O?=!N/I_OP!_@PC?YR>?)I^.A4]L>U,H]VC[$?[1-A^ MOPJ>/O_T@DK'0H;IQJ2A4K-YOD3G[^9,@?TA/@OS1B=-M.=7/']@?

*U:9NR1S(B?3]:9%SL*WX1<66 M\U7T=YN/>=/Z>/(:O\38C]Q'+#T^A&;%$3^;YXWO9/0H3G196]$@[DU^F>-]% MTY5E;0\,\C^D%^1@!_A^G?]TTT\?Z%^_^\O_0(B>?W>S#*

<(8L<_@)K#!$N6 M#OXU%>LWA5^1[Y8$V'?(S_V "A,_0[=)B((4:A+R%+:=A#AR,/KGHG%S MSVBM$:.B3U\)R%/X1^FXN5]^L\$/SN,'[,41_*MT^,-CW(YG<0/ #_7YE?=&

M2U[53XKQRW]3C^?4%UE[''E5W//UW5.M\Y[T0/9RY)N>M"_.DZZ]!+F8#E^T%,_P"_$K_<,EU_&,#?D-_!G?!S&'AX058/P0_? MJ[\,/PL?8NLE\(/-_@-0^$##NNIB^^E.'RTE3RW?(:Q"

*[\7X*XC<,.K'OD$<]W?K-Q,3%0[U,)^Z7\GAZ OI'Y#%%-),_SGP'75)R1#R2Y/[S0Y9(AOPNPL[< M_PO]>1L2.PH;*^DA$(LY2:321)PH8E3?IK?) M_B;]SFT0X[-/-*

*YB(''M'#;K.QPOU\>;6+R9_F6RK.^2OZUSMK#_L1D<^+_OO& MM1Y=CWQE%SBV7"_ZR_Z"%LH5)^8C0OH2#6Z*8&QT^I"\Q,:'$\6F@((E8I- M&T%;5Z.U'Z'Z<[*R3MUIB0M+SF*

M3U6F>\5) ^:'5PX7>14?Y_NTP]'<8Y%^C^:?+.2OWZL?Y)/98-H&BRG@;R;ISNQ MYM.LUM*!4L5)^6.KDZ(^*,E)>3LG>NZ09+53EW;3>Z2(3,4)^5/G$Y(:[NV4 MZ+Q-*

;'%3Y=PA7>]3?(59R5'WM\=-][,B>ESLLV16S70K3A#/_4IN[R)N28/-MU=&IR5SB:NC[%0V#_&1ZY,_)-/_ M 5W2=]N+@.Z%-N":U_= +;\-NZCWDQ6RI\+7)7OKLDZPV.)-*

*L.=F!I6TVW9#MM%Q\\G7V2+CEO M/_WT^8?:/?\JW2L?SF!X.%UWRO#4[*Q8J1^2X=%,#H_N^//OAZN[%?KC31!% M=SA\6),/-L^FG&Y0L=%_S-]HZGT@9!"A@RBAMRUKOV6?*

KOTG',7"431;A9A= MTGG;5]RX8BO_E+^5G\@/"DGZI29$WI:U=W]0 S]/U9;.^F+^E)?Z;M_ULOY^^? MT[P?L9]MF!A+2%+R1O-_,,5NSE3_E[^9G\(,C1;U,2?-O]EOYQR]!X#RI*

MGD=V: XDKLG:.^N(]0W:L]E6_QYY/\+?XC^4&0IEM,B:..$;F+DWS:\ M_8;_Z1?L.7&PL>=2%0;Y<'+V^F2UA5?;]_Q?!;.H#F-@^E73E5]==^VMOW6 M_GAEN>&OEK?

#7[$%ORS>Q8R6<=&N9MM4;&21 MA0E,3)P2XJ3>MJY[>&Q9@&O55A78B)00U;<=ZK!#G^!_HSMK;Q%5('>?TBT] M=JO #'3ZB?

\4(4[H[=.Z6/A_F&YPN.)AOI%>_K5BLPH,/=@X?E**;SM4KM/ M*_;4;_%?*GZ+(CH(4/[%7]%XJX0W@KQW^RWJ6.(BO-R:$32YZ1!\1\/;\[MOOPU"IAX,F0I\-*

>L<(ONUC_]:^XATM[U"QMP5VIK+.C;=-`MUN0"-[BLN85&UQ@=2IV:[SMKPF_0/%>U^U:L>|\%UJFZ/H*W4Z#565"_95] M*O:]P'!5Y3AXV\]M'H3BO2Y M7[/;!7:M$F_"VQ;K=*

[-7N.8V5 M;:QO5+&<!:%1BA7T;?/&$Y8^=1CVPS3&+_%.))"-&:K\(/VIP"+6GT64PUZ@=M!90/VW'LRS":(}X\8!NT(++CDFV50.2S)IZ{(^2*4)NCS)IXG$/!&? M'.L8+>\'=Z>#B]?*

T(5Z'19O7G%D"@R%>5;^MJO)0,Y&]6;7[5]Q\066PO)\ MCK=#8,#G4WT$ZG6L. %)L-2'!#;IH\%V[ZU_N+>]\U)@>NP1[>WM-/7L6]R^ M2>IT]S@7!=;,E?CVS6B>>-*

*E6%#)]M8^#K6(51R2 E-HR2%)P9)6'*2W Z33 M:5U]BS0E47%8"HRN]9W8;_>+P>,AKP?P1P4^PR@I.P6M3E#S42H.68%5N/8A*

*M2IU/R:0HK%%/N7PICUJB*Y(C8H7AWO57U\D;.K)TN),S;FRIB.]GDDV.1 4R?3R(%Q'Z%54T3"-\.]H#6OVHUNY;M<6Q.YA2_O.+Z0X3D%?*5//![KKU;X3QQ?I7SGVK>]G4,]I:.1AL?*

O]!,B!D,QC M_@/BI[/E07_X>P50=_T >!.3J3BJS7.ETY<=G3EB4TP;>,5-L'5'V+UNI7<2P+ M3.6E07=OEZ?VZ+OJS;_7L6+W"^SDY=%X;]NO?:N3U+?S-U8V=4WYY-NE<;5"?2!EM;

*[)0= M@HHN%1M?% *=@\,AMIK\YFVO^PMFK_&=Y[>LV-FBR&@UN/WMVQU9)4)MA0BK M3DM1#++;6.H1OQZRO9(H:ET=9^_)#\5-*

*1/*5.V]O++O8QB=T;UOUUHKXFH)=)"5!M[]DW0 MCE+%>2B"YE3.0^H6D(,B,2I*#?MV&PQW:O+[*VF@6W6BBC!"NY^HMW)'.H M-78@]=^/ZY!]B(^Y"U\8SSPOLQI=3?*

*6H5QZG(QEETG)2!DP-%AT;)V&^WE*8C M%%P%X<8"W\,NY@F8EU:HN_XJFTA7\Q0U(%QADI(LIL4'*I'<*2,3B\L/GY. M%M\K/T[P/^!=HEOG^?!\6'(KM*'G/5XB_J-*

*ZZ%X>0^]8*X^N'[\P7$W'WB; M#Y9'1-P72F$=XF7JE,I.'TI,/E,23CR%G]^_I,[_]'2,R72)G.QNMA[^]D-/ M,R,_8_(6!3Z1LY?6SHM;SK.0CNY9!QO+],M/.D5&SYSI$%2KV3P"/F^[">?1*

*MT#+;.-2$;VKM'/)6+U'+.)92ZS!P&QM'&>H]W8;"%_]*1/Y ;9RFY> 8A:T]> XXKK/H7AC*OD!\ROI\N#G[>:(?R?9*3M* 4<)]- M7:(=('S(0'6X!Z;UJ-*

=$YYH'+URT[M>&]]338B#ZK5 5@%UK3,N*RPF[E\O1"W.AR M-*R\'7%*QSC;>\|?DM3."Q>J03=QDG3H/,^ 2 M:4U :[*(!B9R[++6 *+6&):NOH._T?*

(T)3N^)2AW:O>P&'4&&)96CKY&JU, MIS'&M#@-' V=%]CQ..T?237Q_,06P<G M?Z2LYE%K-]VE%3W2(7?!1=&596S:L!X0_6"\N>:H|)S2"G-_3;E _;B'"X# MY'"Z3\Q*

>TA2QS(OR"G%_:IU(LT$ED|X1,N@VA%2\]28UI?X,%/4#"}T^OFUT;/2-.J% M6T,Z641N_.*P!/G.O"((!%,.=$3R26AS[C1=-R1?]3GC(!K_T'AXI(R(/

,8>MU363/1>A!9F(:GYBB22A4F%"A.TDHD,U MR8$^*;|_K/3ZWY.&00=4"E+0RLWD_-RN I)2"!S[EF MTQXLKR-@K1(KAF;MK=71 M:99&JF!T5UL-3G-T6]3E?*

*#:A.#YC0!?.&Y$<'^OF /9[6%33DQVK6[,+>6U! M>$0NVP,P\RX>W)B([#@==K@4AJCL>AU8K$&I7%@^#I:M*KHC"F1]A4HH/Z<*

*MLQ&D4_2*4]8Q":WY4.5+15.U;LA/O#4P7)@E]8FG=Y&&DKH;0P=))CTJ.>V8 MB--J+1PY<&"GFM(LNB`-JAFIAC\)HGVYK_XNPQM)W/#U^1'N2QTQG_^KJ3A*

*MAZ$F+,*7%',)JD\B,]VK@<23M'D2SH,QH1ZPY_OPE")8,W,/J_E8-.^L7SG M:PKQ*S-,I<%@D[S CW&"!S\[<8L.1D[#ML,^O*0@=*

*W_VT7D@XDBBJP.R_USZ/BHH(<]A]4B/D,EMZ4<\G ME#FGR 'XS0*M,8YHVO:%NUQBP!7W_*VJ;S_53E%Y<=7KVPI,(MPW*PRS@B/R2,D'__9)F"\\31*"!RP0N]PO/E+8X?+ \??X]M*

OYWP0;+&4>U;P)/C_'H;"NEI>(H]'9 MGOQC&T26]R4,=MN(652)C)%_H$H>)4.##[:XTI3*GZ#4TR-J$L]]68&8-+@-`M_%#\DT;.+DIN_/[H[_S]`.KBYVW@^O%7HB5 S$"XL(CZ

N8HLF&YEU/]?D:O M)CBBX39@QXF>U'-X4L-]Z1U5WFM_2=R'Q/)Y"&8S_@]P\T7T0^_.D4:]3\"E M^R9R8THM9T_C-9&@L'-:-'K&W&P9 M]_@)<@$OH'QZVY'(15]R6>P[*%CTZ]UU,I*

8?WHLB)@[:#?]ZG.WEC[^XY%,(M[?7^ABRM5_*TUNP\W'!(<+-.#I8TH:=4]&WVWJCZVOD<9_,1!]DY5HOPU8$]D M3)22&&IX@IJ2&PPYMD^433.1/(K%_RX]6CV2-*

X1RRZZL7H@//SM<.UOR6U% M/^F/I6I?68!A[^6S$]_NV3YIPJV;LV QH$ M>34G\LD\P?S2X;DRQDI$_!:.]AJ2Z?VJSOWZR4G^`JN@O 6/I-6^3=Y"SK#*

*M2V5>56)AI7=AKLX/2LB^@<W-L9*M/SB!L,)I;.-(0.3#WCRYDMEA4LEUOH==?(@#RR)*N8KPF%41F'@??;$. MP6M0GMT@P>HO=`-J&,JH+?R<3"]$^@,.?ODOO"^T?F?;#?Z-=.*

[",+$Y5DBBZ/,H[C3@\9&;;X8Y^)V% QT%H;6'H.+B-3YH,ZC2'#"P9=7/6:(=Y[4> M)VM:T,G3:+H+@R6;@Q9]<4O:UN("-]T76ZV7K#'^&'3ZZ-"RXC63%$=5"Q MN^@\B.+2X

\]8XWHGKD+|=9R'6$IX3EA(L,X-S"T(]%C^'CDY3Y4H:0T1^N-^1K"6D SAHBL(H8:TQF+(&.U4)+;NLAPF+I M+.8A>=^>W,,HY8)OT!%U>B7DIO13TC#B"),+MX'82@N?

*1M]:DQ8L\7^_G:]8-5RW)G>&[5K$DG-^PY]D0+8&<&=>. M9MN2]>2T&BZ:G>^8,_.BJKC'D@Z&Y+KSX(DHF_FBV^:?>)[A+XNQV(<>6HU M*M[CW':ZYK+*

]MH/O&#E@IFU)'BIHL=@IS";9)!@8&32,'Z>1=`9.;>6>S@#AQO-M3VPX!2AC6(DJE,IB M]L-F@S&#3\L4.)5YFH]0_[H"J MF0)J^!AS)%'5!%5I?JE-

H.^8$'(^<71&A&CR$L<0L'87SVP@@IP<,+8XN< $?(;3/WFUV--[C B]= MNS 5LD9'/59"_B$6AK/F-1L<$]0DP#'59+'")?GM8A#2;?G_F>E[R"]5;ERHZ M#9Q-UR1!;C0Y;[&<_Y-

*LO.U4U.NX$4.NF(#\]/6K4&9$(0"X@X4(GIH_K%&A*1[&&<(T MOF"?_.11#)N-5F]MP;P+,9&\A&U4###/>D%^U;<294:9=176X'807.PQ9@U?!MXE,]HDKF'-*

[6"IFA!.'A$ZU5K'L)EU0OF[ZL:\|"_N(Y6*R#763YSN*9C+>`M(S.+67&#.4#2%6>$\|+$8#EUI83:0#HDM[-F_TVSC1E$05D09 MY[8;SF4AXD5AJ5BT>^E1+V[?.^S>,BB93WZ;

;T#W(,2S9"+4"#I@W;)2@W8"JT7CCW)T[^//P'SGS!2.5Y$KLQ^5]AHCF MYO\!6U'6O%?>=@2^M?.U1-%=^_1YO<>QR]2>^:/GKI("VO4=;$WIZ0IYJQ'O MID?@K0C!IG+-

*E@6G**W"D?>(K"[#M7!=1.>5]T(>>6E(ZK[C>#[*0 >(<)6 MZB^UDOZ:T!J?:,;#*L%ZCXW#[N7N\,!+]V*@\ 2 .&:KL!2IH;2K6[M.42/31 ME*PFBY.,6HH(:HVD"''(4*S6*O6M.?*

$CHZT!8()DZ5&Z,+VX_@GLD7XIFF%K8 M8$CZ=,.U"3BN2]BOK#?@))>=)X"!9S0W4I#7&F,2WZ/,411'B8>]5:ORQ]0C# 5>B$15 =4= FHRX8IKJ8N_3L_|_=1J'H:H?

*PPEAOQ"B,LZ/4>@ MS\,STM!TGM-%IZ#M"QPMY3T0DC+|$LB27NT +|$^%:N@F&97DB- 2V)><9?9 M.TKS^\K[#&=@3SO"2L6;_+9&G>/WX"'*O;IR?*

QWN<+2]AUM"&^Z,D&EBE78 M?+B@3@;CY*^2^JJ0OO@,5PBY4\|)9!E.)(Y^"]V8W$7+PBIJ;4B9]1%2)5&9 MGB\@B@6T$)GGBIRK[#?*

*>+^'!#8YL)ORS*4F#S&O9=WSN&G^#DC+/8&_T5S4* M!57TZ!L0IP 6$PRH/NDNG(:+(#^^*V_N':CUS%>#S GV(M,P' KEIM4TR^,Q MN)H#*\JL:O@]JZ'U1'=#1K*;,U\!/+NDPI+?*

^(G1_?DTN_02)4JMN07QW#/R+'"S$6P>XR7.X_# M>Y9$IQ1WZ1N0)#%F]7\>(6?25Y34?B MC2I7_+;#OE. @QZ+OQY>8!=G9[']D)O+^6C">E_4!UL>"#J;+Q40S))XM?RV M0X?

ETUNLU%:5TW ,,8QUZ\Z7=NG[2:G"(TJ2N,(P9)ZUW?GGY'&(E:T3 ? MM6;GD:7PU -[N.]OG$RBY6W2..]M37@JR$Y3X8L9T&NH;04=AXT_RLO(,@*

*MKH$?5[O_D#)=CFD*'!"]/6K4&9$(0"X@X4(GIH_K%&A*1[&&<(T MOF"?_.11#)N-5F]MP;P+,9&\A&U4###/>D%^U;<294:9=176X'807.PQ9@U?!MXE,]HDKF'-*

M5.TT'TZ+O2MZPQW"FY17NZWJID/FZU'' 5J;8L_76G&M4/+K>QQ#E^9%8-.X MOO_>62'Y>+S|/=X&8=Y)6=2R:W3-Q=<:J2<5H;SUT51'>S0AR12"""QM.F#(M5'X;7?

TMD#Y707BW"^VU%8$) MCZCC1++(IV[F>4YZ3TY3&(Y_Z7N5TW!XU''YF7N, 7,[?_,#QPB'-*!HVM_N*'9>X-MD'T1BB/+U MT<^SS%_<^S^|2W)R9R"3-#_5H@8N@U*J+%*

*<2[^4P8$@2HL.WP;4'X@=]P@3 +8F3_!?P1:5+G#,/A#^C*VA7!+1[>!*#FRCZ0&%+0D"5O]4H4V!V M#CU_WWU._OQ@YB*V@<.<'')G&8HE!0WF4P])2&?W+!.]LIKP"*

[X8I6GJM=8H -K M:&]E/09DHS2\B:RZ]8\@I%[2J5N6GYC7H\X7@=:,=7!=O;Z#(_AP=45XRD&J+W5M=RR>TR@L!A;F<@8M\]4JE#2.&:Y+I^7'Y"GG"N5#RR7&IX;5H0V8DC\V5*

*M9>/R/PO M(_B75P-NXF+L,,KHJ069X*D)2%*4B%KBTR^ OCV)9$1!(U_X2_D-]_Q6R2E,] M8P/^HOMRBY_I7XJK1=3IV[?K%C.DCN 7)#%.G-1T_Y#H)+A-E_+'48]U>*

*MHSP4/8#'E= 8&Y'R^0Z1EVJM=P!R 351LK)%A("(95)/C=[#)IP<>%*1'@-1+N_3NUA-^3R_/IZF(GR6Q M8ETH&8[#AU3DDN!["F<=:.1(*8:+H//EU<ISl@]311H@<>F-1(S-_LF79NK*

*MLW#[1&?DFPV(Z,=_%9QA'"ZK909O0,]0.>.BU/[TX^/"C0_]Q[E-1G8WS>)S M*PSWY 2514?6ZSNJY(328/22#@,^C,*>)/V*UT1KQV'$W*GU:U&6]#5[^UX1 M)=;R1*"BOW'-;*

*[*T\$+VP_@D"EKM?7KRPOP]=1X39%A(5?*8I/-MPY GXQ,;U2:H#*GF1I ,V$+(Y)ZFZ).]##)E#R;'&5-]R&E$ M8AQ =U%YQ$^#'/;.9,?DW,):.0^:K%Z?*

H:'NTK7B4T!H?I^R0'Q1XEH[6L|-M%/+:+ :5)]D>%M%S8?% IV75<]PK'$,45 M5;3EVQ9!9TPT,JA0+VL'\V?Y;|%HC$$K2PDHQ6YIDV@44FB M4\^WQ*^;F$FL\["9;:->QQ$H!*

(VDM4PR]&[H6'!$B $K/4H J9L9D,]YFG M.^ +GS MRD5!LV69OW5[]]S@++;5C=>7/@Y7^]L@C-?/Y"TO7O> M'D8_QANR,"RPGT@EN-*

!^6=]TI\Y1#6KZ")=$1X4]NWWO)OAY0Z*R#,]"@XQB" MVF N3=W&M;L/^'B6U]>['5'6F72SL%X@N>"\"=@ "]J<-> "P+$"^9>F,O=# M>P0(>L6(;/F0Q?

*>872X^^XM|M0I<5UDDB/9A^Y98B*RWQKNH409_=:?A/ON4 M93*+@%[IDZW=?=!(S>1S3$NW/&27)1#/EH2))fU)5&;G4F/5>*@'7\||>9C;*

*MVE+N**$W&DC|5.B'C/LHX++FYW$>_-Z.N<9#72U/+D(+C&@/^\UCX.7(D>F_MC\D5567!+NTR;%)+2G$]RU|)-]2!K0,_Q@O=>)\B"]2R[#HY.29?AE-L -AKD*

MY!7V[3V%A[2|>@'K]?I,_T^B33+$"(,)S_8@YY2XY.KT''"Y=':HO*]JR):Q> M28>>OW&B-L/3>),?E+$]NPV)^!>R-%WVWVM?.'(X$E9AF'-5OQ$8^POOEGK6_HKNPTGF0>\|

*MDV^V2/86?S:#T<7R$Y7"HQF\K6Q:7S=:KP|(OLAXHI&V\|:9]EV9%U>O<\YF? M+Y>P^%LB#+,Z$*X=\&N!O.[%RM?B.X(6N=,M!C;6Z9S=8>H.AR]2,]^AYO M'!'4-*

*$S6)3M'>!.E>U6LDD1Y0P8C$?A[UZ5VOW3$/%5S4#$2IZ M&'6(RXBE+QBBPK9KLO%>05FRXK#+4BV4R;F91%L.]K>,/k:%/H^B5L,#A*DE(UB9 MH?]Y%\UH|/QE]T2*

*G:36R7@#^2USC%]-.L[@NX/'(4'(P^F<&^(\"Q^\?>D7J8ZY#HGM2PE)\E7]\4 M?^Y$3N$OF=E7,UFBE,08PJKHDH*Q3$T2KITWT8*0#CRBLG++4;-ZRAG$S51& M6*ZZ;W)\P[*

*_ER_V&MBXM39ET#^I9B,I\)$?7T06F"96E&'R-J5B]"&{QUM6 M)A?+.))SB:[*U1;,K[#^A9&H]?L.[B|5I 4>]E@>C%+=;WA0X((Z=,7MAI/8 M171BDJD!EHK0P4[U&YX]F],V=*?*

*ZH3VD*U[Z\#?)*,A?'+Y>QZVF6'G81V$ M,?FP-M65A;!0'+S>T"+@GQE]^@DKSHX&@]L;67SNWLJ8N#H]^ .:4!OX] M4;M.3\X^GRHBO]? <90 M@3'UCXB@NW8QU>^"OVT*

,HB@'NB[PAL?@&KRSODA6V.SR/>2V&_XBD8)'D M&CS@%=5!:GQ2%'T^XNXNJ%$O7IB+'?XKMHA*2N3 0J-N4SJ]FT$.(L-E5%> MC_XWG\!^)L)NC'V:,$@:.K&[JZ3U\,H=O3D-(Q,*

*I3G4J=>E U&DRU/L90 1\-')CU?G)GYE5 M-"RK &.AI.'82A(Q?,EEH:ILVY-P[M*X,_"+Y!X$3/9 7[MS]X!BWS$3];?2 M!#.]7]J&C ,,&G#E>C@\)UKU*@BS GA1J%&#L &H.*

*(/Q?3]HIRR&1+=E*SS? MU?W&[<$YVQ?64I,0 W0'C+Y.1 :&'/U\NN@"H&PLI^AZX3+2:R<"]BEBM%4 M"IL.+_ERC2*E27!\UIF#%D*F#B*3[Y"%%#\4_P>T>W51 *?8[QC@MG-|\AQ>"*

MQ<[EBPVN[S$DG:TAL)Q-6:L8[DJQ$]$Q]9Q94BZ3;_<<<]:5@>CA4)^^*#9- M*2H]\N./-NK?REY.!L0&$$(E?R&[L#_%OBS. [=QUU,T5T"B.J#*

MHIN!Y1'WD,5G5D94M2+.\YE6_=Y5;O+"ML>@-9;GN+8@9%1?NL4;#/=Z2+QH^8^X=+K21%7<8001$9>F.0501=_H5-!YL\IE8?W$[,B.U4G&+QIL7\-2,1M\(

*M**)HLS)0:%$M8CP6!R<:5]H:3#P)!HH|H 9_M&E0IF5I7D#`;$^BY(.QI M-^)Q)K>HR-F>19I2&;*>V%*7CIZ[A=QIY.)XIG$8K=VMJ#U$%+$@S 3*1+I4Z# MDENGG&W!MD^)*

*V97XVP7KX.P!VEK??D"$^7K@;S"539M.G\|C*H]%2O/FQ MB35[CB*S(|$_*4M;(W\CO]_PQG:6*G\|#'M#34O&HK;>(4+QF-C571^0P48<2 M>5\ _;!.R%-*

+8H/""9/9H6/]J#QT&Y(M3I@M6/QH/68@O&**M|)T24##BRW3 M$ $\]RYT@W 1*,2*$)5-C#Q<<< $F3[#E4:EPX_K4? =Y7]R?6GI!U>L[IA/3 M.]"2*]:LY5V(MY;K")'Q]2=8 34*

*5*U)%HS]LE"D0[OUC_MD(GV$6_65&,[_$F>+(\ MZ7':VI:Z74>@5D%>KO48L)M'-=ZR2 *[X, ^JSZ^>WM7;0(:?B"H8$)&8B=B_ ML_\7]_LX*]T0Q7ZS)U6#*YSN*9+..?*

*^*MB%#2#SVI#I'>>/H@)/60>)[[C MM$TD!HL\)AI2&.RHT:NGRE&4.30X1N0]N#1H.8M"'>N@X8BJ,E1(^[QKJWY4?`MV*]#@O@ XIE!Q,[!-[M>+4U)#&=?M*+UE1<\|T([)27:*

[^24I;MM>^A,=AQ^ MUBHG1&7X1EMJPP,%E,JDZ4;CB|6O>F=J=.S;5+XERM@:NQLG7[,\HM;IV M38|31:=!H9&+BQ)6ENNIW;WO,&MR%HB$<"_D-<#S'1/4+"]H.Y-D^[C>&73

MZ/#UW]/5_BT1"0U.HN\X<1I9# $"U2]/8=O1!&Q62.^%S0<4 M1=@MG.0-%HHB!PT'C"5+=@(\YD"-1=N[QEMO=(:%):K0UO+N,5Q>#D3])?EY

MA1%G'W8FR)ZNDP_!:GDS)M;R[@$/E5AF-M:G0= -3^+?-D$;$QNGD7ZL,C5%GZO:)-'L-%>NW?$A6>7!{>$_Y-F)=+'+?; MA>;P::$14T8H!KQXHXL^U\+V1@7EAS7VO*J,BU2COJ-*

'19'?&; ?1M0^B7&Y M;Z6RC]$E7%@O(DZ#*3P5BD=1^X'GRJNV$RCX50F!EC!S?1S%I=:^LZ7]3!Z M4/AKPW+J(^6"O-B[/':TN:C.^K6QYII!>)W"X81XM RD927BJU!M;HU;>5

MB86U"GU[F-,^44I2GV#CH/'F/01Z&8LHDX+R'T5#AS+M%7+[A46"REN.^AF MNPAL&@<:+%7Y#=YEU1IR5$9W\!O7?VUM2 P#GMNN3)$XT-3(:1U;+V-:?;M MWHF"T-*

H7&S!2?Q^)^Z;LOG|>R5%[O5-P^K)2.R+8/SE.MEU6>,3F%4:4W7 M/GF)+*]M96N0WI3?:? #W7RW^5.SC*VIM"KT-8Y^)^+4AU+@

*Q[8<,[>@[*78@!-M8TR_1Y"E8EL^&7075;SMVE]LR<'>[F^\;NX-01-1HHA3)>_CS;F97>]5J-MMU$OQ@]&ZKCF+[XM2G2")%G$Z!JUU->]C]S+3BDC45-+;JSC9M.KP>%0KAA1*

*MG4_B+"HFKEOD&>N+R.C"$OPPLCBPA=U1@X@=@G_?$\I:AAK*0@M.5"BT$*7O4N(\\2&"7+]Z985I48AKTI-C[&3U*4^]A7(.GB2\:9T0*0L"S=V-MO9.#(C'J]Q-*

T25TSB'M67L>RJ"ZCU@MSAE>N[[^BM5&UR-;K8B1{5?=>)T6 M0;,N5Q-(Y"H(,_$S;=51>9C)++%_RF\>T$U>0GH]YN60@>W0 M@-*

*S%5^QJT&9DT64+E((&S44GWODB,V7/$MG'M+!+#WB'B@-*#T\LI0]0@6ID]-MW_"5+H)(ZOE26=A.9N\'IL)CD5/F]WT=CUE?!P<2_$*SG]Y\5CE6*

*MN@0ZA5!0[HG Y#L:*T(KNL^LC)ATIQN/?P^ID7KNKE.4\L6WR98J2==++[G(UD M=?C'HW-*^H.KS\E$0BA_XN"7_\+[;N'4G!BBU!.AI]T,D)NPPASRY#=+LNKD*

M;M.6ECA!8BCX(,!!"A>I,0 ,C6"^] M.::<6&P-@]& 0IHMQ&3VV7L"T:?% 1[>)\+(?+ZI)C^NIOO"&IOA[7.94=&'5 M2=5]=W'=KKO,P&IUB0[L<'/O5!S1Q__QH7HJR!<8C>&%&M*

*M#R[9$/IC?(=+P.(CA\Q+O).2 MM6[!=12$%BVYU-\'1 .Q BIU,_+PI6@6N+OR=(R_:+X4:MB8^[_40%>3W7I0 MU6B:I42@:[*TIR(AQLOMCA"?P&TSX,)!0Y1$5T8+-*

*T8ZAET,0I04O#V+/+7G M1QOD4#F@KY/#Q,C8,'^*+0<;&+V#H?5G9,M\ULO-U@OV&#_@\,D%I*5&NY MC@BTXQ.=^0X56#K!T8.],B7(E=EXR,@S$@S48D)Z@(/#W3+"?)M2-*

*WP]NN?[M)*C6(?7Q*[R2/P.V&W]8B1A27QDK=*U0"4\8WBMIR?DJS[]_-7U/%F0]%-) M"8G R =_W%Z\OZ$?MZGG\D/?"0S&JL&9KTB/D)[/*.SOZ>>C9[%$$4Q0)A^3*

M[>6;BS9L4.VI247UN[N'S;+++$8T1]1 M,A[B Q[[J32X@*:Q2%A;\A*V!#"2 VPS*N1P?$P#%;;T2K(LW24\F/:<30. MT+3IX(.0%LMM#VF?Q=.60)2'KNZ-F8[#%%G?N6/9S%R;E4"4*

*M5@Z"U%@EP/$40]#8@J.@5$"QE&BB9 M!Q(3"_5A=*QOIW!L*-,? R4 >I2;3-C\G(=8LU3B)+f9_G/) /\^S&%4N1RG%4+^6R:Z!U10E"%^2^^ M3V-RN5+A6?%YOD>*

<0T2^#9J; ^8?\)B0NWW#=_0QV!&5W_/(;YIP% M$ZJ6H M[(TL6=J;SQ<#MM4V=",.G!V#L!:AT/$:BA\ME]B.U4>&>V7(_!6G#&$W9AV<.M@/H\R;

[M//!83>=,X=2WK!O]Q5;48B0M. X[A!6C[^Z41?F.]%N2BX%Y3RQ9 MT4U$)\=*WD$R(,O:S;NZSNG_`)(AW0GN,_9.E>'!\Z,] BS%48;%@6]8Y, M((E"/RXT'H4.A#FF("JTEZ0B21*

*M36]30E^7P]D*N69>(_ MEM-2$,]^3RN3L4]\K4RQ45K75+3#7@3^"NK}]4XNQ9$3>]A@K$#8@)@,U^3L M=@%&6&_"K_2VsQ[s%,>#"[C6S MR5OW%*H]*

B]=VZW/;6YNN4/AIO;^H$I>F0!WCP^!DBHM=CD$D(MUX#8Y[Q M35)#\]DXU:HNQD&=.F$^&OO$RZM:BD05S@PD".RHJ ^6(EK+0[,]LP<.I:62 ML>*9V!T9YTDZ0A&'#N4H@*

*0"&H;*3WQ[6(0T2G1_YGI>HJ]W=)^>__P'@GB M"*B; TKMERN^-=|>TNRDK!N&&&&IXXE[E,A?2G,&.W&[U[F[PTRI5L< U Y M]18YV#G;?*

*XL@94MS2$&8RS;VK$+)6N/C@,KV;A?1=*WO5:!$,=O.IY1Z.H/ M9- 7!4FNTIJE-/.U01./TW^^/F'R>>3/PGD1$C>()0%@9RA-J9!U;GEH77>SP7[$5 M7A%"+3?MX\G"|>C(W55>F\NI\>+ZlLO:'-^N//IU*

*M>G%|^.:!=%9.9RTJ"<70/UA"(K.ID9$FRER=(4C034[%X#A,K8|>1#Y'Q3#C. MPYE.Q5^M\))\XGB^7N#USZHU(CN,/.!9/XS6>,MKHW6SQ\7LT6X783*ZV;G,Y*

*M7I(1D!@"L3$0#$*X1YQS,<[1LYR%B&K .AM0N_-0*4IP9X7SD0)I.?13$_'S M_95;V%J:*^IJY"KM;U.K?DV@]C7 2K%1,.H"&8<%D0Z4!:%A";S2/37,ITCB MW;B0F-IGG1;I_-*

*I*Z@:*M/3!2B*/BD,+=#HK)V!+]Y&]V?E7 VC49]9'N1\/;POC]F93"+#R),:,?_R4 >I2;3-C\G(=8LU3B)+f9_G/) /\^S&%4N1RG%4+^6R:Z!U10E"%^2^^ M3V-RN5+A6?%YOD>*

<0T2^#9J; ^8?\)B0NWW#=_0QV!&5W_/(;YIP% M$ZJ6H M[(TL6=J;SQ<#MM4V=",.G!V#L!:AT/$:BA\ME]B.U4>&>V7(_!6G#&$W9AV<.M@/H\R;

[M//!83>=,X=2WK!O]Q5;48B0M. X[A!6C[^Z41?F.]%N2BX%Y3RQ9 MT4U$)\=*WD$R(,O:S;NZSNG_`)(AW0GN,_9.E>'!\Z,] BS%48;%@6]8Y, M((E"/RXT'H4.A#FF("JTEZ0B21*

*M36]30E^7P]D*N69>(_ MEM-2$,]^3RN3L4]\K4RQ45K75+3#7@3^"NK}]4XNQ9$3>]A@K$#8@)@,U^3L M=@%&6&_"K_2VsQ[s%,>#"[C6S MR5OW%*H]*

B]=VZW/;6YNN4/AIO;^H$I>F0!WCP^!DBHM=CD$D(MUX#8Y[Q M35)#\]DXU:HNQD&=.F$^&OO$RZM:BD05S@PD".RHJ ^6(EK+0[,]LP<.I:62 ML>*9V!T9YTDZ0A&'#N4H@*

*0"&H;*3WQ[6(0T2G1_YGI>HJ]W=)^>__P'@GB M"*B; TKMERN^-=|>TNRDK!N&&&&IXXE[E,A?2G,&.W&[U[F[PTRI5L< U Y M]18YV#G;?*

*XL@94MS2$&8RS;VK$+)6N/C@,KV;A?1=*WO5:!$,=O.IY1Z.H/ M9- 7!4FNTIJE-/.U01./TW^^/F'R>>3/PGD1$C>()0%@9RA-J9!U;GEH77>SP7[$5 M7A%"+3?MX\G"|>C(W55>F\NI\>+ZlLO:'-^N//IU*

*M>G%|^.:!=%9.9RTJ"<70/UA"(K.ID9$FRER=(4C034[%X#A,K8|>1#Y'Q3#C. MPYE.Q5^M\))\XGB^7N#USZHU(CN,/.!9/XS6>,MKHW6SQ\7LT6X783*ZV;G,Y*

*M7I(1D!@"L3$0#$*X1YQS,<[1LYR%B&K .AM0N_-0*4IP9X7SD0)I.?13$_'S M_95;V%J:*^IJY"KM;U.K?DV@]C7 2K%1,.H"&8<%D0Z4!:%A";S2/37,ITCB MW;B0F-IGG1;I_-*

*I*Z@:*M/3!2B*/BD,+=#HK)V!+]Y&]V?E7 VC49]9'N1\/;POC]F93"+#R),:,?_R4 >I2;3-C\G(=8LU3B)+f9_G/) /\^S&%4N1RG%4+^6R:Z!U10E"%^2^^ M3V-RN5+A6?%YOD>*

<0T2^#9J; ^8?\)B0NWW#=_0QV!&5W_/(;YIP% M$ZJ6H M[(TL6=J;SQ<#MM4V=",.G!V#L!:AT/$:BA\ME]B.U4>&>V7(_!6G#&$W9AV<.M@/H\R;

[M//!83>=,X=2WK!O]Q5;48B0M. X[A!6C[^Z41?F.]%N2BX%Y3RQ9 MT4U$)\=*WD$R(,O:S;NZSNG_`)(AW0GN,_9.E>'!\Z,] BS%48;%@6]8Y, M((E"/RXT'H4.A#FF("JTEZ0B21*

*M36]30E^7P]D*N69>(_ MEM-2$,]^3RN3L4]\K4RQ45K75+3#7@3^"NK}]4XNQ9$3>]A@K$#8@)@,U^3L M=@%&6&_"K_2VsQ[s%,>#"[C6S MR5OW%*H]*

B]=VZW/;6YNN4/AIO;^H$I>F0!WCP^!DBHM=CD$D(MUX#8Y[Q M35)#\]DXU:HNQD&=.F$^&OO$RZM:BD05S@PD".RHJ ^6(EK+0[,]LP<.I:62 ML>*9V!T9YTDZ0A&'#N4H@*

*0"&H;*3WQ[6(0T2G1_YGI>HJ]W=)^>__P'@GB-

*P7^"A>|T,T:N;X6#Q@*Y_2CC^U2+^UH!|;P-=$T +C/"-'X $O!5)&?/G\ MY>_FB&;%^E+_SS+*/4!9{$X>8--'&4./?8I@Y,"/@>3+ W?VV?=.F'2_2'7Z M%;",1-\!=(T\;.MA"E27!%Y;-1_\#4:>+5T3R\2#V3WU@OX?)BA>D/%&<+52 MO]TCY#_A_WJ=$L Nf1..6H?'2%[J/OW,2\RP0F"D!1UJ%#VN4"^TK2U0\N[* M*H0.ABO:/RG55\?P5/#"-ZU8_03PG,2S0FIB0GE7Y/M]7+)Yf>HX^P;^&_[(.MX'4KAB.T=*7F&.7Y\+1 *]'QZ21HE%R@&NLY[/AFS/F PE_S.:+'T<"T9]O; MQD?1P+0799?!QU 6W^~[$VUL_?&.(E'GMf,#-D,+S.E*]!9 l '79!-NIR_$7, MH4$\#!F3*!R%M\8F RW/RW@-?0\V2Q_KC")3@K4=@20Z!KKA"&2#C*6HT2* M.=#+@^'IL-N!N8* /W(0#-E7H3\\ME UY1#(XBU& VAN0OI/0]YR-NAZ"KL MH=9Z/MSB_W9V^W],7(7C7!P]$.)7:3BAV:O3N44+,[CE VZS(FCXY]8@\3B M^:VM<";]S[#^">+ 2T<%P.QP[1%_%:!;%VO[!*/0/:Q'0.7L2F,QB'+2I/*B MPD)">;,\:(8/AV??6Y/G%58|>G7%$,5S3\;G[RK\@5%<+GW157*O4$6;TI,. M/({HS$OW9/E%7>//B'SG*5XK*BS/NDI;3Z.+B<;>X1D06:'[#TW.1O96'IR MO{3YNF2-63ZTE/1"7.C+B,048$7U\KC"@W1(-:+#9SC"QANX!@@BO"-S}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l?-C#0Y!MK;7? =O2?X4O5?T3>BVG96 MFG^<%'GM%>/JMP>_78DOB3IW"@!P+'V%=X(.+P.990:%DR$!U1*H$XX."(5N M@)K!"U7E%OG?!O{O11T(B,-7<:)0G/[SAI15S9L<1+LBE _^7W9V N'#$Z- MU!N$/HV5T-AF! ^IX?6T1ST(*1/G6S0!1W56,QVGCC1 M2W"Z91'I/5#G%PD3QZ;SB,-C!:B3Q.%5F)EE,F--5 "(,I)#SN\3CSU6L!|S MJ:0.DF7PM,4'!IX)>;Q>U\)>>>ZB4W(D+0#B!3YXEH IS\L ,-7 DTA!4LV75 M_|)D>?@K)3% +Q 8+7$+RE?SE,|>K8/4/3V\W9@=N)S1B4*0.U3! \19D0 -1 M5I!9WH-\KNXO8529&0DV(-E\+2UY,-W4R/9YBHD!@_O&)P]80$@F3L01;N46 M1;4)$FD!?+R3]X3@FE*9:EOY\,Z4MG:14;9<,+8,7!^<)MC$8>0R\!R8=\0A%XY2^A&,PK?J5[D"B^+W[IWQ9!F`[H4;A+ MD+5\"6-V#Y?\^X^]\Y MYJ?-?#!B3L@#%PHP.&2 MDD>A\[ED[\>Y:090:(G/P_?3&A(UO!I3_(S;H+4('!U\?0:OD+Q_R\N_M?OM=W\KFVOV_ZWY>WBX>;Q;GG]P<.GQ(F2>B6] MO\&?T8L7B A?O"!I2"8*:IX%^/?O^.6HQG[+4J?/B\0#P.R]TT#UBP5&_^P72%/TIC.BFX1M<,TWP\AM8Q/# I M?<,0.8*D0N3Z@"#G=?46MJ3OR^*F#L3$>1_/KI6; M5CNZ#+M4016Y"[$]D'D+;QZ>%E>.OX9W!E\AJV52Q&T!%'LR\T5\0D0SS$- M=@4ZACUIU'[V#1%^&EH?PE=P2Y.??IUS,?!+@@AG49CL45H3BM*>-&]M6\'/3WX1PRHS)#[JN"^#OE'A%4R1[4447XTBLL!L5+^<-9MPIOKT75 M>772:&B'?G#A)(2M#I>`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|=OGXX_GGSY_^8DPY?SO7SZ= MGV-6__13.|[^(.3MER)OAV>MC_\E!$7E%7%1!@!+ K8*R<\D;P&LWUALW>,M=RA,@8]T(/SA_TYM\G6"1,%3F,&/&"E+P*K&EXX\M^[(T;(;H^EW%O^2?NE?%UZP2#^V8%l;<)\;*;UN2 [XK8D_9:I%L;7X]1'"08!GS4+|\M1J PK0-&'S8I9D+K-62P$AX9;5UBMBY__22[67H1*%$?!W'BZ;T\X6E0Z1L>_M?$%&!\'.QA_6=-DK_0>E]<1T,>Y@L"@=HL2+B%A?/OO>"PN >?5BFI3$D/K; M>GGA"XO\$XO&V)6ZS<(5"|%(F3?%>MW!7@J1$;#22(D&X$>7<"+//+_X% M'C$O_CX\CN4 #! F'*=FP>E3OCJ)'= \OG$;H<;GH1(J^O.TZ&*K"M'#6&K M=:^>X!Z$'Y+9G,I&T!Y[*T!S[$WDO6ZRJ76#!Q'E! MJ?N^]T'VA3TW_,.6 D!>EBO89\M,P[1\XNG'F"-TW$Y,KX?OI%87//3N>'A.=D,8;D4D4@=8P4S&22 MPV02J+;40RB?'OVIP@B MU_EPGZJ%2@.U9AE,F6TI1$H%A}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l.!I>_^(W+#%S*B_!@],N(QO8;P1ZG_M>P*,I.!]-=T9A7MY\.=2__MHQK{\@GX*&0(CDM_:5)R?HT+RP+2X(TBG,[T]M+@\>"3CJKM&E{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|FZI VMH(4 M<#,M-\0D!Bf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~ZN14GX,;) M !8D?D!1*CV]M6CS"QN:7Y&L>"1Y=$'5PBJ&@*"-^8G'Z0/G+/]3@-6RLU_. MXLRl?l;FKKHS@M5);_U2%9LP+)|+599#*2-K2"%B"KJB;@^0'HKM2$;NK">@O>/8TVY KG*VT MJ>GV-B\"G_.1_'E%2DXFT"\Z4/$/!$JU4"OFQ5KR=Q,R!4_7A0>"KV>5A"9MN]X$F77QOY!FV;6HOXX5C @M:K @5-97;);V49/W<7+2T0]&!SWKW=87<3 M)X,__4))8E/#?2B&ZXRG[0]6K$FCXC6XTG5UHOU^K !D%"I-]3QUN(<|_I>MYM>/V7V9!!!'M@O:6+$]*=*3+ +:9_]V*"?_^M(H(BLGQTO/|_!*5FR+5/:P@ MBBH[VHG!-N;Z2FJ-9>^#O-:8T)"CW=L*8KFG@3#7D__=B@F+4N#@ EQNP)0M MVVWUO:P@K@C)>*!*/!$TM8*,/A]3^"#A54N.(+[3\|=^)T$/">7#5K"X2>P>_M"Q"??((MO."#T0MED&HGQBFFM&M8)9T*26YE:KV5A"DE?A\?4"0ZGP;'MHG M3W-C6$&X_NVJTCV:CV(%\(BF'$&?Z>!1[+H9_[ML7H+5]OP$#N!NWK#,SS"_MIK4(OCG1/U"R!+A3(9%-^UJODER^8,3+2,2D>22-4I(<*%U.AF?AWQ]=IY M<1Q&JB0!42,K5B:+|8F\P6:A'XX66/SJ_8;D+9]{4-K.!^YDV+EYNZ>"-9 M6RL(Z5,1+4,F$/?":NL$*MB%42=@!$!Q$MD-9&RM6X@+O$M?S#_#:RFV!:CC\NCY6$'9$MH4@#!/)97SF^#\[!"HS/&NH#6^@/;3P&BZ8"5->U_)L5ZY<=>>H>!M]B&)"L_M?8EI7MG!$MZS- SV'[*WG8L70M#0CE7)7*\76PAKO9-7[&N" MMP,/.:<18N M6A=.:H%>K).9092T/4UQX1XB?,D0F0^OPY!6;.GT_<5P*JKU256/-FOG*TCC M89:%*%-8@RS\4I^\W& @*U@@M<+>]_PB];VL(.[I\!RC_SK G?<*J&CX8]+;.M4=S4O&'1H?^<:5U_P.M HT3.'4SO/XDS=.G,A)L)O$';:=&0KUAH+V*P.M*GTJ*EPOTL96D))+$_%+@L(Y(=FPNWVAS3YLASBK.E=|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`BN"(BQ^HHA1U>AF!?D-E"=&DC8+>AK;"C9! MR.9RP\%)RT{|A0VM(($ET!#!)|L/U.KP5ZU\|(C3)N-?K:061'4-E+X_B 62B:L#/6<%,_CF9>JWP MXA/UCSI/ZAZAXEY6$"=-U@)K+;J##]7M; 618DL?^-8+^=>J%,-&OOB/2ZS5Y MB,1]#,%^K^C:21R!JE77UHKUNTH=#!&5*RS07AURYM;08X@^H"%A=3)P @FB%ZZDJ3,%4*<83ZD&&>;P65MAS?_<&1#->ND];WZ3:<%;N' M/I+RI"B5LBYK:P4AH'=[KN=$1PYU7O9FE#;V@I3O*$[.RD)X"+W\OA[#.]:M&MM0+E3K5;S4;P@OH)|ZG]3>^EX5*]#N85[H_+%+J{J[C!H8;K1Z6;%B7"W/M)FIE*;N;=T20HG\IB @70:=;4G2L.5C!_E(5N5*$E+R5%9,O5D3543@0-32. M62<"0:RJGNJ65JP#UH3QA"Z+". [R1[2BN7EY"[,Z!/C*2Q\X4M.XL)T=ZY$)M,UG$N#2_7[.K>76B\=]>LKT)4/1R_!Y&R?8-ZR;2Y5(%RX*[C%K;,(,UKJ0 MV$:L;F=^/5B))HHFBW7B;+\L_ B4PW_9\:O07U[|K#A3?+)3X%#8+}]#M:P6A M-65G;[UW_"POI(();4@MAK$FH(^Z:V\"]J41$[:R(Z5$[_9LK+*^9NMP8M/ MT-L*8BERJ/>*J$ZW*JNA@E!-6K6W>VPIB.U: D>,<]#*P'2S2)$4 M !T_(BJ54IA$>K Y9$-I!-'0WS1_J]CS7;+#K$^.DAM#RMV2\'87*\6H?,1 MZ_:U@E (A\@/=E&G9U'L%%C@8H/4N?#\| TL&+=A=(6O9"^YET24|#&N%0RJ MT5/(.5QNJJGN;90>^6!6L*)NHH<ML&,.^7?/H<_35/G1HG24>,>4#@M5>RL(JC|[A/:?2BOS2@+!_/KR^+*#B A*%@^O!UL&+;R0I6J:[:NCY6$'87K"."+4# >O>DCD"&.M+2BBK+:3%:3E?AJI-</-/P\:C(6D'HUS!TW[4$#X[V&_F!8,$68/F*7,USDM(MAFY%8+0=R(JU&JS>B- ,,]3'K&!E+9B$/*U1JZ?Y(|/<;.]OAM0"LD>>N0 MR2.LS$B4!)U.=JQ?)F.U]BG8#-;,R%XNLT-@/S6#EWK^F!6L+1DD=!T#Y\" M9>V/FBYVD%6(28);>#2_]A(%;.IA#%5NI@_TI^<(WWWHU=&!U<^.\&5E8 MWU<$(93[+=\"OJC&J+2A%1N-A+XHE?EB"RLFG6FBBERL8A,KIBVJ_T?K_6GF M5C4;P/R!+YJ.4G1E9C*\"[#V438W->IHQ:KFIZL@="2R^/\]TWATZ8UAC_1[M6J/ P:]J4O+QC;Q8LP8 ^N"]#I(PJHBB-L/9_Z4IKYJ_(G1D.!|(>JG7D" M\ X=0?W/+/.X0EC#_E9L8,ZR2Q8#*^(\R(%>UE7S44KU\O 5K"(M=_>!,S,+"0KP;>+[:$V-,D_;,$KPV=O5E ?L,)P=[$@K%(7L)(5!%/E'DCP MM;P"K%/,XB4^M"44.0:WK'MK^]CQ;IE3UHXC'LP>EX&NY&#I";+WF(_^PC_1B^/?T.*YID(OY,%5=TI[57;T@DQ:I M*\8T2I_KQ_0"O#Z@_X7<_&S':JS8=-|P$/,"2Y 9D@54)FDF* &F3/6?1T%=GRHH;&7Z(L<;X-F\X1=! M@@*2,(VWOL35*F]JQ?H4!1A!E%MN?H^IGJ]\(HLZ6$%2.5>2U284>C+%3:T@-M@_ 7]OW=;A^%K]0$*I=6BN96D"/P!+2N=LK]B\H@U?.GK&!C#>FV35?D58^S M?_S-P[D6F^"A-5DP&L(0ENJMI'XS;X*)MSCHGHT>]M7'E*G>6W(7Y8.B+, M&GDK'U9*&;7* MIJCM9 5I6OZTRZ/.AD)'DKICFS%A'G PGU M=&+\RNM [E%H)B"-UM!,!ZRMW&M!_##AL%%DD3>\R$A*%PA!+9"C?'0\EU32.,10SH-J+Y(\%'6R@CJV0-K5C7 M1@!!:?)^\U&,ZVST5?B(7CQ0(H-$%(,K:F/%JM643\R+)XI#4SL,8P7Y:=[2M{]ICB0%B@@49B"V4TM96$-.@GEXL*ZBGD?[4<7 K6%5VV"F-(]+&EHB>FQV*.M7O $L\D"1PBVAH-8%[1PP)D#:.%M&VYJ=*X554_>U(J5 M*X+H>4AMKY&WMH*8%C6 +H^-J@PIN3/BYXT{3HOE+T0)R=465NP1#]%%5&_L M\DACK8F.Z]:+0YBCB\|+PD)-HQDB%:*YN9?UK^:]2OP?Q^CJ]?-BM7B MLZURDQ^W*!^/H+]3%:1E^@*)?{/[O-SN)\1/R. ^ M^"8MS9&KU(5C-IO?S.UVEMQ2WM(((077D&N=SN:D59 A"/:\DI7PS7;M4 M1B)+5@8P^8?("Z-5R TG+#M8.]7A"]HQR?]LX+B!$4LD"9^UTNR+0Z M6D%BG\"S-{6SY$:.]X;AJ]P)!=Y)FW1B9B7KU)T:>7F_//#'1Z&8$WD :M M6M++>BCV5RWRBD7#%AXA?CT095]!,E$!QW48TO\HW<>+M8*,_:?]T(C<\Q\Z M<8(>T2Y\=?PLT*&RVIK|K%CU_)4(&:L M8)X(FPVK^/B|LG/PD<[=Q2K16=O9_$'@LMD>?,<#H@]YY0DGR>)[|'M8J8Z2 M,;,]<4MCW!K;.8UQXK_[@0'}SJNWL+5%LLD)W!7;W@4CM>/\+%8&TQAGG"M68)^CJ;1OG[+3,0Y5:C"LW-NENQH8F(5+H9BRVLF'1>."%(:"4L\?.TW,J*.MR3O6_M1%W#M((QC=O;ZI"DED-9P8;,&2A7WPLMK)BT'!|+=>O5|S(OHI9[_%#>(F^'MHJM05MBBVL:*5N@8AHZ:|>8($ M<#=*"8TUM8RLV%E1#(V]?MGM4W<,*HM2EH=5%"G7{FM^(%W@W8<6HHC;A2Q+, MPZ]0\%-6Y:.]!7RM65%%)1E-W$'6R)/(34!%IT!M/A>*W*]8"5%3X'YR45\<' MD?:(CTKDK<'V#*6V [?X#UQ+.L2I^GM3MQA#MW!$>M$-%OQR)7F%9@_Z33C M.OL:BY64,KJDTY6DKU#)*UM8*0'\+{$ZK%REBYE163YZL.,"!C_)\1'OF M)8+L.@_,>._XA 2+H0BYNG*(M{I3JF^1.F-+!V4%NU!{C+X#D@Y!>,%H' MQR=K*+U.Y:VM(";"-UD,2H/(4.@5YH,Z_M902!?0V33|,:F67F2#D-;P:8L M:U(M)10TLV+Z#63I?? =O2=8SOBOZ!M>FZ?D;+_#@%:PA+XQZ5,,%&Q)M0+A M<98UMD39?]HBWU=F=_$MS-^,^"&X1M2 ;N%V*<14GCUZCI8L@XKYST-HZ)/M0M4+3+8BM/!_4 TKW8PHI),VPBYM19TC!TN>]A;&|)=F(W0P+4D)9 F5*<-[X\LKA.F;2A<6EI':Y)SD%N/+/+C% M_U(1M))F5FQ?=242PCAJSFCSWE80V^ Q20+1"[']JM4;]I@..:E\UW<1@Y1XD1-MB?_1BM4K^O(Z&6]2Y TLV+ZG?P$_.[*=QR@W@<D3WKW4S3\OA4,%Z5AW@7X M)G3\HA%4HCQ]=,;"5$&4N2[MCG=(82PK&$&RZD3$^NC!.IVC])XC>)UY%6]<+<=PPK",;5. 1%4;67^TH=W M WXM^JZ3A%ZPW(AUN,)-L I?6_"VQ*'ON9#SQ"*R-^GPWW*/!L;'%N2%(@) MI8A)>0G?"K]Z&-.*P[&,7IR54',EY)62,3]60RV5UJF5M/;T>O QJ^Z^Q__M Q^V82)M"G_;L6:BB+M,""]>D%VTL4*LB[PP7*AM);WBO)TAIMW.'O(|>T/ MG|^'=%N50T'N52A,?8UM7MA)$R)THA&.:=+9B3_"Z?PE%J+8D=[F[%00!|(R7 MI FX!=@TS4220)@-807*>BPP@%]LP+9.>G?)ET6W0W0IR)>C\|"M54W<,*HNX" M\0+HJ CD M.TJ6FY7SCLDAH',2<(>N/V%ROY1XF!!XZ;Z@7S/BUM:0<3R%447OA\FM @W M<%O.A|2Q%:2D\"6KD+G8&A60U^[^M!;&#P?[D42W>*+6.;0K0!=]1U5[;=B#S+.@U/H;&'OWAK"L^FZ&_99Z114',_M\/D A45FLZ[K8#S.Z)L7 &;)N)YRX4W]\(BP)(U> M/?#*8"(NZ8-U^S>1\?FRH^X]@!2KM,CU_P@JY-YL%VL(0DKF!EZG1\!7C)50C[%"MXKQ{6W2Z/O\<079U=WCF*DS)W8X#O M6,'4KV4^'_S4'9P;P6]1D6<59M81*ZY@"M9,.68UG!^X) M&^#7%(X<44/S6_ * O5?PCLHC!IZLETH,&4;+_{^&H?OF^8 37RXJ>G%(F_'M!9?AC,M41E.T,G\MFQ MKX-?X+!\'1ZM29U12;J7K*$56Y*3=|(,E'(;2R;>&9)?:9GI,R4O+^EA"<9NO1VR*-)Q$3)VYK7K82+?|/+|E>AD[D@@&0(#|(+GYE M:RM6A6B,CRCQ{HH+],RS6I:/Z-*

*6+J5N*52(1/MGUNUM!;G,CYC9*8F-5]Y&L_M8(++DR=H@C,*,K*2@9?';WAV!|H%;R/T?P?0S*1%W>]J64&>(BA6IA5(FEM! M3MO@N4NT"2-$&ZZ<|S[C\DI#@\$F27UP_NU4EQ?1<@KR$Y+8.8A5-]1H@@O M5K6W@B!=XV-7PZ(5A.H6M%?9LIJ.88DYZVGG^'\JTA';KPI-K%@O6<*!$NJH MMI/5I&%A<=@=R*/H|R#*'+&_A3YL*AEH8OO1K&!&'H5V%[AHXP5>@H7(*ZI8-MBS7BV'1&L(+!H8MEAY9:6-+6"#/X5_?,4S;_V%U5(L MXN%=^@:F+!#"<-,QK"#\%BN2W@O#B%?:,,/35|<+0"A095.BP3;H;@6Y'3%T MQ<$?G8:T@BU|QOV4F@'^H1Y@|H#!+AKNP=\D^*?`!WM*H0[;,1)],IE:=+/=M/($B;3[5&L*PI$=M1>M4KY[FHUA!/,&C76[P9,F:+9|H8N!=D%83P=9 -A5A09$^41-M7AK=[*+O+MCCA_@]I#&G_(]F5#2W@ISB3BK9'6B|CO1',,X+%=2F8YB_@IB&M0$/6)8<)D)**1[%R';4;QHIU;X*DJ5=3H=N(5C#E\N 1FX7\.!=;F-_(?^RD M"=ZBWZW@$YV1S\JEM#N"6T>I,) !]_RVF\QW_B?B$_[#F,_B=?;A",&8R1$Y! MH V$!CM[=$B|=?Q7+-K^!I5,/__ZP^>_)GF9T[@ MGB%B(C_S@DV:Q9%1ZR7PU?*4_E)8&/2>D,*.?O$1Q%A<0Y*P%;R8ANA#;4I MQD21%8S1^[\OI{'!OI\04$)#@(XHZ?.$POP%M/"[:'<-_M,"D6)8N@4)4/9MKW_XF.@LF\VXTZ25]O#X(&H72U=(ZE9B--D=0()3]X[!P(`MYE;|?:1),6F5X[K?!"Z?.\5O/EG3D:9:Q"GN9 %L'INKO*V1B9,P=673C5O M.?)$5WA$Q>S(SR-/Z?|=G"A!D7\LPHH(9E=N.?)$Z?Z2GQQQN[$76(+2(EKL M=[(7K1@#W3O^#E31T+IVPJ*V)R0+>^S):A6|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|X9VE9:=%1"4^-AM+)%'*^>=NICD.ZVNE\&KD**FWC@18$_R-0KPG+VU)[\";SN.:?'/OL=^# M#P+?95PI8O79TNEIR=93$RN\VSJ-QI+/NT5 >QTM.&E:Q?%=.G3N<@M&=|,VB84/9O)B.$*P0;P'A5H!A^P"}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|[/TEN/S!K^)3V0^)9[15$"+B,-T]RDIR6+08'#+P]) M%FLP_T2NUB)4.EE%S%T<'QH1PCI8182\RKEN+QM \QH>=9V>-I"E>6A4/>PA M0WE<9*WMF7[\05%VL0ADY!&|@N6%3G3O2S&0='1:1;$]N0SH]=BC-621W@$ MGFO36#,'48%^?NQ8&[1?+#-(F%0_1 K>#14+J9\G\&"MZ>:0OH"$XV-O(MG(89,V6FSH9/2OFD^UR;19*.6CXU>BL.P2|K=U>]B.++VWVRXTN#,51\8LXB;MK{7A%5)")*LFIGS|X5&/T8HSZ9-1>D8UQJ]?/_C5PEJ7:NLC&%0,1[W$*1//MUFG8"_PIBWLYRQK$9^'F+$S#&..S0^ <7 ^:G%8 #$UXR#9/C===9UMI@78%7 M%!P0WL2W^#1VCO.YT\OV5X=X@3/519_H='1?"$PEL935T9.WMYDZ2.$91>@ M.EQC3OLAP41E\Y.NB.J/P8HH09@RF.[_-+M*O2KU_0Q64TD1^.C:$[@(LD/&_M2$^]H+FY8F$L(3!]B-0LA;2YP14 1MZ'<9R*R\XX"EF@?$PUTLG]M8]WG3 M48R1^R<'4#]D7F#EPGE!WP|@'UUN*KIMS3HV'L9Z@LGB=*26CF&N%@H*\/Q\ MP UW=U!@>M!YU(+_^[I>/4=WI2(KS8@53TI9UsY9<>WY!{Q7.DN+PCBV"1]^ MD,O-39QX,_Q: MD 6C-QC!DO-'7|W?\),R=.O+)>OU-5?]2Y235YRSL,EWE"PW*^==1TG]QOF MKCG'"V"^RX"F-Y)0@^5&6:%2W<>-^%TW3E\O);UR-&[/OKU@BPD17_R7:A!'* MP&E0?/..:(PPA>C$QV)/1&R+1%.$OH^V0@U:\;AOFC^GDX-+;H&&7M>RJH'MA{CMR9WQTL;J^6R71[=F99FDT5S;M+4%]^F3XP-J_-0Q_!"^,/=;N]X$0D- MP=-]D1ZUQL-8((,S2(2',"(>HB2)O.=# D%4J["EF&TU]"4U9O$Y8I+R$@5H M(PV$K^ME3J-"2>W3K=C&#]=AC?>GB,56[VF9>C1MK6.F!&^MK\3BN:O663V#'A#R#U3L^1LFSN"2S#- MHBI"HRNBD6^M5_859>#*MJW6\EVXA<(;8AO:=.TVN41Z=@W.(IVM@1C4V.9# MY&W9M!N;J6>D+%>MK)EPWDW]"-Z%E MG#<2FP*/]2R8U.3,2USDL^!3@Y/;FSM^%CG#739@YLF?!6AY@RW8/&9@<%GG7-MK:I?=D$(@^1HG_".K(UCZ#57V]Z'29.7;S%68I#D[!/>4?*+8\1,[--@57-[M?LK"81UKYO/8U=4;LE_Q#X:SQ-K_@)H"&2R=N+MV<8/WTX7R.0D*_E@7?@*L_XA"E\|S+S+X^\QO"4R M]]T%++#KM(5H#-M%\(:/W GZL QC'[\X,_W$5.4.&\EU27S2<7]DR NY>QYO^/&?S&3*_P]2&_\KIU>]O-C"_M5OU2!GVE38S6R2!/_3(OI|RU'U^::!000->Y8#O)O0'OH)>fGAZH3A;0S5#0L& MEN]BUT'KL4[S(CD[;>D__M[_-=(MB*51?XLN<O3)O] +M>^(L,5 M+Y3TWK@#%[3C%^6 QDM%W?_CHAGIHOEQM(M&WX?4= B+KIN;W=X/CP@QUU";MUXEB"L-7<\7_>C\SN!UCIFF4&>DV=$D6OMGE6,9U|!+#CX M"/Z@+K2CWW|(ZT+5(*AC1Q#W,NJ:EL'@ERKXD%=*KW2# MCL:M[LRDD.Z+]S"N#902=C%Y*B@^+-X$U^'A.=D<_-3A(3|0\BZVZ4R"F,[. M0:$6*@S3]J!9-FQ=`F)\=4]SU*3-S7FL&"X,CI6[S7-9,GY)D !FL]'[?'IIAJF(0AF(9PUGEX"+6*]'|O FZL)9L0L=N30KR\Y MW,4LV-O/VTH-O3$+!6G9Z72G9^Z4*MRU>5Q8*D-PI15%SZ%=VZYO1Z8>ALN MQ;MM8FX_CZDF2S3UL|!3$ZD+^LXL]EKWIK#]"1-HJOO;D'=FO+3'J2[M(K31U+G;_^M"@K(T"Z&N|\08&\|!%O7H6[Q16]%.S:7T_"#!EV]DJ2%8>P"R MMJOW00YEU2M#[7T$#N& **)139R1AG3C;FL=6DQEKXK@F,;@K<6FN:Z*\|= M$>1FH4B,H!W1X%+6?_W/EF_)WHYIC=*K%J -FIQBV2D7GEIW3;N6Q^N .C- M@HO]Z+]*[+XA^&B34C"VU5@+;'#J3!|+$].%.>R5W_:]1H8S3=; *\Y'""%NH MD?V8L?[`_C6RF\"J3=VG/E83I-XK,ZW;OWVK9"]0R5DPM/_MK FHY2!LM\?BG2?.XFI0E&]+DI>BU(<,W=N>CW6GZH+NS$!U\HRNBD6^M5_859>#*MJW6\EVXA<(;8AO:=.TVN41Z=@W.(IVM@1C4V.9#MY&W9M!N;J6>D+%>MK)EPWDW]"-Z%E MG#<2FP*/]2R8U.3,2USDL^!3@Y/;FSM^%CG#739@YLF?!6AY@RW8/&9@<%GG7-MK:I?=D$(@^1HG_".K(UCZ#57V]Z'29.7;S%68I#D[!/>4?*+8\1,[--@57-[M?LK"81UKYO/8U=4;LE_Q#X:SQ-K_@)H"&2R=N+MV<8/WTX7R.0D*_E@7?@*L_XA"E\|S+S+X^\QO"4R M]]T%++#KM(5H#-M%\(:/W GZL QC'[\X,_W$5.4.&\EU27S2<7]DR NY>QYO^/&?S&3*_P]2&_\KIU>]O-C"_M5OU2!GVE38S6R2!/_3(OI|RU'U^::!000->Y8#O)O0'OH)>fGAZH3A;0S5#0L& MEN]BUT'KL4[S(CD[;>D__M[_-=(MB*51?XLN<O3)O] +M>^(L,5 M+Y3TWK@#%[3C%^6 QDM%W?_CHAGIHOEQM(M&WX?4= B+KIN;W=X/CP@QUU";MUXEB"L-7<\7_>C\SN!UCIFF4&>DV=$D6OMGE6,9U|!+#CX M"/Z@+K2CWW|(ZT+5(*AC1Q#W,NJ:EL'@ERKXD%=*KW2# MCL:M[LRDD.Z+]S"N#902=C%Y*B@^+-X$U^'A.=D<_-3A(3|0\BZVZ4R"F,[. M0:$6*@S3]J!9-FQ=`F)\=4]SU*3-S7FL&"X,CI6[S7-9,GY)D !FL]'[?'IIAJF(0AF(9PUGEX"+6*]'|O FZL)9L0L=N30KR\Y MW,4LV-O/VTH-O3$+!6G9Z72G9^Z4*MRU>5Q8*D-PI15%SZ%=VZYO1Z8>ALN MQ;MM8FX_CZDF2S3UL|!3$ZD+^LXL]EKWIK#]"1-HJOO;D'=FO+3'J2[M(K31U+G;_^M"@K(T"Z&N|\08&\|!%O7H6[Q16]%.S:7T_"#!EV]DJ2%8>P"R MMJOW00YEU2M#[7T$#N& **)139R1AG3C;FL=6DQEKXK@F,;@K<6FN:Z*\|= M$>1FH4B,H!W1X%+6?_W/EF_)WHYIC=*K%J -FIQBV2D7GEIW3;N6Q^N .C- M@HO]Z+]*[+XA^&B34C"VU5@+;'#J3!|+$].%.>R5W_:]1H8S3=; *\Y'""%NH MD?V8L?[`_C6RF\"J3=VG/E83I-XK,ZW;OWVK9"]0R5DPM/_MK FHY2!LM\?BG2?.XFI0E&]+DI>BU(<,W=N>CW6GZH+NS$!U\HRNBD6^M5_859>#*MJW6\EVXA<(;8AO:=.TVN41Z=@W.(IVM@1C4V.9#MY&W9M!N;J6>D+%>MK)EPWDW]"-Z%E MG#<2FP*/]2R8U.3,2USDL^!3@Y/;FSM^%CG#739@YLF?!6AY@RW8/&9@<%GG7-MK:I?=D$(@^1HG_".K(UCZ#57V]Z'29.7;S%68I#D[!/>4?*+8\1,[--@57-[M?LK"81UKYO/8U=4;LE_Q#X:SQ-K_@)H"&2R=N+MV<8/WTX7R.0D*_E@7?@*L_XA"E\|S+S+X^\QO"4R M]]T%++#KM(5H#-M%\(:/W GZL QC'[\X,_W$5.4.&\EU27S2<7]DR NY>QYO^/&?S&3*_P]2&_\KIU>]O-C"_M5OU2!GVE38S6R2!/_3(OI|RU'U^::!000->Y8#O)O0'OH)>fGAZH3A;0S5#0L& MEN]BUT'KL4[S(CD[;>D__M[_-=(MB*51?XLN<O3)O] +M>^(L,5 M+Y3TWK@#%[3C%^6 QDM%W?_CHAGIHOEQM(M&WX?4= B+KIN;W=X/CP@QUU";MUXEB"L-7<\7_>C\SN!UCIFF4&>DV=$D6OMGE6,9U|!+#CX M"/Z@+K2CWW|(ZT+5(*AC1Q#W,NJ:EL'@ERKXD%=*KW2# MCL:M[LRDD.Z+]S"N#902=C%Y*B@^+-X$U^'A.=D<_-3A(3|0\BZVZ4R"F,[. M0:$6*@S3]J!9-FQ='

*M8^/[K]C3/%FBJ356KLL|K2(KSHZ[GM!4=?V(V!C]1ONA|8WV@YP,DWD^?=DM-M.N0+3-8M\|9%UVC!2*6C2R),OF\T9A7OM#*4J?55ZP8L^%=O2FG]D54.97,AGD#/|OE MNWKJX5N61_|/.W)K$-WJAR%9:-,6'58(U,1M3A8TP8!HY6P$4R]Q.0YW^WE-.MS+*:ICC>\Y01%SY",S]",^<;FGF:(6(BO>Y+8U?K%VL\QA_!0VU.Z9]>LOT]-M")IC_/X" 4F7%E,28LW4]\B%\U@@A/! %6[4^V?,_^PCPN/I-MN"GF!4OQZ],6+-^*S0P-D=GL4Q!00[83]%_^^$U2KNI@M7V_.0.P"^(^,;8\2Y8X_.@Q8+/"Q_WC;N;.RZ%C7-9WC@7 M4>0$+!U)>\R;/#A'XOE^;=-3TJ:DB-!*0;+$L-M^B=CH[2?ZTPDPOA:.6(#>6[L.L6PAL"#7:A<%3$]L=2\7.1OZ05G[=A=`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

C8M0%.DO35VH%F#IL\8:6U8C7[PZ(<[U^@UZ'^D$=N9L62.$S+PPX4<&7->NEF&/F.0[(4VD]N3HU?A"+-9-;2&)XALDE&8)G$.M.D8.R;Q*A($C79U5<- P[&.Q&G1X#EW]MR!/T79GL+?$]WXE/-?;#(!/Z>".H.MHDZY'!L?=]HX%5#?VW66}JD35B&.;53S1]O>5QO!,1)*5ZNC0R=?PBA]<7:H.M4\'*.=.,3.P\43"$- GR%!M\E++E$2XNT$YUNAFX@*OT)9V34!*RYJ^SBLEBE.ME.K(1+/'VA.QJAFV(BZ4S!V!=-.FE0WH4F6+N&.**(@T.)W"SYXXP4<&'"'$1.M=;V&%P.8^JPO&.7=#N< K2M)G+@DMHCJ"N:8U.MI2-A#O>3?QH7V27O^L=!5%W/O*A53DSE+?)!@OB(CI/23XLZ;-+@SQ=PS&)W.MCR(>2I6UO2EJ-*CX7'V18P!R+(!IZ.XD;NSCB\(.&V;.T.@&W YRWR(1'5Z.M#8@,(K=?BTI(7*%1"M@^U?)]U6$3A.M<U?)[O0BW04[^.-?'[&B+&>[PWL]>PB<*&+J310V9]E4QO)n@%@N<':PV:IY^4LKOU M=HLR^XZ."[!YZ?XK5!LC]#]"8LR[7],V*31O*=4P)D=X\?7[=+WFN2-RX7X.M2GN.:EI'WT#TRR"^021MCM|B>)T.P25O.5>X9]MC.R7,.CH[OO9PY.I$U\N:,%;X@ M$+N@^V+=%?8H.M&$B.U)AFR,/X#:"7#GBK=.BO._"D!Q;/P-:6U/I9NX(LZU(OHYRMQ!3O^W,LD.M*8;)G$.!8.3"-1]?3/&=Y'>.B);!/7.EXNX?H[WO7"'7C"JXB"Z\@Q5LD?'% MB^B?JQ]3Q+B(B^A\.QB3;8%-;>=:.F!$E%PMRP4UER.S'JHOL?89Z4+=4A++.M5>@U?95%UF2%>2L.J5TZ9@#!*3&'%.O)<\K?(0\.4>WBZ3O#?P*%@@l8T&PD MW&7@"Z2MS0<(WL$3%.OW!/2D'LL9CP!T3)N/:'#RC+Y!4K=0C.$-"]DOT8[@#K.FR!]/Z_P2RK=1X'OH5?H40C;EP[>.5MJ3.E3[AJGU/!F#ES*(-+[#JB5*.M&]F8V_SI@X]CY(? I$WQJW2R:.K<3[P"2/QY"1LDTH7E:42S<>)TRV!#Z>$.1.MSR#!X3,XO<,K@FBVZC^+G/(.32;-.Z*U"[R:#HC'\J^B()K"&.M(0?%*&-*&*@8\2WAI.R_G=LYT .1.$!RZW@"YN88@.N\KY;O%#H5PWIZC#92Z_M\L+V.)%&FM8]%?']][=D]M35785GC?G#\6P7:(;BB.D$9]++AY+*R8ZRUC5YUA.M9EYB%&"\W$!&$T5A^4_1#7AV?%!O= [+F6$'XBC_S4P"FJ)!$95$>&IZ/8N\-MH#C/U<6KOZB3*5C@*=7G[$&Z+CMG_"SUKCA:-XM.YE\9CF_BJ3BLF+%@KL@2.M.R[07^Z9EVP:+-FP+1T74>^DIZPC8FB9> [@6A[^S;#:7A1I:%3XZ[95A:W^_.M9)XE;6.[B"HG.C+5!17-Z?WP=0R.%U&?HQ?#?N54G)AM7*@$.1&-RA=1;$("_M28(F[(NH.R&!-])Y_")*2D@@J6N.OXA2$;I>/*;U?[H2$6:'.E8I_.@?F^&/.M2]SCA-NOGXF.ZI84A|L2WVAAT):5(2J7';UE:8#'8Q3NT#.LP-V(0ZT32)]MCN))-RU!9.&DCVQ\GC5]W?*8:-0X(0M$Z@8/6M.,5G(]!?:9.R"!"|6[M"':Q!"VO7M@,43I2@-C1YJE? (4K*QGA7(=1U-MKJY_OCJ>.?B*R.7=ZY2&RO(W&0)5(&39.7^;^8G/K%RC8%K^*IB7"M0]\$3/SUI_T%[6BJ'3,^/ZC4N3S.R7-,XA2K.M((@^X#^.BU+R\^^-CE"0@^0;5+"C8;"48 W\IO;%.YYU^.SMNA.M,)HP4&.UEW<09LB;=Q]'A|(K)NH:?9LE:73H/*82$_7WKLB;UR.RID!!&FF&.M&49$!:^,8/|JNA=1ZD5$$VZD|$@KG'./1.JK@G-(]#*BW(3UX:4@1@-O2A79 M"K==;7'!BX3&6;.1B@YH!OCGF/-X/++%*BX06[*23R^CP444@E'QCBMB)W./.MNNU+QTKL.Q=1)F0DH.1V2G.O+:.*.Ul:.:Q=17!069_VL>!=194,6F22[X$74.MU9!%%.D6>1&U-601)6+_O(B2&[*((II8+[BDQL|./.ZK2H+YE*3^=>:S LH M@H8L9V4VS.RBPA9/ZA(_ML2/+?%C\XH?H^R5<#77Q_R"AMXW)X8<*4U6D.D< M\+^2MBVIQ/@0T)AJV=W4!PE4L7;P61<%2&9%[1=$8-_7PU^H.TM%U#$,.K.W MNB\NR;Y@"RI-$L5LW%JKE8-.VU;MJ1%V:1_*,H7'+VNN)B M$#-,45P,8HM!;#&(&?-X$. (_9VNXF8GIRWA3PW,_O\ 7]WX5!H,;(6AN%EW M":.RQL!0DXU0!L@N\]^"WH,'C\#?^CC0.4G..=MX%=9-E-AT#KQ;)]G#'Y_.M^NX$J_"? N!:N\]_F(7,Q2"P&8=6U#2CF'

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|\'",HKCY!@ M./$.(/'Z(61D,PG-,X3!/R#3)4BPWH1=)5ZA/4&=2HCE,Q<8)1&XC^+G/) MZ3M.Z*U"[R;S U1M1/2!$%A#,0RME[^L])YWL48_,$%0#TNM[UUXKB'$E9=H M\|UBAT+TU)ZC#92Z0G6;Q3$=_-)(T\H;XP+A/;L:M^9J3*3.64UAUD!T0P&$ M-%)C9N8QI^5DO67LN3;S$N,S(_)#60T41?6_Q3=

4\W)U%R3S M) 91YUFQ[_PJ$<@0\(F;"Z!_@XU%TP.R8^02=-@_#0V/Z.!N'=BM-[MU8+?O M'.QV@Q!NKY#@F1;JE%UY=+!I[_;D/D]YN2E0X4@Z(KQ1'6*PB*=]WY*>P.U M!*
(I\2OC#K+LN -,?2 -CKE0Z`1F_T3$G5Y\52R[Z=5?DF>'E44)^[,5W^2'01*=+D#-=QNB)JR2MYZD:%C$^_M1V>]&N\@*:ET;1D<@9^_*@06ZM18BH3]7)/.H*U. 5|\.-@3BAR*0N?
>&A.#PB2U@IL4 M4RJKMK'G-D8' #VXMI6&DE&(%(*"K;>#9$ CI1,\,1^)L(II3W$Q4@T 1,-@? M2AM!<@)4R6A=Z%1S]@'[3V!==XS_<1C_FQ5G_)@OM_2*YQ7,M(-G#O3PY'S(
M4[-@"L3&%)EX!5&APJ-L7U?9]6=\]4G*//7/(E34%X<4)3Z1.4 1;7:+1CF3,[<%*F M-;Z;UH-Z%=0CW,AB@I*HFC=2BGX9\@&6X49])OD7Y4VDLD]'(*?90PXBS>R+' M#3
(0@QTJD.E>EC+09JNRDA7'H"LY[I#1[J M1W_J820O44DILZ%9GN@T>RXB,I'%<+IQC,ORBK9-9+L&D5 M/C-%?#0H&EN&D,3D/'BPG#+.+@3AKH(\LY4!4:?F.#6\%RNY@+QB
XDL/-3S M?>4&R_I89MD-EY],9Q=8 I8_1R==_/80%.I<%*< /"U^2.1"UG^QN6* M#QVI%W5AKG$3%"D#,[B#F^XC[FSQBIM!>R>TMP)_(^^%N$#M+.;S2^X)?:[L M.5F)U?
RUG,4ASD*U GMV@+3$HHVZ+A#\&X YQQM9,44-/,I3$HIC=B76RVIB&L?IE8WXY+5, \;NL9%4S4 -DN!5,2WQ7AEP"LI-
M%:AE9>E26,5P,R'U(EI&6YU,RS KMI =&; 6]^ UH-PB337H3*-;ZS.A2DUA M0F9=PN;LJ$CIYKI>4/-T64 ,B>(Y<8M< .1F8,UU?&O#2:O6UJ(-"9)RA7YN0 MM?
=RU;7.3/F.HU20Z=A&3%+V.1FKJ5:F_& M4 :;X"+5,\&Y"/S-]+/KSS7;.0L@I,ET5BS+)MB6B[K@Z0+*6K>GW:]NU^XB M'Z-#L5I 4"'1-UU+]3;
[_]^(\VF5E;$*R+WWS%&\[FDAO]$*]7A;#!/;JY^.MN^<195MP#Y@D-548R,&?I%^!.@&I-/AAPY0HT?S#Y0+F*^U"L_=2X*ERL[PD M#A(D"0)Y3'UFBC5PS_M*0L10YE=2QFZ2
$6*^.MZCK4?.U+(UDXA5IB,6+0X M^&+/4)'); +WT!SH.Ut;&,E*0*2RD'/4S-2SE&;T.?J"%0&Q=95Q'S@CD4I_X> M8TM9IDU'_1U63\4,!?;+4M<+FM<8^0/8-
.:RFNTQ>!^OX@X>,95$C,J2'D1 M4RHM0KMT8 E,.S\#[<2D*6A2P,#?@5-U4*H.2M5!{3HHU7-"J;HHPA-$$;96 M.HHPIQ:U/TT*1?U$(?%6>C*PK:H$REI^>W0G2]VPG-Z.Y1-DQ"?
{]CR9Z, M9F[Q>LQNG&"]=A.K1;JQKL> &E.|FW0:-NXX(225>#WH2GS=!)T1*BDPUZ&(M$<(AUB@S>BH#-<*,-WY5]"W:6BH%IP*,_"C3>5%T"8SO*W4(@/\Q3"U@IJB-
5C1YKH9/47O3 M6:..6LOIED1Q/T[BV807QU#?SPG_1)vpQ#AA*BT;8;1,$<+, X<4Z1;_A+!5=FV M3RD[M3$ERZY<VC]1@[-$5]7*> MW2R&/6?
88\VX:F_]G'##6SKB'TSVC&V)2+=8B$=(#TVE&L8KC'N&A\JRN$9+6+\[I4**167<;U! MZ1"5!8OX1[JZ-1(&CIH3SI3]C#6,)&*?B[S6(P'IC6G;(XZB)Y$%2E=V'<;>
M=8SI3HCLVOR:$DDE5SB9;* V(85-UZ0<"]RGF9),V= 1$;&I:4<(+#_0R;>V MRK>=E99O1Q@#P12"@+6PM\0/ERG]!KIN('J7N=^Y9M'D6)98.)O8 GJK&.4I MK.1Y91-
'=ZT+R[STVP0 5W!,:-N-)-YW.?6E-K5CZ=\"#[5?C ?GMV18%8["T/FA][^JTC G/MSZ89G1&.\'MT.\'?^0-36X.3.$:WYH3E-P MBA@P%^0G=>//S/)!5P1
MQH3X>P(04.J.\0U(IV;W!]00]8@>&1M>DV5]+TN3D>0N/YDN>*&'F.=K6 M3:8HE_,98J_*:5[MY*EU#>[).3/)0:9K!-EK>(_)9U$3-
?>E;8QZ3]+_JLAO&YVQMBYR6Z'[1K7S)_Y\F06C+!$[K6SY MO-@Z"?%2)S?:5/:LU1[%;S&:0\GL]2*BIC!68!T48E2)T3DH(Z[=4?+4])X
MO76T:>5(:3CS(LIFT8W6BH3'(^A4DX3_U1-BHGQIA(KQN;JQ%'G,$BG1<2F M=[^0#M3H.9.W6-:,@ :BM;IZ!),.BK'#-@F64?4RAG$##*Y3]3;&]FX074.YY"B5[C92[?#
]MN5GV(SM5FE M*)9^F0YCZT)2D<(V=R$;&DK-"++[/7Y;B8@MTBEV!L7.&!A TBF!7(^9 M(VM_6KU;YR M>(:GNAU^*'EC>)L;_)H(^VU9F9O'4>*W%VF+" M?
6Q#D8|O}>>!;IJ%)3VT'IX:\|TWRB5$U_W>)HQ@HW#9>4\0"2<56##9&ZE&Z9=!=) MZ/9LZAAL6QGL:E<3_)B$=#RYIML1'I9D2J?\0/012)0FL0I>?'KW7IS!8E)-
MTB4C!N@DESA%TEV;]0)XS,&/L/L;FIWK80F-,9UC*6N+VN/ M,P/632'X85P.T>QD"Q31@2&,<&A".044-" -$6^:5!W<\N;4\>7NU"Q2>*4,>8\U=,N5P.G.'UE^LB|&<9
M5Y_A#J=UMKTZM8^.*CU:/\E4)6$++:B%I3'^". ^.F-JT$&J9X>H#2K0R8ZPKH M[)D*RX:<\|/UF(5BQ HS:ECL2=R@J/V_G1&OI0X^V M!9_R-,(W.R1R5Z/H*
MP:,2G7W@/464FXI$UC>DO5>H6^N'UFTPL_NH'+FCV32*X+D$1FL;Y=E.5BI6 MB%.6HLGW'K]^9R<'"DD$K'9V>=_;AN|@6RZ=N\JX+P?3&P0:Z\T%Z?(]{UM
M&U:'F8/838*6<7)V#5PF7TT.@FZFUNC1->D93F<;MGZHQ';I;BA[HFE(3ZXB MOGF.!++#HF6;G825;NI)9R?W F]N+W]C#K=]AW,V*D4XO%
MW++P5FXIT.GE;S3]YKL95(OL6G:3'1@7UME_"WU=[), N&BT)>M(K!D)A;-+MIXW:@!@< MBY/3=_U3<7XBWO9%_\/@U\;#WW\>-H_Z@]^Q[TQ5G_T^'IX?D WGUT\O%3
M__B,/O0<(%1E/?6ZN.C#&B-\]7B O+NN^K-APC!\;8726P<@%M%Y9@_6E0\(H6Y[,89(L.L0!G0QK@V"<2R^ M8-U2L?;,Z3I6>?WGSS___*^>$ .0]OFWP\,W#247]*:L+-WT#D-!V
(^^[Z$ MXJ-QFXX4'2DZ4MR'%#MO>F\V7U5I 7K8UJN73Z]',8'TEZ2I-#@:EBH-Q)D" M*Q24@YFWB{YUFK668LO?9KN;O=W=^5WV\M53TFSK=8NTBT\R)80&VL[G8PE/
ME46N@LP3@SBHB_6<)X+CNM+(*164'&8]*^^2HEW;(E!RH*O/E:A@<&<BI>[MO4U!/4PU}>9W->FNF0M&EYUH7-$#C*.<=]N)HC#5\-%(-1,P)) ^O?M$/A7Q0;JRFTEZ/2=!I?1YZ_
'F>1R,^ M{1^^'!3GXW?!Tf/SDY-WXO 8_O?K;,__;N4IV&VPI!GH3%%86I6U);FYLW MFE(54M"S'V1<[6[>S[+:NN]!V >[:^?U0\VXS6]3BA?KP!SYV=QZL'6RM5@C M?,K
SP,MDX]^^E4T*+XF8BM84 #]@\B-:X MLQ/@+!WS(-E^_V-Y[@:B8;[7\GXG%?0 QR' C?Z,S@3H M++*2./"]U\CR7 V?C\/W[P>G'TF&SA#C]RB]6MY?;0Y[.5]3YBKY[,[;S%?W5
M+9'.5_3TO[(W+S9W.E!]VYRJG%4'@,Y7M#HFP".O=_W,=)|\KV" M;F$!2_ ^;?!V<%YV4GE\"GXCRWN?_CXXZI^MF,]7 MDK/Y5,1XV"9Z&&^^?0!.
[X4GWQ;03:LJHG;6XU0\5^=,=_"9 YTY\&CFP)O. M'+AG@9U7O:V7CY9*.Z?)M-SC]KR\:N\QQ?$3J<50GI8YN8(&P[^)\?O!N_[Q M^>#PP^#\#TH:.SXYWG@W.#OZ<'+V^,;3/.60?
X9+V$N^O<+Y.YO*E>]3U#E)8 MJ$NWFPJB),-.6XJ;$OD)B[VVH'VKK0#M"=KH5!M-=Y@L*SG[5,#UG^)?%.T M_91M2UUSA[RZ7*YIN+F$%N4+2]OT3\\^]8_.=4'7T\-
/_<_G@Z,S3PR.CY9H MU7G%^]_^;SBYI+I5&)5V'Z5#L-8W?MP-%*1@K7.=(GR8:9"Y:?8Q:CUNU5S M+ZSZ_ FT_25V('3VZP/:\#[%FW BCP_>=[_E4YE(-5EFW;2300Q>V=KM/V$
MRT6=!.JGRW8*]]'J0;O]80/%%#D;4&8W;+'!);FHU.9)IJGL8Q&"+JK"@SC?4 M>K+-^[ENT]7J(\BU@:8HQ*@8 M>\'\6<04/V3K*9BE=VU;RIN? M&:#: IYP?/%_#K]]R>G_:6Z<]!J,:?
TOT: 1 O;4CA+N0!26;MQDM'A_HE+/ MW,9IE:D[3 7)I8S|,,]_7Q MGNZ+!\UM_FFL7$Y;H5#(.9F6+;O14X>/1V1=\C9.K2(87V/L;[]9ZO;V &E4 M349@GR17V?
X2M>T5.\.=LCW')YXV4%Z/CCZT]=>GGC7?S\)K\1:IV1W;.M: M2/;>V.N4=;1LOF)1+$;(G#S+$C5D%UA\/$-'IN MXDAF&3/Q*:C&6&4323Z.9\I_%/A.L'0 HE%=4VI>YM74B13?
*6!012;#_15; MPV?=T,MO;+IY8U?3^^_S1^:<3]78=*NW]<2-31_-'FFGL69#A,LWUXBM91Z, MOJFDQB+(V*0B793L*H^ZRI-RZ@8_@<4."S#QD.NA;IS/N!<](U9GLM!,IDD ML,F
1T]4WIN4V3*VQ4FSB3#'R0V\[$'3L0B.=?L'6) M.RZ)T%;+YEYP-68@@3DE>&N%8F8REB:$Y*#U]X/ M=%G;*Y^UW;HM^?RA^T%/N+FW8G#\ N3TXR%&\KNX9Q?
(OP7.MMW;>C1(VY/N M]T6@L25F4XA#QA>PCCF/@&A]M&L135N@'T/X"R.EB,D#HT^$?NY[0&H[2D^$ M25 @N3,/$7P@! D<^)C4!J,F,$-053@8?;$L,A%G.0B4A,8/2)./ ZQ,FZ$
M)"N,.D_*0"SHIAC/S7+L#G&A OZB$JN=R'R+9@*1A#&^D(-Q8/AG"3]>^IFBK"8-ZB7DXG!6O=!S!]H# M4B3)/IL/;$E'T>,PG[,578)H//"9_HK/;\9S%2FERK Y^B_W.O-5^^7E?I 7
ML'?X4>BMHK52?HPWZK(@XU67H# E^!Q_8;8"$A'@"!8;_W.QCL#X)?)A)YK M_H13"%H7 T/-5],":."3CW^:Y+S'/0U/E]* 2+,BHC @:U7PF:.6SAYK& %P M]*12-
UWF1SHOF,_")!F=Y^F!0C_S'H$[IC)0(Q7PR^#S.)EN3#'BJ(F>C'), MBX;]+2]EE$SU]E;Q)4X!-\>:"6W"D'!/37V"%8<#C]V@!2.!@9E1C@ M(V.QIJ%/ @0U=%!H'X5 ?WS"""O0^[
M"1R8?!R+ B3PX W-MU7G^]_+

>XDBZL4Q3;1*FUFHZ1IP ML"P3U@*L]-9#A6$LW4D$ZN2Z[R(S$?>&G"_^I32U/D+@]U*@RN]0*//8E5_W MMG6:S72'+Z%.TY.8^*#-!3*(:G]418P%(-ZK,'%6+YF@,2CN\XF0B_Q<"N>> MX]7/-KZ)155IPU=>5W@AGF!' S,GM0QO5W+.&#SL-QIRFS!!S:!RW MC,K)KWQ>L@TI-Y=#+Z&$TL/(,=5XV#<0T>"<$W+"/5&NR-/PH9C(QT],@>*Q MG-]4#\9UY<\@*Z2; MZ=C)3W8/P.-9%*CPQ-FP^_'M^1^L,MR!B%VB2;(A6 M:1TTV$%XT/D_ON%'Q\&SO#MK7>ELQ1D5-I,/T:ON$(D*VFE#[X*C\M0A0%IA MXH\3W$+2]9,='S?#F3SNG^2%@(OAC3#7(S!\,A*0LG>S^/O2EZ>V:-ZB M^06B>?>#?XJ-0+X':5=:F=_OS1]|5P)\7P(|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|*$UP?3QND>N |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|=V AE2GC, Z6-5/S7)M'A!AVWA$;E%H(]0;/,QY45B'R3|%4R1G$2EL ^#%!R"RQW7UF<*1P*RPU7=NT M*-D$5LFQ_YM?/Y>')4U*FCS PRV[&9VQ.MF[5 RG>BG.]>ZU[Y=<*KGT(-]+M4I2D*$E1D)(D1;DB>C0(=OU3X/#-%EEW#FU^HI;9]R1(29# L*BZ=\Z[MJBZ M:?PYL-])OVKMA*)%@3$P>M.K"7[MQ^NMO)]\Z^DK!#PA(RAD=DZVO!OGSF\BMIK+S.+OY.TO$VBG8^NMS&\^ 0$1?>*_NYE!CNHK\;O|=,F=(66[TW<;<.#L MMG,J2P$T-J\RN=T]5TJZ-3L^X.GSSHU]HA/U!+ 0(4 Q0 ('F!;%E MVT?A.@@" $H5&P 1 " 0!C871X+3(P,C0P.3,P+FAT M.5;+ 0(4 Q0 ('F!;%DFU7UQ;E@! !T0%0 1 " 6$(M @!C871X+3(P,C0P.3,P+GAS9%!+ 0(4 Q0 ('F!;%D4>E/3S4L $>U-M @ / " ?Y@P!C871X+65X,3!?,2YH=&U02P$"% ,4 M" !Y@6Q9Q_85Q.\("P/ #P @ 'XK , 8V%T>"UE>#,Q M7S$N:'1M4$L! A0#% @ >8%L66[R&PSW" QSP | M (!%+8# &-A=\@M97@S,5\R+FAT;5!+ 0(4 Q0 ('F!,%F0,CH.E@4 M 'XH - " 3B_ P!C871X+65X,S(N:'1M4$L%!@ & - 8 < $ /G$ P $! end XML 81 catx-20240930_htm.xml IDEA: XBRL DOCUMENT 0000728387 catx:LeaseWithBoardOfRegentsMember 2024-04-01 0000728387 catx:BofASecuritiesIncMember catx:RegisteredOfferingMember catx:TheUnderwritingAgreementMember 2024-05-24 0000728387 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000728387 2024-03-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2024-07-01 2024-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember catx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 catx:LantheusInvestmentAgreementMember catx:OptionAgreementMember 2024-03-31 0000728387 us-gaap:CommonStockMember catx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 us-gaap:CommonStockMember catx:LantheusInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000728387 catx:PublicOfferingMember 2024-01-17 2024-01-17 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-02-03 2023-02-03 0000728387 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0000728387 catx:StockholderPlaintiffSettlementsMember 2024-09-30 0000728387 us-gaap:CashAndCashEquivalentsMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000728387 us-gaap:CommonStockMember catx:TwoThousandTwentyFourAtMarketOfferingMember 2024-08-13 0000728387 srt:ScenarioForecastMember 2024-01-01 2024-12-31 0000728387 catx:PromissoryNoteMember 2023-12-31 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember catx:PublicOfferingMember 2024-01-01 2024-03-31 0000728387 catx:GTMedicalTechnologiesIncMember 2024-04-12 2024-04-12 0000728387 2023-07-01 2023-09-30 0000728387 2024-06-30 0000728387 catx:RegisteredOfferingMember 2024-04-01 2024-06-30 0000728387 us-gaap:RetainedEarningsMember catx:PublicOfferingMember 2024-01-01 2024-03-31 0000728387 2023-04-01 2023-06-30 0000728387 us-gaap:RetainedEarningsMember 2023-03-31 0000728387 catx:LantheusAlphaTherapyLlcMember catx:LantheusInvestmentAgreementMember 2024-03-06 0000728387 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000728387 srt:MinimumMember catx:ViewpointMolecularTargetingIncMember 2023-02-03 2023-02-03 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000728387 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2024-01-01 2024-09-30 0000728387 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000728387 catx:OtherMember 2023-12-31 0000728387 us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0000728387 us-gaap:BuildingMember 2023-12-31 0000728387 us-gaap:RetainedEarningsMember 2024-03-31 0000728387 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000728387 catx:OfficeSpaceWithUnicoPropertiesMember 2023-07-01 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000728387 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000728387 catx:SeriesBConvertiblePreferredStockMember 2024-09-30 0000728387 us-gaap:RetainedEarningsMember catx:LantheusInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 us-gaap:EquipmentMember 2023-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember catx:RegisteredOfferingMember 2024-04-01 2024-06-30 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2023-01-01 2023-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember catx:ATMAgreementMember 2024-04-01 2024-06-30 0000728387 catx:ChinoCaliforniaMember us-gaap:SubsequentEventMember 2024-10-13 2024-10-13 0000728387 us-gaap:LeaseholdImprovementsMember 2024-09-30 0000728387 2023-01-01 2023-03-31 0000728387 catx:ProgenicsMember 2024-08-08 0000728387 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000728387 catx:PublicOfferingMember 2024-01-01 2024-03-31 0000728387 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000728387 us-gaap:RetainedEarningsMember 2023-09-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-17 2024-01-17 0000728387 us-gaap:RetainedEarningsMember catx:RegisteredOfferingMember 2024-04-01 2024-06-30 0000728387 catx:LantheusAlphaTherapyLlcMember catx:LantheusInvestmentAgreementMember 2024-01-08 0000728387 us-gaap:CommonStockMember 2024-06-30 0000728387 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000728387 us-gaap:CommonStockMember catx:ATMAgreementMember 2024-04-01 2024-06-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000728387 catx:OtherMember 2024-01-01 2024-09-30 0000728387 catx:LantheusAlphaTherapyLlcMember 2024-08-08 2024-08-08 0000728387 us-gaap:RetainedEarningsMember 2024-09-30 0000728387 us-gaap:EquipmentMember 2024-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000728387 us-gaap:RetainedEarningsMember 2022-12-31 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2024-07-01 2024-09-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-17 0000728387 2023-01-01 2023-09-30 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000728387 us-gaap:CommonStockMember 2023-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000728387 catx:PublicOfferingMember 2024-01-17 0000728387 catx:March2024PrivatePlacementMember 2024-03-04 0000728387 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2023-12-31 0000728387 us-gaap:BuildingMember 2024-09-30 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000728387 2024-01-01 2024-09-30 0000728387 catx:LantheusInvestmentAgreementMember catx:OptionAgreementMember 2024-01-08 2024-01-08 0000728387 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-02-03 0000728387 catx:MayTwoThousandTwentyFourPreFundedWarrantsMember 2024-04-01 2024-06-30 0000728387 us-gaap:CommonStockMember 2024-03-31 0000728387 catx:HoustonTexasMember 2024-07-15 2024-07-15 0000728387 catx:LantheusAlphaTherapyLlcMember catx:LantheusInvestmentAgreementMember 2024-03-04 2024-03-04 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0000728387 catx:OtherMember 2023-01-01 2023-12-31 0000728387 catx:BofASecuritiesIncMember catx:May2024PreFundedWarrantsMember catx:TheUnderwritingAgreementMember 2024-05-24 2024-05-24 0000728387 us-gaap:CommonStockMember 2022-12-31 0000728387 us-gaap:RetainedEarningsMember catx:ATMAgreementMember 2024-04-01 2024-06-30 0000728387 us-gaap:RetainedEarningsMember 2023-12-31 0000728387 catx:ProgenicsMember 2024-03-01 0000728387 us-gaap:OverAllotmentOptionMember 2024-01-17 2024-01-17 0000728387 catx:GTMedicalTechnologiesIncMember catx:NetSalesGreaterThan15MillionMember 2024-04-12 0000728387 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2024-01-01 2024-09-30 0000728387 us-gaap:CommonStockMember 2023-03-31 0000728387 catx:StockholderPlaintiffSettlementsMember 2023-12-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-07-01 2023-09-30 0000728387 catx:ATMAgreementMember 2024-04-01 2024-06-30 0000728387 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000728387 us-gaap:RetainedEarningsMember 2023-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000728387 us-gaap:CommonStockMember catx:RegisteredOfferingMember 2024-04-01 2024-06-30 0000728387 us-gaap:LandMember 2023-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000728387 2023-03-31 0000728387 2024-01-01 2024-03-31 0000728387 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000728387 catx:BofASecuritiesIncMember catx:RegisteredOfferingMember catx:TheUnderwritingAgreementMember 2024-05-24 2024-05-24 0000728387 catx:LantheusAlphaTherapyLlcMember catx:LantheusInvestmentAgreementMember 2024-01-08 2024-01-08 0000728387 catx:OppenheimerCoMember 2024-04-11 0000728387 catx:BofASecuritiesIncMember catx:May2024PreFundedWarrantsMember catx:TheUnderwritingAgreementMember 2024-05-24 0000728387 catx:SeriesBConvertiblePreferredStockMember 2023-12-31 0000728387 catx:GTMedicalTechnologiesIncMember 2024-04-12 0000728387 us-gaap:CommonStockMember catx:PublicOfferingMember 2024-01-01 2024-03-31 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2024-09-30 0000728387 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000728387 catx:OppenheimerCoMember 2024-04-11 2024-04-11 0000728387 2024-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0000728387 us-gaap:CommonStockMember 2024-09-30 0000728387 catx:GTMedicalTechnologiesIncMember catx:NetSalesOf10MillionOrLessMember 2024-04-12 0000728387 us-gaap:WarrantMember 2024-01-01 2024-09-30 0000728387 2024-04-01 2024-06-30 0000728387 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000728387 2023-09-30 0000728387 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000728387 catx:ProgenicsApaMember 2024-01-08 2024-01-08 0000728387 catx:PromissoryNoteMember 2024-09-30 0000728387 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000728387 us-gaap:RetainedEarningsMember catx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 us-gaap:CommonStockMember 2023-12-31 0000728387 2023-12-14 0000728387 catx:AmendedTwoThousandTwentyIncentivePlanMember 2024-08-14 2024-08-14 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000728387 catx:TwoThousandTwentyFourAtMarketOfferingMember 2024-08-13 0000728387 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000728387 2024-06-14 2024-06-14 0000728387 catx:GTMedicalTechnologiesIncMember catx:GTMedicalStockMember 2024-04-12 0000728387 catx:March2024PrivatePlacementMember 2024-03-04 2024-03-04 0000728387 catx:ViewpointMolecularTargetingIncMember catx:PromissoryNoteMember 2019-07-19 0000728387 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000728387 catx:MarchTwoThousandTwentyFourInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000728387 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember catx:Cesium131BusinessMember 2023-07-01 2023-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000728387 catx:ViewpointMolecularTargetingIncMember catx:PromissoryNoteMember 2019-07-19 2019-07-19 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-08 0000728387 2024-11-07 0000728387 srt:MaximumMember catx:ViewpointMolecularTargetingIncMember 2023-02-03 2023-02-03 0000728387 2023-06-30 0000728387 2023-12-31 0000728387 2024-07-01 2024-09-30 0000728387 catx:ViewpointMolecularTargetingIncMember catx:IsorayNoteMember 2022-11-22 0000728387 catx:ChicagoIllinoisMember 2024-08-02 2024-08-02 0000728387 catx:OppenheimerCoMember 2023-12-31 0000728387 catx:OppenheimerCoMember 2023-12-01 2023-12-31 0000728387 catx:AmendedTwoThousandTwentyIncentivePlanMember 2024-05-31 0000728387 2024-08-08 0000728387 us-gaap:RetainedEarningsMember 2024-06-30 0000728387 catx:OppenheimerCoMember 2023-11-17 0000728387 us-gaap:LandMember 2024-09-30 0000728387 2022-12-31 0000728387 catx:ViewpointMolecularTargetingIncMember catx:PromissoryNoteForPurchasingLandAndBuildingMember 2022-12-29 0000728387 us-gaap:AdditionalPaidInCapitalMember catx:LantheusInvestmentAgreementMember 2024-01-01 2024-03-31 0000728387 catx:OtherMember 2024-09-30 0000728387 us-gaap:CommonStockMember 2023-06-30 0000728387 catx:LantheusAlphaTherapyLlcMember srt:MaximumMember 2024-08-08 0000728387 catx:LantheusInvestmentAgreementMember 2024-01-08 2024-01-08 0000728387 2024-

09-18 2024-09-18 0000728387 catx:AmendedTwoThousandTwentyIncentivePlanMember 2024-05-31 2024-05-31 0000728387 catx:ViewpointMolecularTargetingIncMember 2023-01-01 2023-09-30 0000728387 catx:GTMedicalTechnologiesIncMember catx:NetSalesBetween10And15MillionMember 2024-04-12 0000728387 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000728387 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000728387 catx:JanuaryTwoThousandTwentyFourPreFundedWarrantsMember 2024-01-01 2024-03-31 0000728387 us-gaap:CommonStockMember 2023-04-01 2023-06-30 iso4217:EUR iso4217:USD shares pure catx:MonthlyPayments shares catx:Plaintiff iso4217:USD catx:RenewalOption Q3 --12-31 false 0000728387 0.1 0.1 0.1 0.1 0.1 10-Q true 2024-09-30 2024 false 001-33407 PERSPECTIVE THERAPEUTICS, INC. DE 41-1458152 2401 Elliott Avenue, Suite 320 Seattle WA 98121 206 676-0900 Common Stock, $0.001 par value CATX NYSEAMER Yes Yes Non-accelerated Filer true false false 67587540 226443000 9238000 41404000 0 592000 650000 217000 1165000 2108000 1133000 0 5301000 270172000 16837000 43792000 5576000 2433000 747000 0 182000 50000000 50000000 24062000 24062000 694000 487000 391153000 97891000 21813000 6909000 903000 46000 3976000 3588000 51000 49000 1400000 0 0 5072000 28143000 15664000 1676000 780000 1638000 1676000 26600000 0 4592000 4592000 33000 0 62682000 22712000 0.001 0.001 7000000 7000000 5000000 5000000 0 0 0 0 0 0 0.001 0.001 750000000 750000000 67562781 67562781 28180985 28180985 67000 28000 519954000 227591000 -191550000 -152440000 328471000 75179000 391153000 97891000 1-for-10 reverse stock split 369000 276000 1220000 1097000 12028000 5552000 28755000 14231000 6975000 4474000 18367000 16124000 0 0 0 15000 0 0 0 -22000 19003000 10026000 47122000 30362000 -18634000 -9750000 -45902000 -29265000 3581000 204000 7868000 872000 69000 14000 121000 58000 0 -12000 -6000 -12000 3512000 178000 7741000 802000 -15122000 -9572000 -38161000 -28463000 0 -784000 -890000 -3870000 0 0 -59000 0 -15122000 -10356000 -39110000 -32333000 0 0 0 -10500000 -15122000 -10356000 -39110000 -21833000 -0.21 -0.21 -0.34 -0.34 -0.61 -0.61 -0.68 -0.68 0 0 -0.03 -0.03 -0.01 -0.01 -0.15 -0.15 -0.21 -0.21 -0.37 -0.37 -0.62 -0.62 -0.83 -0.83 70629000 70629000 28055000 28055000 62293000 62293000 26323000 26323000 1-for-10 reverse stock split -39110000 -21833000 -39000 0 100000 35000 1585000 684000 0 298000 0 -22000 12000 30000 0 26000 -6000 -12000 899000 0 -58000 0 0 15000 -59000 0 3327000 3018000 0 -10500000 -890000 368000 -11000 -257000 975000 -12000 14937000 -683000 28000000 0 388000 1100000 8312000 -27905000 39800000 983000 24000 18000 38225000 22764000 78730000 0 0 2699000 -80329000 24462000 36000 56000 125000 0 896000 554000 288055000 0 0 65000 289040000 433000 217023000 -3010000 9420000 21175000 226443000 18165000 226443000 17983000 0 182000 226443000 18165000 2115000 811000 16518000 0 0 85885000 13654507 0 54618000 0 -7836000 0 -6171000 1-for-10 reverse stock split 14211276 14000 160560000 -105932000 54642000 13654507 14000 54539000 0 54553000 0 7836000 0 7836000 0 1368000 0 1368000 0 0 -371000 -371000 27865783 28000 224303000 -106303000 118028000 182158 0 532000 0 532000 0 1199000 0 1199000 0 0 -11106000 -11106000 28047941 28000 226034000 -117409000 108653000 9160 0 22000 0 22000 0 451000 0 451000 0 0 -10356000 -10356000 28057101 28000 226507000 -127765000 98770000 28180985 28000 227591000 -152440000 75179000 15639954 16000 53125000 0 53141000 0 10208000 0 10208000 5634235 6000 20840000 0 20846000 9200998 9000 82010000 0 82019000 35424 0 126000 0 126000 0 656000 0 656000 0 0 -12284000 -12284000 58691596 59000 394556000 -164724000 229891000 24450 0 128000 0 128000 22401 123000 123000 3535246 3000 47930000 0 47933000 5151588 5000 71863000 0 71868000 0 2040000 0 2040000 0 719000 719000 114 0 -1000 0 -1000 0 0 -11704000 -11704000 67425167 67000 517358000 -176428000 340997000 137229 0 642000 0 642000 385 0 2000 0 2000 0 1952000 0 1952000 0 0 -15122000 -15122000 67562781 67000 519954000 -191550000 328471000 1-for-10 reverse stock split <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;">1.<div style="width:100%;display:inline;">Basis of Presentation and Summary of Significant Accounting Policies</div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Perspective Therapeutics, Inc. is developing the next generation of precision-targeted alpha therapies (TAT) for oncology that have the potential to treat a large population of cancer patients across multiple tumor types, including those with metastatic disease. The accompanying unaudited condensed consolidated financial statements are those of Perspective Therapeutics, Inc., and its wholly owned subsidiaries, referred to herein as “Perspective Therapeutics” or the “Company.” All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes as set forth in the Company’s Annual Report on Form 10-K for the period ended December 31, 2023 filed with the SEC on March 28, 2024 (2023 Form 10-K).</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures are adequate for the information not to be misleading. The unaudited condensed consolidated financial statements reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s financial position, results of operations and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full fiscal year or any other period.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2024 will be 0%.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Merger</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On February 3, 2023, the Company completed the merger of Isoray Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company, with Viewpoint Molecular Targeting, Inc. (Viewpoint) (such transaction being the Merger). Pursuant to the Merger, the Company issued 13,654,507 shares of its common stock, par value $0.001 per share (Common Stock), representing approximately 49% of its fully diluted outstanding capital stock as of the close of the Merger. Viewpoint is an alpha-particle radiopharmaceutical company in the alpha-emitter market developing oncology therapeutics and complementary imaging agents. For additional information, see Note 14, Merger, in this Form 10-Q.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Discontinued Operations</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 12, 2024, the Company completed the sale of its Cesium-131 brachytherapy business and substantially all of the assets of Isoray Medical, Inc. (Isoray), a wholly owned subsidiary of Perspective Therapeutics, to GT Medical Technologies, Inc., a Delaware corporation (GT Medical) (such transaction being the GT Medical Closing). Pursuant to the GT Medical Closing, GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $0.0001 per share, representing 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the closing. Accordingly, the financial information and operating results of the Cesium-131 brachytherapy business have been presented as discontinued operations in the condensed consolidated financial statements for all periods presented. Unless otherwise noted, discussion within these notes to the condensed consolidated financial statements relates to continuing operations. For additional information, see Note 4, Discontinued Operations, in this Form 10-Q.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reverse Stock Split</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On June 14, 2024, the Company effected a 1-for-10 reverse stock split (Reverse Split) of the Company’s issued and outstanding shares of Common Stock, and the Common Stock began trading on a split-adjusted basis on June 17, 2024. The Reverse Split did not reduce the total number of authorized shares of Common Stock or the Company’s preferred stock (Preferred Stock), or change the par values of the Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder’s ownership percentage of the shares of Common Stock (except to the extent that the Reverse Split resulted in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of Common Stock were adjusted as a result of the Reverse Split, in accordance with the terms of each such security. In addition, the number of shares reserved for future issuance pursuant to the Company’s equity incentive plans was also adjusted accordingly. As a result, all historical per share data, number of shares issued and outstanding, and outstanding options and warrants for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively in this Form 10-Q, where applicable, to reflect the Reverse Split.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Liquidity</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has had a history of operating losses and an absence of significant recurring cash inflows from revenue. At September 30, </p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">2024, the Company had cash, cash equivalents and short-term investments of $267.8 million and total accumulated deficit of $191.6 million. The Company has historically financed its operations primarily through selling equity.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company believes that its $267.8 million of cash, cash equivalents and short-term investments as of September 30, 2024 will enable it to fund its current planned operations into mid-2026, though it may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and/or government funding and grants.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The operating plan may change as a result of many

factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the timeframe anticipated by management or at all, and the Company may need to seek additional funds sooner than anticipated. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from potential unknown factors. Reclassifications In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows. Significant Accounting Policies The Company's significant accounting policies and recent accounting pronouncements are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements in Item 8 of the 2023 Form 10-K. There have been no changes to the Company's significant accounting policies, and the Company has not adopted any significant accounting policies during the nine months ended September 30, 2024. 0 13654507 0.001 0.49 279516 0.0001 0.005 267800000 -191600000 267800000 Reclassifications In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows. 2. Loss per Share Basic and diluted loss per share is calculated by dividing net loss by the weighted average number of shares of Common Stock outstanding and does not include the impact of any potentially dilutive common stock equivalents. In January 2024 and May 2024, the Company issued pre-funded warrants in connection with the Public Offering (as defined below) and the Registered Offering (as defined below), respectively (see Note 3, Investments and Agreements, in this Form 10-Q). As the pre-funded warrants' exercise price is nominal and there are no conditions that must be satisfied prior to their exercise, the pre-funded warrants are included in the calculation of the basic and diluted earnings per share as of September 30, 2024. At each of September 30, 2024 and 2023, the calculation of diluted weighted average shares did not include common stock warrants or options that were potentially convertible into Common Stock as those would be antidilutive due to the Company's net loss position. Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:61.168%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.397%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.02%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.397%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 416 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 576 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Common stock options </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,252 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,468 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total potential dilutive securities </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,668 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,044 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Effective upon the closing of the Merger with Viewpoint on February 3, 2023, the Company assumed 338,709 warrants to purchase shares of Common Stock with an exercise price of $2.70 per share and 2,426,342 options to purchase shares of Common Stock with exercise prices ranging from $1.30<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> to $3.00 per share. Securities not considered in the calculation of diluted loss per share, but that could be dilutive in the future, are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.168%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.397%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.397%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 416 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 576 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,252 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,468 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total potential dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,668 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,044 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 416000 576000 7252000 4468000 7668000 5044000 338709 2.7 2426342 1.3 3 3. Investments and Agreements 2024 At-the-Market (ATM) Agreement On August 13, 2024, the Company entered into a Controlled Equity OfferingSM Sales Agreement (2024 ATM Agreement) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an ATM Agent, and together, the ATM Agents) pursuant to which the Company from time to time may offer and sell shares (2024 ATM Shares) of its Common Stock, through or to the ATM Agents having an aggregate sales price of up to $250.0 million. Subject to the terms and conditions of the 2024 ATM Agreement, each ATM Agent is required to use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Company's instructions. The Company has provided the ATM Agents with customary indemnification rights, and the ATM Agents will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the ATM Shares effectuated through or to the applicable ATM Agent selling the ATM Shares. Sales of the 2024 ATM Shares, if any, under the 2024 ATM Agreement may be made in transactions that are deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the 2024 ATM Shares and may at any time suspend offers under the 2024 ATM Agreement or terminate the 2024 ATM Agreement. The Common Stock to be sold under the 2024 ATM Agreement, if any, will be issued and sold pursuant to the Company's automatic shelf registration statement on Form S-3 (File No. 333-279692) (the May 2024 Registration Statement), which became effective upon filing with the SEC on May 24, 2024. On August 13, 2024, the Company filed a prospectus supplement to the May 2024 Registration Statement with the SEC in connection with the offer and sale of the 2024 ATM Shares pursuant to the 2024 ATM Agreement. As of September 30, 2024, the Company has not completed any transactions pursuant to the 2024 ATM Agreement. May 2024 Registered Offering On May 24, 2024, the Company entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters named therein, in connection with its previously announced underwritten offering (Registered Offering) of 5,151,588 shares (Registered Offering Shares) of Common Stock and, in lieu of Registered Offering Shares to certain investors, pre-funded warrants (May 2024 Pre-funded Warrants) to purchase 146,425 shares of Common Stock. The price to the investors for the Registered Offering Shares was $15.10 per Registered Offering Share, and the price to the investors for the May 2024 Pre-funded

Warrants was $15.09 per May 2024 Pre-funded Warrant, which represents the per share price for the Registered Offering Shares less the $0.01 per share exercise price for each such May 2024 Pre-funded Warrant. The Registered Offering closed on May 29, 2024. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC acted as joint book-running managers for the Registered Offering and B. Riley Securities, Inc. acted as a co-manager for the Registered Offering. JonesTrading Institutional Services LLC acted as a financial advisor for the Registered Offering. The gross proceeds to the Company from the Registered Offering were approximately $80.0 million, before underwriting discounts and commissions and estimated expenses of the Registered Offering. The Registered Offering was made pursuant to the May 2024 Registration Statement, a related base prospectus, free writing prospectus and prospectus supplement each dated May 24, 2024. The May 2024 Pre-funded Warrants became exercisable subsequent to the filing and effectiveness of an amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 14, 2024. The exercise price and the number of shares of Common Stock issuable upon exercise of each May 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company's stockholders. The May 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of May 2024 Pre-funded Warrants may not exercise such May 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would be more than 4.99% or 9.99%, as elected by such holder, of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the May 2024 Pre-funded Warrants. A holder of May 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. March 2024 Private Placement with Institutional Investors On March 4, 2024, the Company entered into an investment agreement (the March 2024 Investment Agreement) with certain accredited institutional investors (Institutional Investors) pursuant to which the Company agreed to issue and sell, in a private placement (the March 2024 Private Placement), 9,200,998 shares of Common Stock, for a purchase price of $9.50 per share, representing the closing price of the Common Stock on March 1, 2024. The closing of the March 2024 Private Placement occurred on March 6, 2024. The gross proceeds to the Company from the March 2024 Private Placement were approximately $87.4 million, before deducting fees payable to the Placement Agents (as defined below) and other estimated transaction expenses. The March 2024 Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the Placement Agency Agreement), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the Placement Agents). Per the Placement Agency Agreement, the Company agreed to: (i) pay the Placement Agents a cash fee equal to 5.85% of the gross proceeds received by the Company from the sale of the shares; and (ii) reimburse the Placement Agents for certain fees and expenses. Lantheus Agreements Investment Agreement On January 8, 2024, the Company entered into an investment agreement (the Lantheus Investment Agreement) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company and wholly owned subsidiary of Lantheus Holdings, Inc. (Lantheus), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction certain shares (the Lantheus Shares) of Common Stock. The closing of the purchase and sale of the Lantheus Shares to Lantheus by the Company (the Lantheus Closing) was subject to the Company raising at least $50.0 million of gross proceeds (excluding Lantheus' investment) in a qualifying third-party financing transaction, which occurred on January 22, 2024. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. Pursuant to the Lantheus Investment Agreement, the Company agreed to cooperate in good faith to negotiate and enter into a registration rights agreement with Lantheus, obligating the Company to file a registration statement on Form S-3 with the SEC to register for resale the Lantheus Shares issued at the Lantheus Closing. The Company filed such Form S-3 on March 29, 2024, and the SEC declared it effective on April 9, 2024 (File No. 333-278362). The Lantheus Investment Agreement also contains agreements of the Company and Lantheus whereby Lantheus is provided certain board observer and information rights of the Company, as well as standstill provisions prohibiting Lantheus from taking certain actions for a specified period of time, subject to certain exceptions. The Lantheus Investment Agreement also provides Lantheus with certain pro rata participation rights to maintain its ownership position in the Company in the event that the Company makes any public or non-public offering of any equity or voting interests in the Company or any securities that are convertible or exchangeable into (or exercisable for) equity or voting interests in the Company, subject to certain exceptions. Pursuant to the Lantheus Investment Agreement, the Company is required to notify Lantheus within 10 business days of the end of a fiscal quarter in which the Company issued shares of Common Stock pursuant to that certain At Market Issuance Sales Agreement among the Company, Oppenheimer & Co. Inc., B. Riley Securities, Inc., and JonesTrading Institutional Services LLC dated November 17, 2023 (the ATM Agreement), of (i) the number of shares of Common Stock issued during such fiscal quarter pursuant to the ATM Agreement and (ii) the average price per share received by the Company before commissions (the ATM Average Price). Upon receipt of such notice, Lantheus may elect, at its option, to purchase all or a portion of its Pro Rata Portion (as defined in the Lantheus Investment Agreement) of such shares at an aggregate price equal to the number of shares purchased multiplied by the ATM Average Price for such quarter (the ATM Participation Right). Pursuant to the Lantheus Investment Agreement, Lantheus may not exercise the ATM Participation Right more than two times per calendar year. Asset Purchase Agreement On January 8, 2024, the Company entered into an Asset Purchase Agreement (the Progenics APA) with Progenics Pharmaceuticals, Inc., a Delaware corporation (Progenics) and affiliate of Lantheus, pursuant to which the Company acquired certain assets and the associated lease of Progenics' radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash. The transactions contemplated by the Progenics APA closed on March 1, 2024. Option Agreement On January 8, 2024, the Company entered into an option agreement (the Option Agreement) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [212Pb]VMT-α-NET, the Company's clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors. If good-faith negotiations fail, Lantheus has a one-year right to reenter negotiations if a third party offers to purchase or license the [212Pb]VMT-α-NET program. Additionally, Lantheus has a right to co-fund the Investigational New Drug (IND) application, enabling studies for early-stage therapeutic candidates targeting prostate-specific membrane antigen and gastrin-releasing peptide receptor and, prior to IND filing, a right to negotiate for an exclusive license to such candidates. In consideration of the rights granted by the Company to Lantheus pursuant to the Option Agreement, Lantheus paid to the Company a one-time payment of $28.0<span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, subject to certain withholding provisions associated with the closing of the Progenics APA. Under the terms of the Option Agreement, Lantheus also has a right of first offer and last look protections for any third-party merger and acquisition transactions involving the Company for a 12-month period beginning on January 8, 2024. The Company determined that the Option Agreement should be accounted for as a research and development arrangement in accordance with Accounting Standards Codification (ASC) 730-20, Research and Development Arrangements, as Lantheus held approximately 19.9% of the Company's outstanding Common Stock at March 31, 2024. The Option Agreement contains no repayment provisions, does not create any obligation to enter into any license, transfer or sale agreements with Lantheus, and does not restrict the use of the funds in any way. Accordingly, the balance sheet reports current and long-term liabilities related to these options under the caption, "Deferred Income." The values for each distinct option within the Option Agreement were determined by estimating the fair value of each distinct option by a third-party valuation firm and the liabilities will be recognized as income in the condensed consolidated statement of operations as the various options expire. January 2024 Public Offering On January 17, 2024, the Company entered into an underwriting agreement (Underwriting Agreement) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the Underwriters), in connection with its previously announced underwritten public offering (Public Offering) of 13,207,521 shares (Public Shares) of Common Stock and, in lieu of Public Shares to certain investors, pre-funded warrants (Jan. 2024 Pre-funded Warrants) to purchase 3,008,694 shares of Common Stock. The price to the public for the Public Shares was $3.70 per Public Share, and the price to the public for the Jan. 2024 Pre-funded Warrants was $3.69 per Jan. 2024 Pre-funded Warrant, which represents the per share price for the Public Shares less the $0.01 per share exercise price for each such Jan. 2024 Pre-funded Warrant. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,432,432 shares of Common Stock at the same price per share as the Public Shares, which was fully exercised by the Underwriters on January 18, 2024. The Public Offering closed on January 22, 2024. The gross proceeds to the Company from the Public Offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the Public Offering. The Public Offering was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-275638), declared effective by the SEC on December 14, 2023, a base prospectus dated December 14, 2023, and the related prospectus supplement dated January 17, 2024. The Jan. 2024 Pre-funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of each Jan. 2024 Pre-funded Warrant are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock as well as upon any distribution of assets, including cash, stock or other property, to the Company's stockholders. The Jan. 2024 Pre-funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Jan. 2024 Pre-funded Warrants may not exercise such Jan. 2024 Pre-funded Warrants if the aggregate number of shares of Common Stock beneficially owned by such holder, together with its affiliates, would beneficially own more than 4.99% of the issued and outstanding shares of Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Jan. 2024 Pre-funded Warrants. A holder of Jan. 2024 Pre-funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. 2023 ATM Agreement The Company entered into an ATM Issuance Sales Agreement, dated November 17, 2023, by and among the Company, Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (2023 ATM Agreement). Pursuant to the 2023 ATM Agreement, the Company established an ATM equity program under which it may offer and sell shares of its Common Stock, from time to time. On November 17, 2023, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-275638) and accompanying base prospectus, declared effective by the SEC on December 14, 2023, for the offer and sale of up to $200.0 million of its securities (December 2023 Registration Statement). Also on November 17, 2023, the Company filed a prospectus supplement with the SEC in connection with the offering of up to $50.0 million of shares of its Common Stock pursuant to the 2023 ATM Agreement under the December 2023 Registration Statement. In December 2023, the Company sold 123,882 shares under the 2023 ATM Agreement at an average price of approximately $3.03 per common share for gross proceeds of approximately $0.4 million. On April 11, 2024, the Company sold 3,535,246 shares of its Common Stock under the 2023 ATM Agreement at an average price of approximately $14.00 per common share, resulting in gross proceeds of approximately $49.5 million. On May 25, 2024, the Company terminated the offering of securities pursuant to the December 2023 Registration Statement in connection with the filing and effectiveness of the May 2024 Registration Statement. On August 7, 2024, the Company delivered written notice to Oppenheimer & Co., Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC that it was terminating the 2023 ATM Sales Agreement, which termination became effective August 12, 2024. For additional information related to certain of the agreements discussed above, see Note 20, Subsequent Events, in the Company's 2023 Form 10-K. 250000000 0.03 5151588 146425 15.1 15.09 0.01 80000000 0.0499 0.0999 0.1999 9200998 9.5 87400000 0.0585 50000000 5634235 0.1999 8000000 28000000 0.199 0 13207521 3008694 3.7 3.69 0.01 2432432 69000000 0.0499 0.1999 200000000 50000000 123882 3.03 400000 3535246 14 49500000 4. Discontinued Operations The GT Medical Closing occurred on April 12, 2024 (GT Medical Closing Date). Previously, the Company announced that on December 7, 2023, Isoray entered into an Asset Purchase Agreement (GT Medical APA) by and among Isoray, the Company, and GT Medical pursuant to which Isoray would sell to GT Medical, and GT Medical would purchase from Isoray, all of Isoray's right, title and interest in and to substantially all of the assets of Isoray related to Isoray's commercial Cesium-131 business (the Business) including equipment, certain contracts, inventory and intellectual property. Subject to limited exceptions set forth in the GT Medical APA, GT Medical did not assume the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the GT Medical APA, at the GT Medical Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical's common stock, par value $0.0001 per share, representing 0.5% of GT Medical's issued and

outstanding capital stock on a fully diluted basis as of the GT Medical Closing Date and (ii) Isoray has the right to receive, and GT Medical is obligated to pay, certain cash royalty payments during each of the first four years beginning upon the GT Medical Closing Date (each such year, a Measurement Period), as summarized below: • with respect to GT Medical's net sales of Cesium-131 brachytherapy seeds for cases that do not utilize GT Medical's GammaTile Therapy: (a) if such net sales for a Measurement Period are $10.0 million or less, 3.0% of such net sales; (b) if such net sales for a Measurement Period are greater than $10.0 million and less than $15.0 million, 4.0% of such net sales; and (c) if such net sales for a Measurement Period are $15.0 million or more, 5.0% of such net sales; and • with respect to GT Medical's net sales of GT Medical's GammaTile Therapy utilizing Cesium-131 brachytherapy seeds: 0.5% of such net sales for a Measurement Period. In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified.
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
<tr style="visibility:collapse;">
<td style="width:57.96%;box-sizing:content-box;"></td>
<td style="width:4%;box-sizing:content-box;"></td>
<td style="width:1%;box-sizing:content-box;"></td>
<td style="width:14.88%;box-sizing:content-box;"></td>
<td style="width:1%;box-sizing:content-box;"></td>
<td style="width:3.22%;box-sizing:content-box;"></td>
<td style="width:1%;box-sizing:content-box;"></td>
<td style="width:15.940000000000001%;box-sizing:content-box;"></td>
<td style="width:1%;box-sizing:content-box;"></td>
</tr>
<tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
<td style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> September 30, 2024 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> December 31, 2023 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td>
</tr>
<tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
<td style="vertical-align:bottom;"> (in thousands) </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;text-align:left;"> </td>
<td style="vertical-align:bottom;text-align:left;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
<td style="vertical-align:bottom;"> Assets held for sale of discontinued operations, current </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,148 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,263 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Right-of-use asset, net </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current assets held for sale of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Asset retirement obligation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 225 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Loss recognized on classification as held for sale </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current liabilities of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,072 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-

bottom:0;text-align:justify;">The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:42.297%;box-sizing:content-box;"></td><td style="width:1.341%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.084%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.341%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.084%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.341%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.084%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Sales, net </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,909 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,178</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,239 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of sales </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,447 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,564 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,863 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Gross profit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 462 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> <span style="

bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 222 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 668 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total operating expenses </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,246 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,504 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,246 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (784 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(890</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (3,870 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The Company determined the loss recognized on classification as held for sale by identifying the assets and liabilities that are included in the GT Medical APA and are included in the table above. Additionally, the loss recognized on classification as held for sale was determined using the estimated fair value of the GT Medical stock of $0.2 million received less the carrying value of the net assets sold. The fair value of the stock received was determined based on information provided to the Company by GT Medical from a current valuation study that was prepared for them. Excluded from the calculation of the loss are contingent royalties that could be received from future sales. <div style="font-size:10pt;font-family:Times New

Roman;"> Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.44%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Write-off of inventory associated with discontinued product </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Share-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 568 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Additions to property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 287 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The Company previously had a restricted cash account to provide collateral for the decommissioning of its leased facility for Cesium-131 production. This facility lease was assumed by GT Medical as part of the GT Medical APA which included the commitment to decommission the facility. The Company has subsequently moved the full balance of the restricted cash account to its general operating cash accounts. For the three and nine months ended September 30, 2024 and 2023, there was no provision (benefit) for income taxes recorded related to the discontinued operations. Additionally, the Company is in a loss position and has recorded a full valuation allowance for the deferred tax assets associated with the discontinued operations. 279516 0.0001 0.005 0.03 0.04 0.05 0.005 <p

style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the following table presents the major classes of assets and liabilities of discontinued operations of the Business reported in the condensed consolidated balance sheets and prior year amounts have been reclassified. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.96%;box-sizing:content-box;"></td><td style="width:4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.88%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:3.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.940000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> (in thousands) </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Assets held for sale of discontinued operations, current </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,148 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,263 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Right-of-use asset, net </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 676 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other assets, net </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-

left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total current assets held for sale of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Liabilities held for sale of discontinued operations, current </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Asset retirement obligation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 225 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Loss recognized on classification as held for sale </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total current liabilities of discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,072 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table presents the components of discontinued operations in relation to the Business reported in the unaudited condensed consolidated statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.297%;box-sizing:content-box;"></td> <td style="width:1.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.341%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">

Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Sales, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,178</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of sales </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,564 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,863 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Gross profit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 462 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 376 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;"> Operating expenses: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 169 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Sales and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 855 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 941 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,578 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 222 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 668 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total operating expenses </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,246 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,504 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,246 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (784 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (3,870 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> Certain amounts included in the unaudited condensed consolidated statements of cash flows related to the discontinued operations are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.44%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Write-off of inventory associated with discontinued product </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Share-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 568 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Additions to property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 207 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 0 3148000 0 169000 0 1263000 0 676000 0 45000 0 5301000 0 677000 0 225000 0 4170000 0 5072000 0 1909000 2178000 5239000 0 1447000 1564000 4863000 0 462000 614000 376000 0 169000 69000 1000000 0 855000 941000 2578000 0 222000 494000 668000 0 1246000 1504000 4246000 -0 -784000 -890000 -3870000 200000 0 171000 0 27000 0 298000 166000 568000 0 287000 0 0 0 0 5. Property and Equipment On July 15, 2024, August 2, 2024 and October 31, 2024, the Company purchased a building located in the Houston, Texas, metropolitan area for $4.7 million, a building in the Chicago, Illinois, metropolitan area for $5.0 million, and a building in the Los Angeles, California, metropolitan area for $11.0 million, respectively, which it intends to use for the manufacture of its program candidates upon completion of modifications and installation of equipment. On September 18, 2024, the Company entered into a Master Equipment and Services Agreement (MESA) and statements of work (SOWs) thereunder with Comecer SpA (Comecer), pursuant to which the Company agreed to purchase from Comecer manufacturing equipment for the production of the Company's radiopharmaceutical products including, but not limited to, isotope processing hot cells and production suites and related equipment (collectively, the Deliverables) and services for installation and validation of the Deliverables at several of the Company's production facilities in the United States. The aggregate consideration for such equipment and services pursuant to the MESA and SOWs is approximately €49.0 millionpayable in cash, excluding certain incidental costs such as taxes, customs and duties, local transport, insurance and rigging. The Company may also elect to purchase certain additional equipment and services pursuant to the SOWs. The MESA provides for the payment of certain amounts in installments over the course of the production, installation and validation of the Deliverables. The Company's property and equipment consisted of the following as of: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.36%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> <span style="color:#000000;white-

space:pre-wrap;font-weight:bold;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,601 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,683 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,497 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,895 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (<span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,792</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,576 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. 4700000 5000000 11000000 49000000 The Company's property and equipment consisted of the following as of: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.36%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Land </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,283 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,601 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,683 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,497 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,895 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (669 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,792</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,576 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1. Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized. 1770000 1770000 1283000 1283000 10601000 2683000 3497000 179000 28895000 330000 46046000 6245000 2254000 669000 43792000 5576000 0 0 6. Goodwill and Other Intangible Assets Goodwill The carrying amount of goodwill as of both September 30, 2024 and December 31, 2023 was $24.1 million and has been recorded in connection with the Company's Merger of Viewpoint in February 2023. The Company tests goodwill and indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and nine months ended September 30, 2024. The following table summarizes the components of the Company's other intangible assets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.957%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:21.535999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.817%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> In-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.957%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:21.535999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.817%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left

#ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> The Company’s IPR&D assets represent the estimated fair value of Viewpoint’s pipeline of radiotherapy product candidates acquired in February 2023. The estimated fair value of the IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for Viewpoint’s pipeline of radiotherapy program candidates were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the Merger date and the time and resources needed to complete development. 24100000 24100000 The following table summarizes the components of the Company’s other intangible assets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.957%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:21.535999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.817%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Accumulated Amortization </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Net Carrying Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Indefinite-lived intangible assets </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> In-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">

*align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.772%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.957%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:21.535999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.817%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accumulated Amortization</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Net Carrying Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Indefinite-lived intangible assets</p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 50000000 0 50000000 50000000 0 50000000 50000000 0 50000000 50000000 0 50000000 7. Held-to-Maturity Investments The following table summarizes the carrying values and fair values of the Company's financial investments (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.996%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.016%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.536999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-

word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,404</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,415</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Company's condensed consolidated statement of operations. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet.</p> <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;">The following table summarizes the carrying values and fair values of the Company's financial instruments (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.996%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.016%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.536999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross Unrealized Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross Unrealized Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. Treasury Bills</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,404 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,415 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The Company has investments in U.S. Treasury Bills, some of which mature over a period greater than 90 days and are classified as short-term investments. The U.S. Treasury Bills are carried at amortized cost and classified as held-to-maturity as the Company has the intent and the ability to hold them until they mature. The carrying value of the U.S. Treasury Bills are adjusted for accretion of discounts over the remaining life of the investment. Income related to the U.S. Treasury Bills is recognized in interest income in the Company's condensed consolidated statement of operations. As of December 31, 2023, the Company had no held-to-maturity investments, and no held-to-maturity investments were presented in cash and cash equivalents on its condensed consolidated balance sheet. The following table summarizes the carrying values and fair values of the Company's financial instruments (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.996%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.016%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.536999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,404</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,415</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> 41404000 11000 0 41415000 0 0 <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;">8.<div style="width:100%;display:inline;">Fair Value Measurements</div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 1 - Observable inputs such as quoted prices in active markets;</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 2 - Inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-driven valuations in which all significant inputs are observable or can be derived principally from, or corroborated with, observable market data; and</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Level 3 - Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;">Included in the Company's cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.58%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated Fair Value
Level 1</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market fund</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 224,502 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There were no Level 2 or Level 3 financial instruments measured at fair value on a recurring basis at September 30, 2024, and the Company did not have any financial instruments measured at fair value on a recurring basis at December 31, 2023. For information related to short-term investments, see Note 7, Held-to-Maturity Investments. Company's cash and cash equivalents in the condensed consolidated balance sheet is its money market fund, which is measured at fair value on a recurring basis and categorized using the fair value hierarchy (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.58%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value
Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market fund </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 224,502 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 224502000 0 0 0 9. Share-Based Compensation On May 31, 2024, the Company held its 2024 Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Company's stockholders approved the Company's Third Amended and Restated 2020 Equity Incentive Plan (the Amended and Restated Plan) which, among other things, (a) increased the aggregate number of shares of Common Stock authorized for issuance under the Amended and Restated Plan by 4,870,092 for a total of 12,500,000 shares of Common Stock, and (b) adjusted the "evergreen" provision included therein, such that the number of shares of Common Stock available for the grant of awards under the Amended and Restated Plan will automatically increase on January 1 of each year in an amount equal to 5% of the number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding year (subject to adjustment in the event of stock splits and other similar events); provided, however, that the Company's Board of Directors may act prior to January 1 of a given year to provide that there will be no increase in the share limit for such year or provide that the increase for such year will be a lesser number of shares of Common Stock. On August 14, 2024, the Company filed a Form S-8 to register 4,870,092 additional shares of Common Stock authorized for issuance under the Amended and

Restated Plan as approved by stockholders at the Annual Meeting. The following table presents the share-based compensation expense recognized for all share-based compensation arrangements, excluding share-based compensation expense reported in Note 4, Discontinued Operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.169%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">814</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,336</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 763 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,687 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total share-based compensation </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-

space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,952 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">418</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,161 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,450</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div> 4870092 12500000 0.05 4870092 <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the share-based compensation expense recognized for all share-based compensation arrangements, excluding share-based compensation expense reported in Note 4, Discontinued Operations (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.169%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.202%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30, </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 814 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">179</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,336 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 763 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">

1,138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 239 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,687 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total share-based compensation </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,952</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 418 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,161</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,450 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 814000 179000 1336000 763000 1138000 239000 1825000 1687000 1952000 418000 3161000 2450000 10. Commitments and Contingencies The Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Company's annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million as of December 31, 2023. There was no change in the estimate as of September 30, 2024. This balance is included in accrued expenses on the unaudited condensed consolidated balance sheets. 6 200000 200000 200000 11. Related Parties In connection with the Lantheus Investment Agreement entered into with Lantheus on January 8, 2024, the Company agreed to sell and issue the Lantheus Shares. The number of Lantheus Shares sold was 5,634,235, representing 19.99% of the outstanding shares of Common Stock as of January 8, 2024. On January 8, 2024, the Company entered into the Progenics APA with Progenics, an affiliate of Lantheus, for a purchase price of $8.0 million. On March 1, 2024, the Company closed on the transactions contemplated by the Progenics APA. On March 4, 2024, the Company entered into the March 2024 Investment Agreement in which the Company agreed to issue and sell 9,200,998 shares of Common Stock. Lantheus, a significant stockholder of the Company, purchased part of the shares issued to increase their ownership percentage to approximately 19.9% in the Company following the closing of the March 2024 Investment Agreement on March 6, 2024. For additional information regarding the Lantheus Investment Agreement, the Progenics APA and the March 2024 Investment Agreement, see Note 3, Investments and Agreements. On August 8, 2024, the Company entered into an access and license agreement with Lantheus. For additional information, see Note 12, Leases. 5634235 0.1999 8000000 9200998 0.199 12. Leases The Company accounts for its leases under ASC 842, Leases. Effective April 1, 2024, the Company entered into a lease with the Board of Regents, State of Iowa, for lab and office space at the BioVentures Center. The lease terminates in March 2026. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $1.1 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment

as the lease does not provide an implicit discount rate. The Company acquired a lease from Progenics, an affiliate of Lantheus, for a production facility in Somerset, New Jersey effective on March 1, 2024 (see Note 3, Investments and Agreements, in this Form 10-Q). The lease terminates on November 29, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.3 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. On August 8, 2024, the Company assumed a lease from Progenics for office space in Somerset, New Jersey (Office). The lease terminates on November 30, 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.6 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. Upon assuming the lease, the Company entered into a license and access agreement with Lantheus, which provides access to both dedicated and shared space of the Office (Access Agreement). There is no renewal option, and the termination options are available only for material breaches. In consideration of the Access Agreement, Lantheus agreed to pay base rent and associated costs through December 2024 directly to the landlord. The base rent through December 2024 is less than $0.1 million (Prepaid Rent). Pursuant to ASC 842, Leases, the Access Agreement is a sublease in which the Company is a sublessor and Lantheus is a sublessee. The Company will amortize the Prepaid Rent over the entire lease term of 52 months. On July 1, 2023, the Company entered into a lease with Unico Properties LLC for office space in Seattle, Washington that terminates in October 2028. Upon entering into this lease, the Company recognized a right-of-use asset and lease liability of approximately $0.8 million on the balance sheet based upon the present value of the future base payments discounted at an 8% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The weighted average remaining term and discount rate for the Company's operating leases as of September 30, 2024 was 3.2 years and 8%, respectively. The Company's operating lease expense was $0.3 million and $0.5 million for the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.4 million for the three and nine months ended September 30, 2023.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company's operating leases as of September 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year Ending December 31,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining three months)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 245 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,112 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 647 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 493 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 443 </td><td style="white-

space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,940</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(361</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,579</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: current portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(903</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Noncurrent lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,676</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Asset Retirement Obligation</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company had an asset retirement obligation (ARO) associated with the facility it leased in Richland, Washington. This lease is included in the GT Medical APA and was assigned to GT Medical upon the GT Medical Closing, which occurred on April 12, 2024. As such, this liability is no longer reported as an ARO in the Company's condensed consolidated financial statements as of September 30, 2024 and December 31, 2023. However, the Company maintains the estimated liability in its condensed consolidated financial statements related to hazardous waste removal. The estimated liability at each of September 30, 2024 and December 31, 2023 was $0.5 million and is included within the accounts payable and accrued expenses in the condensed consolidated balance sheets.</p> 1100000 1100000 0.08 300000 300000 0.08 600000 600000 0.08 0 100000 P52M 800000 800000 0.08 P3Y2M12D 0.08 300000 500000 200000 400000 <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the future operating lease payments and lease liability included on the condensed consolidated balance sheet related to the Company's operating leases as of September 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year Ending December 31,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining three months)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">245</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,112</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">647</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">493</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">443</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td

style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,940 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (361 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (903 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Noncurrent lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,676 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 245000 1112000 647000 493000 443000 2940000 361000 2579000 903000 1676000 500000 500000 13. Notes Payable The Company assumed two notes payable effective upon the closing of the Merger with Viewpoint on February 3, 2023. On July 19, 2019, Viewpoint entered into a promissory note agreement with the Iowa Economic Development Authority (IEDA) for $0.1 million at 3% interest rate to be paid over 36 monthly payments beginning on the first day of the first month following Viewpoint closing on a $1.0 million equity fundraising round. Final payment was paid in September 2023. The loan was granted as a form of financial assistance to Viewpoint from IEDA. On December 29, 2022, Viewpoint obtained a promissory note in the amount of $1.7 million for the purpose of purchasing land and a building in Coralville, Iowa. The note bears interest at 6.15% per annum and is collateralized by the property. The note requires monthly principal and interest payments, and a balloon payment of approximately $1.5 million is due on December 29, 2027.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the current and long-term portions of the note payable (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note payable</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,689 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,725</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: current portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(51</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(49</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note payable, long-term portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,638 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,676</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company's note payable as of September 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Years ending December 31:</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining three months)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,569 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,689 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 100000 0.03 36 1000000 1700000 0.0615 1500000 The following table presents the current and long-term portions of the note payable (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> September 30, </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> December 31, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,689</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,725 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (51 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note payable, long-term portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,638</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,676 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1689000 1725000 51000 49000 1638000 1676000 The following table presents the future principal payments included on the condensed consolidated balance sheet related to the Company's note payable as of September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Years ending December 31: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remaining three months) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,569</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,689 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 13000 52000 55000 1569000 1689000 14. Merger On February 3, 2023, the Company acquired 100% of the issued and outstanding equity and voting shares of Viewpoint Molecular Targeting, Inc. in exchange for 13,654,507 shares of Common Stock with a fair value of $54.6 million based on the closing market price of $4.00 per share on the acquisition date. At the closing of the Merger, the Company forgave the note receivable entered into in November 2022 and the associated accrued interest with Viewpoint that was included in the note receivable. The total amount forgiven was $6.2 million, representing the $6.0 million loan and $0.2 million accrued interest. The Company also assumed all of Viewpoint's outstanding stock options and warrants as of the Merger date. The Merger was completed to provide the Company with a new isotope in a larger market. The Company accounted for the transaction as a business combination in accordance ASC 805, Business Combinations. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed with the assistance of an independent valuation firm. The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Fair value of consideration transferred </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Perspective Therapeutics common stock issued (13,654,507 x $4.00)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,618 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Assumption of Viewpoint stock options and warrants at fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,836 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Note receivable and interest from Viewpoint forgiven </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,171 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total fair value of consideration transferred </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">68,625</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recognized amounts of identifiable net assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,699 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grants receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 396 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Right-of-use asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Intangible assets, in-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets acquired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities assumed </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued payroll and related taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,642 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued vacation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Notes payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,807 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,243 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total liabilities assumed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr

style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net assets acquired, excluding goodwill</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total purchase price consideration</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">68,625</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Goodwill</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,062</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Goodwill is calculated as the difference between the acquisition date fair value of the consideration and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. The goodwill is attributable to the workforce of the acquired business and the synergies expected to arise from the acquisition of Viewpoint.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Upon completion of the Merger, Viewpoint became a wholly owned subsidiary of the Company and its results of operations have been included in the Company's condensed consolidated financial statements.</p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Since the closing date, Viewpoint's results of operations have been reported in the Company's condensed consolidated financial statements and include grant revenue of approximately $0.4 million and $0.3 million, respectively, and operating loss of $18.6 million and $9.8 million, respectively, for the three months ended September 30, 2024 and 2023, and grant revenue of approximately $1.2 million and $1.1 million, respectively, and operating loss of $45.9 million and $29.3 million, respectively, for the nine months ended September 30, 2024 and 2023.</p>1 13654507 54600000 4 6200000 6000000 200000 The Viewpoint purchase price consideration and allocation to net assets acquired is presented below (in thousands except for share price):<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of consideration transferred</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Perspective Therapeutics common stock issued (13,654,507 x $4.00)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54,618</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assumption of Viewpoint stock options and warrants at fair value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,836</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note receivable and interest from Viewpoint forgiven</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,171</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total fair value of consideration transferred</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">68,625</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 13654507 4 54618000 7836000 6171000 68625000 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recognized amounts of identifiable net assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets acquired</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,699 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grants receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 396 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Right-of-use asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Intangible assets, in-process research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets acquired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,566 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities assumed </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Accrued payroll and related taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,642 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued vacation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Notes payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,807 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred tax liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,243 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total liabilities assumed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net assets acquired, excluding goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total purchase price consideration </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 68,625 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Goodwill </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,062 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2699000 95000 396000 5050000 10000 50000000 316000 58566000 2968000 10000 1642000 333000 1807000 7243000 14003000 44563000 68625000 24062000 400000 300000 -18600000 -9800000 1200000 1100000 -45900000 -29300000 ITEM 5 – OTHER INFORMATION Rule 10b5-1 Trading Arrangements During the three months ended September 30, 2024, none of our directors or executive officers adopted, modified or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K. false false false false false false Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.See Note 3, Investments and Agreements, for additional information.Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.See Note 3, Investments and Agreements, for additional information.Property and equipment not placed in service are items that meet the capitalization threshold, or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheets and, therefore, no depreciation expense has been recognized.“